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Abstract 
Reactive oxygen species (ROS) are known to play a significant role in cellular 
signalling pathways, associated with growth, differentiation and survival and in many 
cancers, elevated ROS levels have been linked with aberrant signalling. Previously, we 
showed that human haematopoietic progenitor cells expressing mutant RAS (a common 
abnormality in AML) had elevated NOX2 derived ROS which led to increased cell 
proliferation. However, it is currently unknown how ROS mediates these effects. 
Previous preliminary data suggests significant ROS attributable gene changes are 
associated with glycolysis, a feature also common in solid tumours. Using human 
haematopoietic progenitor cells, it is reported here for the first time that, elevated ROS 
leads to changes in extracellular lactate production and increases in glucose uptake. 
Furthermore, modulation of ROS levels in AML cell lines also generate results 
consistent with a ROS induced model of increased glycolysis. Gene expression profiling 
identified ROS related changes in specific glycolytic enzymes, whilst immunoblotting 
verified ROS dependent increases in protein expression of a key regulatory glycolytic 
enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), in both 
human cells and AML cell lines. Metabolomic analysis using mass spectrometry, was 
performed on AML cell lines in which ROS levels were manipulated and AML patient 
samples were characterised according to ROS production. This revealed changes in 
concentrations of metabolites associated with glycolysis and metabolic pathways 
important in ROS regulation. Modulation of PFKFB3 expression generated changes in 
glucose uptake consistent with ROS mediated changes in this enzyme. In summary, this 
study establishes for the first time that increased ROS production in AML models leads 
to increased glycolysis and metabolic reprogramming as a consequence of modulation 
of PFKFB3 expression by ROS. 
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1 General Introduction 
The average adult human contains five litres of blood, which consists of plasma and a 
heterogeneous mix of different cell types. Cells constitute approximately 46% of total 
blood volume, with plasma, composed of water, proteins, glucose, minerals and clotting 
factors, making up the rest (reviewed in Kumar, 2015). Haematopoietic cells are 
commonly divided into three major subgroups, comprising of those derived from the 
erythroid, lymphoid and myeloid lineage. The erythroid cells are composed of 
erythrocytes which bind oxygen via haemoglobin for transport around the body and 
thrombocytes which are involved in haemostasis. Cells derived from the lymphoid 
lineage are leukocytes and consist of lymphocytes (T-cells and B-cells) which are 
highly specialised cells involved in adaptive immunity, and natural killer cells, which 
whilst classically considered to be cells involved in innate immunity, also exhibit 
features of the adaptive system. The third subgroup comprise of those derived from the 
myeloid lineage; they are involved in innate immunity and can themselves be further 
divided into monocytes and granulocytes. Monocytes ultimately differentiate into 
macrophages which are phagocytes, and dendritic cells which process and present 
antigens to T-cells. Granulocytes are distinguished by the presence of granules in the 
cytoplasm and consist of three types of cell, neutrophils which are phagocytes, 
basophils which secrete histamine and eosinophils which destroy parasites and affect 
allergic responses. 
The average lifespan of mature haematopoietic cells varies; in adult humans 
erythrocytes circulate for around 100-120 days before being engulfed by macrophages, 
whereas neutrophils are relatively short-lived, with a circulatory half-life of between 6-
90 hours (Tak et al., 2013). Consequently, to maintain haematopoietic cells at stable 
levels, new blood cells must be constantly generated. This process of haematopoiesis 
occurs, in adult humans, primarily in the bone marrow (BM), from haematopoietic stem 
cells (HSC) which are self-renewing and have the capacity to differentiate into any 
blood cell, at the rate of 1x1012 cells per day (reviewed in Doulatov et al., 2012). 
Leukaemia is a cancer of the blood which develops, typically in the bone marrow due to 
disruption of the haematopoietic process. In acute myeloid leukaemia (AML) (1.2.1) 
this can be characterised as a failure in proper differentiation and the accumulation of 
immature myeloid progenitor cells, occurring due to successive genetic alterations to 
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critical genes involved in cell survival, differentiation and growth. Approximately 55% 
of AML patients present with cytogenetic abnormalities, whilst the rest have a normal 
karyotype. Of these, FMS-like tyrosine kinase receptor 3 (FLT-3) internal tandem 
duplications (approx. 30%) or somatic mutations to genes like nucleophosmin-1 
(NPM-1) (50-60%) or rat sarcoma (RAS) (15-30%) (Estey and Dohner, 2006), are most 
frequently observed. 
Reactive oxygen species (ROS) are small molecules, that react readily with a large 
number of molecules, due to the presence of an unpaired electron, or their ready 
conversion into free radicals (1.3.1). Initially ROS were identified for their destructive 
function, as part of a cellular immune response (1.3.3.1), but more recently their role in 
cell signalling has gained prominence (1.3.3.2). There are multiple cellular sources of 
ROS (1.3.2). Their reactivity means they are highly regulated, with dysregulated ROS 
production, signalling, and regulation, and its role in cancer (1.3.3.4) a much studied 
area (reviewed in Galadari et al., 2017). 
Metabolism (1.4) is a highly integrated network of chemical reactions, that in animals 
are used by cells to either break down biomolecules and generate energy, or to build the 
substrates into more complex molecules, a process with a net energy loss. There are four 
main classes of biomolecules, proteins, nucleic acids, lipids, as well as carbohydrates 
such as glucose. Glucose is central to metabolism, as it is the primary fuel in the 
generation of energy, both in the form of adenosine triphosphate (ATP) which is a 
product of the glycolytic pathway (1.4.3) and in supplying intermediates for oxidative 
phosphorylation. Oxidative phosphorylation is much more efficient than glycolysis in 
ATP generation and is the primary energy source in normal cells, however it requires 
oxygen to proceed so under low oxygen conditions (hypoxia), cells produce energy 
anaerobically via the glycolytic pathway alone. The German scientist Otto Warburg was 
the first to notice that in many cancer cells glycolysis is enhanced (Warburg, 1956), 
even in the presence of sufficient oxygen for oxidative phosphorylation to proceed 
(1.4.1), whilst the reasons for this are an ongoing area of active research (reviewed in 
Liberti and Locasale, 2016). 
This study then aims to investigate the role that ROS has on metabolic (primarily 
glycolytic) function, from an AML perspective. 
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1.1 Haematopoiesis 
In order to maintain haemostasis, new blood cells must be constantly generated to 
replace those lost through injury, disease or age. Haematopoiesis, the process by which 
HSC differentiate into mature blood cells, occurs via a series of stages known as lineage 
commitment (reviewed in Cvejic, 2016) (1.1.2) and is tightly regulated by the BM 
environment (or stem cell niche; reviewed in Ho et al., 2015) (1.1.1), signal 
transduction pathways (reviewed in Luis et al., 2012), cytokines (reviewed in Tarasova 
et al., 2011, Metcalf, 2008, Robb, 2007) (1.1.3), transcription factors (reviewed in 
Wolff and Humeniuk, 2013, Rosenbauer and Tenen, 2007) (1.1.4), epigenetics, 
(reviewed in Alvarez-Errico et al., 2015) and metabolic pathways (reviewed in 
Oburoglu et al., 2016) (1.4). HSC are rare, constituting only 0.001% of peripheral blood 
(PB) and 0.05% of BM cells, but are responsible for producing a lifetime supply of 
blood cells (reviewed in Mendelson and Frenette, 2014). In order to achieve this, they 
undergo a process of self-renewal, either symmetric renewal, which generates two 
undifferentiated stem cells or two differentiated cells, or asymmetric renewal resulting 
in one stem cell and one differentiated cell. As above, this process is regulated by both 
intrinsic and extrinsic factors (reviewed in Zon, 2008) (1.1.1). 
Blood is mesodermally derived tissue. Ontogenetically, blood is derived initially from 
the embryonic stem cells (ES) of the epiblast. The cytokine bone morphogenetic protein 
4 (BMP4), is a critical signalling molecule in the differentiation of these early ES 
towards a haematopoietic fate. Haemogenic endothelium cells (HE) then develop in the 
mesoderm which requires the transcription factor Scl, with primitive HSC first 
emerging in the aorta-gonad-mesonephros (AGM) and yolk sac 4 weeks post 
conception in humans (reviewed in Wang and Wagers, 2011). The process of HE to 
primitive HSC is known as endothelial-to-haematopoietic transition and is under the 
control of the transcription factor runt-related transcription factor 1 (RUNX1) (Landry 
et al., 2008). These primitive HSC, or erythroid-myeloid progenitors (EMP) have the 
capacity to develop into erythrocytes, macrophages and megakaryocytes, but not 
lymphocytes and do not have the capacity to self-renew. In humans, 5 weeks post 
conception, HSC then migrate from the AGM to the foetal liver and placenta. Whilst the 
factors responsible for this migration are still not fully established, both the chemokine 
CXCL12 (Sugiyama et al., 2006) and the cytokine stem-cell factor (SCF) (Barker, 
1994) are known to be critical for this process. Several signalling pathways including 
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NOTCH, BMP4, Hedgehog, TIE2-angioprotein and vascular endothelial growth factor 
(VEGF), are then responsible for establishing HSC in the BM, around 12 weeks post 
conception (reviewed in Kim et al., 2014). Postnatally, HSC mainly reside in the BM, 
where, with the exception of T-cells which develop latterly in the thymus, adult 
haematopoiesis occurs. 
 Human haematopoietic stem cells 
To qualify as a HSC, a cell must be able to durably self-renew whilst also being 
multipotent, i.e. capable of differentiating into all types of blood cell. This 
differentiation is generally considered to occur via several intermediate progenitor cells, 
ultimately terminating in the specific mature blood cell through a process termed fate 
restriction or lineage commitment. These stages of lineage commitment can be observed 
by changes in the expression of proteins on the cell surface of the differentiating cell. 
Civin et al., 1984 were the first to report a cell surface marker for primitive 
haematopoietic cells. Using a monoclonal antibody (anti-My-10, raised against the 
morphologically primitive leukaemic cell line, KG-1a) they identified a small 
population (1-2%) of undifferentiated haematopoietic BM cells which were not 
observed in PB, but were also present on greater than 30% of blasts obtained from some 
patients with AML. This cell surface protein, CD34, is now routinely used in the 
laboratory to separate HSC and haematopoietic progenitor cells (HPC) from 
differentiated haematopoietic cells. Subsequent work identified CD90 (or Thy1) as a 
marker to separate HSC from more differentiated progenitor cells (Baum et al., 1992), 
whilst more recently CD49f + cells (Notta et al., 2011) have been shown to correlate 
with properties of long term HSC (LT-HSC) as distinct from CD49f - short term HSC 
(ST-HSC) (reviewed in Doulatov et al., 2012). 
The difference between LT-HSC and ST-HSC is defined by their relative abilities to 
sustain long term blood production of all lineages in lethally irradiated mice that have 
received a BM engraftment. LT-HSC have traditionally been seen as those capable of 
self-renewal and blood production in these mice for a period greater than 12 weeks, 
whilst ST-HSC only sustain blood production for a shorter period (2-3 weeks for 
myeloid cells and 4-6 weeks for lymphoid progeny) (reviewed in Doulatov et al., 2012). 
Work by Benveniste et al., 2010 identified a population of HSC termed intermediate 
HSC (IT-HSC) that maintain reconstitution potential in engrafted mice for 16-44 weeks. 
Other studies examining reconstitution kinetics have also identified subpopulations of 
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HSC with some clones preferentially generating cells of a lymphoid lineage (Ly-bi 
HSC), some a myeloid lineage (My-bi HSC) and others a more balanced lineage 
commitment (Bala-HSC) (Muller-Sieburg et al., 2002). Recently a review by Ema et 
al., 2014 has noted that HSC defined as My-bi predominantly overlap with LT-HSC and 
Ly-bi with ST-HSC. The exact process of HSC self-renewal, lineage commitment 
(1.1.2) and cell fate determination (1.1.3 & 1.1.4) is still a matter of contention, 
however it is in part at least determined by the stem-cell niche.  
1.1.1.1 The haematopoietic stem cell niche 
The hypothetical idea of a stem cell niche, as an anatomically defined site in which stem 
cell differentiation is inhibited, was first proposed by (Schofield, 1978). However it was 
not until 1998 that his hypothesis was experimentally validated in ovary tissue of 
Drosphilia (Xie and Spradling, 1998), whilst definitive identification of the mammalian 
HSC niche did not occur until 2003 (Zhang et al., 2003, Calvi et al., 2003). Using 
different mechanisms, these independent murine studies generated increased levels of 
osteoblasts in the BM and both observed concomitant increases in levels of HSC. 
Furthermore, Zhang et al. 2003 demonstrated that the cell adhesion protein N-cadherin 
was a point of contact between osteoblasts and HSC, whilst Calvi et al, 2003 
demonstrated that the Notch ligand, Jagged 1, was the protein responsible for this 
increase. Current understanding of the HSC niche microenvironment now encompasses 
not only these, but several other cell signalling molecules and cytokines, as well as 
many non-proteinaceous factors. 
The HSC niche can be physiologically divided into the endosteal niche and perivascular 
niche. These niches are populated by several cells that, in addition to HSC, have been 
shown to be important in their maintenance, and include mesenchymal stem cells 
(MSC), CXCL12-abundant reticular (CAR) cells, endosteal cells, osteoblasts, 
adipocytes, chondrocytes, osteoclasts, immune cells and neuronal cells (reviewed in Ho 
et al., 2015, Reagan and Rosen, 2016). Until recently, the role of osteoblasts (which 
reside in the endosteal niche) appeared to be particularly crucial. In addition to 
expression of N-cadherin and Jagged 1, osteoblasts have also been shown to express 
anigiopoietin-1, thrombopoietin (TPO), osteopontin and WNT and to secrete 
granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage CSF (GM-
CSF), interleukin-6 (IL-6) (reviewed inWang and Wagers, 2011) and c-x-c motif 
chemokine 12 (CXCL12) (Ponomaryov et al., 2000), all of which have been shown to 
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be important in the maintenance or physiological function of the niche. In particular 
osteoblast secretion of CSXCL12 was thought to be crucial in HSC homing and 
engraftment (Ponomaryov et al., 2000), whilst expression of angiopoietin on the 
osteoblast cell surface was shown to interact with tyrosine kinase receptor Tie2, a ligand 
expressed on the LT-HSC subpopulation of HSC (Arai et al., 2004). However, the 
importance of osteoblasts in HSC maintenance has recently been questioned (reviewed 
in Crane et al., 2017). Improved HSC purification resulting from the identification of 
signalling lymphocyte activation molecule family markers have shown that quiescent 
HSC primarily reside near sinusoidal blood vessels of the perivascular niche. 
Furthermore, whilst loss of osteoblasts from the stem cell niche resulted in the depletion 
of early lymphoid progenitors, loss of HSC’s was severely delayed, occurring only once 
the BM was pancytopenic. Additionally, SCF has been shown to be crucial for HSC 
maintenance and has been shown to be primarily expressed by perivascular cells, whilst 
SCF deletion from osteoblasts in murine models showed no effect of HSC function 
(Ding et al., 2012). In contrast CAR cells found in the perivascular region of the BM are 
the major source of BM SCF and they additionally express CXCL12 at levels three 
orders of magnitude higher than that of osteoblasts (Ding and Morrison, 2013). 
CXCL12 is required, as HSC express CXC-chemokine receptor 4 (CXCR4) and 
CXCL12-CXCR4 signalling regulates HSC proliferation and quiescence (Nie et al., 
2008). Megakaryocytes and non-myelinating Schwann cells are also important in 
maintaining HSC quiescence through activation of transforming growth factor beta 
(TGFβ), whilst depletion of macrophages has also been shown to reduce CXCL12 
expression and increased HSC proliferation (reviewed in Crane et al., 2017). 
Additionally adipocytes also positively regulate HSC survival through expression of 
CXCL12 (Mattiucci et al., 2018),  whilst immune cells such as osteomacs and myeloid-
derived suppressor cells protect HSC from cytotoxic lymphocytes and maintain HSC 
homeostasis (reviewed in Reagan and Rosen, 2016). 
Physiochemical factors also are important in HSC niche regulation. Mechanical support 
by the extracellular matrix can be important in stem cell differentiation, shear stress is a 
factor in the upregulation of the haematopoietic transcription factor RUNX1 in 
embryogenesis and calcium ion concentration of the HSC niche is crucial in the 
chemoattraction and engraftment of LT-HSC (reviewed in Wang and Wagers, 2011). 
Furthermore, oxygen levels vary with the HSC niche, with low hypoxic regions 
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reported in areas that correlate with higher levels of quiescent LT-HSC (Parmar et al., 
2007, Winkler et al., 2010), which include the perisinusoidal region of the BM (Spencer 
et al., 2014). It has been demonstrated that LT-HSC manage the hypoxic environment 
through the upregulation/stabilisation of hypoxia inducible factor alpha (HIF-1α) 
(Takubo et al., 2010), a master regulator of hypoxia (1.4.2.1), and through a 
concomitant increase in glycolytic function and decrease in mitochondrial activity 
(Simsek et al., 2010). Mitochondrial oxidative phosphorylation, generates ROS 
(1.3.2.1). Changes in the intracellular levels of ROS have been shown to impact on HSC 
quiescence, with higher levels leading to increased HSC differentiation and proliferation 
(reviewed in Ludin et al., 2014) potentially mediated via hyperactivation of 5’ 
adenosine monophosphate-activated protein kinase (AMPK) (Liu et al., 2015). 
Interestingly AMPK activation has been shown to stimulate increased glycolysis via the 
upregulation and phosphorylation (Ser 461) of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3 (PFKFB3) (Domenech et al., 2015, Esteban-Martinez et al., 2015, 
Mendoza et al., 2012) (1.5.1.1). 
Clearly, the microenvironment of the HSC niche is tightly controlled and subject to 
numerous positive and negative feedback mechanisms, that are important in maintaining 
the quiescence and long-term viability of HSC, whilst ensuring appropriate levels of 
HSC lineage specific differentiation occur, in order to retain suitable levels of mature 
blood cells in the PB. The mechanisms by which this process of differentiation occurs 
will be introduced below. 
 The myeloid model of haematopoiesis 
Adult human haematopoiesis has traditionally been described as a process in which 
HSC gradually differentiate in a stepwise manner into different mature blood cells, via a 
series of intermediate progenitor cells. As differentiation occurs cells lose the capacity 
to self-renew and progenitor cells emerge that are increasingly committed to a given 
branch of haematopoietic lineage in a process known as cell fate determination. Fate 
decisions occur as a consequence of changes in the regulation of lineage specific gene 
expression, that stem from changes in the cellular microenvironment as a result of cell-
cell interactions, changes in physiochemical factors (1.1.1.1) and the relative 
concentrations of certain cytokines (1.1.3) (Rieger and Schroeder, 2012).  
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The compartmentalisation of HSC, their progenitors and terminally differentiated blood 
cells, into different stages of differentiation, has traditionally been done on the basis of 
the expression of different cell surface proteins (Figure 1-1) (reviewed in Doulatov et 
al., 2012). These can be isolated by fluorescence activated cell sorting (FACS) and their 
differentiation potential determined by colony-forming cell assays or xenograft models. 
Initial work in mice led to the identification of common myeloid progenitors (CMP) 
(Akashi et al., 2000) and common lymphoid progenitors (CLP) (Kondo et al., 1997), 
which gave rise to a hierarchical model of haematopoiesis being developed. This model 
pictured haematopoiesis as a developmental tree with HSC representing the trunk and 
differentiation occurring via intermediate progenitor cells, through serial bifurcation, 
until unipotent mature blood cells were generated (Figure 1-1). This positioning of CMP 
and CLP at the earliest lineage committed step of the hierarchical tree has proved 
problematic, leading to a number of alternative models being proposed (reviewed in 
Kawamoto and Katsura, 2009). In particular, the failure to detect CLP that did not also 
have myeloid potential led (Kawamoto et al., 2010) to propose the ‘myeloid-based 
model’ of haematopoiesis. This model suggests that initial HSC differentiation, leads to 
the formation of common erythroid progenitors and common lymphoid progenitors, 
both of which retain myeloid differential potential. This myeloid potential is retained 
throughout subsequent bifurcations and only lost upon terminal differentiation into 
specialised mature blood cells. However, more recently, evidence has emerged that 
megakaryocytes can be generated from multiple pathways, including a subset of HSC 
(reviewed in Woolthuis and Park, 2016), which would place this lineage committed step 
at the apex of the hierarchical tree.  
The recent emergence of single cell technologies such as fluorescent in situ 
hybridisation, high-throughput single-cell quantitative PCR, single cell mass 
spectrometry and mass cytometry (Ye et al., 2017), have led to further re-analysis of 
these models of haematopoietic differentiation. Discrete progenitor cell populations, as 
determined by cell surface markers, have actually been shown to consist of 
heterogenous populations with different differential fates (reviewed in Cvejic, 2016). 
Single cell transcriptome analysis recently indicated that association of LT-HSC with 
von-Willebrand factor, primed these cells for megakaryocyte-erythroid differentiation, 
lending support to the idea that these progenitor cells branch first from the hierarchical 
differentiation tree (Sanjuan-Pla et al., 2013). More recently, a study by Velten et al., 
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2017, further challenged the idea of a hierarchical model governing haematopoiesis. 
Using a combination of single cell technologies and xenotransplantation as functional 
validation, they proposed that early haematopoiesis consists of, a cellular continuum of 
low-primed undifferentiated (CLOUD) haematopoietic stem progenitor cells (HSPC), 
with simultaneous lineage gene expression for multiple directions. This study suggested 
that early discrete stable progenitors do not exist, with any lineage determination 
occurring further downstream than originally presumed. 
Whilst these studies have generated further debate regarding the order of progression 
and delineation of haematopoietic differentiation, they have also provided additional 
insight into a much debated issue within the field of haematopoiesis, how HSC 
differentiation is determined (1.1.3). 
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Figure 1-1. Human haematopoiesis. Schematic diagram showing classical model of haematopoietic lineage commitment, with phenotypical cell surface markers (red), 
transcription factors determining differentiation (green box) and growth factors involved in myelopoiesis (blue). Haematopoietic stem cell (HSC), cluster of differentiation 
(CD), haematopoietic progenitor cell (HPC), common myeloid progenitor (CMP), common lymphoid progenitor (CLP),.interleukin (IL), granulocyte macrophage (GM) 
colony-stimulating-factor (CSF), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), granulocyte myeloid progenitor (GMP), runt-related transcription 
factor 1 (RUNX1), transcription factor stem cell leukaemia (SCL), ccaat enhancer binding proteins (C/EBP), friend of GATA protein 1 (FOG-1).  
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 Cytokines 
Cytokines are small soluble proteins that can be secreted or remain membrane bound 
and are produced by a wide variety of cells either within the HSC niche or for 
transportation through the bloodstream. There are currently over 60 that are identified as 
being involved in haematopoiesis (reviewed in Tarasova et al., 2011) and include, 
interleukins, colony-stimulating factors, interferons, erythropoietin and TPO. They 
signal via two major classes of receptors, tyrosine kinase receptors such as c-KIT and 
FLT3, or those belonging to the cytokine receptor superfamily, such as type I and type 
II cytokine receptors (reviewed in Endele et al., 2014). Type I and type II cytokine 
receptors share similar structural features and are composed of homodimeric or 
heterodimeric extracellular receptor chains and Box1/Box2 intracellular regions for 
binding of signalling molecules. Type 1 cytokine receptors have a tryptothan-serine-x-
tryptophan-serine motif in the extracellular portion of the chain, which is not present in 
type II cytokine receptors. Binding of a cytokine to a cytokine receptor, induces 
conformational changes leading to the activation of Janus Kinases (JAKs) bound to the 
Box1/Box2 domains, phosphorylation of tyrosine’s of the cytoplasmic portion of the 
chain, which leads to the generation of docking sites for Src homology 2 (SH2) domains 
of signal transducer proteins, which can translocate to the nucleus and activate 
transcription (1.1.4) (reviewed in Robb, 2007). 
The process by which basal and emergency haematopoiesis occurs, is mediated mainly 
by cytokines. They interact with cellular membrane cytokine receptors, initiating cell 
signalling pathways that ultimately lead to lineage characteristic gene expression which 
governs differential fate. Individual cytokines can be lineage specific or regulate 
multiple cells, with some cells such as HSC and megakaryocyte progenitors requiring 
simultaneous action of multiple cytokines. Furthermore, different cytokine receptors 
may activate similar signalling pathways but generate different lineage commitment 
(reviewed in Metcalf, 2008). Other factors such as signalling molecule availability, 
epigenetics and even the nature of signalling dynamics activation (Marshall, 1995), 
have been shown to be significant in lineage determination. 
Whilst individual cytokines cannot on their own be prescriptive for a defined 
differentiation outcome of any given cell, many studies have demonstrated that the 
action of certain combinations of cytokines on given cells, promote particular patterns 
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of cell survival and differentiation (Figure 1-1) (reviewed in Robb, 2007). However, 
whether cytokines determine cell fate, or whether they facilitate cell fate has long been 
disputed. Two models governing the determination of cell fate have been proposed, a 
deterministic model and a stochastic model. The deterministic model, proposes that all 
HSC have an equal capacity to differentiate down any haematopoietic lineage and that 
cell fate is determined by cell surface interactions between the HSC and cytokines, 
which then generate intracellular signals that drive changes in gene expression. The 
stochastic model in contrast argues that different HSC (and early progenitors) are 
primed for different lineage commitment, through the expression of different 
transcription factors, and that the presence or absence of particular cytokines simply 
generate a permissive or suppressive environment for their proliferation and survival, 
dependent on their pre-defined lineage preference (reviewed in Enver et al., 1998). 
Evidence supporting the deterministic model initially came from the observation that 
when GM-colony forming cells were treated with either GM-CSF or macrophage-CSF 
(M-CSF), then granulocytes or macrophages were cultured, and that clones of these 
cells still gave rise to different lineages dependent on the cytokine environment (Metcalf 
and Burgess, 1982). Another study demonstrated that CLP treated with IL-2 was able to 
divert these cells from a lymphoid fate to develop granulocytes and monocytes (Kondo 
et al., 2000). More recently, using single cell time-lapse bioimaging, murine 
granulocyte-macrophage progenitors were tracked in culture conditions containing 
either M-CSF or GM-CSF. The authors reported that, almost exclusively, culturing with 
M-CSF or GM-CSF led to monocytic or neutrophilic development respectively (Rieger 
et al., 2009). Nonetheless, the majority of evidence supports the idea of a stochastic, or 
permissive model, of haematopoiesis. Mice engineered to be deficient in cytokines or 
cytokine receptors were still able to generate cells of associated lineage (reviewed in 
Robb, 2007), whilst overexpression of apoptotic regulator bcl-2 into the IL-3 dependent, 
multipotent haematopoietic cell line, FDCP mix, allowed multi-lineage differentiation 
in the absence of cytokines (Fairbairn et al., 1993). Furthermore, analysis of EML cells, 
another multipotent haematopoietic mouse cell line, showed metastable transcriptome 
states within individual cells, that pre-determined lineage commitment (Chang et al., 
2008). Recently, studies employing single cell analysis have also lent support to the idea 
of a stochastic rather than deterministic model of cell fate determination (reviewed in 
Cvejic, 2016). It appears then that whilst cytokines allow proliferation and survival of 
progenitor cells, lineage decisions are more likely determined by transcription factors. 
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 Transcription factors 
Transcription factors are nuclear proteins that drive the expression of target genes. 
Whilst debate remains as to the precise mechanism by which, and at what stage, 
different haematopoietic lineages differentiate from each other (1.1.2), different 
transcription factors have been shown to drive phenotypically distinct haematopoietic 
cells to different lineage fates. Furthermore, whilst there is not yet definitive evidence 
that cytokines do not drive haematopoietic cell fate, deletion of genes encoding key 
haematopoietic transcription factors in mice typically generate graver phenotypes than 
deletions involving cytokines or cytokine receptors (reviewed in Rosenbauer and Tenen, 
2007). Activation of signal transduction pathways lead to nuclear localisation of 
transcription factors, for example via association with carrier proteins containing 
nuclear localisation sequences or their release from cytosolic anchor proteins (reviewed 
in Cyert, 2001). In haematopoiesis, cytokine activation of JAK generates SH2 domains 
(1.1.3), resulting in the docking of signal transducer and activator of transcription 
(STAT) transcription factors and its subsequent phosphorylation. Dimerisation of 
STAT’s then allows nuclear translocation and inducement of haematopoietic STAT 
target genes, important in differentiation, proliferation and survival (reviewed in 
Dorritie et al., 2014). Other signalling pathways important in haematopoiesis include 
the Wnt signalling pathway (reviewed in Undi et al., 2016), the NOTCH pathway 
(reviewed in Suresh and Irvine, 2015), the transforming growth factor beta (TGF-β) 
pathway (reviewed in Blank and Karlsson, 2015), and the phosphatidylinositol 3-kinase 
(PI3K) pathway (reviewed in Martelli et al., 2010), and dysregulation of these pathways 
are important factors in haematological malignancy (1.2.1 and 1.2.2.2). 
The role of transcription factors in haematopoiesis involves the interplay of a number of 
transcription factors which may be mutually antagonistic or synergistic to each other 
and whose expression levels are controlled by cis-regulatory elements and regulated by 
post-transcriptional modifications. Transcription factors important in myelopoiesis and 
megakaryopoiesis/erythropoiesis include RUNX1, transcription factor stem cell 
leukaemia (SCL), PU.1, GATA-(1&2), ccaat enhancer binding proteins (C/EBP) 
(α,β&ε), growth factor independent 1 (GFi1), interferon regulatory factor 8 (IRF8), 
erythroid Krüeppel-like factor (EKLF) and friend of GATA protein 1 (FOG-1), whilst 
in lymphopoiesis, Ikaros, transcription factor 1 (TCF-1), GATA-3, early B-cell factor 
(EBF), and paired box protein-5 (PAX-5) are all important in early lymphocyte 
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development (Figure 1-1) (reviewed in Wolff and Humeniuk, 2013). For example, 
conditional deletion of RUNX1 in mice using a Cre-loxP recombination system resulted 
in defective T-cell, B-cell and megakaryocyte maturation (Ichikawa et al., 2004), whilst 
conditional deletion of SCL also resulted in the loss of megakaryocyte and erythroid 
differentiation (Mikkola et al., 2003). The transcription factor PU.1, is downstream 
from RUNX1 and is considered the master regulator of myelopoiesis (reviewed in 
Imperato et al., 2015). Conditional deletion of PU.1 in mice resulted in loss of HSC 
self-renewal, a block in generation of CMP and CLP, and disruption of granulocyte 
myeloid progenitor (GMP) differentiation (Iwasaki et al., 2005). Levels of PU.1 
expression are also important in determining cell fate. Downregulation of PU.1 is 
required for megakaryopoiesis/erythropoiesis and T-cell development, high levels of 
expression in GMP support macrophage development, whilst low (but not zero) 
expression levels are required for neutrophil production (reviewed in Rosenbauer and 
Tenen, 2007). Macrophage/neutrophil determination is note solely regulated by PU.1 
however, increased levels of C/EBPα upregulates expression of GFi1, which inhibits 
PU.1 expression and drives neutrophilic differentiation (Laslo et al., 2006), whilst 
synergistic expression of IRF8 and PU.1 is required for macrophage development 
(Tamura et al., 2000). Expression levels of PU.1 and GATA-1 offer a further example 
of antagonistic transcription factor regulation in haematopoiesis. GATA-1 is considered 
to be the master regulator in erythropoiesis and activation of this transcription factor in 
murine GMP resulted in redirection of these cells to an erythroid fate (Heyworth et al., 
2002). Conversely, activation of PU.1 in avian megakaryocyte-erythroid progenitors 
(MEP) resulted in commitment to the myeloid lineage (Nerlov and Graf, 1998). Given 
the importance and array of transcription factors in haematopoiesis, it is perhaps then 
not surprising that their dysregulation or mutation is a major factor in AML (1.2.1). 
1.2 Leukaemogenesis 
Leukaemia is characterised by the accumulation of immature white blood cells (blasts) 
in the BM. There are four main types of leukaemia, chronic lymphocytic leukaemia 
(CLL), chronic myeloid leukaemia (CML), acute lymphocytic leukaemia (ALL) and 
AML. The acute form of the diseases is characterised by a rapid increase in immature 
blasts, whilst the chronic forms are typified by a slower build up in abnormal 
haematopoietic cells. In the UK, leukaemia was the 12th most common cancer between 
1987 and 2006 and accounted for 2.5% of all cancers. Mortality rate is 4,300 people per 
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year with 7,000 new cases diagnosed annually, with children under the age of 10 
constituting 4.5% of these cases (Bhayat et al., 2009). In the U.S.A., leukaemia 
accounted for 4% of new cancers reported in 2016 and 4% of cancer mortalities. Five-
year survival rate has improved from 34% in the mid 1970’s to 62% between 2005 and 
2011. In children (0-14 years) leukaemia accounts for 30% of all childhood cancers, 
with ALL being the most common. The five-year survival rate in children with ALL is 
currently 91%, whereas in children with AML this is reduced to 67%. In contrast, AML 
was the most commonly diagnosed form of leukaemia in adults in the U.S.A in 2016, 
accounting for 37% of new cases and 59% of the leukaemic mortality rate, whilst CLL 
accounted for 35% of new cases and 26% of mortalities, CML 15% of new cases and 
6% of mortalities and ALL 12% of new cases and 8% of mortalities (Siegel et al., 
2016). 
 Acute Myeloid Leukaemia  
AML is a heterogenous disease, resulting in a block in haematopoietic myeloid 
differentiation as a result of one or more genetic insults including chromosomal 
abnormalities, mutations of genes involved in signalling pathways or transcription and 
genetic effects such as methylation and histone modification (Table 1).  
Originally, AML was classified according to the French-American-British (FAB) 
disease classification system (Bennett et al., 1976), which has now been superseded by 
the World Health Organisation (WHO) classification system (4th edition) which 
incorporates genetic information alongside the traditional morphological, cytochemical, 
immunophenotypic and clinical information (Swerdlow et al., 2016). The WHO system 
uses consensus classification to define clinically distinct diseases entities and 
incorporates provisional entries, such as AML with mutated NPM1, for data that is yet 
to be fully established. For a diagnosis of AML PB or BM must contain greater than 
20% myeloid blasts with the exception of AML with t(8;21)(q22;q22), AML with 
inversion (16)(p13.lq22) or t(16;16)(p13.1;q22) and acute promyelocytic leukaemia 
(APL) with t(15;17)(q22;q12) where the genetic abnormality is sufficient on its own. 
Percentage blast counts are derived from 200-cell leukocyte differential counts of PB 
smears and 500-cell differential counts of all nucleated BM cell smears. Multi-
parameter flow cytometry is used to determine blast lineage, cytogenic analysis of BM 
cells is used to establish baseline karyotypes and real-time polymerase chain reaction or 
fluorescence in situ hybridisation allows for detection of specific gene mutation, such as 
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RAS, which are increasingly useful in determining prognosis outcome (Vardiman et al., 
2009). Recently, the WHO classification (4th edition) was updated to incorporate the 
prognostic significance of a number of these genetic mutations, such as FLT-3, C/EBPα 
and NPM1 (Arber et al., 2016). These factors led to a recent refinement of European 
Leukemia Net risk stratification for AML, which is now based on three risk groups 
favourable, intermediate and adverse (Bullinger et al., 2017). 
AML patients typically present with anaemia, fatigue, shortness of breath, difficulties 
clearing infections, dizziness, bruising and excessive bleeding. Predisposing factors 
include genetics, smoking, alcohol use, obesity and exposure to radiation or alkylating 
agents. The median age of diagnosis is 75 in the UK, 67 in the U.S.A. and 72 in 
Sweden. In the UK remission rates in patients under 60 have improved to nearly 80%, 
whilst overall survival is between 40-45%. In the over 60’s, between 1980 and 2000 
remission rates improved to 65%, but overall survival after 5 years remained at around 
12% (Newland, 2002). In Sweden, the adult five year survival rate for the under 70’s 
improved from less than 10% in the 1970’s to between 28-64% between 2006-2011, 
however, in the over 70’s five year survival has remained below 10% (Bower et al., 
2016). In patients fit enough to tolerate chemotherapy, the standard treatment for AML 
since 1973 has been a seven-day continuous intravenous infusion of cytarabine (Ara-C) 
(100-200 mg/m2) and 3 daily doses of daunorubicin (45-90 mg/m2), sometimes 
followed by allogeneic or autologous stem cell transplantation. Recent attempts to 
improve treatment outcomes have involved higher doses of Ara-C (>1000 mg/m2) 
alongside nucleoside analogues such as fludarabine, cladribine and clofarabine, which 
in the case of fludarabine showed a 20% improvement in 8 year overall survival (OS) 
compared to standard regimen chemotherapy (reviewed in Tamamyan et al., 2017). 
Recently a phase III clinical trial involving CPX 351, a drug which packages Ara-C and 
daunorubicin into liposomes reported improved OS (9.6 vs 6 months) in high risk 
secondary AML patients (Medeiros et al., 2016). 
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Table 1. Common abnormalities in AML. Class and frequency of gene mutations involved in AML 
(reviewed in Naoe and Kiyoi, 2013). * denotes most common mutation; N-RAS position 12 glycine to 
aspartic acid (G12D) 9-14%; K-RAS position 12 glycine to valine (G12C) 5-17%; H-RAS position 12 
glycine to valine (G12V) not detected in AML. 
 
 
Group Gene Mutational Frequency 
 
 
Class 1 
(Signal 
Transduction) 
 
 
FLT-3 25-45% 
c-KIT 6-10% 
PTPNII 2-5% 
RAS* 15-30% 
CBL 2-3% 
JAK 2-3% 
 
 
 
Class 2 
(Transcriptional) 
 
 
 
RUNX1 6-11% 
C/EBPα 4-9% 
NPM1 25-35% 
GATA2 3-5% 
RUNX1-ETO 10-15% 
CBFβ 3-8% 
PML-RARA 5-10% 
MLL 5-9% 
 
 
 
Class 3 
(Epigenetic) 
 
 
 
 
TET2 8-27% 
IDH1 6-9% 
IDH2 9-12% 
DNMT3A 18-23% 
TP53 7-12% 
WT1 10-13% 
ASXL1 3-11% 
BCOR 5% 
BCOR1 6% 
miRNA miR15, miR16 miR17-92, 
miR125, miR155, miR196 
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Historically it has been difficult to determine the initiating events in AML, but more 
recently clonal evolution studies and information from the cancer genome project have 
suggested that mutations of genes involved in epigenetic regulation occur in self-
renewing HSC and precede leukaemia initiating events such as chromosomal 
translocations and the driver mutations involved in cell signalling molecules (Jan et al., 
2012, Welch et al., 2012, Bullinger et al., 2017). Population studies have shown that 
pre-leukaemic mutations, for example of DNA (cytosine-5)-methyltransferase 3A 
(DNMT3A) (an enzyme that catalyses the transfer of methyl groups to DNA), can be 
detected in HSC of AML patients with CR and have a multilineage repopulation 
advantage over HSC not carrying the mutation (Shlush et al., 2014). The evidence that 
class III mutations occurring in HSC prior to initiating events, fits with the concept of 
leukaemia stem cells (LSC), first proposed in 1994, when severe combined immune 
deficient (SCID) mice were transplanted with PB from AML patients and it was found 
that only CD34+ CD38- haematopoietic cells (a phenotype indicative of HSC or HPC 
status) engrafted and that the resulting leukaemia had a immunophenotype identical to 
the donor cells (Lapidot et al., 1994). Subsequently it has been shown that analogous 
with HSC, LSC reside in the BM and have the capacity for both self-renewal and multi-
lineage differentiation. Additionally they can exhibit characteristics that allow evasion 
of the cytotoxic effects of chemotherapy and immuno-surveillance and their frequency 
in patients at diagnosis has been correlated with increased residual disease and the 
likelihood of relapse (reviewed in Lane and Gilliland, 2010)).  
Additionally, signalling pathways such as Wnt/β-catenin, Hedgehog, JAK/STAT and 
PI3K/AKT, which play important roles in maintaining LSC self-renewal and 
differentiation have also been targeted. Activation of Wnt/β-catenin results in inhibition 
of glycogen synthase kinase 3β (GSK-3β) (involved in proteasomal degradation β-
catenin), which promotes translocation of β-catenin to the nucleus where it activates a 
number of genes associated with proliferation, including c-MYC, cyclin D1 and c-JUN. 
Currently an inhibitor of β-catenin, CWP232291, is undergoing phase I clinical trials in 
relapsed or refractory (R/R) AML patients (Cortes et al., 2015). GSK-3 is also involved 
in the regulation of the PI3K/AKT pathway, the RAS/RAF/MEK/ERK pathway, the 
Hedgehog pathway and the NOTCH signalling pathway and as such, has generated 
particular interest as a target in leukaemia. To date over fifty inhibitors of GSK-3 have 
been developed, however while some in vitro studies have shown inhibition of growth 
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in leukaemic cell lines, other studies in breast cancer and medulloblastoma have 
reported GSK-3 overexpression induces apoptosis, and their potential benefit remains 
unclear (reviewed in McCubrey et al., 2014). Inhibitors of the PI3K/AKT (which 
activates mammalian target of rapamycin (mTOR) important in cellular proliferation) 
such as CAL-101, perifosine and MK-2206 have also been developed and are currently 
in phase I/II clinical trials (reviewed in Wang et al., 2017). 
Recent advances in microarray and next generation sequencing have led to improved 
understanding of AML heterogeneity and the possibility of tailored treatments based on 
genome sequencing. In conjunction with this, several clinical trials are currently taking 
place examining the efficacy of drugs specifically targeted at specific AML phenotypes. 
Epigenetic modifiers such as DNMT3A which catalyses the methylation of DNA are 
commonly mutated in AML (Table 1). Trials involving guadecitabine, a second 
generation hypermethylating agent which inhibits DNMT3A activity showed promise in 
R/R AML patients and is currently undergoing phase III clinical trials. Isocitrate 
dehydrogenase (IDH) an enzyme of the citric acid cycle that catalyses the D-isocitrate 
to α-ketoglutarate reaction is also frequently mutated in AML, generating high levels of 
2-hydroxyglutarate which competitively inhibit α-ketoglutarate enzymes. Treatment of 
R/R AML patients with the IDH inhibitors AG-120 and FT-2102 in phase I clinical 
trials showed CR of 18% and 9.5% respectively, whilst treatment with the IDH2 
inhibitor Enasidenib also resulted in 18% CR of R/R AML patients and is currently 
recruiting for phase III clinical trials in R/R AML patients over 60. Other inhibitors of 
epigenetic modifiers such as bromodomain and extraterminal proteins and lysine 
specific demethylase-1 inhibitors are also currently in phase I clinical trials. In addition 
to inhibitors of epigenetic modifiers, signal transduction receptor such as JAK/STAT 
and FLT-3 are also therapeutic targets for inhibition and a number of clinical trials are 
underway. FLT-3 is the most frequently mutated gene in AML (Table 1) and several 
inhibitors have been developed such as Midostaurin, Sorafenib, Quizartinib, Gliteritinib 
and Crenolanib. In particular, Crenolanib has shown promise, with one study reporting 
an increased OS of 42 weeks in R/R AML patients which were FLT-3 inhibitor naïve, 
and interim analysis of a phase II clinical trial in newly diagnosed FLT-3 AML patients 
reporting CR of 88% at 6 months (reviewed in Saygin and Carraway, 2017). Finally, 
microRNA’s (miRNA) which are 18-22 nucleotides in length, non-coding and regulate 
gene expression via the promotion of mRNA degradation or inhibition of translation, 
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are also known to be important both in haematopoiesis and leukaemogenesis. In 
particular, aberrant expression of miR125, which regulates haematopoietic 
differentiation, has been implicated in a number of AML subtypes (reviewed in 
Alemdehy and Erkeland, 2012) and their targeting using chemically modified antisense 
oligonucleotides offer further therapeutic targets. 
 RAS 
The RAS superfamily are small guanosine triphosphatases (GTPase) proteins that are 
divided into five major classes, RAS, RHO, RAB, RAN and ARF, based on functional 
and structural data. The RHO family regulate signalling networks involved in actin 
organisation and cell cycle progression, the RAB and ARF families are involved in 
intracellular trafficking of proteins between different organelles, the RAN family 
transport RNA and proteins between the cytoplasm and the nucleus, whilst the RAS 
family are involved in signal transduction controlling gene expression regulating 
cellular proliferation, differentiation and survival (reviewed in Wennerberg et al., 2005). 
The RAS subfamily of proteins consists of 36 genes encoding 39 RAS proteins. Of 
particular importance from an oncology perspective are four isoforms, H-RAS, K-
RAS4A, K-RAS4B and N-RAS, which are together mutated in approximately 16% of 
all cancers. Within the context of leukaemia, RAS mutations occur in approximately 
15% of haematological malignancies, with K-RAS accounting for 5%, N-RAS 10% and 
H-RAS less than 1% (Prior et al., 2012). 
RAS proteins are functionally analogous to G-proteins and act as molecular switches 
inside cells. X-ray crystallographic structures have been determined and consist of a 
hydrophobic core of six stranded β-sheets and five α-helices connected by ten loops (Pai 
et al., 1989). They function as molecular switches that activate a variety of signal 
transduction pathways in apoptosis, survival, differentiation, and proliferation.  
1.2.2.1 The GTPase cycle and RAS 
RAS proteins are synthesised in the cytosol and require post-translational modifications 
to translocate to the plasma membrane, which is crucial for their function in cell 
signalling. Initially, the hypervariable C-terminal region, containing a CAAX motif 
(where ‘C’ is cysteine, ‘A’ are aliphatic amino acids and X is any amino acid) is 
farnesylated at the cysteine residue, followed by cleavage of the AAX sequence, prior to 
carboxymethylation of the cysteine residue by the enzyme isoprenylcysteine 
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carboxymethyltransferase (Casey et al., 1989). In the case of K-RAS4B, this is 
sufficient for membrane anchorage, however K-RAS4A, N-RAS and H-RAS require 
the addition of two further palmitic acids to cysteine residues that are upstream of the 
initial farnesylation site (Hancock et al., 1990). 
RAS proteins bind to guanosine nucleotides, which determines their functional 
activation status, where RAS, bound to guanosine triphosphate (GTP) is active, and 
when bound to guanosine diphosphate (GDP) is inactive (Figure 1-2). They possess 
intrinsic GTPase activity, which involves hydrolysis of the γ-phosphate group of GTP, 
leaving RAS bound to GDP (RAS-GDP). However, because this intrinsic activity is 
relatively slow (t1/2 = 16 mins, koff = 6 x 10-4 s-1 (Hunter et al., 2015)), physiological 
GTP hydrolysis is catalysed by GTPase activating proteins (GAP), such as p120-RAS-
GAP, neurofibrimin-1 and synaptic RAS GTPase-activating protein-1 (reviewed in Bos 
et al., 2007). In contrast, inactive RAS-GDP is activated by guanine nucleotide 
exchange factors (GEF), which contain domains specific to the major classes of the 
RAS superfamily. GEFs specific to the RAS subfamily all contain the cell division 
cycle-25 (CDC25) domain of which, son of sevenless (SOS) and the RAS guanyl-
releasing proteins (RAS-GRP) are best characterised from a haematological perspective. 
SOS (and other CDC25 domain containing GEFs) bind to RAS, resulting in 
conformational changes that release GDP and its replacement with GTP (Boriack-
Sjodin et al., 1998). Whilst GEFs do not promote preferential binding of GTP to RAS 
(RAS-GTP), physiological levels of intracellular GTP are an order of magnitude higher 
than GDP, which result in increased levels of RAS-GTP and RAS activation (Figure 
1-2).  
The mechanisms by which these reactions occur is the result of different preferential 
binding to the loops which connect the α-helices and β-sheets of the RAS protein 
(1.2.2). In particular, loops 1, 2 and 4 provide the binding pockets for GDP and GTP, 
whilst loops 3 (amino acids 30-38) and 5 (amino acids 59-76), termed switch 1 and 2 
respectively, generate conformational changes in loops 1,2 and 4, resulting in the 
preferential binding of GDP or GTP. When GTP is bound to RAS, the amino acids T35 
and G60 of switch I and II respectively, form hydrogen bonds with the γ-phosphate 
group of GTP, resulting in the active form of RAS. To hydrolyse GTP, GAP interacts 
with switch II by stabilising Q61, allowing interaction with a water molecule. 
Additionally, a conserved arginine finger protrudes into the phosphate binding pocket, 
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which neutralises the negative charge on the γ-phosphate. This allows extraction of a 
hydrogen ion from the water molecule, generating a hydroxyl group which then cleaves 
the γ-phosphate, resulting in a conformational change in switches I and II and 
inactivating RAS. Different GEFs are structurally unrelated, but all interact with the 
RAS-GDP structure by sterically occluding a Mg2+ ion in switch I, which co-ordinates 
binding of GDP/GTP in the phosphate binding site. For example SOS contains an α-
helix, which interacts with switch II, resulting in a conformational change that opens the 
phosphate binding site, and releases GDP (reviewed in Simanshu et al., 2017). GEFs 
themselves are subsequently replaced by GTP, via a series of intermediates, specific to 
individual GEFs that still are not fully elucidated (reviewed in Cherfils and Zeghouf, 
2013). 
1.2.2.2 RAS Signalling 
The RAS subfamily of signalling molecules are involved in cell survival, apoptosis, 
motility, differentiation and proliferation. Haematologically, activation of RAS occurs 
as a result of haematopoietic cytokines binding to their receptors, subsequent activation 
of JAKs and the generation of docking sites for SH2 domains of signal transducer 
proteins, such as growth factor receptor-bound protein 2 (GRB2) (1.1.3). The c-terminal 
of GRB2 then interacts with a proline rich domain of SOS, whilst the pleckstrin-
homology domain of SOS provides anchorage to the plasma membrane via its 
interactions with phospholipids. This opens the RAS exchanger motif (REM) site, 
which is an allosteric binding site for RAS (Figure 1-2). Interestingly, binding of RAS-
GDP to REM results in much lower levels of SOS activity than binding to RAS-GTP. 
The CDC25 domain of SOS can then interact with membrane bound RAS, resulting in 
the displacement of GDP for GTP and activating RAS signalling pathways (reviewed in 
Buday and Downward, 2008)). The GRB2-SOS complex is only active when GRB2 is 
in the monomer form. Phosphorylation of tyrosine residues by proteins such as c-src 
(itself activated by tyrosine kinase receptors) results in the dissociation of GRB2 from 
its inactive dimeric form (Ahmed et al., 2015). Termination of RAS signalling results in 
GRB2 dimerisation, dissociation of the GRB2-SOS-RAS complex and the subsequent 
hydrolysis of RAS-GTP to RAS-GDP by GAP. 
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Figure 1-2. RAS signalling. Growth factor (GF) interacts with tyrosine kinase receptor (TKR) (1), 
resulting in activation of Janus Kinases (JAK), phosphorylation (P) of tyrosine’s of the cytoplasmic 
portion of the TKR chain, and the generation of src homology 2 (SH2) docking site. Growth factor 
receptor-bound protein 2 (GRB2), is then recruited to the membrane (2) and reacts with the proline rich 
(PR) domain of Son of Sevenless (SOS) (3). The pleckstrin-homology domain (PH) then binds to the 
membrane (4) to complete docking of the SOS complex and allow binding of allosteric RAS to the RAS 
exchange motif (REM). The cell division cycle 25 (CDC25) domain of SOS then binds to RAS, resulting 
in the displacement of guanosine diphosphate (GDP) (5) and its replacement with guanosine triphosphate 
(GTP) (6). This results in activation of RAS effector molecules such as phosphatidylinositol 3-kinase 
(PI3K), rapidly accelerated fibrosarcoma (RAF), RAS related protein guanine nucleotide exchange factor 
(RalGEF), phospholipase C epsilon (PLCε), T-cell lymphoma invasion and metastasis 1 (TIAM1) and 
RAS association domain family (RASSF) and their respective signalling cascade pathways. Dbl 
homology domain (DH), Histone like domain (HD) 
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Activation of RAS results in the interaction of RAS with downstream effectors 
including RAS related protein GEF (RalGEF) important in endocytosis, T-cell 
lymphoma invasion and metastasis 1 (TIAM1) important in cell cycle progression, RAS 
association domain family (RASSF) important in apoptosis and cell cycle arrest, rapidly 
accelerated fibrosarcoma (RAF), PI3K, and phospholipase C epsilon (PLCε) (Figure 
1-2). In haematopoietic cells, the RAS-RAF-MEK-ERK pathway targets genes involved 
in cellular proliferation and survival. Activation of RAS recruits RAFs, such as B-RAF 
(a serine/threonine kinase) to the cell membrane, where dimerization, changes in 
phosphorylation states of different domains and dissociation from its inhibitory protein 
occur. The RAS-GTP/B-RAF complex then phosphorylates meiosis specific 
serine/threonine-protein kinase (MEK) 1 and 2. MEK1/2 in turn phosphorylate 
extracellular signal-regulated proteins (ERK) which then activates a range of 
transcription factors such as c-JUN, c-FOS and c-MYC, which translocate to the 
nucleus where they target gene expression involved in cell growth and cell cycle 
progression (reviewed in McCubrey et al., 2007). In particular, c-jun and c-FOS form a 
heterodimer which bind to a cyclin-D promoter, initiating transcription of this protein 
(Schutte et al., 1989). Cyclin-D binds to cyclin dependent kinase (CDK) 4 and 6, which 
allows cellular progression through the G1 phase of cell cycling, thus promoting 
proliferation (reviewed in Shaulian and Karin, 2002). The PI3K/AKT/mTOR pathway 
constitutes another important target of RAS signalling. RAS-GTP binds to P110α a 
catalytic subunit of PI3K, resulting in the translocation of PI3K to the plasma 
membrane. In turn PI3K phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to 
produce phosphatidylinositol-3,4,5-triphosphate (PIP3), which results in translocation 
of protein kinase B (AKT) to the plasma membrane. Activation of AKT results in 
translocation to the cytosol and nucleus where it promotes cell survival through the 
inactivation of pro-apoptotic transcription factors such as forkhead and B-cell 
lymphoma 2 associated agonist of cell death (BAD) (reviewed in Vivanco and Sawyers, 
2002). RAS activated PLCε signalling also constitutes an important haematopoietic 
pathway. PLCε binds directly to RAS-GTP, resulting in hydrolysis of PIP2, generating 
diacylglycerol and inositol-1,4,5-triphosphate which release Ca2+ and activates protein 
kinase C (PKC) (Song et al., 2001). In turn PKC has been shown to have important 
functions in haematopoietic development by promoting monocytic lineage commitment 
of progenitor cells (Pearn et al., 2007). Given the central role that RAS signalling plays 
in cellular proliferation, survival and growth, it is not surprising that dysregulation of its 
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pathways as a result of genetic mutations of its DNA, are commonly implicated in many 
cancers including AML. 
1.2.2.3 Mutations of RAS and their effect in AML 
As noted above, the three RAS isoforms implicated in haematological malignancy are 
N-RAS, H-RAS and K-RAS (1.2.2), which occur as the result of point mutations to 
amino acids at position (p) 12,13 or 61, resulting in constitutively active RAS. 
Mutations to p12 of N-RAS account for 51% of haematological malignancies 
containing an N-RAS mutation (56% of which are, N-RASG12D (glycine to aspartic acid) 
mutations) with mutations to p13 and p61 accounting for the other 32% and 17% 
respectively. In haematological malignancies involving K-RAS 70% of mutations occur 
at p12 (51% K-RASG12D) with 24% at p13 and 6% at p61 (Prior et al., 2012). 
In RAS, p12 and p13 occur in loop 1 of the GDP/GTP active binding site whilst p61 
occurs in loop 5 (switch II) (1.2.2.1). Hydrolysis of RAS-GTP to RAS-GDP occurs as a 
result of interactions with GAPs. An important structural feature of GAPs, are an 
arginine finger which inserts into the active GTP/GDP binding site and is stabilised as a 
result of van-der-Waal forces with glycine p12. Substitution of the glycine with aspartic 
acid sterically hinders these van-der-Waal forces, as aspartic acid contains a side chain, 
leaving no room for insertion of the arginine finger (Franken et al., 1993), thus 
preventing hydrolysis of GTP. Glutamine at p61 in switch II enhances GTP hydrolysis 
via an amide group on its side chain. The amide group forms a hydrogen bond with the 
GAP arginine finger, positioning it so that a carbonyl group can form a hydrogen bond 
with the nucleophilic water involved in the hydrolysis reaction. Substitution of 
glutamine with other amino acids prevents formation of the hydrogen bond between the 
carbonyl group and the nucleophilic water, inhibiting GTP hydrolysis (Gremer et al., 
2008). 
As described above (1.2.1), initiation and progression of AML is characterised by a 
multistep process, (likely preceded by mutations to genes involved in epigenetic 
regulation of haematopoiesis (Bullinger et al., 2017), which involves mutations to genes 
involved in haematopoietic differentiation, along with mutations to genes involved in 
proliferation and survival (Table 1). Whilst expression of mutational RAS in HPC has 
been shown to impact on haematopoietic differentiation (Darley et al., 2002, Pearn et 
al., 2007), RAS signalling in the broader context is predominantly associated with 
     Chapter 1 
 
26 
 
cellular proliferation and survival (1.2.2.2) and requires co-operating mutations for 
transformation of cells. Early evidence for this was observed from the failure of H-
RASG12V to transform normal hamster fibroblast cells (Newbold and Overell, 1983). 
More recently work in mice has shown that whilst transgenic mice expressing N-
RASD12 under the control of myeloid related protein 8 (MRP8) promoter do not develop 
AML like disease, crossing these mice with mice expressing BCL-2 (a regulatory 
protein of apoptosis frequently overexpressed in AML (Wojcik et al., 2005), results in 
progression to human like AML disease (Omidvar et al., 2007). Indeed, overexpression 
of RAS has been shown to cause cell senescence and quiescence through activation of 
the tumour suppressor proteins TP53 and p16INK4A (Serrano et al., 1997). TP53 induces 
cell cycle arrest through upregulation of p21Cip1 which inhibits CDK, and TP53 is a 
known mutation in AML (Table 1). Overexpression of mutant RAS has also been 
shown to lead to increased levels of extracellular ROS (Hole et al., 2010) (1.3.3.4), 
which is linked with increased proliferation. 
RAS mutations together with co-operating mutations can then lead to the activation of 
RAS signalling pathways, that collectively generate increased cellular proliferation and 
survival. Unsurprisingly, several efforts have been made to target this aberrant 
signalling. Inhibition of RAS mRNA translation using RNA interference technology, 
has shown promise in inhibiting growth of pancreatic, lung, colorectal and ovarian 
cancers in cell lines and animal models, but difficulties in delivering the drug to tumour 
sites and neutralisation by the immune system mean it has not yet progressed to human 
trials. Disruption of post-translational modifications of RAS using farnesyltransferase 
inhibitors (FTI), to prevent the translocation of RAS to the cell membrane have 
undergone phase III clinical trials, but no improvement in OS has so far been observed. 
Targeting of RAS downstream effector pathways such as PI3K/AKT/mTOR and RAF-
MEK-ERK have also been attempted. Inhibition of PI3K with BKM120, AKT with 
MK2206 and mTOR with Temsirolimus and Everolimus, are all in human clinical trials. 
Sorafenib, which targets both C-RAF and more crucially B-RAF has been approved for 
use in advanced renal cell carcinomas, whilst Vemurafenib which preferentially targets 
mutant B-RAF, has been approved for use in patients with advanced melanoma. 
Inhibition of MEK using Trametinib is also being investigated in several phase III 
clinical trials in melanoma patients. However whilst all these drugs have shown some 
efficacy in improving progression free survival rates, up to now drug resistance has 
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been a major issue and overall survival rates have not improved (reviewed in Takashima 
and Faller, 2013). 
1.3 Reactive Oxygen Species 
Reactive oxygen species (ROS) is the collective term for several oxygen containing free 
radicals and other reactive molecules, such as hydrogen peroxide (H2O2) (1.3.1). 
Physiologically there are a number of sources of cellular ROS; oxidative 
phosphorylation in the mitochondria which generates ROS as a result of electron 
transport chain activity (ETC) (1.3.2.1), the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase family of enzymes (NOX) (1.3.2.2), the cytochrome P450 
enzymes, peroxisomes and the metabolic enzyme xanthine oxidase (XO) (1.4.2.1). 
Functionally, ROS is important in innate immunity (1.3.3.1), protein folding in the 
endoplasmic reticulum and also as a cell signalling molecule involved in cellular 
proliferation, survival, differentiation and gene expression (1.3.3.2). 
Haematopoietically, ROS has been implicated in both HSC quiescence (via signalling 
pathways downstream of RAS), and haematopoietic differentiation (1.3.3.3). ROS is 
known to be important in a number of diseases, such as atherosclerosis, rheumatoid 
arthritis as well as a number of cancers, including leukaemia (1.3.3.4). Consequently, 
ROS is of considerable interest as a therapeutic target, with both pro-oxidant and anti-
oxidant cellular modulation being explored (reviewed in Hole et al., 2011). 
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 ROS chemistry 
Physiologically, ROS are initially generated via the univalent reduction of molecular 
oxygen which generates superoxide (O2•-) (Figure 1-3). Superoxide (t1/2 = 1μs) 
dismutates to H2O2 (t1/2 = 1ms) (Bienert et al., 2006), either spontaneously or via the 
catalytic action of the enzyme superoxide dismutase (SOD). Alternatively, it may react 
with other ROS molecules, such as hypochlorous acid (HOCl) (itself formed via the 
catalytic reaction of peroxidase on H2O2) to form hydroxyl radicals (OH•) (t1/2 = 1ns) 
(Sies, 1993), or nitric oxide to generate peroxynitrite, a reactive nitrogen species. H2O2 
in the presence of Fe2+ ions, is catalysed to form a OH• radical and hydroxide ion OH-, 
whilst the resulting Fe3+ ion is reduced by O2•- resulting in the generation of O2 and 
Fe2+, in a set of reactions collectively termed Fenton chemistry. Copper ions (Cu2+ and 
Cu+), can also catalyse these reactions, via a similar redox process, although given that 
the upper limit of ‘free’ copper is reported to be less than an atom per cell, it’s 
physiological significance is likely limited (Rae et al., 1999). 
Cellular levels of ‘free’ iron are also severely restricted. It is transported around the cell 
by transferrin and stored by ferritin, which bind the iron and prevent it reacting with 
H2O2, thus leading to high levels of potentially damaging OH• (reviewed in Ponka, 
1999)). However, low levels of ‘free’ iron are found under normal physiological 
conditions and for haematopoietic cells are estimated to be in the region of 0.2-1.5μM 
(Epsztejn et al., 1997, Ma et al., 2007). Patients with β-thalassemia have frequent blood 
transfusions leading to iron overload, which is then free to generate ROS, which may 
help explain the high levels of oxidative stress encountered in these patients (Sengsuk et 
al., 2014). Whilst ROS is necessary for a number of biological functions (1.3.3), high 
levels are often associated with oxidative stress, which can result in DNA damage, 
oxidation of proteins, enzyme inhibition and lipid peroxidation, and for this reason 
cellular ROS levels are tightly regulated (reviewed in Valko et al., 2007). 
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Figure 1-3. Formation of reactive oxygen species (ROS). Diatomic oxygen (O2) is univalently reduced by peroxisomes (PO), xanthine oxidase (XO), the electron transport 
chain (ETC), or NADPH oxidase (NOX) to generate superoxide (O2•-). PO may also reduce O2 directly to form H2O2. O2•- may then dismutate to H2O2 either spontaneously or 
through the enzymatic action of superoxide dismutase (SOD). Hydroxyl radicals (OH•) may then be formed from H2O2 via the formation of hypochlorous radical (HOCl) in 
the PO, or via Fenton chemistry. Reactive nitrogen species (RNS) may also be formed through the reaction of nitric oxide radical (NO•) with O2•-.
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 Sources of ROS production 
1.3.2.1 Mitochondria as a source of ROS 
One source of cellular ROS is via the mitochondrial ETC which consist of four 
complexes; complex I (nicotinamide adenine dinucleotide (NAD)H:ubiquinone 
oxidoreducatase or NADH dehydrogenase), complex II (succinate dehydrogenase 
(SDH) or succinate co-enzyme Q10 (CoQ) reductase), complex III (cytochrome bc1 
complex) and complex IV (cytochrome c oxidase). These complexes are located on the 
inner membrane of the mitochondria, with complexes I, II and IV establishing a proton 
gradient across this membrane, which, when protons flow back across the membrane, 
ATP synthase (complex V) uses to generate ATP from adenosine diphosphate (ADP), in 
a process collectively called oxidative phosphorylation (Gu et al., 2016). The 
underlying mechanism behind the establishment of this gradient are a series of redox 
reactions involving the transfer of electrons, which drive protons into the 
intermembrane space generating an electrochemical gradient. Briefly, NADH, generated 
as a result of glycolysis (1.4.3) and the citric acid cycle (1.4.4), donates two electrons to 
flavin mononucleotide (FMN), which forms part of complex I. These electrons are then 
transferred via the iron-sulphur (Fe-S) clusters of complex I to CoQ in complex II, 
reducing it to CoQH2 and transferring four protons across the inner membrane in the 
process. SDH (an enzyme that catalyses the reaction of succinate to fumarate in the 
citric acid cycle and reduces flavin adenine dinucleotide (FAD) to FADH2 forms part of 
complex II. FADH2 also donates its electrons to CoQ via Fe-S clusters, but does not 
contribute to the proton gradient as the free energy released is too small. The electrons 
are then transferred sequentially to cytochrome b, then c1 of complex III and two further 
protons are pumped across the membrane. The final step, transfers four further protons 
across the membrane, as the reduced form of cytochrome c transfers the electrons to 
molecular oxygen, generating two water molecules. ATP synthase, a transmembrane 
protein of the inner mitochondrial membrane, then generates ATP from ADP as the 
electrochemical gradient, generated in the mitochondrial inter membrane space by the 
proton pump, drives protons back into the mitochondrial matrix. 
Generation of ROS by the mitochondria is primarily a function of ‘electron leakage’ 
from the ETC, however, mitochondrial ROS may also be generated as a result of 
numerous enzymes including monoamine oxidase, cytochrome b5 reductase, glycerol-
3-phosphate dehydrogenase, aconitase, pyruvate dehydrogenase and α-ketoglutarate 
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dehydrogenase (reviewed in Angelova and Abramov, 2016). Mitochondrial ROS 
production resulting from the ETC generates O2•-, and is thought to occur as result of 
one of three mechanisms. The first mechanism is a consequence of a high NADH/NAD+ 
ratio, and results from O2 interacting with fully reduced FMN. Mitochondrial ROS 
generated by this mechanism has been observed due to mitochondrial mutation, 
physiological damage such as ischaemia or aging, and only small amounts of ROS are 
thought to be generated via these mechanisms in normally respiring cells (reviewed in 
Murphy, 2009). The second mechanism occurs when there is a high level of CoQH2 in 
complex II, which in the presence of a high proton motive force generated by the proton 
pump, force electrons back into complex I in a process known as reverse electron 
transport (RET). Whilst RET generated ROS has also been implicated in diseases such 
as ischaemia, it is now also thought to be involved as a cell signalling molecule in 
metabolic adaptation, myeloid differentiation and response to bacterial infection 
(reviewed in Scialo et al., 2017). The third mechanism of ROS generation by the ETC 
occurs at complex III and has also been implicated in ROS signalling. The formation of 
O2•- occurs at the ubiquinol oxidation centre (Qo) site of the cytochrome bc1 complex, in 
which fully oxidised CoQ supports formation of O2•-, through the transfer of electrons 
from reduced haem b1 to molecular oxygen (Drose and Brandt, 2008). Generation of 
O2•- by complex I and II occurs exclusively in the mitochondrial matrix, whereas O2•- 
generated by complex III also occurs in the intermembrane space. O2•- generated in the 
mitochondrial matrix is rapidly converted to H2O2 by mitochondrial SOD (Mn-SOD), 
whereas O2•- generated in the intermembrane space travels through the outer 
mitochondrial membrane prior to conversion to H2O2 by cytosolic SOD (Cu/Zn-SOD). 
1.3.2.2 NADPH oxidase (NOX) as a source of ROS 
The NOX family of enzymes comprise of seven members, NOX1-5 and dual oxidase 
(DUOX) 1 and 2. They are transmembrane proteins that transfer electrons from 
NADPH to molecular oxygen, generating O2•- (or H2O2), which can then be converted 
to other forms of ROS (1.3.1). In mammals, they are distributed widely in most tissues, 
although high levels of expression of different isoforms, are more tissue specific. NOX1 
is highly expressed in the colon, NOX2 in phagocytes, NOX3 in the inner ear, NOX4 in 
the kidney and blood vessels, NOX5 in lymphoid tissue and testis, and DUOX1 and 2 in 
the thyroid. From a haematopoietic perspective, intermediate levels of NOX1 
expression are also found in osteoclasts, of NOX2 in B-cells and HSC, and of NOX4 in 
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osteoclasts and HSC (reviewed in Bedard and Krause, 2007). Different NOX isoforms 
share conserved structural features comprising of six helical transmembrane domains 
(TM) (with helix III and helix V containing two haem-binding histidines), and a C-
terminus cytosolic domain (DH), which allows binding of FAD and NADPH (Figure 
1-4). Difficulties in obtaining suitable levels of NOX proteins mean that to date 
relatively little crystal structure data is available. However, a recently published report 
(Magnani et al., 2017), has elucidated the structure of the TM and DH domains 
(common to all NOX isoforms) of Cylindrospermum stagnale NOX5 in complex with 
FAD. In this structure, the six transmembrane helices of TM domain form a pyramidal 
shape with the base on the cytosolic side, a N-terminus α-helix runs parallel to the 
cytosolic side of the membrane and the haem groups sit in cavities formed by helices II-
V, so that one is positioned near the cytosolic side of the membrane (haem 1) and the 
other on the outer side (haem 2). The DH domain, located on the cytosolic side, 
contains two pockets, one for FAD binding and one for NADPH binding. The FAD is 
positioned so that the flavin is in direct contact with haem 1 of the TM, to promote 
interdomain electron transfer. The proposed mechanism of electron transfer then 
involves NADPH donating its electron to FAD, which in turn donates an electron to 
haem 1 and then to haem 2 via Trp378 (equating to Phe 215 in human NOX2, Phe 200 
in human NOX4 and Val 362 in human NOX5) of the loop between helix II and III of 
the TM, before reduction of molecular oxygen, via a final electron transfer step 
generates O2•- (Figure 1-4). 
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Figure 1-4. Generation of superoxide (O2•-) by NADPH Oxidase (NOX). Schematic diagram showing the major structural features of NOX2, it’s activation by 
phosphorylation (P) of p67phoxand p47phox and the assembly of the major subunits of the NOX complex, and the generation of superoxide via electron transfer from NADPH 
to flavin adenine dinucleotide (FAD) to haem groups to diatomic oxygen. Guanosine triphosphate (GTP), guanosine diphosphate (GDP), homology domain (DH), RAS-
related C3 botulinum toxin substrate 2 (Rac2). 
IV
I
II
VI
III V
Fe
Fe
FAD
NADPH
DH
O2•-
e-
O2
NOX2
p22phox
p67phox p40phox
p47phox
RAC2
P
P
GTP
GDP
Membrane
     Chapter 1 
 
34 
 
The NOX2 complex was the first NOX isoform to be identified and consists of six 
subunits, the catalytic core comprising of gp91phox (NOX2) and p22phox, and p40phox, 
p47phox, p67phox and RAS-related C3 botulinum toxin substrate 2 (Rac2). Gp91phox and 
p22phox reside at the membrane and together form the catalytic core of NOX2 known as 
cytochrome b558. The subunits p40phox, p47phox and p67phox exist as a multidomain 
complex in the cytosol. Phagocytic stimulation, results in the phosphorylation of p47phox 
at multiple sites by various PKC isoforms, p38MAPK, p21-activated kinase and AKT. 
Phosphorylation of p67phox by PKCδ also occurs (Zhao et al., 2005) which together 
cause a conformational change in the complex, which allows it to interact with p22phox. 
The complex translocates to the membrane where the conformational changes allow it 
to dock with cytochrome b558. Simultaneously, cytosolic RHO-related RAC-2 (bound to 
RHO GDP dissociation inhibitor (RHOGDI) in its resting state) is activated, exchanging 
GDP for GTP, and it too translocates to the membrane where it interacts with gp91phox 
and p67phox and completes the activation of the enzyme complex, allowing generation of 
O2•- (Figure 1-4) (reviewed in Groemping and Rittinger, 2005). Whilst the mechanisms 
governing deactivation of NOX2 are not fully understood, evidence suggests that the 
complex is likely activated, deactivated and then reactivated in rapid cycles (reviewed 
in DeCoursey and Ligeti, 2005). Other NOX isoforms also require activation, but the 
mechanism of activation differs. NOX1-4 all associate with p22phox, though this is not 
required in NOX5 and DUOX 1and 2, which are activated by Ca2+ via their long N-
terminus which contains the calcium binding EF hand domain. NOX1 and NOX3 
additionally require the cytosolic subunits NOX organiser 1 and NOX activator 1, 
which are homologs of p47phox and p67phox respectively, whilst activation of NOX4 does 
not require cytosolic subunits. NOX1 additionally requires RAC GTP, whilst its role in 
NOX3 and NOX4 activation is still a matter of debate (reviewed in Panday et al., 2015). 
1.3.2.3 Transportation of ROS across the cellular membrane 
ROS is generated both intracellularly, for example in the mitochondria by the ETC, and 
extracellularly, for example by NOX2 (1.3.2). As described further below (1.3.2.4) the 
extracellular O2•- produced by NOX2 rapidly dismutates, either spontaneously or as a 
consequence of the enzymatic action of extracellular SOD (EC-SOD), to generate H2O2. 
In order for this extracellular H2O2 to participate in cell signalling (1.3.3.2), it is 
necessary for it to traverse the cell membrane. H2O crosses the cell membrane either 
through natural diffusion, or active transportation via a large family of transmembrane 
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channel proteins, major intrinsic proteins, which can be further divided into the water 
permeable aquaporins (AQP) and the glycerol permeable aquaglyceroporins. This AQP 
facilitated transport of H2O across the cellular membrane occurs via a hydrophilic 
channel which allows the passage of molecules based on size and their ability to form 
hydrogen bonds with the channel walls. Whilst H2O2 is relatively similar in size, 
stereochemistry and polarity to H2O, the differences in structure and polarity mean it 
diffuses across the cellular membrane more slowly than H2O, suggesting that its role as 
a signalling molecule requires active membrane transport (reviewed in Bienert and 
Chaumont, 2014). Despite these differences however, the similarities in physiochemical 
properties between H2O2 and H2O, as well as its ability to form hydrogen bonds, does 
allow AQP facilitated transport, by some, but not all AQP isoforms. Using HEK293T 
cells treated with a H2O2 selective dye (peroxy yellow 1-methyl ester) and 
overexpressing AQP1, AQP3 or AQP8, it was shown that both AQP3 and AQP8 allow 
transportation of H2O2, whilst AQP1 does not (Miller et al., 2010). In the same study, 
further confirmation of the role of AQP3 in H2O2 transport was performed in the human 
colon adenocarcinoma cell line, HT29, which express AQP3. Knock-down of AQP3 
using shRNA, prevented H2O2 uptake as measured by the H2O2 fluorescent sensor 
HyPer. Further, treatment of the HT29 cells with epidermal growth factor, activated 
extracellular NOX production, correlating with an increase in AKT phosphorylation, 
which was not observed in the AQP3 knock-down cells, suggesting a role for 
extracellular NOX generated ROS in cell signalling. In another study, treatment of the 
HeLa cell line (expressing HyPer) with exogenous H2O2, showed decreased 
fluorescence when the cells were treated with the AQP inhibitor HgCl, whilst knock-
down of AQP8 resulted in no change in HyPer fluorescence in these cells upon 
treatment with extracellular H2O2 (Bertolotti et al., 2013). In the AML cell line B1647, 
cells pre-treated with the AQP inhibitor silver nitrate, then treated with exogenous H2O2 
showed decreased intracellular H2O2 levels as measured by 2,7-
dichlorodihydrofluorescin diacetate (DCFH-DA). Overexpression of AQP3 and AQP8 
but not AQP1 in these cells led to increased intracellular H2O2, whilst knockdown of 
AQP3 and AQP8 with siRNA led to a decrease in intracellular H2O2 levels in cells 
treated with 100μM H2O2 and a decrease in H2O2 basal levels in the case of AQP8 
knock-down cells. Interestingly, changes in intracellular H2O2 levels as a result of 
overexpression or knock-down of AQP8 in these cells, correlated with increased and 
     Chapter 1 
 
36 
 
decreased proliferation respectively both at basal levels and when treated with 100μM 
H2O2 (Dalla Sega et al., 2014). 
1.3.2.4 Cellular antioxidant systems 
Whilst ROS plays a role in cell signalling (1.3.3.2), high levels of ROS are toxic to cells 
resulting in DNA damage, lipid peroxidation and protein degradation, and their 
regulation is therefore tightly controlled (reviewed in Valko et al., 2006). Several 
intracellular mechanisms exist for the purpose of ROS detoxification including, the 
thioredoxin, peroxiredoxin and glutathione systems, the enzymes SOD and catalase 
(Figure 1-5) and dietary antioxidants such as vitamins A, C and E. 
The thioredoxin system consists of thioredoxin (Trx), thioredoxin reductase (TrxR) and 
NADPH. In mammalian cells, there are three isoforms of Trx, cytoplasmic Trx (Trx1), 
mitochondrial Trx (Trx2) and spermatozoa Trx (SpTrx), all of which have a TrxR 
isoform equivalent. Trx reduce proteins or oxidised peroxiredoxins through transfer of 
two electrons, the first from cys-32 and then from cys-35 of a conserved active site Cys-
Gly-Pro-Cys, followed by the formation of a disulphide bridge between these two 
adjacent cysteines. Trx is then reduced back to its dithiol form by interaction with TrxR 
which contains one FAD unit and a c-terminus with a Gly-Cys-Sec-Gly-COOH motif. 
The selenium and SH group of the neighbouring cysteine donate electrons to oxidised 
Trx, forming a disulphide bridge in the process. This in turn is reduced by the donation 
of electrons from NADPH to TrxR via the FAD unit (reviewed in Nordberg and Arner, 
2001). It is worth noting that while the Trx system is important as an antioxidant it also 
has other roles. So, whilst Trx1 is found in the cytoplasm, it can also be excreted from 
the cell or translocated to the nucleus where it serves different functions (Nakamura et 
al., 1997). For example, in the cytoplasm Trx inhibits activity of the transcription factor 
nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB), whereas in the 
nucleus it promotes its ability to bind to DNA (Hirota et al., 1999). 
Linked to the thioredoxin system are the antioxidants peroxiredoxins (Prx). Prx are 
highly abundant in mammalian cells and like Trx are also implicated in H2O2 cell 
signalling. In mammalian cells six isoforms have been identified (PrxI-VI), which can 
be divided into three classes, 1-Cys Prx, typical 2-Cys Prx and atypical 2-Cys Prx. PrxI, 
PrxII and PrxVI are localised to the cytosol, PrxIII and PrxV to the mitochondria (with 
PrxV additionally found in peroxisomes) and PrxIV is found extracellularly. 
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Figure 1-5. Cellular antioxidant systems. Schematic diagram showing the major antioxidant systems in cells. Superoxide (O2•-) is reduced by the catalytic action of 
superoxide dismutase (SOD) to hydrogen peroxide (H2O2), which can then be reduced to water via the actions of the glutathione system or the action of peroxiredoxins (Prx). 
Prx are reduced by thioredoxin (Trx), which in turn is reduced by thioredoxin reductase (TrxR) and both TrxR and glutathione reductase (GSR) are reduced by nicotinamide 
adenine dinucleotide phosphate (NADPH). Additionally, H2O2 can be converted to oxygen and water by the action of the enzyme catalase. Glutathione (GSH), glutathione 
peroxidase (GPX). 
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All Prx isoforms have a conserved active site, which in PrxII is centred around cys-51 
and includes pro-44, which limits access to the oxidised sulphenic acid group on the 
cysteine preventing further oxidation, thr-48, which forms a hydrogen bond with non-
conserved residue 45 which in turn forms a hydrogen bond with cys-51 and arg-127 
which stabilises the thiolate form of cys-51. In all three Prx classes, cys-51 is initially 
oxidised to form the sulphenic acid intermediate. Typical 2-Cys Prx (PrxI-IV) are 
homodimers (with two identical active sites) and contain an additional conserved 
cysteine in the c-terminus region. Following oxidation of the active site cysteines two 
disulphide bridges are formed between these cysteines and the c-terminus cysteines of 
the corresponding dimer. Atypical 2-Cys-Prx (PrxV) is monomeric, which following 
oxidation of its active cysteine forms a disulphide bridge with another cysteine residue 
further along its polypeptide chain, whilst 1-Cys-Prx (PrxVI) does not contain an 
additional cysteine and maintains a sulphenic acid group following oxidation (reviewed 
in Rhee et al., 2005)). Both typical and atypical 2-Cys-Prx are only reduced by Trx, 
whilst 1-Cys-Prx is reduced by the glutathione system (Manevich et al., 2004) and 
ascorbate (Monteiro et al., 2007). 
The glutathione system comprises of glutathione (GSH), glutathione peroxidase (GPX) 
glutathione reductase (GSR) and NADPH. GSH is synthesised in the cytosol by γ-
glutamylcysteine synthetase and GSH synthetase (reviewed in Meister and Anderson, 
1983) and is the most abundant thiol in mammals, with concentrations ranging from 1-
11mM in they cytosol, 3-11mM in the nucleus and 5-11mM in the mitochondria 
(reviewed in Valko et al., 2006). GSH is oxidised by H2O2 in the presence of the 
selenium containing enzyme GPX to form glutathione disulphide (GSSG). Initially 
H2O2 oxidises the selenium of Sec in GPX generating a selenic acid group on the Sec 
residue (R-SeOH), which in turn is reduced by GSH to form GS-SeR, which then reacts 
with another GSH to generate GSSG (reviewed in Masella et al., 2005). GSR contains a 
FAD unit which when reduced by NADPH, breaks a disulphide bond on the conserved 
cys-58 and cys-63 residues of GSR, by the formation of a covalent bond with cys-63. 
NADP+ is then released and replaced by another NADPH, GSSG binds to GSR 
whereupon cys-58 breaks the disulphide bond releasing one GSH, before cys-63 and 
cys-58 reform a disulphide bond releasing the other GSH (Berkholz et al., 2008). 
Catalase consists of four identical polypeptide chains surrounding a haem group which 
is the active site. In mammalian cells, it is normally found in the peroxisome where it 
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catalyses the reaction of H2O2, via a two-step reaction. On entering the active site, H2O2 
donates an oxygen to the haem group, which then reacts with another H2O2 molecule, 
ultimately generating one oxygen and two water molecules (reviewed in Chelikani et 
al., 2004). 
Whilst Prx, GSH and catalase are involved in the reduction of H2O2, SOD are 
responsible for catalysing the dismutation of O2•- to H2O2 and oxygen (McCord and 
Fridovic.I, 1969). Three forms of SOD exist in humans, the manganese containing 
mitochondrial SOD (Mn-SOD) which comprises four identical 22-kDa subunits each 
containing a Mn ion, cytosolic Cu/Zn-SOD containing a Cu-His(61)-Zn active site 
(Djinovic et al., 1991) in both of its two identical 16-kDa subunits and extracellular 
SOD (EC-SOD), which like cytosolic SOD also contains a copper and zinc active site, 
but is a glycoprotein composed of four 30-kDa subunits (Carlsson et al., 1995). SOD 
catalysed dismutation of O2•- occurs via reduction of the metal cation generating O2, 
which then reduces a second O2•- to O22- which then reacts with 2H+ to generate H2O2. 
 Cellular functions of ROS 
1.3.3.1 The role of ROS in innate immunity 
The role of ROS in innate immunity was established in the 1960’s and 70’s, when it was 
discovered that ROS was generated by phagocytes, as a consequence of a previously 
identified glycolytic ‘respiratory burst’. Initially, it was believed that the ROS generated 
was H2O2 (Iyer et al., 1961) but it was later discovered that the O2•- was the initial 
product (Babior et al., 1973). During the same period, it was noted that the phagocytes 
of patients suffering chronic granulomatous disease (a disease characterised by recurrent 
pyogenic infections) did not generate a ‘respiratory burst’ and that cytochrome b558 was 
absent from these patients (Segal et al., 1978). Identification of other subunits of the 
NOX2 complex followed, although it was not until 1993 that the final cytosolic subunit, 
p40phox was identified (Wientjes et al., 1993). Whilst still a matter of debate, it is 
believed that ROS is responsible for the direct killing of microorganisms, for example 
by lipid peroxidation or through inhibition of microbial virulence factors, and indirectly 
via pH modulation and changes in ion concentrations of the phagosome interior 
(reviewed in Bedard and Krause, 2007). H2O2 may additionally be important in 
directing granulocyte migration to the site of infection, via activation of Src family 
kinase, Lyn (Yoo et al., 2011). NOX2 generated ROS has also been shown to be 
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important in generating a neutrophilic chemoattractant gradient through the inhibition of 
the phosphatase and tensin homolog (PTEN) and the resulting accumulation of PIP3 
(Kuiper et al., 2011). Whilst NOX2 was initially discovered in phagocytic cells due to 
its role in innate immunity, the discovery of the other NOX isoforms and the 
development of more sensitive ROS probes showing that these isoforms also generated 
low levels of ROS in non-phagocytic cells, led to questions concerning their role. 
1.3.3.2 The role of ROS as a cell signalling molecule 
The role of ROS in signalling was only appreciated following the publication of a study 
in the late 1980’s indicating H2O2 was responsible for the tyrosine phosphorylation of 
insulin receptor substrate 1 in a rat hepatoma cell line (Heffetz and Zick, 1989) and 
concentration dependent proliferation/inhibition of proliferation, in human fibroblasts 
(Murrell et al., 1990). Since then, the role of ROS as cell signalling molecules has 
become established and is recognised in diverse biological functions such as hypoxic 
response, autophagy, cell growth and differentiation, stem-cell renewal, wound healing 
and apoptosis. Whilst O2•- has been shown to be involved in cell signalling, for example 
in the activation of ERK via peroxisome proliferator-activated receptor-γ activation in 
the mouse myoblast cell line C2C12 (Huang et al., 2002), its rapid dismutation to H2O2 
by SOD, means that the majority of ROS signalling appears to be mediated by H2O2. 
The direct mechanism by which this occurs involves the oxidation of cysteine (or 
methionine) residues on redox sensitive proteins. Physiological pH, means that 
approximately 10% of sulphurs on the cysteine residue exist as a thiolate ion (S-) 
(although this may be increased due to the local electrostatic environment) rather than a 
thiol group (SH), allowing for greater reactivity with H2O2. Oxidation of the thiolate ion 
by H2O2, results in its conversion to SO-, which then generates a conformational change 
in the attached protein and resultant activation/inactivation. Hyperoxidation to SO2- or 
SO3-, can also occur, but as this is generally irreversible in the case of SO3-, the SO- ion 
on the protein normally forms a disulphide (S-S) or sulphenic-amide (S-N) bond, with 
another SH group. Termination of the signal is achieved through reduction of the 
protein by the glutathione or thioredoxin (Trx) system (1.3.2.4). However, proteins 
involved in redox signalling, including phosphatases such as PTEN, protein tyrosine 
phosphatase 1B (PTP1B), CDC25 and MAPK, kinases and transcription factors, occur 
at much lower concentrations than that of cellular antioxidants. Furthermore, the known 
rate constants of target phosphatases are significantly lower than that of antioxidants 
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such as Prx and Gpx (Sohn and Rudolph, 2003, Denu and Tanner, 1998). As a result, it 
appears that any direct signalling by H2O2 would be negated by H2O2’s reaction with 
cellular antioxidants before signalling could be instigated. 
Consequently, it was proposed that transduction of cell signalling could be facilitated by 
the antioxidants themselves via a redox relay. In this model, H2O2 initially oxidises Prx, 
which is abundant in the cell and has been brought into close contact with the target 
protein. The target protein is then oxidised by Prx, before it can itself be reduced by 
Trx. Alternatively, in a variation on this model, the oxidised Prx is reduced by the Trx, 
which in turn oxidises the target protein. Yet another proposal, termed the ‘floodgate 
model’ (which also involves co-localisation of Prx), suggested that Prx could be 
inactivated either by hyperoxidation to SO2-, or post-translational modification, which 
would then allow direct activation/inactivation of the target protein by H2O2. 
Experimental evidence exists for both models. In the yeast Saccharomyces cerevisiae, 
oxidant receptor peroxidase-1 (which operates as an antioxidant), reacts with H2O2, 
before transducing the signal to a target transcription factor (Delaunay et al., 2002), 
whilst in HeLa cells Gpx4 also activated roGFP2 when part of the fusion protein 
(roGFP2-Gpx4), upon activation by H2O2 (Gutsche et al., 2009). Additionally, in the 
AML cell line U937 and in HeLa cells, Prx1 was shown to transduce a H2O2 signal to 
activate the ASK1/p38MAPK pathway (Jarvis et al., 2012). With respect to the floodgate 
model, growth factor stimulation of NOX in various cell lines has been shown to 
promote localised Src mediated Prx1 inactivation, which would presumably allow H2O2 
activation/inactivation of target proteins in the Prx1 inactive area (Woo et al., 2010). 
Interestingly, in mouse embryonic fibroblasts it was shown that peroxiredoxin 1 
protected PTEN inactivation by H2O2 protected the cells from RAS activation of AKT, 
which was reduced at high concentrations of H2O2, offering support to the idea of local 
Prx inactivation as a signalling mechanism (Cao et al., 2009). Nonetheless, although the 
high concentration and reactivity of Prx seem to exclude direct oxidation of signalling 
proteins by H2O2, this mechanism cannot be ruled out (Marinho et al., 2014). This is 
because whilst most of the H2O2 in direct signalling may be nullified by the action of 
antioxidants, a proportion will react with the target protein. Application of 
experimentally obtained kinetics for PTP1B and tyrosine-protein phosphatase non-
receptor type 11 (PTPN11) analysed by mathematical modelling that accounted for both 
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their oxidation and reduction during signalling indicated that PTP1B, but not PTPN11, 
was compatible with a direct signalling mechanism (Brito and Antunes, 2014). 
Regardless of mechanism, it is important to note that the reactivity of ROS mean that its 
role as a signalling molecule is likely to be localised to the subcellular compartment in 
which it is generated, dependent on NOX isoform and likely tissue specificity (1.3.2.2). 
In addition to the stimulation of NOX2 as part of an immune response, NOX isoforms 
are also stimulated by a variety of ligands such as pro-epidermal growth factor (Bae et 
al., 1997), platelet-derived growth factor (Sundaresan et al., 1995), tumour necrosis 
factor α (Lo and Cruz, 1995) and angiotensin II (Ushio-Fukai et al., 1999). This 
stimulation and resultant ROS production then effect changes in phosphatases, kinases 
and transcription factors as part of their signalling role. Protein tyrosine phosphatases 
(PTP) contain a conserved His-Cys-(X)5-Arg-Ser/Thr (with the exception of CDC25 
which does not contain the Ser/Thr residue) motif in the active catalytic domain, which 
hydrolyses phosphotyrosine via the nucleophilic cysteine present in this active site 
(reviewed in Jackson and Denu, 2001). ROS inactivates PTP’s by reaction with this 
same cysteine, which is selected in preference to other cysteines due to the nucleophilic 
charge caused by its proximity to the arginine residue. In the case of PTPB1, oxidation 
by H2O2 of the cysteine thiolate group generates a SO- group, which is stabilised in the 
active cleft, prior to regeneration of the active enzyme (Denu and Tanner, 1998). A 
similar process occurs with the oxidation of PTEN and CDC25 by H2O2, only in this 
case oxidation of cysteine in the active site is stabilised by the formation of a disulphide 
bridge, between cys-124 and cys-71 in PTEN (Kwon et al., 2004) and cys-377 and cys-
330 in CDC25C (Savitsky and Finkel, 2002). Of note from a RAS perspective, PTEN is 
a known inhibitor of the PI3K/AKT pathway, which promotes cells survival (1.2.2.2) 
thus oxidation of PTEN results in increased activation of this pathway (Leslie et al., 
2003). Additionally, RAS is also direct target of ROS, with S-glutathionylation (the 
addition of glutathione to an oxidised cysteine residue) of cys-118 having been shown 
to increase RAS activity in vascular smooth muscle cells (Adachi et al., 2004). 
Conversely, CDC25 is the active domain in GEFs important in activating RAS (1.2.2.1) 
and are also responsible for activating CDKs important in cell cycle progression. ROS 
mediated CDC25 cyclin D dependent cell cycle arrest under exposure to high levels of 
H2O2 (Pyo et al., 2013), demonstrating perhaps, the importance of ROS subcellular 
localisation and relative ROS concentration in ROS signalling. Whilst the His-Cys-(X)5-
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Arg-Ser/Thr conserved motif establishes an active site for redox signalling in PTP, no 
similar motif has been elucidated for the site of redox signalling in protein kinases. This 
further complicates the picture, as both kinase activation and inactivation have been 
reported as a consequence of redox signalling. So, for example, S-glutathionylation, as a 
result of redox signalling, has been reported to inhibit the RAF/MEK/ERK pathway, 
PKC and cAMP-dependent protein kinase. Conversely, ROS signalling has been shown 
to lead to both activation and deactivation of Src kinase, dependent on both the 
subcellular location of Src and the relative levels of the activating/deactivating ROS, 
whilst tyrosine kinase receptors such as epidermal growth factor receptor have also been 
shown to be activated by ROS (reviewed in Corcoran and Cotter, 2013). 
ROS is also important in the regulation of transcription factors. H2O2 has been shown to 
upregulate the transcription of transcription factors such as c-JUN, c-FOS, TP53 and 
HIF-1α, increase translation of transcription factors such as nuclear-related factor 2 
(Nrf2) and specificity protein 1 (SP1) and target degradation of transcription factors, via 
the ubiquitin proteasome pathway or via post translational modifications such as 
acetylation of activator protein 1 (AP-1) or decreased hydroxylation of HIF-1α. 
Additionally ROS can induce proteolytic release of transcription factors such as 
NOTCH or sterol regulatory element-binding protein 1 from anchor proteins, allowing 
translocation to the nucleus, or directly increase affinity of transcription factor binding 
to DNA such as with heat shock factor 1 (reviewed in Marinho et al., 2014). 
1.3.3.3 The role of ROS in normal haematopoiesis 
HSC reside in the bone marrow (1.1.1.1) and their quiescence is known to be negatively 
regulated by ROS. Forkhead box O (FOXO) transcription factors are involved in cell-
cycle arrest and apoptosis and are activated in response to oxidative stress whereupon 
they translocate to the nucleus (Essers et al., 2004). Translocation of FOXO4 to the 
nucleus has been shown to be a function of redox signalling, where oxidation of cys-239 
by ROS mediates the formation of disulphide bonds with nuclear import receptor 
transportin-1, which in turn allows nuclear localisation (Putker et al., 2013). FOXO 
deactivation occurs as a result of phosphorylation in response to activation of the 
PI3K/AKT pathway (1.2.2.2), resulting in their export from the nucleus and subsequent 
degradation in the cytoplasm (Brunet et al., 1999). Studies in murine HSC have shown 
that deletion of FOXO3a, which upregulates transcription of Mn-SOD (Kops et al., 
2002), results in decreased HSC renewal (Miyamoto et al., 2007) which is mediated by 
     Chapter 1 
 
44 
 
the tumour suppressor protein ataxia-telangiectasia mutated (ATM) (Yalcin et al., 
2008), and is accompanied by elevated ROS levels and myeloid lineage expansion 
(Tothova et al., 2007). Deletion of ATM in mice resulted in BM failure which was 
restored following treatment with antioxidants (Ito et al., 2004). In a different study, 
isolation of murine HSC into ROS high and ROS low populations showed that the ROS 
low population maintained self-renewal capacity following serial transplantations, 
whilst the self-renewal capacity of the ROS high population was exhausted following 
the third serial transplantation. Treatment of the ROS high HSC with the antioxidant 
NAC, the p38 inhibitor SB203508 or rapamycin (a mTOR inhibitor), restored self-
renewal activity (Jang and Sharkis, 2007). Interestingly, the ROS high population in this 
study also exhibited a decreased ability to adhere to cells containing calcium sensing 
receptors, whilst NOX generated ROS has additionally been implicated in osteoclast 
differentiation in human mesenchymal cells, further emphasising a potential regulatory 
role of ROS, in the BM niche (Huang et al., 2009).  
Whilst these increased ROS levels are associated with HSC losing quiescence, it has 
also been shown, in the human megakaryocytic cell line MO7e, that haematopoietic 
cytokines, such as GM-CSF, IL-3, SCF and TPO all increase ROS levels (Sattler et al., 
1999). In megakaryopoiesis, ROS has been shown to increase platelet production and 
maturation in the CML cell line MEG-01 and primary human megakaryocytes (O'Brien 
et al., 2008), which in murine models is mediated by the transcription factor NF-E2 
(Motohashi et al., 2010). Following lineage commitment, megakaryocyte progenitors 
undergo endomitosis (chromosomal replication in the absence of cell division), which in 
murine cells is potentially mediated by NOX1-derived ROS (McCrann et al., 2009). In 
human HSC, NOX-derived ROS has also been shown to be crucial for megakaryocyte 
differentiation via activation of ERK, AKT and JAK2 (Sardina et al., 2010), whilst 
another study revealed the importance of cytochrome P450 2E1-generated ROS in 
megakaryocyte differentiation in human HSC (Tang et al., 2014). As noted above, 
increased ROS in HSC has been associated with expanded myelopoiesis. Interestingly, a 
recent study using murine CMP, showed that higher levels of ROS actually impeded 
megakaryopoiesis, instead directing differentiation of CMP into GMP (Shinohara et al., 
2014). Finally, ROS has also been shown to induce differentiation of the promonocytic 
cell line, U937, into macrophages (Yamamoto et al., 2009), and the differentiation of 
primary human monocytes into dendritic cells (Del Prete et al., 2008). 
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1.3.3.4 The role of ROS in solid tumours and AML 
ROS is implicated in numerous diseases including atherosclerosis, Alzheimer’s, 
Parkinson’s, diabetes, ischaemia, rheumatoid arthritis and cancer (reviewed in Valko et 
al., 2007). One of the first studies implicating ROS in carcinogenesis was performed in 
mice subcutaneously injected with C3H mouse fibroblasts, that had been previously 
cultured in vitro with neutrophils (12-O-tetradecanoylphorbol-13-acetate (TPA) 
stimulated or unstimulated) or with the ROS generating enzyme XO and hypoxanthine. 
In this study approximately 20% of mice treated with these cells developed tumours 
within 13-22 weeks compared to none of the control mice (Weitzman et al., 1985). In 
1991, analysis of H2O2 production in human melanoma, colon, pancreatic, 
neuroblastoma, breast and ovarian cancer cell lines, revealed constitutively active H2O2 
production over a 4h period, generating H2O2 levels similar to those observed in TPA 
stimulated neutrophils, suggesting increased ROS production may be a feature of 
transformation (Szatrowski and Nathan, 1991). Later, studies in patients with liver 
disease suggested ROS plays a part in hepatocarcinogenesis (Valgimigli et al., 2002), 
and levels of Cu/Zn-SOD are significantly lower in hepatoma tissue than normal human 
liver tissue (Liaw et al., 1997). Further, homozygous deletion of Cu/Zn-SOD in mice 
results in decreased lifespan, with 70% developing hepatocarcinoma or benign nodular 
hyperplasia (Elchuri et al., 2005), whilst homozygous deletion of Mn-SOD in mice is 
lethal within two weeks of birth (Van Remmen et al., 2003). In the same study, 
heterozygous deletion of Mn-SOD resulted in increased incidence of haemangioma and 
adenocarcinoma and significant increases in the incidence of lymphoma. Currently, 
elevated ROS levels have been reported in many solid tumours and the role they play in 
tumourigenesis is complex and multifaceted (reviewed in Galadari et al., 2017). 
Haematologically, a study which collected blood samples from ALL and CML patients 
samples and compared them with normal blood samples showed elevated levels of ROS 
in both ALL and CML patients (Devi et al., 2000), whilst studies in our group have 
additionally revealed elevated levels of NOX generated ROS in AML patient samples 
when compared with healthy controls (Hole et al., 2013). 
The role of ROS in DNA damage 
Physiologically ROS is important both in innate immunity (1.3.3.1) and as a signalling 
molecule (1.3.3.2), with both intra and extracellular ROS levels tightly maintained 
through cellular antioxidant systems (1.3.2.4). Increased levels of ROS or decreased 
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levels of cellular antioxidants can cause oxidative stress leading to overactivation of 
signalling pathways, hyperoxidation of signalling proteins (1.3.3.2), lipid peroxidation 
(1.3.3.1), structural alterations in protein structures resulting in change of function, as 
well as damage to DNA and RNA. Reactions of ROS with DNA generate numerous 
oxidised bases, including 8-hydroxy-2-deoxyguanosine (8-OHdG) which causes G:C to 
T:A DNA transversions (reviewed inCooke et al., 2003). Increased levels of 8-OHdG 
have been observed in patients with breast cancer (Matsui et al., 2000), gastric 
carcinomas (Borrego et al., 2013), lung cancer (Gackowski et al., 2005) and colorectal 
cancer (Obtulowicz et al., 2010). In leukaemia a study of 116 Chinese children with 
either ALL or AML revealed significantly elevated levels of 8-OHdG, whilst 8-OHdG 
levels were also significantly elevated in relapsed AML adult patients (Zhou et al., 
2010). 8-OHdG levels were also significantly elevated in the murine cell line 32D 
transfected with FLT3 with an internal tandem duplication (ITD) compared to FLT3-
wild type (WT) (Stanicka et al., 2015). Furthermore, 32D cells containing FLT3-ITD 
showed a 75% increase in DNA double strand breaks (DSB) compared to WT cells, 
which was reduced by 30% in cells with p22phox knocked-down. FLT3-ITD is a 
common mutation in AML (Table 1) and has been shown to be responsible for 
increased levels of NOX4 generated ROS in the AML cell line Mv4;11(Jayavelu et al., 
2016b). These studies suggest that ROS induced DNA damage may be important in the 
initiation of both solid tumours and in leukaemogenesis. 
ROS increased proliferation in cancer 
In transformed cell lines, ROS has been shown, in several studies to contribute to 
increased proliferation. Overexpression of NOX1 in mouse fibroblast cells led to 
increased superoxide production and proliferation (Suh et al., 1999), whilst in the 
human colon cancer cell line, HT29-D4 and the prostate cancer cell line DU145, NOX1 
and NOX5 generated O2•- respectively, was associated with an increased proliferative 
rate in these cells (de Carvalho et al., 2008, Brar et al., 2003). Previous work in our 
group has shown that NOX2 induced ROS, generates increased proliferation in mutant 
RAS expressing HPC (Hole et al., 2010) and in AML cell lines and in patient AML 
blasts (Hole et al., 2013). Additionally, overexpression of NOX isoforms is common in 
many cancers with overexpression of NOX1 being observed in colon and stomach 
cancers, NOX2 in CML, NOX4 in ovarian, liver and breast cancer, NOX5 in breast, 
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colon, lung and prostate cancers as well as melanoma and DUOX2 in colorectal cancers 
(reviewed in Roy et al., 2015, Graham et al., 2010) 
ROS and its role in metastasis 
ROS has also been linked to metastasis via processes such as epithelial-mesenchymal 
transition (EMT), Wnt signalling, PTP signalling and p21-activated kinase 1 signalling 
(reviewed in Sosa et al., 2013). In particular, EMT, a process in which epithelial cells 
gain migratory properties, have been shown to have a ROS dependent component. For 
example, treatment of rat proximal tubular epithelial cells with H2O2 results in TGF-β1 
activation of the MAPK pathway and EMT initiation (Rhyu et al., 2005). Additionally, 
matrix metalloproteinase (MMP) an enzyme important in the breakdown of the 
extracellular matrix, has also been reported to be upregulated in breast cancer and to 
induce EMT (Lochter et al., 1997). MMP3 generates mitochondrial ROS via RAC-1 
and inhibition of this ROS with NAC in murine mammary epithelial cells blocked 
MMP3 induction of EMT (Radisky et al., 2005). Additionally, RAC-1 generated ROS 
is important in VEGF signalling which has been shown to induce angiogenesis in 
endothelial cells via the ROS sensitive adaptor protein p66Shc (Oshikawa et al., 2012). 
VEGF is also a crucial regulator in tumour angiogenesis, is upregulated in many human 
cancers, with cytokines, hypoxia and increased ROS all leading to increased VEGF 
levels (reviewed in Sosa et al., 2013). 
ROS disrupts cell signalling in cancer 
The role of ROS as a signalling molecule important for cellular proliferation, 
differentiation and survival is discussed in detail above (1.3.3.2). Unsurprisingly, 
increased levels of ROS in cancer cells has been shown to lead to aberrant signalling of 
these pathways. The role of the ROS activated RAS/RAF/MEK/ERK pathway in cell 
cycling (1.2.2.2) and AML was discussed previously (1.2.2.3), whilst ROS activation of 
the JNK and p38MAPK pathways has been shown to have both pro and anti-oncogenic 
effects dependent on context (reviewed in Wagner and Nebreda, 2009). Overexpression 
of mutant RAS has been shown to lead to increased levels of extracellular ROS (Hole et 
al., 2010), known to activate the p38MAPK pathway (Kulisz et al., 2002), which in turn 
upregulates p16INK4A and inhibits CDK, as well as inducing apoptosis as part of the 
cellular response to oxidative stress. However, whilst mutant H-RAS expression has 
been shown to induce cell cycle arrest in primary human fibroblasts, several ROS 
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producing cell lines have been shown to upregulate glutathione S-transferase (GSTM) 
which inhibits p38MAPK activation. This silencing of p38MAPK then, suggests a 
mechanism by which cancer cells may escape ROS induced apoptosis (Dolado et al., 
2007). In support of this, whilst expression of H-RASG12V in human HPC led to 
activation of p38MAPK, a corresponding increase in p16INK4A expression was not 
observed, suggesting this mechanism becomes decoupled in these cells (Hole et al., 
2010). Furthermore, in AML blasts, high ROS levels associated with increased 
proliferation, which did not correlate with increased p38MAPK activation, although 
GSTM expression did not appear to mediate this effect. These studies suggest then that 
suppression of this ROS induced pathway maybe multimodal (Hole et al., 2013).  
The tumour suppressor PTEN (reviewed in Kitagishi and Matsuda, 2013), which is 
inhibited by ROS, is an inhibitor of the RAS targeted PI3K/AKT pathway (1.3.3.2). 
Activation of the transcription factor FOXO promotes apoptosis and it is upregulated by 
ROS and inhibited by AKT. Upregulation of FOXO additionally upregulates Mn-SOD 
which is an important feature in HSC self-renewal (1.3.3.3). Therefore, under normal 
cellular conditions a balance between ROS activation of FOXO and ROS inhibition of 
PTEN maintains cellular homeostasis. However excessive ROS can lead to 
hyperactivation of the PI3K pathway, a common feature of many cancers, resulting in 
increased cell survival, VEGF production, secretion of MMP (reviewed in Gao and 
Schottker, 2017) and inactivation of FOXO (reviewed in Tothova and Gilliland, 2007). 
In AML, constitutive activation of the PI3K/AKT pathway is frequently observed (Xu 
et al., 2003, Altomare and Testa, 2005), however the role of FOXO is less clear. A 
recent study revealed that FOXO1 expression in osteoblasts mediated β-catenin initiated 
AML (Kode et al., 2016), whilst a study of AML patient samples showed that 40% 
exhibited FOXO activation, that upon inhibition resulted in myeloid differentiation and 
AML cell death (Sykes et al., 2011). Additionally, in both CML and AML the BCR-
ABL fusion protein and FLT3-ITD have been shown to lead to phosphorylation of AKT 
resulting in increased activation of NOX, and increased ROS production (reviewed in 
(Jayavelu et al., 2016a), which may in turn reinforce PI3K/AKT activation. 
The role of ROS on transcription factors in cancer 
Other ROS regulated transcription factors important in cancer development include 
Nrf2, NF-κB, TP53 and HIF-1α. Nrf2 governs the expression of numerous antioxidant 
     Chapter 1 
 
49 
 
genes including GSR and PRX and is considered the master regulator of cellular 
antioxidant response. Nrf2 binds to Kelch-like ECH-associated protein (KEAP1) in the 
cytosol under normal conditions, but under conditions of oxidative stress Nrf2 levels are 
increased and ROS attenuates binding of KEAP1 to Nrf2, leading to its translocation to 
the nucleus. Aberrant activation of Nrf2 as a result of mutations to Nrf2 or KEAP1 are 
frequently reported in numerous cancers (reviewed in Taguchi and Yamamoto, 2017), 
with high levels of Nrf2 also reported in AML (Rushworth et al., 2008). Whilst the 
resulting increase in antioxidants are protective to cells under normal conditions, 
paradoxically they are believed to give cancer cells increased protection against 
chemotherapeutic agents. Like Nrf2, NF-κB is bound in an inhibitory form to, nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα), until 
activation of IκBα by ROS results in dissociation of the complex, translocation of NF-
κB to the nucleus and activation of target genes involved in proliferation, metastasis, 
angiogenesis and apoptotic inhibition (reviewed in Gao and Schottker, 2017). NF-κB 
has been much studied in AML, due to its role in chemoresistance (Rushworth et al., 
2010) and it has also been shown to be responsible for high levels of Nrf2 observed in 
primary human AML cells and AML cell lines (Rushworth et al., 2012). The tumour 
suppressor gene TP53 has been found to be mutated in most cancers and is frequently 
mutated in AML (Table 1) (reviewed in Renneville et al., 2008). Nearly 50% of all 
malignancies involve mutation of TP53 and in cancers such as lung, triple negative 
breast, serous ovarian and oesophageal it is as high as 80% (reviewed in Duffy et al., 
2017). There is a complex interplay between ROS and TP53 protein levels. ROS can 
both induce TP53 expression via activation of various pathways such as p38MAPK, and 
suppress TP53 expression through oxidation of cysteine residues. Furthermore, 
activation of TP53 can result in activation of TP53 inducible protein-3, a pro-apoptotic 
protein which increases ROS levels (Polyak et al., 1997), or the upregulation of 
antioxidant genes such as GPX1 and Mn-SOD (reviewed in Vurusaner et al., 2012). 
Therefore, there appears to be a balance, whereby lower levels of ROS induce an 
antioxidant response in TP53, whereas higher levels induce apoptosis (Sablina et al., 
2005). 
The role of anti-oxidants and pro-oxidants in cancer treatment 
This pro-oxidant/anti-oxidant interplay is an important feature of ROS in cancers and 
has implications for treatment  in AML with both anti-oxidant treatment and pro-
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oxidant treatment offering therapeutic potential (reviewed in Hole et al., 2011). As 
discussed above, high ROS levels are observed in cancer cells and in AML which can 
lead to a pro-proliferative phenotype. Anti-oxidant treatment might therefore be 
expected to relieve this proliferative burden and as a prophylactic reduce cancer 
incidence. However, studies involving antioxidant treatment and epidemiological 
studies have shown mixed results (reviewed in Poprac et al., 2017, Yasueda et al., 
2016). Whilst a variety of reasons have been postulated for this, one major argument 
against the use of antioxidants is that chemotherapeutic agents typically generate ROS 
as part of their cytotoxic effect and anti-oxidants serve only to reduce the ROS burden. 
Consequently, the use of pro-oxidants to augment chemotherapy have been examined in 
a number of clinical trials and have proved promising in treating a variety of cancers 
(reviewed in Gorrini et al., 2013). Arsenic trioxide has transformed survival rates in 
patients with APL (reviewed in (McCulloch et al., 2017) and has also been used in the 
treatment of lung cancer. However, as discussed above, cancer cells often upregulate the 
production of antioxidants, and downregulate pro-apoptotic pathways such as TP53, as 
a response to high ROS, allowing them to escape apoptosis. In addition, it has been 
shown that both cancer stem cells (Diehn et al., 2009, Kim et al., 2012) and LSC 
(Lagadinou et al., 2013) exhibit low ROS levels, suggesting that even if treatment with 
pro-oxidants eliminates the bulk of cancer cells, cancer stem cells or LSC may survive 
and relapse occur. Interestingly a recent study showed apoptosis of LSC but not HSC as 
a result of selenium activated ATM-TP53 production of ROS (Gandhi et al., 2014), 
suggesting that a pro-oxidant approach to eliminating LSC may be feasible.  
NADPH is a link between ROS and metabolism in cancer 
Activation of ATM by ROS also promotes glucose-6-phosphate dehydrogenase (G-6-
PD) activity, the first step of the pentose phosphate pathway (PPP) (1.4), which also 
generates NADPH (Cosentino et al., 2011). Given that major cellular antioxidant 
systems, ultimately rely on NADPH to provide their reducing power (Figure 1-5) it is 
perhaps not surprising that ROS in both normal and aberrant cellular processes is 
inextricably linked with metabolism. In the cytosol NADPH is primarily generated 
through the PPP (1.4.4), whilst a number of mechanisms exist for mitochondrial 
NADPH generation (reviewed in Ciccarese and Ciminale, 2017), which include the 
serine synthesis pathway (SSP) (via the folate cycle) (reviewed in Yang and Vousden, 
2016) and the action of IDH1 and IDH2. IDH1 and IDH2 are commonly mutated in 
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AML (reviewed in Dang et al., 2010), although in this context NADPH is consumed, 
and D-2-hydroxyglutarate generated leading to stabilisation of HIF-1α (Zhao et al., 
2009). HIF-1α as a target of ROS is controversial, however it is overexpressed in many 
cancers where it induces expression of numerous glycolytic genes and will be discussed 
in more detail later (1.4.2.1). Of note, Nrf2 activation has also been shown to modulate 
metabolism in lung cancer cell lines, through the upregulation of enzymes involved in 
the NADPH production, notably G-6-PD, IDH1 and malic enzyme 1 (Mitsuishi et al., 
2012). Furthermore, TP53 is also important in regulating metabolism. Homozygous 
deletion of TP53 in mice results in decreased oxygen consumption resulting from 
decreased mitochondrial respiration occurring as a consequence of reduced TP53 
activated ‘synthesis of cytochrome c oxidase 2 (SCO2)’ production (Matoba et al., 
2006), resulting in decreased mitochondrial ROS production. Additionally both glucose 
transporter (GLUT) 1 and 4 and the glycolytic enzyme phosphoglycerate mutase 
(PGAM) have all been reported to be inhibited by TP53 expression (reviewed in Zhao 
et al., 2016a) leading to decreased glycolysis and potentially increased metabolism via 
the PPP and SSP. Finally, TP53 also upregulates TP53-induced glycolysis and apoptosis 
regulator (TIGAR) an enzyme which has an active domain similar to PFKFB (1.5.2). 
TIGAR catalyses the reaction of fructose-2,6-bisphosphate (F-2,6-BP) to fructose-6-
phosphate (F-6-P), which inhibits glycolysis, redirects metabolites into the PPP, 
generating NADPH (Bensaad et al., 2006). 
1.4 Metabolism 
Broadly defined, cellular metabolism involves a series of catabolic or anabolic chemical 
reactions which generate or use energy as part of this process. In chemotrophs this 
energy is obtained through the oxidation of nutrients, with the energy typically stored in 
the form of ATP. Whilst in higher organisms a plethora of enzymatically catalysed 
metabolic reactions occur, which are all part of different interconnecting metabolic 
pathways with multitudinous feedback mechanisms. These pathways are evolutionarily 
highly conserved with the citric acid cycle, for example, essentially a feature in all 
terrestrial life. There are three main classes of molecules involved in metabolism, 
carbohydrates, proteins and lipids that are either catabolised to generate energy or 
energy stores or used by anabolic pathways in the synthesis of, for example, nucleotides 
and structural molecules such as cell membranes. In mammals, a triumvirate of 
glycolysis (1.4.3), the citric acid cycle (1.4.4) and the ETC (1.3.2.1) are central to the 
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generation of ATP, with glycolysis and the citric acid cycle contributing 2 ATP 
molecules each and the ETC generating up to 34 ATP molecules in a process 
collectively termed aerobic respiration (reviewed in Mikawa et al., 2015). 
 The Warburg effect 
A key requirement of aerobic respiration is that sufficient cellular oxygen levels are 
available, as under anaerobic conditions oxidative phosphorylation cannot occur and 
instead cellular energy demands are solely met through the less efficient process of 
glycolysis and the generation of lactate. Initially, it was Otto Warburg who observed 
that aerobic glycolysis was a hallmark feature of cancer cells (Warburg, 1956), an effect 
to which he ascribed defective mitochondria as being the cause, a hypothesis that is now 
known in most cancers to be incorrect (reviewed in DeBerardinis and Chandel, 2016). 
Instead, it has been shown that mitochondrial respiration is often necessary in 
tumourigenesis (Weinberg et al., 2010). Given its ubiquity and despite its inefficiency 
when compared with oxidative phosphorylation, it is clear that the Warburg effect must 
offer cancer cells some competitive advantage, although its exact ontology remains 
unclear. One hypothesis contends that whilst inefficient, aerobic glycolysis generates 
ATP at a rate 10-100 times faster than oxidative phosphorylation, therefore supplying 
cancer cells with energy at a faster rate. Additionally, this increased glycolytic flux 
could potentially generate more nucleotides, amino acids and lipids for biosynthesis and 
perhaps more pertinently would, via the PPP and SSP (1.4.4), generate more NADPH to 
deal with the increased ROS levels common in many cancer cells (reviewed in Liberti 
and Locasale, 2016) and the impact of this on ROS signalling pathways (1.3.3.2 and 
1.3.3.4). Alternative proposals suggest that the increase in excreted lactate as a result of 
aerobic glycolysis generates a more acidic microenvironment which breaks down 
stromal membrane structures, increasing cancer cell motility and metastasis. 
 Regulation of metabolic pathways 
Changes of cellular ROS levels in both normal cell signalling (1.3.3.2 and 1.3.3.3) and 
as cell signalling following cellular transformation (1.3.3.4) result in changes in 
numerous signalling pathways controlling multiple cellular functions including growth, 
proliferation and differentiation. A number of these signalling pathways, in turn, 
exercise regulatory control over various metabolic pathways, which in turn via several 
feedback mechanisms modulate ROS levels (Figure 1-6). Increased RAS expression 
activates the PI3K/AKT/mTOR pathway (1.2.2.2 and 1.3.3.4) and activation of mTOR 
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is known to activate both nucleotide biosynthesis and lipid synthesis (reviewed in 
Efeyan et al., 2012) as well as HIF-1α, which upregulate glycolysis via the activation of 
numerous glycolytic genes (1.4.2.1). In addition to HIF-1α, other ROS activated 
transcription factors are important in metabolic regulation such as STAT3, which has 
been shown to upregulate glycolysis in hepatocellular carcinoma cell lines (Li et al., 
2017b), FOXO3A, which inhibits glycolysis via activation of tuberous sclerosis 1 
protein (Khatri et al., 2010) and NF-κB which was shown to upregulate GLUT3 in 
mouse embryonic fibroblasts (Kawauchi et al., 2008). Nuclear localisation of the 
glycolytic enzyme pyruvate kinase muscle 2 (PKM2) is also ROS mediated, where it 
acts as a co-factor in the activation of c-MYC (1.4.3). RAS also activates c-MYC 
(1.2.2.2) which is overexpressed in greater than 50% of human cancers and c-MYC has 
been shown to activate glycolysis via the upregulation of GLUT, the glycolytic enzymes 
hexokinase (HK), phosphoglucose isomerase (PGI), phosphofructokinase (PFK), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase 
(PGK), PKM2, as well as lactate dehydrogenase A (LDHA), pyruvate dehydrogenase 
kinase 1 (PDK1) (1.4.3) and PFKFB3 (1.5) (reviewed in Hsieh et al., 2015). Increased 
glutaminolysis is also a target of c-MYC, which upregulates the glutamine transporter 
ASCT2 and a key enzyme glutaminase. Additionally, c-MYC was shown to upregulate 
both phosphoglycerate dehydrogenase (PHGDH) which catalyses the first step of the 
SSP, serine hydroxymethyltransferase, part of the folate cycle as well as several genes 
involved in fatty acid metabolism and the citric acid cycle (reviewed in DeBerardinis 
and Chandel, 2016). 
In contrast TP53 (which is frequently mutated in cancer) is known to inhibit glycolysis 
through inhibition of GLUT1, GLUT4 and PGAM and through activation of TIGAR 
and SCO2 (1.3.3.4). Inhibition of glycolysis also occurs due to the regulatory role of 
miRNA. For example, miR-195-5p inhibits GLUT3, miR-143 inhibits HK2 and miR-
155 inhibits HIF-1α. Furthermore, TP53 induces miR-34a which suppresses HK1, HK2, 
GPI and PDK1, as well as sirtuin 1, which activates FOXO1, NF-κB and in a positive 
feedback loop TP53 (reviewed in Zhao et al., 2016a)   
     Chapter 1 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6. Regulation of metabolic pathways. Schematic illustration outlining some of the regulatory 
mechanism involved in glycolysis and other key metabolic pathways. Transcription factors are in pink 
and signalling pathways in blue. Reactive oxygen species (ROS), forkhead box O (FOXO), pyruvate 
kinase muscle 2 (PKM2), signal transducer and activator of transcription (STAT), nuclear factor kappa-
light-chain-enhancer of activated B-cells (NF-κB), glucose transporter (GLUT) hypoxia inducible factor-
1 alpha (HIF-1α), tumour suppressor protein 53 (TP53), glycogen synthase kinase 3β (GSK-3β), isocitrate 
dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH), protein kinase B 
(AKT), mammalian target of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K), synthesis of 
cytochrome c oxidase 2 (SCO2) and prolyl-hydroxylase domain (PHD). 
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1.4.2.1 Hypoxia Inducible Factor-1 alpha (HIF-1α) 
HIF-1α is a transcription factor whose stabilisation and translocation to the nucleus, as a 
result of low oxygen tension, leads to increased expression or suppression of hundreds 
of genes via binding to the hypoxia response element (HRE) of promoters (reviewed in 
Greer et al., 2012)). It is a heterodimer consisting of the subunits HIFα and HIFβ 
(sometimes referred to as aryl hydrocarbon receptor nuclear translocator (ARNT), 
which contain a helix-loop-helix domain, as well as a PER-ARNT-SIM domain. Three 
isoforms of HIF-α exist in humans, all of which contain an oxygen-dependent 
degradation domain containing two preserved proline residues, which under conditions 
of normoxia are hydroxylated by prolyl-hydroxylase domain (PHD) enzymes. PHD 
requires O2 for its catalytic activity, with the hydroxy-HIF-α, being recognised by von 
Hippel-Lindau tumour suppressor protein’s (pVHL) β-domain, which targets it for 
ubiquitylation and degradation by 26s proteasome. Additionally, factor inhibiting HIF 
(FIH), in the presence of O2, also hydroxylates HIF-α at Asn803 of the C-terminal 
transactivation domain, which prevents association of HIF-α with transcriptional 
activators. Under hypoxic conditions Asn803 is not hydroxylated and HIF-α is 
stabilised, whereupon it dimerises with HIF-β, translocates to the nucleus and interacts 
with transcriptional co-activators p300/CBP.  
HIF-1α is important in the differentiation of a several tissues, including those involved 
in osteogenesis and haematopoiesis (1.1.1.1) (Takubo et al., 2010), where it is important 
in maintaining LT-HSC in the HSC niche (Kocabas et al., 2015). It is also required for 
embryogenesis in mice as homozygous deletion is embryonically lethal by day 10.5, 
whilst mice lacking HIF-2α are either embryonically unviable or die shortly after birth 
(reviewed in Semenza, 2012). Furthermore, knockdown of HIF-2α was shown to 
impede the repopulating ability of human HPC in vivo, resulting in increased ROS 
levels and increased endoplasmic reticulum stress, and suggesting a regulatory role in 
haematopoiesis (Rouault-Pierre et al., 2013). HIF-1α is implicated in a number of 
diseases, performing a protective role in coronary artery disease, limb ischemia and 
wound healing, whilst contributing to disease in pulmonary artery hypertension, sleep 
apnea and cancer. Increased levels of HIF-1α are seen in numerous cancers including 
bladder, breast, colon, lung, pancreas and prostate and it is known to activate 
transcription of genes involved in stem cell maintenance, immortalisation, EMT, 
immune evasion, vascularisation and glucose metabolism. 
     Chapter 1 
 
56 
 
HIF-1α is downregulated by TP53 and GSK3 and upregulated by mTOR following 
activation of the PI3K/AKT pathway, which in turn upregulates the glycolytic enzymes 
HK, aldolase (ALDO), PGK, enolase (ENO) and PKM2, as well as GLUT, LDHA and 
PDK1 (reviewed in Semenza, 2010a). Additionally, PHD2 activity (and thus HIF-1α 
inhibition) is activated by IDH, SDH and fumarate hydratase which are all enzymes 
involved in the citric acid cycle. HIF-2α is also implicated in cancer biology through 
regulation of c-MYC, angiogenesis and the promotion of metastasis and 
chemoresistance (reviewed in Zhao et al., 2015). 
Whilst the role of HIF-1α is well established in solid tumours, in leukaemia the 
literature is less certain. Increased expression of HIF-1α has been reported in all 
leukaemias, including AML (Gao et al., 2015), and is associated with chemoresistance 
(Song et al., 2014). Inhibition of HIF-1α with echinomycin using a xenogenic model of 
AML in NOD-SCID mice prevented serial transplantation of AML (Wang et al., 2011), 
whilst a syngeneic AML mouse model showed elimination of LSC (without impact on 
HSC) and cured 40-60% of the mice with relapsed AML (Wang et al., 2014). 
Mechanistically, HIF-1α has been shown to lead to progression of leukaemia through 
activation of both the NOTCH and Wnt pathways and inhibition of tumour suppressor 
genes such as TP53 (reviewed in Deynoux et al., 2016). HIF-2α has also been reported 
as important in AML disease maintenance with one study reporting that knock-down of 
HIF-2α in AML patient samples resulted in a decreased ability of these cells to engraft 
in mouse models (Rouault-Pierre et al., 2013). However, HIF-1α has also been shown 
to lead to the differentiation of AML cell lines through binding and activation of C/EBP 
and c-MYC and miRNA suppression (1.4.2), whilst in vivo, mouse models have shown 
accelerated development of AML as a result of HIF-1α knock-down (Velasco-
Hernandez et al., 2014) or conditional deletion or HIF-1α and HIF-2α (Vukovic et al., 
2015). 
The interplay of ROS and HIF-1α is also controversial (reviewed in Hagen, 2012). 
Initially it was reported that mitochondrial ROS was required for HIF-1α stabilisation 
under conditions of hypoxia (Guzy et al., 2005, Mansfield et al., 2005) and that this 
may occur as a result of PHD inhibition by ROS (Pan et al., 2007). However a lack of 
consensus over whether mitochondrial ROS production was enhanced or reduced under 
conditions of hypoxia along with the finding that inhibition of PHD require high levels 
of H2O2 suggested this mechanism was unlikely (Masson et al., 2012). Furthermore, the 
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same study reported that the greater sensitivity of FIH to ROS inhibition meant that, 
whilst this was a more likely mechanism of HIF-1α inactivation, the extremely slow 
reversibility of the reaction precluded it from any short-term role in hypoxic response. 
However, other sources of ROS such as NOX and XO may be important in HIF-1α 
regulation. NOX4 generated ROS has been reported to promote transcription of HIF-1α 
(Bonello et al., 2007), whilst a recent review highlights that mitochondrial ROS 
released from the intermembrane space is increased under conditions of hypoxia and 
that this is important in HIF-1α stabilisation and tumourogenesis (reviewed in 
Sabharwal and Schumacker, 2014). Furthermore, whilst the low affinity of PHD and 
slow reversibility of FIH inhibition by ROS make it unlikely to function as a regulatory 
molecule in normal hypoxic response, it could be hypothesised that the increased levels 
of ROS found in many cancers are able inhibit PHD, whilst inactivation of HIF-1α by 
FIH may not be a requirement of transformed cells. Finally, it has been shown that 
intermittent hypoxia increases activity of XO an enzyme important in the catabolism of 
purines and a major source of cellular ROS (Nanduri et al., 2013). XO activation leads 
to increased ROS, which induces Ca2+ activation of PKC, migration of p47phoxand 
p67phox to the cell membrane, resulting in activation of the NOX2 complex (1.3.2.2). 
Interestingly, knock-down of XO or NOX2 completely ablated HIF-1α protein 
expression in cell lines suggesting a ROS dependent, but mitochondrial independent, 
component to its stabilisation (Nanduri et al., 2015). 
 The glycolytic pathway 
The glycolytic pathway involves the metabolic breakdown of glucose into pyruvate via 
a series of intermediary steps (Figure 1-7) with the overall reaction being summarised 
as:  
 C6H12O6  + 2NAD+ +2ADP +2Pi → 2C3H3O3 + 2NADH + 2ATP + 2H+ + 2H2O 
where C6H12O6 is glucose, NAD is nicotinamide adenine dinucleotide, 2ADP is 
adenosine diphosphate, Pi is inorganic phosphate and C3H3O3 is pyruvate. 
Glucose (from digested saccharides or synthesised via gluconeogenesis) is taken up into 
the cell via GLUT, which are integral membrane proteins consisting of 12 
transmembrane helices with both the C and N-termini located in the cytosol. The active 
binding site is located on the 7th transmembrane domain containing the QLS (glutamine-
leucine-serine) motif and between the 10th and 11th transmembrane domains and a N-
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glycosylation site either on the 1st or 5th extracellular loop. Fourteen isoforms of GLUT 
have been identified in humans, GLUT’s 1, 3, 5, 6 and 9 are primarily expressed in 
haematopoietic cells, with GLUT1 and GLUT3 primarily responsible for glucose 
transport and GLUT5 the transport of fructose (reviewed in Vrhovac et al., 2014). 
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Figure 1-7. Glycolysis. Schematic illustration of the glycolytic reactions, showing the glycolytic intermediates, as well as the first three NADPH generating steps of the 
pentose phosphate pathway (PPP) catalysed by glucose-6-phosphate dehydrogenase (G-6-PD), gluconolactonase (G-6-PGL) and 6-phosphogluconate dehydrogenase (6-
PGD) (yellow box). Glucose is transported across the cell membrane by glucose transporters (GLUT) before being catalysed to glucose-6-phosphate by hexokinase (HK). 
The other non-reversible steps in glycolysis are catalysed by phosphofructokinase (PFK) and pyruvate kinase (PM), shown by single headed arrow. Double headed arrows 
indicate reversible reaction. Pyruvate can be converted in to lactate by lactate dehydrogenase (LDH) or into acetyl CoA by pyruvate dehydrogenase (PDH) which is inhibited 
by pyruvate dehydrogenase kinase (PDK). Lactate can be secreted from the cell by monocarboxylic transporters (MCT). Phosphoglucose isomerase (PGI), aldolase (ALDO), 
triosephosphate isomerase (TPI), glyceraldehyde phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), phosphoglycerate mutase (PGM), enolase (ENO), 
adenosine-5-diphosphate (ADP), adenosine-5-triphosphate (ATP), nicotinamide adenine dinucleotide (NAD), NAD phosphate (NADPH) and inorganic phosphate (Pi). 
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The first glycolytic step is irreversible and involves the phosphorylation of glucose 
to glucose-6-phosphate (G-6-P) by ATP and is catalysed by the enzyme HK. There 
are five isoforms of HK, with HK1 being ubiquitously expressed and HK2 mostly 
expressed in heart, skeletal and adipose tissues. Both these isoforms are inhibited by 
G-6-P, can bind to the outer mitochondrial membrane and use ATP derived from the 
ETC thus linking oxidative phosphorylation with glycolysis (reviewed in Wilson, 
2003). The next step is the reversible isomerisation of G-6-P to fructose-6-
phosphate, catalysed by PGI. PGI is a dimer with two α/β sandwich domains which 
is also known as neuroleukin in its role as a neurotrophic factor and is secreted by 
cancer cells where it is known as autocrine motility factor (AMF) (Jeffery et al., 
2000). The third glycolytic reaction, the phosphorylation of F-6-P to fructose-1,6-
bisphosphate (F-1,6-BP) by ATP, is one of the rate limiting irreversible steps in 
glycolysis and is catalysed by the enzyme PFK (Xie et al., 2016). PFK occurs as 
three isoforms PFK-muscle, PFK-liver (PFK-L) and PFK-platelet (PFK-P) and 
whilst synthesised as a monomer is only active in tetrameric form. It contains two 
binding sites for ATP, a catalytic binding site which has an association constant (Ka) 
of 0.15mM and an inhibitory allosteric binding site with a Ka of 2.5mM. PFK is 
additionally inhibited by phosphoenolpyruvate (PEP), palmitoyl-CoA, citrate and 
lactate and is activated by adenosine monophosphate, the signalling molecule cyclic 
adenosine monophosphate and the metabolite F-2,6-BP, whose role will be discussed 
further below (1.5). Hormonal regulation by insulin, serotonin and epinephrine occur 
as a result of phosphorylation of PFK by protein kinases, which stabilise its 
tetrameric active form (reviewed in Al Hasawi et al., 2014). 
The six carbon unit of F-1,6-BP is subsequently split into two three carbon units, 
either glyceraldehyde-3-phosphate (G-3-P) or its isomer dihydroxyacetone 
phosphate (DHAP), in a reversible reaction catalysed by ALDO. In humans there are 
three isoforms of ALDO, and in addition to its role in glycolysis it is also involved in 
Wnt signalling (Caspi et al., 2014), and the assembly and activity of vacuolar 
proton-translocating ATPases, important in proton transport and endocytosis) (Lu et 
al., 2007). Isomerisation reactions between G-3-P and DHAP are catalysed by triose-
phosphate isomerase (TPI). TPI is inhibited by binding of PEP to its catalytic 
binding site, which results in increased flux into the PPP and away from glycolysis 
(Gruning et al., 2014). Continuation along the glycolytic pathway involves reversible 
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oxidative phosphorylation of G-3-P to 1,3-bisphosphoglycerate (1,3-BPG) by 
GAPDH which also reduces nicotinamide adenine dinucleotide (NAD+) to NADH 
(required for oxidative phosphorylation (1.3.2.1)) as part of this reaction. GAPDH is 
additionally involved in apoptosis (as a result of NO induced S-nitrosylation) (Hara 
et al., 2005) and also potentially as a ROS sensor, in which S-glutathionylation of 
GAPDH leads to its inactivation and cycling of glycolytic intermediates into the PPP 
to generate NADPH (Peralta et al., 2015). Notably, GAPDH has also been 
implicated as a positive regulator of mTOR where, under conditions of high glucose, 
the GTPase RAS homolog enriched in brain, is released and mTOR activated 
(1.2.2.2) (Lee et al., 2009). 
The first ATP generating glycolytic reaction is catalysed by PGK, a reversible 
reaction which transfers a phosphate group from 1,3-BPG to ADP to generate 3-
phosphoglcerate (3-PG) and ATP. PGK exists as two isoforms, PGK1 which is 
ubiquitously expressed and PGK2 which is confined to sperm cells (Bowler, 2013). 
The phosphate group in 3-PG is then moved via a reversible reaction catalysed by 
the enzyme (PGAM) to generate 2-phosphoglycerate (2-PG). PGAM exists as three 
isoforms, PGAM1 which is ubiquitous, PGAM2 found predominantly in muscle 
tissue and PGAM3 found mainly in cardiac and skeletal tissue. Expression of PGAM 
is negatively regulated by TP53 (1.3.3.4), decreased expression of PGAM increases 
3-PG levels which inhibit 6-phosphogluconate dehydrogenase (6-PGD) the enzyme 
that catalyses the third step of the PPP, by binding to its active site and decreases 2-
PG levels which decreases PHGDH activity, which catalyses the first step of the SSP 
(Hitosugi et al., 2012). The enzyme ENO catalyses the penultimate glycolytic 
reaction through the reversible dehydration reaction of 3-PG to PEP. ENO occurs in 
humans in three isoforms, ubiquitous ENO1, ENO2 found mainly in neuron tissue 
and ENO3 found mainly in muscle tissue and is a metalloenzyme requiring 
magnesium to be catalytically active. ENO1 is additionally found on the surface of 
haematopoietic cells where it acts as a plasminogen receptor (reviewed in Diaz-
Ramos et al., 2012). 
The final step of the glycolytic pathway is irreversible and involves the conversion 
of PEP to pyruvate catalysed by pyruvate kinase (PK), which requires the transfer of 
a phosphate group from PEP to ADP to generate ATP. PK has been the subject of 
numerous excellent reviews and its role in tumour initiation and progression much 
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studied (Mazurek, 2011, Tamada et al., 2012, Yang and Lu, 2013). In humans, PK 
exists as four isoforms encoded by two distinct genes, PKL expressed mainly in liver 
cells and PKR expressed mainly in erythrocytes are encoded by the PKL/R gene 
whilst, PKM1 expressed predominantly in neuron and muscle tissue and PKM2 
which is expressed particularly in proliferating cells is encoded by the PKM2 gene. 
PKM1 exists as a tetramer and has a strong affinity for PEP, is not allosterically 
regulated or subject to phosphorylation. PKM2 exists in both tetramer and dimer 
with a strong or weak affinity for PEP respectively. High levels of tetrameric form 
correlate with high levels of lactate production, whereas high levels of the dimeric 
form correlate with increased nucleic acid synthesis. Association of the tetrameric 
form is induced by F-1,6-BP and serine whereas dissociation into the dimeric form 
occurs due to increased levels of numerous amino acids and lipids. Conversely, high 
levels of ROS have also been shown to induce PKM2 dimerization via oxidation of 
cys358 (Anastasiou et al., 2011), as has phosphorylation by fibroblast growth factor 
receptor 1 (Hitosugi et al., 2009). Interestingly PKM2 dimer form has been shown to 
translocate to the nucleus (Wang et al., 2015) where it promotes activation of HIF-1α 
genes, acts as a co-activator of β-catenin induced expression of c-MYC and 
phosphorylates STAT3 (1.1.4) (reviewed in Dong et al., 2016). 
Under aerobic conditions, the fate of pyruvate in normal cells is oxidative 
decarboxylation, catalysed by the enzyme pyruvate dehydrogenase (PDH), to form 
acetyl CoA, and entry into the citric acid cycle (1.4.4). Under hypoxic conditions 
stabilisation of HIF-1α (1.4.2.1) leads to transactivation of a gene encoding PDK1, 
which phosphorylates PDH leading to its inactivation (Kim et al., 2006a). HIF-1α, 
also upregulates LDH expression, which catalyses the conversion of pyruvate into 
lactate and oxidises NADH in the process (reviewed in Miao et al., 2013). 
1.4.3.1 Glycolysis and cancer 
As discussed above (1.4.1), a key aspect of cancer cell metabolism is the Warbug 
effect. This elevated rate of glycolytic flux and subsequent lactate secretion even in 
the presence of sufficient oxygen is common to most cancers and dysregulation of all 
steps of the glycolytic pathway have been shown to contribute to this phenotype. 
GLUT1 is ubiquitously expressed in human tissues, has a high affinity for glucose 
and high levels of expression are associated with many cancers, whilst 
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overexpression of other isoforms have also been linked to tumours specific to their 
tissue expression (reviewed in Barron et al., 2016). A recent meta-study of GLUT1 
overexpression found that it correlated with unfavourable overall survival, increased 
metastasis and larger tumour size (Yu et al., 2017b). In AML, upregulation of 
GLUT1 mRNA (Song et al., 2016) and the fructose transporter GLUT5 (Chen et al., 
2016b) have been recently reported to be associated with poor outcome in AML 
patients. Song et al similarly identified HK2 overexpression as a feature of AML 
patients who failed to show remission. HK2 is frequently overexpressed in many 
cancers including brain (Wolf et al., 2011), pancreatic (Anderson et al., 2017), 
colorectal (Katagiri et al., 2017) and liver (Guo et al., 2015) and in a recent meta-
study was associated with poor prognosis in gastric liver and colorectal but not 
pancreatic cancer (Wu et al., 2017). PGI also known as AMF is secreted by cancer 
cells and is associated with EMT transition in breast (Ahmad et al., 2011) and 
colorectal cancers (Tsutsumi et al., 2009), whilst decreased proliferation in the AML 
cell line, KG-1, was observed upon knock-down of PGI with shRNA (You et al., 
2014). 
The role of PFK in cancer appears to be mainly determined by changes in its 
regulation, as a consequence of inhibition and activation by several other 
metabolites, particularly F-2,6-BP (1.5). However, increased expression of the PFK-
L isoform correlates with increased glycolysis in breast cancer cell lines (Zancan et 
al., 2010) and is associated with poor OS in lung cancer patients where it is regulated 
via miRNA-128 and AKT signalling (Yang et al., 2016). All three isoforms of 
ALDO have also been shown to be elevated in different cancers where increased 
metastasis and poor prognosis is associated with increased expression of ALDO(A) 
in both lung (Chang et al., 2017) and pancreatic (Ji et al., 2016) cancers, ALDO(B) 
in colorectal cancer (Li et al., 2017c) and ALDO(C) in oesophageal cancer (Tao et 
al., 2017). Proteomic studies revealed elevated levels of ALDO(A), ALDO(C) and 
ENO1 in the chemoresistant leukaemia cell line K562/A02 when compared with 
parental K562 cells and in the case of ENO1 this was confirmed by western blot (Shi 
et al., 2015). Elevated levels of ENO2 have also been reported in patients with ALL 
where it is associated with lower OS (Liu et al., 2016), whilst proteomic studies have 
also suggested elevated levels of TPI can occur in human lung squamous cancer (Li 
et al., 2006). 
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GAPDH is also frequently upregulated in numerous solid tumours including lung, 
breast, gastric, liver, brain, renal and pancreatic (reviewed in Guo et al., 2013), 
whilst increased PGK1 expression is observed in breast cancer where it is associated 
with poor OS (Sun et al., 2015) and colon cancer where it is associated with 
increased metastasis (Ahmad et al., 2013). PGAM is also upregulated in colorectal, 
breast, lung and liver cancers (reviewed in Jiang et al., 2014), and in both AML and 
CML patient samples (Hitosugi et al., 2012). 
The role of PK in solid tumours, and in particular the isoform PKM2 whose 
expression is elevated in most cancers, has been the subject of much study (reviewed 
in Wong et al., 2013). As introduced above PKM2 upregulation allows control of 
glycolytic flux via it tetramer to dimer ratio. Knock-down of PKM2 in cancer cell 
lines lead to decreased glycolysis and proliferation, whilst increased expression of 
PKM2 led to increased xenograft establishment (Christofk et al., 2008). Expression 
of PKM1/PKM2 isoforms occurs due to alternative splicing, where c-MYC induced 
upregulation of heterogenous nuclear ribonucleoprotein leads predominantly to 
expression of PKM2 (David et al., 2010). Additionally, HIF-1α (1.4.2.1), increases 
expression of PKM2, whilst PKM2 interacts with HIF-1α via prolyl hydroxylase 3 
(PHD3) leading to transactivation of HIF-1α target genes. Increased mTOR activity 
(1.2.2.2) also leads to increased PKM2 expression, whilst increase in PTEN (1.3.3.2) 
inhibits PKM2 expression. Increased levels of PKM2 have been found in patients 
with lung (Schneider et al., 2002), and colon (Eigenbrodt et al., 1997) cancers, 
whilst a more recent study showed increased PKM2 levels in sixteen different 
tumour types, although this was only due to an isoform switch in glioblastoma 
(Desai et al., 2014). In contrast to solid tumours, little work has been done on PKM2 
in leukaemia. One study suggested increased PKM2 phosphorylation (and associated 
dimer formation) may be a function of LSC’s (Sturgill and Guzman, 2014), whilst a 
recent study reported that conditional expression of Runx1-ETO in the AML cell line 
U937, resulted in downregulation of PKM2 (Yan et al., 2017). 
PDK activity and expression has been shown to be upregulated in cancer as a result 
of HIF-1α and c-MYC activation (Kim et al., 2006a), whilst TP53 has also been 
shown to be a negative regulator of PDK2 both in vitro and in vivo (Contractor and 
Harris, 2012). Increased PDK1 expression is observed in non-small cell lung cancer 
tissues (Liu and Yin, 2017), overexpression of PDK2 is seen in cervical cancers 
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where it significantly correlates with metastasis (Lyng et al., 2006), whilst PDK3 is 
overexpressed in colon cancers (Lu et al., 2011). Given the observation that the 
Warburg effect increases glucose uptake, decreased oxidative phosphorylation 
resulting from increased PDK activity results either in increased conversion of 
pyruvate into lactate, or increased diversion of glycolytic intermediary metabolites 
into other metabolic pathways. LDH is a tetramer which exists as five isoforms, 
comprising of two subunits LDHA and LDHB in different combinations and 
encoded by the LDHA and LDHB genes. LDHA has the greater affinity for pyruvate 
and isoforms predominant in this protein strongly catalyse the pyruvate to lactate 
reaction and it is over expressed. The isoform LDH5 is composed of four LDHA 
subunits and is upregulated in head and neck squamous cell cancer (HNSCC) 
(Koukourakis et al., 2009), non-small-cell lung cancer (Koukourakis et al., 2003) 
and is associated with metastasis in colorectal cancer (Koukourakis et al., 2005). A 
recent study involving 204 patients with acute leukaemia also reported that LDH 
plasma levels were significantly elevated compared to healthy controls and were also 
increased in relapse patients compared to those in CR (Hu et al., 2016). 
Monocarboxylate transporters (MCT) are responsible for transporting lactate across 
the cell membrane, with MCT1 involved in both import and export, MCT2 import 
and MCT4 primarily export of lactate, with all these isoforms reported to be 
overexpressed in different tumours (reviewed in Baltazar et al., 2014). Interestingly 
in lung adenocarcinoma cells expressing mutant K-RAS, shRNA knock-down of 
LDHB resulted in decreased proliferation in vitro and in vivo and elevated 
expression of LDHB was additionally observed in K-RAS mutated tumour tissue of 
patients with lung cancer, although not in other tumour types containing this 
mutation (McCleland et al., 2013). LDHB preferentially catalyses the lactate to 
pyruvate reaction and may provide a mechanism (especially in combination with 
changes in MCT expression) by which extracellular lactate can be recycled by some 
cancers into metabolic pathways used in biosynthesis (4.4.2). 
1.4.3.2 Glycolytic inhibitors 
Given all glycolytic enzymes have been shown to be dysregulated in cancer, a 
considerable body of research exists with a view to targeting these or associated 
enzymes. As increased glucose uptake facilitated by overexpression of GLUT is a 
feature of many cancers, inhibition of these proteins represents an attractive target in 
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cancer therapy. WZB117 is a polyphenolic ester which specifically inhibits GLUT1, 
it has been shown to decrease glucose uptake and proliferation in lung and breast 
cancer cell lines, whilst a xenograft model of human lung cancer showed a 70% 
reduction in size with a daily dose of 10mg/kg (Liu et al., 2012). Natural flavonoids 
such as Naringenin have been shown to inhibit glucose uptake in the AML cell line 
U937, whilst Kaempferol inhibited both glucose uptake and lactate uptake in the 
breast cancer cell line MCF7 (reviewed in (Granchi et al., 2016). Other synthetic 
GLUT1 inhibitors such as enolic anilide fasentin 32, STF-31 as well as a series of 
methyl-ketoxime and thiazolidinedione derivatives have also been shown to reduce 
glucose uptake and decrease proliferation in cell lines. 
HK, which catalyses the first step in glycolysis has also been targeted. 2-
Deoxyglucose was one of the first drugs used to target this pathway, it is metabolised 
by HK to 2-deoxyglucose-6-phosphate which cannot be metabolised by PGI 
resulting in the inhibition of isoforms HK I, II and III. However, HK IV is not 
inhibited and the 2-deoxyglucose-6-phosphate can be metabolised through the PPP. 
Clinical trials using 2-DG alone were shown not to be effective, however in 
combination with other chemotherapeutic agents treatment efficacy was enhanced 
(reviewed in Zhao et al., 2013). Another HK inhibitor 3-bromopyruvate (which is 
also known to inhibit GAPDH) has been shown to be effective both in vitro and in 
vivo in various cancers, including AML and ALL (Akers et al., 2011) and was 
recently granted FDA orphan drug status in the treatment of liver cancer (reviewed 
in Granchi et al., 2014). Lonidamine specifically targets HK II which is frequently 
upregulated in cancers. However, despite showing efficacy in pre-clinical trials, 
phase II and phase III clinical trials showed no significant improvement in OS and 
were terminated in 2006 due to hepatotoxicity, although interest in its use has 
recently been revived (reviewed in Cervantes-Madrid et al., 2015). Targeting of 
PGAM has also recently been investigated using MJE3, which inhibited proliferation 
in breast cancer cell lines and PGAMI-004A which inhibited proliferation of both the 
AML cell line KG-1 and AML and CML cells from patients (Hitosugi et al., 2012). 
LDH inhibition has also been the target of much research, due to the increased 
expression of LDHA in many cancers, the potential role of lactate acidosis in 
metastasis (reviewed in Han et al., 2013) and the fact that its inhibition would have 
limited toxicity on normal cells, where pyruvate is typically converted to acetyl CoA. 
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Compounds such as gossypol (AT-101) is currently undergoing phase I clinical trials 
in patients with prostate cancer (Liu et al., 2009) and phase II clinical trials in 
patients with lung cancer (Baggstrom et al., 2011). FX-11 (a gossypol derivative) 
and galloflavin have also been shown to be effective in xenograft models and 
hepatocellular cell lines respectively. Using a similar rationale as for LDH, the 
lactate transporters MCT have also been targeted for inhibition. MCT inhibitors such 
as α-cyano-4-hydroxy-cinnamate and AR-C155858 (developed by AstraZeneca) 
blocked proliferation in glioblastoma cell lines and activated T-cells respectively, 
whilst the inhibitor AZD3965 is currently in phase I clinical trials for the treatment 
of diffuse large B cell lymphoma (reviewed in Doherty and Cleveland, 2013). 
Dichloroacetate (DCA), which inhibits PDK, has also been widely studied, 
sensitising prostate cancer cell lines to radiation (Cao et al., 2008), inhibiting breast 
cancer metastasis both in vitro and in vivo (Sun et al., 2010) and inducing apoptosis 
in endometrial cancer cell lines (Wong et al., 2008). Phase I clinical trials in 
glioblastoma showed DCA was well tolerated in patients (Dunbar et al., 2014), 
whilst in AML combination treatment of DCA and arsenic trioxide in AML cell lines 
showed synergistic apoptotic effects (Emadi et al., 2015). Furthermore, treatment of 
one patient with refractory AML, with DCA 11 days and arsenic trioxide for 9 days 
was tolerated, before treatment was discontinued following enrolment in an AML 
specific trial. Recently, gene expression studies showed elevated expression levels of 
PDK in BM AML patient samples compared with BM from healthy individuals, with 
in vitro studies in Runx1-eto expressing AML cells showing decreased glycolytic 
phenotype when treated with both DCA and another PDK inhibitor AZD7545 
(Kizilkaya and Reckzeh, 2016). 
 The citric acid cycle, serine synthesis and pentose phosphate pathway  
Following conversion of pyruvate into acetyl CoA, which takes place in the 
mitochondrial matrix, the reaction of this metabolite with oxaloacetate to make 
citrate is catalysed by citrate synthase, which is the first step in the citric acid cycle. 
The citric acid cycle is a series of metabolic reactions that involving 
oxidation/reduction reactions, which generate NADH and FADH via the transfer of 
hydride ions, thus providing electrons for the ETC (1.3.2.1) which is a major source 
of cellular ROS (reviewed in Wallace, 2012). Fumarate hydratase, SDH and IDH are 
frequently mutated in cancer, with IDH mutations frequently reported in AML 
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(Table 1) (1.3.3.4). SDH mutations lead to increased succinate levels and inhibition 
of PHD (1.4.2.1) as well as DNA methylation and epigenetic dysregulation. FH 
catalyses the reaction of fumarate to malate, therefore its inactivation leads to 
increased levels of fumarate which activate NRF2 (1.3.3.4). Mutations in IDH2 are 
known to cause epigenetic dysregulation and blocks in cellular differentiation. AG-
221 has been shown to inhibit this mutant IDH2 in AML cells in vitro and in vivo 
and is currently undergoing phase I/II clinical trials (Yen et al., 2017). Whilst not an 
inhibitor of the citric acid cycle, the compound IACS-10759, which targets complex 
I of the ETC (1.3.2.1) was recently shown to inhibit ATP production and oxygen 
consumption in isolated mitochondria at single digit nanomolar concentrations, 
whilst increasing median survival by greater than 50 days in AML xenograft models 
(Protopopova et al., 2015) and is currently in phase I clinical trials in AML patients. 
The SSP branches from the glycolytic pathway at the glycolytic intermediate 3-PG, 
where it is converted into 3-phosphohydroxypyruvate by the enzyme PHGDH, 
followed by conversion to phosphoserine by phosphoserine aminotransferase 1 and 
finally to serine by the action of the enzyme phosphoserine phosphatase (reviewed in 
Yang and Vousden, 2016)). Regulation of the SSP is achieved through 2-PG which 
activates PHGDH whilst serine activates the tetrameric form of PKM2 leading to 
increased glycolysis and decreased levels of 2-PG (1.4.3). Importantly serine can 
enter the folate cycle, which provides another route for the generation of NADPH, 
which has been shown to contribute to tumour growth in vivo (Ye et al., 2014). 
Overexpression of PHGDH has been reported in melanomas, colorectal and breast 
cancers, whilst knock-down of PHGDH inhibits growth of the leukaemia cell line, 
HL-60 (Polet et al., 2016). 
The PPP generate nucleotides for biosynthesis and is a major source of cellular 
NADPH an important cellular antioxidant (1.3.2.4). The first step involves the 
dehydrogenation of G-6-P to 6-phosphogluconolactone (6-PG) catalysed by G-6-PD 
and the conversion of NADP+ to NADPH (reviewed in Patra and Hay, 2014). 
Gluconolactonase catalyses the hydrolysis of 6-PG to 6-phosphogluconate, which is 
then catalysed by 6-PGD to ribulose-5-phosphate (Ru-5-P) alongside the generation 
of a second NADPH. Ru-5-P can then be converted into ribose-5-phosphate (R-5-P) 
by the enzymatic action of ribulose-5-phosphate isomerase. R-5-P, which can then 
be used in the synthesis of nucleotides. Alternatively, where redox homeostasis and 
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not nucleotide synthesis is the major requirement of the cell Ru-5-P can be catalysed 
by ribulose-5-phosphate epimerase, into xyulose-5-phosphate (X-5-P) and via a 
series of further metabolic reactions back into the glycolytic intermediates F-6-P and 
G-3-P. G-6-PD is the rate limiting step of the PPP and is regulated by the 
NADP+/NADPH ratio, RAS/PI3K signalling and phosphorylation by Src, whilst 6-
PGD is inhibited by 3-PG (Hitosugi et al., 2012). 
In cancer, aberrant RAS signalling (1.2.2.2) or activation of Src (1.3.3.2) can 
promote activation of the PPP. Mutant K-RASG12D has been shown to increase flux 
through the PPP in murine models of pancreatic cancer (Ying et al., 2012), whilst 
PI3K augmented upregulation of NRF2 in several cancer cell lines generated 
increased PPP flux (Mitsuishi et al., 2012). G-6-PD has also been shown to be 
upregulated in prostate cancer, which was reported to be modulated by mTOR 
activation (Tsouko et al., 2014). In AML, a recent study showed upregulation of G-
6-PD mRNA in approximately 60% of patients, although it was not correlated with 
OS or relapse (Chen et al., 2016c). Targeting of xenograft mice injected with the cell 
line K562 with the antimalarial drug dihydroartemisinin and the 6-PGD inhibitor 
Physicon resulted in decreased tumour growth, whilst primary leukaemia cells 
isolated from the PB of AML patients showed significantly decreased viability, with 
no toxicity observed in haematopoietic cells isolated from the PB of healthy 
individuals (Elf et al., 2017). 
1.5 The role of 6-Phosphofructo-2-kinase/fructoste-2,6-
bisphosphatase (PFKFB) in metabolism 
PFKFB is a bifunctional enzyme that catalyses the reaction of F-6-P to F-2,6-BP in 
both directions (Figure 1-8). In humans there are several isoforms encoded by four 
different genes. The PFKFB1 gene contains 17 exons, with alternative splicing 
generating three different isoforms predominantly associated with liver, muscle and 
foetal tissue. Alternative splicing of PFKFB2 generates two different isoforms both 
associated with heart tissue. The gene for PFKFB3 contains 19 exons and via 
alternative splicing generate six different isoforms, although only two are 
substantively different, the ubiquitous isoform and the inducible isoform. The 
ubiquitous isoform is distributed in numerous tissues whilst the inducible isoform is 
named due to its upregulation under conditions of hypoxia. The gene for PFKFB4   
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Figure 1-8. 6-Phosphofructo-2-kinase/fructoste-2,6-bisphosphatase (PFKFB) regulation and 
glycolysis. (A) Schematic illustration of main effectors and inhibitors of PFKFB, both as a 
phosphatase catalysing fructose-2,6-bisphosphate (F-2,6-BP) to fructose-6-phosphate (F-6-P) and as a 
kinase catalysing F-6-P to F-2,6-BP. F-2,6-BP activates phosphofructokinase (PFK) increasing 
glycolytic flux. Phosphoenolpyruvate (PEP) and citrate inhibit the kinase activity of PFKFB. Reactive 
oxygen species (ROS) increases PKM2 dimerisation, which inhibits the conversion of PEP to 
pyruvate. Sn-glycerol-3-phosphate (Sn-G-P) activates PFKFB phosphatase activity. Decreased kinase 
activity and increased phosphatase activity of PFKFB decreases glycolytic flux and potentially leads 
to increase flux through the pentose phosphate pathway, generating NADPH. Phosphorylation, S-
gluathionylation and methylation all modulate PFKFB activity. (B) Activators and inhibitors of 
PFKFB3 which shows a kinase to phosphatase activity of 740:1. Transcription factors (pink) and 
signalling pathways (blue). Glucose-6-phosphate (G-6-P), inorganic phosphate (Pi), fructose-1,6-
bisphosphate (F-1,6-BP), specificity protein 1 (SP1), activator protein 2 (AP-2), hypoxia inducible 
factor-1 alpha (HIF-1α), phosphatase and tensin homolog (pTEN), 5’adenosine monophosphate-
activated protein kinase (AMPK) p38 mitogen-activated protein kinase (p38MAPK).  
PFKFB3
SP-1
p38MAPK
AP-2
HIF-1α
AMPK PTEN
Key:
Activates
Inhibits
A 
B 
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contains 14 exons, several different splice alternatives have been identified, and 
although originally discovered in testes tissue it is also found in other tissues. The 
crystal structures of the liver form of PFKFB1 (Lee et al., 2003), PFKFB2 (Crochet 
et al., 2017), the inducible form of PFKFB3 (Kim et al., 2006b) and PFKFB4 
(Hasemann et al., 1996) have all now been determined. Whilst the catalytic domain 
of each isoform is highly conserved (85% homology), differences in the N-terminus 
and C-terminus impact on their respective kinetic properties (Cavalier et al., 2012). 
The N-terminus of PFKFB is responsible for catalysing the synthesis of F-2,6-BP 
from F-6-P and ATP, whilst the C-terminus catalyses its degradation in the reverse 
direction. The kinase to phosphatase (k/p) activity of each isoform is a key 
determinant in its metabolic role and whilst the k/p activity of PFKFB1 (liver), 
PFKFB2 and PFKFB4 are 1.2, 1.8 and 0.9 respectively, the k/p of PFKFB3 has been 
determined as 740, which is elevated to 3000 upon phosphorylation by AMPK 
(Marsin et al., 2002), resulting in increased PFKFB3 kinase activity, increased F-
2,6-P levels, increased activation of PFK and increased glycolytic flux. Kinase 
activity is additionally stimulated by inorganic phosphate, inhibited by PEP, citrate 
and sn-glycerol-3-phosphate (important in the synthesis of glycerophospholipids), 
which additionally promotes its phosphatase activity (reviewed in Ros and Schulze, 
2013). Importantly, the product of this kinase activity is F-2,6-BP, which is a 
powerful allosteric activator of PFK (Pilkis et al., 1981), a rate limiting step in 
glycolysis (1.4.3). 
 PFKFB3 
The structure of the inducible isoform of PFKFB3 consists of a polypeptide chain, 
comprising of a six-stranded β-sheet and seven α helices which form the N-terminus 
and a six-stranded β-sheet with eight α helices forming the C-terminus. The 
functional form of PFKFB3 is a homodimer with the N-termini forming a twelve-
stranded interlinked β-sheet, whilst the C-termini remain separate. The active 
binding site for ATP occurs between residues 168-179 and for F-6-P between 
residues 72 and 84. Compared with other isoforms, the PFKFB3 isoform has a serine 
at position 80 and a lysine at position 79, which allow a hydrogen bond to form 
between Tyr81 and Asp185, restricting the flexibility of the F-6-P loop, enhancing 
binding of the substrate and providing a rationale for the increased kinase activity of 
PFKFB3 (Kim et al., 2006b). 
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1.5.1.1 Regulation of PFKFB3 
PFKFB3 expression has been shown to be negatively regulated by PTEN (Figure 
1-8B). Mouse embryonic fibroblast cells with PTEN knock-down show 3-fold 
increases in F-2,6-BP concentration levels, which were ablated upon reintroduction 
of PTEN, whilst increased PFKFB3 protein levels were also observed in the knock-
down cells (Cordero-Espinoza and Hagen, 2013). The 5’ promoter region of 
PFKFB3 gene contains SP-1 and AP-2 domains (Navarro-Sabate et al., 2001), and is 
therefore a target of these transcription factors, which have roles in cell 
differentiation, growth, proliferation and apoptosis, and are additionally modulated 
by ROS (1.3.3.2). Additionally, the PFKB3 gene contains a serum response element, 
which is activated by the p38MAPK pathway (1.2.2.3) (Novellasdemunt et al., 2013), 
and a HRE (Obach et al., 2004) which is a target of HIF-1α (1.4.2.1). 
From an oncogenic perspective, increased aerobic glycolysis is known to decrease 
extracellular pH, through increased lactate production (1.4.3) which is important in 
metastasis. One study, using the DB-1 cell line showed increased AMPK activation 
under conditions of low pH resulted in both increased protein expression of PFKFB3 
and increased phosphorylation of PFKFB3 at Ser-461, leading to increased 
glycolysis (Mendoza et al., 2012). Interestingly however, AMPK activation in 
colorectal cancer cell lines showed increased GLUT1, HKII and PFKFB3 expression 
and glycolysis immediately following activation, but long term activation resulted in 
cell death (Yu et al., 2017a). 
1.5.1.2 Post-translational modifications of PFKFB3 
In addition to phosphorylation of Ser-461 by AMPK (1.5.1.1), increased sonic 
hedgehog signalling (which is associated with increased tumour size and progression 
in breast cancer) was shown to lead to increased glycolysis and proliferation in 
breast cancer cell lines, not as a function of increased expression of PFKFB3, but 
due to phosphorylation of Ser-461 (Ge et al., 2015b). In the AML cell line U937, 
methylation of Arg-131 and Arg-134 were also shown to increase PFKFB3 kinase 
activity (Yamamoto et al., 2014). Other post-translational modifications such as by 
IκB kinase β (IKKβ) have been shown to downregulate PFKFB3. As discussed 
previously (1.3.3.4), ROS stimulated IKKβ phosphorylates IκB proteins, resulting in 
their dissociation from NF-κB and its translocation to the nucleus where it regulates 
genes involved in proliferation and apoptosis. However it was also shown, in HEK 
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293T cells, that IKKβ can also directly phosphorylate PFKFB3 at Ser-269 leading to 
its inhibition and decreased glycolytic flux (Reid et al., 2016). S-glutathionylation of 
PFKFB3 has also been shown to occur under conditions of high ROS, resulting in 
decreased kinase activity (Seo and Lee, 2014). HeLa cells treated with exogenous 
H2O2 showed S-glutathionylation of PFKFB3, decreased levels of F-2,6-BP and 
increased concentrations of Ru-5-P and X-5-P. Resolution of the crystal structure 
revealed this modification occurred at Cys-206, followed by the formation of a 
hydrogen bond at Gln-199. Alternatively, downregulation of miR-206 and increased 
mRNA and protein expression of PFKFB3, was shown to be a feature of oestrogen 
receptor alpha positive breast cancer cells (Ge et al., 2015a). Here it was shown that 
miR-206 downregulated PFKFB3 expression, and therefore decreased glycolysis, via 
direct interaction with the PFKFB3 mRNA. 
1.5.1.3 PFKFB3 and its inhibition in cancer 
Immunohistochemical staining for PFKFB3 expression has shown elevated levels of 
this enzyme in colon, prostate, breast, lung, pancreatic, ovarian, kidney and thyroid 
tumour tissue (Atsumi et al., 2002), whilst staining of 111 HNSCC tissues, also 
revealed elevated expression in nearly all samples (Li et al., 2017a). Analysis of 40 
astrocytic glioma brain tissue samples showed protein levels of PFKFB3 are 
markedly elevated in high grade astrocytomas (Kessler et al., 2008), whilst mRNA 
levels of all PFKFB isoforms have been shown to be upregulated in malignant 
gastric tissue (Bobarykina et al., 2006). Overexpression of PFKFB3 has also been 
shown to dysregulate circadian clock genes, which in turn enhance PFKFB3 
expression in tongue cancer (Chen et al., 2016a). In the breast cancer cell lines T47D 
and MCF7, PFKFB3 expression and phosphorylation at Ser-461, were both shown to 
increase in response to progestin (Novellasdemunt et al., 2012). In AML a recent 
study has shown that knock-down of the tumour suppressor protein, tuberous 
sclerosis 2 leads to elevated expression of PFKFB3 in AML cell lines via activation 
of mTOR (Feng and Wu, 2017). Furthermore, treatment of these cells with the 
PFKFB3 inhibitor 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15) and 
rapamycin showed synergistic suppression of proliferation. 
PFK-15 is an analogue of the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-
propen-1-one (3PO) and shows improved pharmokinetic properties compared to 3PO 
(Clem et al., 2013). 3PO has previously been shown to inhibit proliferation, 
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alongside glucose uptake and cellular F-2,6-BP levels, in the Jurkat T-cell leukaemia 
cell line and solid tumour cell lines as well as inhibiting tumour growth in murine 
xenograft models of Lewis lung carcinoma, MDAMB231 breast adenocarcinoma 
and HL-60 promyelocytic leukaemia (Clem et al., 2008). PFK-15 has been shown to 
both, inhibit proliferation and induce apoptosis in gastric cancer cell lines, and 
decrease tumour growth in vivo (Zhu et al., 2016). In HNSCC xenograft models, 
PFK-15 has also been shown to be effective in suppressing tumour growth and 
metastasis (Li et al., 2017a). 
Administration of Oestradiol to breast cancer patients increases glucose uptake and 
has been linked to increased PFKFB3 expression (Imbert-Fernandez et al., 2014). 
Treatment of breast cancer cell lines with both Oestradiol and another analogue of 
3PO, 1-(pyridine-4-yl)-3-(7-(trifluoromethyl)-quinolin-2-yl)-prop-2-en-1-one 
(PFK158), or Oestradiol in cell lines with PFKFB3 knocked-down, resulted in 
decreased F-2,6-BP levels and glucose uptake. PFK158 (which is currently 
undergoing phase I clinical trials) has also been shown to be effective against 
chemoresistant ovarian cancer cell lines (Mondal et al., 2015), whilst treatment of 
A375 melanoma xenograft bearing mice in combination with the RAS inhibitor 
Vemurafenib resulted in >80% tumour inhibition and 50% tumour regression 
(compared to 80% inhibition and no regression in the stand alone therapy) (Telang et 
al., 2015).  
1.5.1.4 Moonlighting functions of PFKFB3 
In addition to PFKFB’s role in glycolysis (1.5), the isoform PFKFB3 also plays a 
role in cell cycle regulation and autophagy. Localisation of PFKFB3 to the nucleus 
was first observed in HeLa and HCT116 cell lines (Yalcin et al., 2009a), whilst a 
later study revealed PFKFB3 catalysed production of F-2,6-BP in the nucleus, which 
promoted the phosphorylation of protein p27 by CDK1 leading to its degradation 
and inhibition of cell cycle arrest (Yalcin et al., 2014). 
Links between autophagy and PFKFB3 were first made in T-cells of patients with 
rheumatoid arthritis, where decreased glucose metabolism and autophagy was 
observed compared to control. Analysis of expression of glycolytic genes revealed 
decreased expression of PFKFB3 mRNA, which was confirmed at a protein level 
(Yang et al., 2013), alongside increased levels of NADPH. A further study suggested 
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that starvation of HeLa cells resulted in phosphorylation of p38MAPK by ROS, 
stabilisation of HIF-1α and increased expression of GLUT3, whilst at the same time 
increasing proteasome degradation of PFKFB3. This proposed mechanism increases 
cellular glucose uptake whilst shifting metabolism away from glycolysis and into the 
PPP and is observed alongside an decrease in autophagy (Desideri et al., 2014). 
However, another study involving pharmacological inhibition of PFKFB3 in colon 
adenocarcinoma cell lines showed decreased cellular glucose uptake, alongside 
increased levels of ROS and increased autophagy (Klarer et al., 2014). These 
apparently contradictory results may reflect different cellular responses to differing 
concentrations of ROS (i.e. S-glutathionylation (1.5.1.2), or differences in regulatory 
mechanisms between the cell lines (i.e. TIGAR (1.5.2)) or be reflective of different 
experimental conditions, such as glucose availability, impacting differently on the 
cellular responses. However, they do suggest that PFKFB3 may be central in 
managing an intricate balance between cellular metabolic requirements and redox 
regulation. 
 TP53-induced glycolysis and apoptosis regulator (TIGAR) 
TIGAR is an enzyme encoded by the gene C12orf5 which is induced by TP53 (Jen 
and Cheung, 2005). It contains an active binding site which is closely related to the 
phosphatase site of PFKFB and catalyses the hydrolysis of F-2,6-BP and F-1,6-BP to 
F-6-P (Li and Jogl, 2009). Consequently, it has been shown that TIGAR can be 
rapidly induced by TP53 in response to cellular stress, leading to decreased 
glycolysis and cellular ROS, as a result of the diversion of metabolites into the PPP 
(Bensaad et al., 2006). Furthermore, knock-down of PFKFB3 has been shown to 
induce TIGAR expression via AKT signalling in HeLa cells (Simon-Molas et al., 
2016). TIGAR has been shown to be highly expressed in a number of cancers 
including breast (Won et al., 2012), nasopharyngeal (Zhao et al., 2016b) and 
glioblastoma (Wanka et al., 2012). Recently TIGAR overexpression has been shown 
to be associated with poor prognosis in patients with cytogenetically normal AML 
(Qian et al., 2016) and CLL (Hong et al., 2016). 
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1.6 Aims and Objectives 
In the last twenty years, it has become increasingly clear that ROS play a significant 
role in cellular signalling, particularly pathways associated with growth, 
differentiation and survival. In many cancers ROS levels have been shown to be 
elevated, leading to aberrant signalling in these pathways. Work in our group has 
previously reported increased levels of NOX2-derived ROS in HPC infected with 
mutant RAS, AML cell lines and AML blasts. Furthermore, this increased ROS was 
shown to be correlated with a pro-proliferative phenotype. Coupled with this, mRNA 
microarray and Metacore pathway analysis of mutant RAS expressing HPC 
identified significant ROS-dependant up-regulation of genes associated with 
glycolysis, linking ROS production to the possible induction of the Warburg effect 
(which increases the rate of aerobic glycolysis in transformed cells). There is 
however, no direct evidence demonstrating a role for ROS in modulating metabolism 
in AML, nor what impact this may have on proliferation of these cells.  
 
Therefore, the main aims of this study are to: 
(i) Determine ROS dependent changes in glucose uptake, extracellular 
lactate secretion and proliferation in AML models.  
To address this the effect of ROS modulation on glucose and lactate 
levels will be assayed, both in HPC expressing mutant RAS and in 
AML cell lines. 
 
(ii) Determine the ROS-dependent transcriptional and translational 
changes affecting glycolytic enzymes in AML models. 
Previously generated mRNA microarray data will be subjected to a 
supervised analysis focussing on glycolytic enzymes. 
Correspondingly, the effect of ROS on the protein expression of 
glycolytic enzymes in the above AML models will be determined by 
immunoblotting. 
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(iii) Determine ROS dependent perturbations of metabolites in AML 
models. 
The impact of ROS levels on the concentrations of cellular 
metabolites in AML cell lines and AML patient blasts will be 
determined using a variety of mass spectrometry platforms. 
(iv) Determine the mechanism by which any ROS-dependent changes in 
glycolysis occur. 
Overexpression, knock-down and chemical inhibition will be used to 
attempt to elucidate the mechanism through which ROS mediates 
changes in glycolytic activity in experimental models of AML. 
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 Materials and Methods 
2.1 Materials and reagents 
Materials are grouped by supplier and listed in alphabetical order below.  
 Ampicillin, 7-aminoactinomycin (7-AAD), boric acid, bovine serum albumin 
fraction V (BSA), Bradford’s reagent, calcium chloride (CaCl2), catalase, 
chloroquine, cobalt chloride (CoCl2), deoxyribonuclease (DNAse), 
Dimethylsulphoxide (DMSO), diphenyleneiodonium (DPI), Dulbecco Modified 
Eagle Medium (DMEM), ethanol, ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA), ethylenediaminetetraacetic acid (EDTA), 
glucose, glucose oxidase (GOX), glycerol, Iscove’s Modified Dulbecco’s Medium 
(IMDM), isopropanol, kanamycin, L-glutamine, magnesium chloride (MgCl2), 2-
mercaptoethanol, poly-L-lysine solution, polyethylene glycol sorbitan (Tween-20), 
Ponceau S solution, potassium dihydrogen phosphate (KH2PO4), Roswell Park 
Memorial Institute 1640 medium (RPMI), sodium chloride (NaCl), sodium 
orthovanadate (Na3VO4) sodium phosphate (Na2HPO4), triethylammonium 
bicarbonate (TEAB) lysis buffer (composed of 0.5M TEAB 5mL, 0.05% w/v SDS 50 
µL, Protease Inhibitor Cocktail 100 µL, Phosphatase Inhibitor Cocktail P0044, 
Phosphatase Inhibitor Cocktail P5726, sucrose, tris(hydroxymethyl)aminomethane 
(Tris), Tris-borate EDTA (TBE) buffer (composed of 89mM Tris, 89mM boric acid, 
2mM EDTA), tris(hydroxymethyl)aminomethane (Tris), 4-(1,1,3,3-
tetramethylbutyl)phenyl-polyethylene glycol (X100 Triton), were purchased from 
Sigma-Aldrich, Poole, U.K.).  
 Agarose, dithiothretiol (DTT), Hank’s Balanced Salt Solution (HBSS), 
human Granulocyte Colony-Stimulating Factor (G-CSF), human Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) human interleukin-3 (IL-3), human 
interleukin-6 (IL-6), Phosphate Buffered Saline (PBS), human Stem Cell Factor 
(SCF), streptomycin, Super-Optimal medium (SOC) (comprising 0.5% w/v yeast 
extract, 2% w/v tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4 
and 20mM glucose), trypsin were purchased from Invitrogen, Paisley, U.K.  
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 Anti-CD34 magnetically labelled microbeads, Fc receptor blocking agent, 
Mini-MACS Kit, MS Column were purchased from Miltenyi Biotec, Bisley, U.K. 
Human Fms-like tyrosine kinase-3 ligand (FLT3) were purchased from Peprotech, 
London, U.K. Complete mini EDTA-free protease inhibitor tablets, 30% iron 
saturated human transferrin were purchased from Roche, Welwyn Garden City, U.K. 
Bacto-TryptoneTM, Bacto-yeastTM, Ficoll-PacqueTM were purchased from BD 
Biosciences, Oxford, U.K. Gentamycin were purchased from Sanofi-Aventis, 
Guildford, U.K.. Heparin were purchased from Leo Laboratories Ltd, Princes 
Risborough, U.K. Tris-acetate-EDTA (TAE buffer) (composed of 40mM Tris, 
20mM acetic acid, 1mM EDTA) were purchased from Thermo-Scientific, 
Loughborough, U.K. Seakem CTGTM Agarose powder were purchased from Lonza, 
Nottingham, U.K. Peq Green were purchased from Peqlab, Lutterworth, U.K. 
Retronectin were purchased from Takara Bio, Paris, France. 2-(N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl) amino)-2-D-deoxyglucose (2-NBDG) and TrizolTM were 
purchased from Life Technologies, Glasgow, U.K. 3-Benzyl-7-(2-benzoxazolyl) 
thio-1,2,3-triazolo (4,5-d) pyrimidine (VAS-2870) were purchased from ENZO-life 
sciences, Exeter, U.K. Magnesium acetate was purchased from Fisons Scientific 
Equipment, Loughborough, U.K. Benzonase were purchased from Novagen, 
Nottingham, U.K. 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), 1-
(pyridine-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one (PFK158) were 
purchased from Axon Medchem, Groningen, Netherlands. Recombinant Human 
HIF-1α protein were purchased from Abcam, Cambridge, UK. Foetal bovine serum 
(FBS) was purchased from Labtech, Heathfield, U.K. Tissue culture grade water was 
purchased from Hameln pharmaceuticals, Gloucester, U.K. Cytarabine (ARA-C) was 
purchased from University Hospital of Wales pharmacy, Cardiff, U.K. Plasticware 
was purchased from Iwaki Biosciences, Iwaki, Japan and Nunc, Roskilde, Denmark 
unless otherwise stated. 
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2.1.1 Antibodies 
Antibodies used in this study are listed below in alphabetical order along with the 
clone number, application, concentration used and manufacturer. 
 
Table 2. List of antibodies used in this study. Antibodies are listed in alphabetical order. BIOSS 
(Aachen, Germany), CST (Cell Signalling Technology, Leiden, Netherlands), MBL Life science 
(Nagoya, Japan), Merck Millipore (Feltham, U.K.), Santa-Cruz (Heidlberg, Germany) Serotec 
(Oxford, U.K.), GE Healthcare (Little Chalfont, U.K.). Abbreviations: murine (Mu), rabbit (Rb) 
monoclonal antibody (mAb), polyclonal antibody (pAb), flow cytometry (FC), western blot (WB), 
concentration (Concn). 
Antibody Clone Use Concn Manufacturer 
Beta actin Mu mAb 8226 WB 0.5ng/µL Abcam 
Aldolase (A) ALDO(A) Rb mAb D73H4 WB 1ng/µL CST 
Aldolase (C) ALDO(C) Rb pAb WB 10ng/µL Abcam 
Anti-mouse HRP Sheep WB 2ng/µL GE Healthcare 
Anti-rabbit HRP Sheep WB 2ng/µL GE Healthcare 
CD34-PE Mu mAb 8G12? FC 5ng/µL BD Biosciences 
CD45-PerCP Mu mAb MEM28 FC 1ng/μl Abcam 
Enolase 1 (ENO1) Rb mAb D2S1A WB 1ng/µL CST 
Fructose-1,6-bisphosphatase 
1 (FBP1) 
Rb mAb 
EPR4620 
WB 1ng/µL Abcam 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
Rb mAb D16H11 WB 0.5ng/µL CST 
Glucose transporter 3 
(GLUT3) 
Rb mAb 
EPR10508(N) 
WB 1ng/µL Abcam 
Glucose transporter 5 
(GLUT)5 
Mu mAb 12F2 WB 2ng/µL Abcam 
Hexokinase 1 (HK1) Rb mAb C35C4 WB 2ng/µL CST 
Histone H1 Mu mAb AG4 WB 2ng/µL Serotec 
Hypoxia-inducible factor 1-
alpha (HIF-1α) 
Mu mAb 54 WB 10ng/µL BD Biosciences 
Immunoglobulin G1-PE 
(IgG1-PE) 
Mu mAb MOPC-
31C 
FC 5ng/µL BD Biosciences 
Lactate dehydrogenase (A) 
(LDH(A)) 
Rb mAb C4B5 WB 1ng/µL CST 
Monocarboxylate transporter 
4 (MCT4) 
Rb pAb WB 1ng/µL Abcam 
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NOX2-PE Mu mAb 7D5 FC 5ng/µL MBL 
p38MAPK Rb pAb WB 2ng/µL CST 
Phospho-p38MAPK Rb mAb 
(Thr180/Tyr182) 
D3F9 
WB 2ng/µL CST 
Phosphofructokinase (P) 
(PFK(P)) 
Rb mAb D2E5 WB 1ng/µL CST 
6-phosphofructokinase/ 
fructose-2,6-biphosphatase 3 
(PFKFB3) 
Rb mAb D7H4Q WB 1ng/µL CST 
Phospho-6-
phosphofructokinase/ 
fructose-2,6-biphosphatase 3 
(phospho-PFKFB3) 
Rb pAb (Ser 466) WB 2ng/µL BIOSS 
Phosphoglucose isomerase 
(PGI) 
Rb mAb 
EPR11663(B) 
WB 5ng/µL Abcam 
Phosphoglycerate mutase 1 
(PGAM1) 
Rb mAb D3J9T WB 2ng/µL CST 
Phosphoglycerate kinase 
(PGK) 
Rb mAb 
EPR14908 
WB 2ng/µL Abcam 
Pyruvate kinase (M) 1 
(PK(M)1) 
Rb mAb D30G6 WB 1ng/µL CST 
Pyruvate kinase (M) 2 
(PK(M)2) 
Rb mAb D78A4 WB 1ng/µL CST 
H-RAS Rb pAb WB 10ng/μl Santa-Cruz 
N-RAS Mu mAb OP25 WB 10ng/µL Merck 
Triphosphate isomerase 
(TPI) 
Rb mAb 
EPR12149(B) 
WB 1ng/µL Abcam 
α-Tubulin Rb mAb EP1332 WB 1ng/µL Abcam 
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2.2 Recombinant DNA methodology 
Full length human cDNA encoding PFKFB3 variant 2 (NCBI reference sequence 
NM-001145443.2) (Figure 2-1A) flanked by DNA sequences for BamH1 and EcoR1 
restriction sites (to allow directional subcloning into the PINCO vector (Figure 
2-1B)), and XbaI and HpaI (to allow directional subcloning into the pHIV vector 
(Figure 2-1C) (2.2.3.2) was purchased from Eurofins MWG (Ebersberg, Germany).  
The sequence was supplied in the pEX-K4 expression vector containing sequences 
for kanamycin resistance (pEX-K4 PFKFB3).  
Five shRNA sequences complementary to PFKFB3 (TRC2 N0000314690, TRC2 
N0000314746-8, TRC2 N0000381874 (appendix 1)), were purchased from 
MissionTM, Sigma-Aldrich in the TRC2-pLKO.5-puro lentiviral vector expressing 
puromycin and ampicillin resistance (Figure 2-1D), which had been transformed into 
DH5α-T1R competent Escherichia coli (E.coli) cells. TRC2-pLKO.5-puro non-
mammalian shRNA control plasmid DNA, dissolved in TE buffer (500ng/µL), 
expressing puromycin and ampicillin resistance was purchased from MissionTM, 
Sigma-Aldrich.  
Five shRNA sequences complementary to HIF-1α (TRC N0000003808-11, TRC 
N0000010819 (appendix 2)) in TRC1-pLKO.5-puro lentiviral vector DNA and 
expressing puromycin and ampicillin resistance (Figure 2-1E), dissolved in TE 
buffer (500ng/µL), were purchased from MissionTM, Sigma-Aldrich. TRC1-pLKO.5-
puro non-mammalian shRNA control plasmid DNA, dissolved in TE buffer 
(500ng/µL), expressing puromycin and ampicillin resistance had previously been 
purchased from MissionTM, Sigma-Aldrich, and THP-1 cells previously infected with 
this control.  
In addition, full length cDNA encoding N-RASG12D (kindly provided by Alan Hall, 
University College of London, U.K.) and H-RASG12V (kindly provided by Julian 
Downward, CRUK London Research Institute, U.K.) had previously been sub-
cloned by blunt cloning into the BamH1 site of the retroviral expression vector 
PINCO (gift of Pier Pelicci, European Institute of Oncology, Milan, Italy), which co-
expresses green fluorescent protein GFP from an internal cytomegalovirus (CMV) 
promoter (Grignani et al., 1998) and into the PINCO vector expressing DsRed 
(kindly provided by Dr. Alex Tonks, Cardiff University, U.K.). Control PINCO 
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vectors (expressing GFP or DsRed alone) for N-RASG12D and H-RASG12V 
experiments had also been previously generated by insertion of non-mammalian 
encoding DNA (1.2Kb) into the PINCO plasmid, to prevent excessive expression of 
reporter genes. Plasmid DNA had subsequently been transformed into competent 
E.coli cells and was available in our laboratory. The integrity of N-RASG12D and H-
RASG12V in the PINCO plasmid had previously been checked by sequencing and by 
functional assay (Hole, 2010). 
2.2.1 Transformation of competent E.coli with recombinant plasmid DNA 
To generate sufficient plasmid DNA for transfection, DNA amplification was 
performed in chemically competent E.coli One Shot Stabl3TM cells (Invitrogen, 
Loughborough, UK). Cells were thawed on ice, 20ng (5µL) of cDNA (see 2.2) 
added, then incubated on ice for 30 min, at 42oC for 30sec then on ice for a further 2 
min. SOC media (250μl) (Invitrogen), prewarmed to 42oC, was added and cells 
shaken at 225 rpm at 37oC for 1h. 
Selective Luria-Bertani (LB) broth was made using Bacto-Tryptone (10g) (BD 
Bioscience), Bacto-yeast extract (5g) (BD Bioscience), NaCl (10g) (Sigma) 
dissolved in dH2O (1L) and autoclaved. LB agar was made as for LB broth but with 
the addition of agarose (15g) (Invitrogen). Transformed E.coli cells (50µL) was 
spread over kanamycin (Sigma) or ampicillin (Sigma) (50µg/mL) selective LB agar 
plates (30mL) and incubated overnight at 37oC. A single isolated colony was 
selected to inoculate kanamycin (Sigma) or ampicillin (Sigma) (50µg/mL) selective 
LB broth (5mL). The broth was shaken at 225rpm, 37oC for 7h, diluted in kanamycin 
(Sigma) or ampicillin (Sigma) (50µg/mL) selective LB broth, before incubation 
overnight at 37oC on a rotary shaker (225rpm). Prior to isolation of recombinant 
plasmid DNA (2.2.2), inoculated broth (850µL) was added to glycerol (150µL) 
(Sigma) and stored at -80oC. 
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Figure 2-1. Plasmid vectors and PFKFB3 sequence used in study. Vector maps showing 
sequences of interest of (A) PFKFB3 (var2) (blue represents PFKFB3 gene, green represents 
additional DNA sequence, coding for restriction sites shown, to allow subcloning of gene) (B) 
PINCO, (C) pHIV-EGFP, (D) p-LKO.2-puro, (E) p-LKO.1-puro and (E) PFKFB3. Black lines show 
digestion sites for restriction enzymes. U6 (RNA polymerase III U6 promoter) , cppt (central 
polypurine tract), hPGK (human phosphoglcerate kinase eukaryotic promoter), puroR (puromycin 
resistance), SIN3’LTR (3’self inactivating long terminal repeat), f1 ori (f1 origin of replication), 
ampR (ampicillin resistance), pUC ori (pUC origin of replication), RSV 5’LTR (Rous Sarcoma virus 
5’ long terminal repeat), ΨPsi (RNA packaging signal), RRE (Rev response element), WPRE 
(woodchuck hepatitis post-transcriptional regulatory element), CMV (cytomegalovirus promoter), 
GFP (green fluorescent protein) DsRed (red fluorescent protein), pUC (pUC prokaryotic control 
sequence), EBNA1 (Epstein-Barr virus nuclear antigen 1), oriP (Epstein-Barr virus origin of 
replication), EF1a (human elongation factor-1 alpha) IRES (internal ribosome entry site).  
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2.2.2 Isolation and quantitation of recombinant plasmid DNA 
Transformed E.coli cells (2.2.1) in selective LB broth (150mL) was centrifuged at 
6,000g, 4oC for 15 min and plasmid DNA was extracted by alkaline lysis and salt 
precipitation, using the QIAGEN HiSpeed Plasmid Maxi Kit (QIAGEN, 
Manchester, UK), according to the manufacturer’s instructions. Briefly, the bacterial 
pellet was lysed in proprietary buffer P1 (containing RNase A) (10mL) and 
proprietary buffer P2 (10mL), mixed by inversion, incubated at room temperature 
(RT) for 5 min, before addition of proprietary buffer P3 (10mL). Lysate was 
transferred to a QIA filter cartridge, incubated at RT for 10 min, then the lysate 
filtered into a HiSpeed Maxi tip (previously equilibrated with proprietary QBT 
buffer (10mL) and allowed to pass through the resin by gravity flow. The tip was 
washed with proprietary QC buffer x2 (30mL). Plasmid DNA was eluted with 15mL 
of proprietary QF buffer, precipitated using 10.5mL of isopropanol (Sigma) and 
incubated at RT for 5 min. The elute was passed through a QIA precipitator using a 
30mL syringe to isolate the plasmid DNA, washed with 70% v/v ethanol (2mL) 
(Sigma) and air dried by syringing air through the precipitator. The plasmid DNA 
was then collected by passing TE buffer (1mL) through the precipitator, the collected 
elute was then passed through the precipitator once more to maximise DNA 
recovery. The isolated plasmid DNA was then quantified using a NanoDrop ND-
1000 spectrophotometer (Thermoscientific, Loughborough, UK), according to the 
manufacturer’s instructions and DNA purity measured by confirming the A260/280 
ratio range was between 1.8-2. 
2.2.3 Generation of retroviral and lentiviral vectors encoding PFKFB3 
2.2.3.1 Excision and isolation of PFKFB3 DNA 
To express PFKFB3 in haematopoietic cells, this gene was directionally subcloned 
into the PINCO retroviral expression vector.  Initially, PFKFB3 DNA was excised 
from the pEX-K4 vector prior to ligation into either the PINCO vector (co-
expressing DsRed as a reporter gene) or the pHIV vector (conferring puromycin 
resistance). PFKFB3 DNA was excised from the pEX-K4 vector using BamH1 high 
fidelity (HF) (50U) and EcoIR1 HF (50U) restriction enzymes, or XbaI HF (80U) 
and HpaI HF (75U) restriction enzymes (NEB, Ipswich, UK) (Figure 2-1B&C). 
Plasmid DNA (pEX-K4 PFKFB3) (5µg) was incubated with restriction enzymes and 
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NEB buffer 4 (NEB) (composed of 5mM potassium acetate, 2mM tris-acetate, 1mM 
magnesium acetate and 0.1mM dithioreitol) for 1h at 37oC in a water bath. 
To separate the PFKFB3 ‘insert’ agarose gel electrophoresis was performed using 
low melting point agar. Seakem CTGTM Agarose powder (1g) (Lonza) was dissolved 
in TAE buffer (100mL) (Thermoscientific) and 25mL poured into a flat-bed 
electrophoresis tank. DNA gel loading dye (Thermoscientific) was added at a ratio of 
1:6 to the digest DNA, loaded onto the gel and electrophoresed at 40V for 3h. DNA 
was visualised using a UV longwave transilluminator (UVP high performance, 
Cambridge, U.K.) and the fragment corresponding to the PFKFB3 insert was excised 
from the gel using a scalpel. DNA was extracted from the gel using a QIAquickTM 
gel extraction kit (QIAGEN), according to the manufacturer’s instructions. Briefly, 
proprietary buffer QG was added in the ratio 3:1 to the gel, incubated at 500C for 10 
min, isoproponal (Sigma) added at a 1:1 ratio to the gel and the mixture added to a 
QIAquick column and centrifuged for 1 min at 12,782g. QG buffer (500µL) was 
added to the column and centrifuged as above to ensure removal of agarose traces. 
Proprietary PE buffer (750µL) was added to the column, incubated for 4 min and 
centrifuged as above. DNA was eluted using proprietary EB buffer (50µL). The 
isolated plasmid DNA was then quantified using a NanoDrop ND-1000 
spectrophotometer, according to the manufacturer’s instructions and DNA purity 
measured by confirming the A260/280 ratio range was between 1.8 - 2. 
2.2.3.2 Ligation of PFKFB3 DNA into retroviral or lentiviral vectors 
To allow subcloning of PFKFB3 DNA, linearization of the target vectors (PINCO or 
pHIV) was performed. PINCO vector (5µg) was added to tissue culture grade 
sterilised water (35µLμ) (Hameln), NEB buffer 3 (5µL) (NEB) (composed of 
100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 1mM DTT) prior to addition of the 
restriction enzymes EcoRI (20U) and BamHI (20U). The pHIV vector (2µg) was 
added to tissue culture grade sterilised water (38.5µL) (Hameln), NEB buffer 4 
(5µL) (NEB), 1% v/v BSA (Sigma) in PBS (Invitrogen), prior to addition of the 
restriction enzymes HpaI (20U) and XbaI (20U). Controls, with the restriction 
enzymes replaced with water were also performed. The vector and restriction 
enzyme mix (or controls) were then incubated for 1h at 37oC, and the DNA purified 
using a Qiaquick purification kit (Qiagen), according to the manufacturer’s 
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instructions. The linearized vector DNA was then quantified using a NanoDrop ND-
1000 spectrophotometer as above. To confirm linearization of the vectors agarose 
powder (0.8g) (Invitrogen) was dissolved in TBE buffer (100mL) (Sigma) and 25mL 
poured into a flat-bed electrophoresis tank with Peq Green (1µL) (Peqlab). The 
control and digested vector DNA was loaded onto the gel alongside a NEB 1Kb 
ladder and electrophoresed for 1h at 80V. Gels were visualised by ultraviolet light in 
a LAS-3000 digital imaging device to confirm different migration rates through the 
gel (data not shown). Subcloning of the PFKFB3 DNA sequence into the PINCO 
and pHIV vectors was subsequently achieved by incubating insert and vector DNA 
at a molar ratio of 1:10 (8µL) with T4 DNA ligase (20U) (NEB) and T4 DNA ligase 
reaction buffer (1µL) (NEB) (composed of 50mM Tris-HCl, 10mM MgCl2, 1mM 
ATP and 10mM DTT) at 16oC for 4h. Plasmid DNA was subsequently transformed 
into competent E.coli cells (2.2). 
2.2.3.3 Verification of PFKFB3 ligation 
To verify successful ligation and orientation of the PFKFB3 DNA, a ‘test digest’ 
was performed using the restriction enzymes SmaI (20U/µL) (NEB) for the pHIV 
subcloned vector and ScaI (10U/µL) (NEB) for the subcloned PINCO vector (Figure 
2-1A-C). Plasmid DNA (0.1-1µg) was incubated with and without the restriction 
enzyme (1µL), CutSmartTM buffer (1µL) (NEB) (composed of 5mM potassium 
acetate, 2mM tris-acetate, 1mM magnesium acetate and 100µg/mL BSA) and dH2O 
(8µL) for 70 min at 25oC in a water bath. The DNA was electrophoresed and 
visualised as above (2.2.3.2) and compared with expected fragment sizes calculated 
using pDraw32 v.1.1.128 (Acaclone software). 
To confirm integrity of the PFKFB3 sequence in the vectors, DNA sequencing was 
performed by Eurofins MWG Operon’s SMARTSeq KIT sequencing service. Vector 
DNA containing the PFKFB3 insert (750-1500ng) was mixed with 2µL of primer 
(Table 3) (20pmol/µL) and sent to Eurofins for direct sanger sequencing (5.3.3.1). 
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Table 3. Primers used for direct sequencing. Table shows the primers used for sequencing of the 
PINCO and pHIV vectors containing PFKFB3 (var.2) DNA. P1 and P2 were used for the sequencing 
of the PINCO vector and P3-5 for the pHIV vector. Full sequence results can be found (appendix 
3&4) 
 
Primer Target vector 
of sequence 
Sense Sequence 
P1 PINCO Forward 5’ TAG AAC CTC GCT GGA AAG GA 3’ 
 
P2 PINCO Reverse 5’ TTA TGT AAC GCG GAA CTC CA 3’ 
 
P3 pHIV Forward 5’ TGG AAT TTG CCC TTT TTG AG 3’ 
 
P4 PFKFB3 Forward 5' AGA AGC CAT GGA CGA CTT CA 3' 
 
P5 PFKFB3 Forward 5' GGA AGG CGC TCA ATG AGA TC 3' 
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2.3 Cell culture and cryopreservation  
All tissue culture work was carried out in a Class II biosafety cabinet and waste 
disinfected with bleach or autoclaved. Cells were cultured under aseptic conditions at 
37oC in 5% CO2 unless otherwise specified. 
2.3.1 Cryopreservation of cells 
Cryopreserved cells were thawed by immersion in 37oC water bath for 2 min 
followed by dropwise addition of 5mL culture medium over 3 min. Cell suspension 
was then centrifuged at 270g for 5 min and resuspended in appropriate growth 
medium at the recommended density as below (2.3.3). Cryopreservation of cells was 
achieved by adding 500µL of IMDM (Sigma) (supplemented with 10% v/v FBS 
(Labtech), 2mM L-glutamine (Sigma) and 20µg/mL gentamycin (Sanofi-Aventis)) 
and additionally containing 30% v/v FBS (Labtech) and 20% v/v DMSO (Sigma) to 
500µL of cell suspension of fully confluent cells (e.g. 1 vial frozen per confluent F25 
flask) in 1.8mL cryovials (Thermoscientific). Cryovials were placed in Nalgene Mr 
FrostyTM controlled freezing containers (Thermoscientific), containing 100% 
isopropanol (Sigma) and stored in -80oC freezer overnight, before transfer of vials to 
liquid nitrogen storage containers. 
2.3.2 Isolation of haematopoietic progenitor cells 
Neonatal cord blood was obtained from healthy full-term pregnancies at the 
Maternity Unit of the University Hospital of Wales in Cardiff, with the informed 
consent of mothers undertaking Caesarian sections with the approval of research 
ethics committee in accordance with the 1964 declaration of Helsinki. Cord blood 
was collected in falcon tubes (50mL) containing 200µL of heparin (1000U/mL) (Leo 
Laboratories Ltd) and 400µL of PBS (Invitrogen). Initially, in order to estimate the 
number of CD34+ cells present, immunophenotyping of cord blood was performed 
and proportion of CD34+ cells was estimated using flow cytometric analysis 
(2.3.2.1). 
Mononuclear cells were isolated from cord blood by density gradient centrifugation 
using Ficoll-PaqueTM (BD Biosciences). Cord blood was diluted with an equal 
volume of HBSS (Invitrogen) additionally containing HEPES (25mM) (Invitrogen), 
gentamycin (20µg/mL) (Sanofi-Aventis) and heparin (1U/mL) (Leo Laboratories 
Ltd). The diluted cord blood was layered (7:5) on top of Ficoll-PaqueTM (BD 
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Biosciences) and centrifuged at 400g for 40 min. The layer of mononuclear cells 
found at the plasma-Ficoll interface was recovered using syringe and quill, added to 
RPMI (15mL) Sigma) (containing 5% v/v FBS (Labtech) and 1U/mL heparin (Leo 
Laboratories Ltd)) and centrifuged at 270g for 10 min. Cells were resuspended in 
RPMI (20mL) (Sigma), (190µL removed and added to zaponin (1.5µL) ( Beckman-
Coulter, Galway, Ireland) for counting by haemocytometer) and centrifuged at 270g 
for 10 min. Cells were frozen at approximately 5 x 107 cells/mL (2.3.1) prior to 
isolation of CD34+ using a Mini-MACS CD34+ Progenitor Cell Isolation Kit 
(Miltenyi Biotec, Bisley, UK), according to the manufacturer’s instructions.  
Briefly, previously frozen mononuclear cells were thawed (2.3.1) in the presence of 
0.45µM filtered FBS (900µL/mL of cells) (Labtech) and DNase (100µg/mL) 
(Sigma). An equivalent volume of degassed MAC buffer (consisting of PBS 
(Invitrogen), 0.5% v/v BSA and 5mM MgCl2 (both Sigma)) was added dropwise 
over 3 min and this step repeated twice. Cells were centrifuged at 270g for 10 min, 
resuspended in MAC’s buffer (6.7 x 108 cells/mL), and incubated at 4oC for 15 min 
in the presence of anti-CD34 antibody (2 x 109 cells/mL) and Fc receptor blocking 
agent (2 x 109 cells/mL). Cells were washed in MACs buffer (2 x 107 cells/mL), 
centrifuged at 270g for 5 min, resuspended in MACs buffer (5 x 108 cells/mL) and 
incubated at 4oC for 15 min in the presence of anti-FC magnetic microbeads (2 x 109 
cells/mL), washed as above and filtered through a MS separation column (previously 
equilibrated with MACs buffer) in the presence of a magnetic field. The CD34+ cells 
were eluted from the column with MACs buffer (1mL) in the absence of a magnetic 
field, counted by haemocytometer (2.3.4) and cultured according to section (2.3.3.3). 
2.3.2.1 Immunphenotyping of cord blood  
CD34 is a cell surface marker for HPC (1.1.1.1). Therefore to determine HPC 
numbers in the sample, cord blood (15µL) was mixed with anti-CD45-peridinin 
chlorophyll (PerCP) labelled antibody (10µL) (BD Biosciences) and either anti-
CD34-phycoerythrin (PE) (BD Biosciences) labelled antibody (10µL) or isotype 
matched control antibody, IgG1-PE (10µL) (BD Biosciences), then incubated at 4oC 
for 30 min. Lysis buffer (BD Biosciences) was added and cells incubated for a 
further 10 min at RT. Cells were washed with PBS (5mL) (Sigma), centrifuged at 
270g for 5 min, resuspended in PBS (200µL) (Sigma) and analysed using an Accuri 
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C6 flow cytometer coupled with FCS express ver.6 software to determine the 
proportion of mononuclear cells (PerCP labelled) and CD34+ cells (PE labelled).  
Flow cytometric analysis is described in (2.12). 
2.3.3 Cell culture 
2.3.3.1 Cell culture of non-adherent cell lines 
The myeloid leukaemic cell lines NOMO-1, THP-1, Mv4;11, KG-1 and U937 were 
obtained from the European Collection of Authenticated Cell Cultures (ECACC) 
(Porton Down, Salisbury, UK). NOMO-1, THP-1 and U937 cells were cultured in 
RPMI (Sigma), supplemented with 10% v/v FBS (Labtech), 2mM L-glutamine 
(Sigma) and 20µg/mL gentamycin (Sanofi-Aventis). Mv4;11 cells were cultured in 
IMDM (Sigma) supplemented with 10% v/v FBS (Labtech), 2mM L-glutamine 
(Sigma) and 20µg/mL gentamycin (Sanofi-Aventis) and KG-1 cells were cultured in 
IMDM (Sigma) supplemented with 20% v/v FBS (Labtech), 4mM L-glutamine 
(Sigma) and 20µg/mL gentamycin (Sanofi-Aventis). 
Additionally, THP-1 and NOMO-1 cells lentivirally transduced (2.5) with shRNA 
complementary to NOX2 mRNA and encoding puromycin resistance and control 
cells (THPSH and NOMOSH) which had been transfected with shRNA coding for a 
non-mammalian target sequence, were kindly provided by Professor Richard Darley 
and cultured as for NOMO-1 and THP-1 cells.  
Cells were cultured at a cell density of between 1 x 105 and 5 x 105 / mL and passage 
number did not exceed 20. Cell density was determined prior to subculturing by 
haemocytometer or flow cytometry (2.3.4). 
2.3.3.2 Cell culture of adherent cell lines 
The packaging cell lines Phoenix (gift of Garry Nolan, Stanford University School of 
Medicine, Stanford) or HEK293T (ECACC) were cultured in DMEM (Sigma), 
supplemented with 10% v/v FBS (Labtech), 2mM L-glutamine (Sigma) and 
20µg/mL gentamycin (Sanofi-Aventis) and incubated at 37oC. Confluent cells were 
detached from plasticware by addition of trypsin (Invitrogen) (500µg/mL), 
incubation for 5 min at room temperature (RT) followed by equal addition of 
appropriate growth medium (5mL) and disaggregation. Cells were harvested by 
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centrifugation at 270g for 5 min, washed in PBS (Invitrogen), counted (2.3.4) and 
then cultured according to (2.4.1).  
2.3.3.3 Cell culture of haematopoietic progenitor cells 
Isolated HPC (2.3.2) at an initial cell seeding density of 2 x 105 cells/mL were 
cultured in ‘HPC media mix’ (IMDM (Sigma) containing 20% v/v FBS (Labtech), 
1% v/v deionised bovine serum albumin fraction V (BSA) (Sigma), 45µM 2-
mercaptoethanol (Sigma), 360µg/mL 30% iron saturated human transferrin (Roche) 
and 100µg/mL streptomycin (Invitrogen)) supplemented with growth factors as 
described below. Following isolation of HPC (subsequently defined as day 0), cells 
were cultured (days 0-3) as above with the addition of human growth factors IL-3 
(50 ng/mL), IL-6 (25 ng/mL), SCF (50 ng/mL), G-CSF (25 ng/mL), GM-SCF (25 
ng/mL) (all purchased from Invitrogen) and Flt3 (50 ng/mL) (Peprotech), 
subsequently defined as 36Shi medium. After day 3, cells were cultured in HPC 
media mix alone, or with the addition of 5ng/mL of IL-3, SCF, GM-CSF and C-CSF 
(Invitrogen), subsequently defined as 3SloGGM medium. In some experiments HPC 
were cultured in 3SloGGM until day 5 and thereafter in HPC media mix alone. Cell 
density culture conditions are described in the individual results section (3.3) 
2.3.4 Cell counting 
Counting by haemocytometer was accomplished by adding 10µL of cells to a 
haemocytometer counting chamber, containing nine, 100nl cuboids and multiplying 
the average number of cells per cuboid by 1 x 104 to obtain number of cells per mL. 
Counting by flow cytometry was performed by adding 100uL of cells to a FACS 
tube, running 25µL through a Accuri C6 flow cytometer and analysing the data using 
FCS express ver.6 software (2.12). After excluding cell debris based on forward 
scattered light and side scattered light (FSC/SSC), the number of events was 
multiplied by 40 to obtain number of cells per mL. 
2.3.5 Determination of cell viability using 7-AAD 
7-AAD is a molecule that intercalates with DNA resulting in a spectral shift with an 
emission wavelength (λ) of 647nm. 7-AAD is excluded from live cells but can 
permeate the membrane of non-viable cells. To determine cell viability, 7-AAD 
(1µg/mL) (Sigma) was added to cells, incubated at RT for 10 min and analysed using 
an Accuri C6 flow cytometer in conjunction with FCS express ver.6 software (2.12). 
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2.4 Generation of recombinant virus 
Generation of retrovirus was achieved using Phoenix packaging cells (gift of Garry 
Nolan, Stanford University School of Medicine, Stanford) and lentivirus was 
generated using HEK293T cells. Virus was generated using either calcium phosphate 
transfection (2.4.1) or cationic lipid transfection (2.4.2). Mock culture supernatant 
was achieved by culturing cells as below, without transfecting DNA. All work was 
carried out in a class II biosafety cabinet and centrifugation steps performed in 
sealed safety cups. Incubation of flasks was performed inside a sealed Perspex box. 
All waste was disinfected with bleach and subsequently autoclaved. Double gloves 
were worn throughout. 
2.4.1 Calcium phosphate transfection 
HEK293T or Phoenix cells were cultured in DMEM (Sigma) as above (2.3.3.2) and 
then transfected with recombinant plasmid DNA. The day prior to transfection cells 
were counted and seeded at 1 x 107 cells / F75 Flask (Phoenix cells) or 7.5 x 106 
(HEK293T cells) / F75 Flask. For HEK293T cells, culture flasks were pre-treated 
with 5mL of 0.01% w/v poly-L-lysine solution (Sigma), incubated at RT for 30 min, 
then washed with PBS (Invitrogen). 
For retroviral transfection, tissue culture grade sterile water was mixed with 45µg of 
plasmid DNA (except H-RASG12V (12µg)) and 45 µL of CaCl2 (2.5M) (Sigma) and 
added dropwise to 450 µL HEPES buffer (50mM) (Invitrogen) to give a total volume 
of 900µL, whilst the solution was bubbled with a pipette. The solution was 
immediately vortexed for 4s and left to precipitate for 20 min. Five minutes prior to 
transfection, 15 µL of 25 µM chloroquine (Sigma) was added to the Phoenix 
cultures, then the DNA was added dropwise and the cells were incubated at 37℃ in a 
humidified incubator with 5% CO2. After 16h the media was replaced with 8 mL of 
fresh medium and cells incubated for a further 24h at 33oC. Viral supernatant was 
collected following centrifugation at 270g to remove cells that had been dislodged 
from the flask, then snap frozen and stored in liquid nitrogen. In some instances, 
cells were collected and lysed for analysis of target protein expression (2.9). In 
addition, where cells were infected with virus encoding for GFP/dsRed expression 
visual inspection by fluorescent microscope and flow cytometric analysis were 
performed (2.12). 
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Lentiviral transfection was achieved using HEK293T cells as above, except 25µg of 
plasmid DNA was used, alongside 8µg of envelope plasmid DNA (pMD2.G) and 
15µg of packaging plasmid DNA (psPAX2). 
2.4.2 Cationic lipid transfection 
Cationic lipid transfection was achieved using the Lipofectamine 3000TM kit 
(Invitrogen), according to the manufacturer’s instructions. Briefly, cells were seeded 
at 9 x 106 cells/mL in 75cm2 surface area culture flasks, on the day prior to infection. 
For retroviral infection, 48µL of proprietary P3000 reagent was mixed with 15µg of 
plasmid DNA and added to proprietary OptiMEM medium to make a total volume of 
2070µL. Proprietary reagent Lipofectamine 3000 (57µL) was then mixed with 
OptiMEM medium (2025µL), added to the DNA mix and incubated at RT for 15 
min. Total flask medium was reduced to 5mL, the DNA added to the cells and 
incubated at 37oC with 5% CO2 for 6h. The flask medium was aspirated, replaced 
with DMEM (9mL) and incubated at 37oC with 5% CO2 for 16h, before the viral 
supernatant was collected as above. Lentiviral transfection was performed as above 
except 4.5µg of plasmid DNA was used, alongside 4.8µg pMD2.G and 8.7µg 
psPAX2. 
2.5 Infection of cells 
In order to infect cells with virus, 24-well plates were coated with retronectin 
(30µg/mL) (Takara Bio) and incubated at 40C overnight. The retronectin was 
aspirated and replaced with 250 µL of 1% v/v BSA (Sigma) in PBS (Invitrogen) and 
left for 30 min. The BSA was aspirated and replaced with 1 mL retroviral or 
lentiviral supernatant. The culture plate was centrifuged at 2272 x g for 2 hours at 
12oC. The supernatant was removed from the wells and replaced with either HPC (2 
x 105 cells/mL) or cell lines (2-5 x 105 cells/mL) and subsequently incubated at 37oC 
overnight. For retroviral infection the process was repeated, the cells were removed 
to an incubator (37oC, 5% CO2), the wells were treated with retrovirus as above and 
the cells returned to the wells and incubated at 37oC, 5% CO2 overnight. 
Cells expressing GFP or DsRed were assessed alongside mock cultures (2.4) by flow 
cytometry (2.12) to measure infection rates (for HPC this was day 3 post-isolation 
(2.3.3.3). Cells were centrifuged at 270g for 5 min, washed in PBS (Invitrogen), 
centrifuged at 270g for 5 min resuspended in PBS and analysed using an Accuri C6 
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flow cytometer and FCS express ver.6 software (2.12). Autoflourescence of the 
mock cultures defined the threshold of GFP/DsRed positivity, which was set at 99%. 
Infected HPC were additionally probed with an anti-CD34-PE conjugated antibody 
or with a matched IgG1 isotype control (both BD Bioscience) to confirm 
homogeneity of the cells. Here cells were treated as above only prior to washing with 
PBS cells were treated with the antibody (Table 2) and incubated for 30 min at 4oC. 
Cells infected with DNA encoding puromycin resistance were cultured in 
appropriate media (2.3.3) treated with puromycin (1µg/mL) alongside mock cultures 
(2.4) and cell viability assessed daily using 7-AAD (2.3.5) until no viable mock 
culture cells remained, thus establishing a pure population of infected cells. 
2.6 Determination of NOX2 expression and detection of superoxide 
using DiogenesTM 
2.6.1 Determination of NOX2 expression 
To determine expression levels of NOX2 in the NOMO-1 and THP-1 cell lines, cells 
(50K) were treated with a NOX2 PE conjugated antibody (5ng/μL) or an isotype 
matched control (Table 2), incubated for 45 min at 4oC and then analysed by an 
Accuri C6 flow cytometer in conjunction with FCS express ver.6 software (2.12). 
2.6.2 Detection of superoxide using DiogenesTM 
Superoxide measurement of KG-1, U937, MV4;11, NOMO-1 and THP-1 cell lines 
was carried out using the chemiluminescent probe DiogenesTM (National 
Diagnostics, Hessle, U.K.). Cells were counted, centrifuged at 270g for 5 min, 
washed in PBS (5mL) (Invitrogen), centrifuged at 270g for 5 min and resuspended in 
standard buffer (KH2PO4 (4.58mM), Na2HPO4 (8.03mM), NaCl (130mM), KCl 
(4.43mM), glucose (5.55mM), MgCl2 (0.5mM), CaCl2 (0.45mM), BSA (0.1% v/v) 
all purchased from Sigma) at 1 x 106 cells/mL. Cells (150K) were added in triplicate 
to a white FluoroNunc Maxisorp 96 well plate and DiogenesTM reagent (50µL) 
added. Luminescence was measured over 2h at 37oC, using a Chameleon Hidex 
fluorescent plate reader, according to the manufacturer’s instructions. 
Chemiluminescent traces were plotted according to light emission rate, measured as 
relative light units (RLU), against time and either peak RLU compared, or the area 
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under the curve calculated, using the trapezium rule, and given as a measure of total 
superoxide production during the assay. 
2.7 Determination of cellular glucose consumption and lactate 
secretion 
To determine cellular glucose consumption and lactate secretion, cells were counted, 
seeded and treated, according to the experimental conditions (see individual result 
sections) before being incubated, at 37oC, 5% CO2, for a time as described in the 
individual result sections. 
2.7.1 Glucose and lactate assay of culture media 
Post-incubation, cells were counted and centrifuged at 270g for 5 min. Supernatant 
from the culture media was filtered using Microcon-10 kDa centrifugal filter units 
(Merck-Millipore, Feltham, UK) at 12,782g for 30 min. The levels of D-glucose and 
L-Lactate were measured by fluorimetry using a glucose and L-Lactate assay kit 
(Abcam, Cambridge, UK) coupled with a Chameleon Hidex fluorescent plate reader 
(Ex/Em 535/590 nm), according to the manufacturer’s instructions. Briefly, samples 
were diluted with proprietary glucose or lactate buffer to a volume of 50µL and 
added in triplicate to a black 96 well flat bottomed microclear plate (Greiner Bio-
One, Stonehouse, UK). Glucose or lactate buffer containing proprietary glucose or 
lactate probe (0.8% v/v) and proprietary glucose or lactate enzyme mix (0.8% v/v) 
were added (50µL) to each well and left to incubate in the dark at RT for 30 min. 
Fluorescence was measured (Ex/Em 535/590nm) and compared with glucose or 
lactate standards assayed in duplicate on the same plate. Glucose or lactate 
concentration of the samples was determined from the linear part of the standard 
curve generated from the supplied glucose or lactate standards (0–1 nmol/well), 
according to the equation:  
y = mx + c 
where y is the average relative light units recorded by the plate reader for each 
glucose/lactate standard, x is the concentration of the glucose/lactate standard, c is 
the point of y-axis intersection obtained from the line of best fit (drawn according to 
the least square method) and m is the slope of the line of best fit.  
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2.7.2 Measurement of individual cellular glucose uptake 
To determine cellular glucose uptake at the individual cell level, the glucose 
bioprobe 2-NBDG (Life Technologies) was employed in conjunction with flow 
cytometry. Cells were washed twice in PBS (Invitrogen) then treated with 2-NBDG 
(10µM) or PBS alone (to establish a background control) followed by incubation for 
10 min (37oC, 5% CO2) and two washes in ice cold PBS (Invitrogen). Cells were 
immediately analysed by flow cytometry using an Acurri C6 flow cytometer in 
conjunction with FCS express ver.6 software (2.12). 2-NBDG emits fluorescence at 
a wavelength of 542nM. Having excluded cell debris based on FSC/SSC, the median 
glucose uptake per cell of the samples was established by subtracting the median 
value of fluorescence of the background control cells from the median value of 
fluorescence of the cells treated with 2-NBDG. 
2.8 Method for determining effective dose of PFKFB3 inhibitors 
using CellTiter-GloTM assay 
To determine the half maximal effective concentrations (EC50) of the PFKFB3 
inhibitors 3PO and PFK158, a CellTiter-Glo luminescent cell viability assay 
(Promega, Southampton, UK) was used, according to the manufacturer’s 
instructions. Briefly, cells were cultured in a white 96-well culture plate in the 
presence of serial dilutions of inhibitor for 24h at 37oC in a humidified incubator 
with 5% CO2. Prior to analysis, the plate was equilibrated at RT for 30 min then 
proprietary CellTiter-Glo reagentTM, was added in equal volume to the culture 
media, mixed on an orbital shaker for 2 min and incubated at RT for 10 min. 
Luminescence was measured immediately, at a single time point, using a Chameleon 
Hidex fluorescent plate reader according to the manufacturer’s instructions. Light 
emission was measured in RLU and plotted against inhibitor concentration to 
generate a sigmoid curve. The EC50 was determined from the sigmoid curve as the 
concentration corresponding to a 50% change from highest to lowest RLU. 
2.9 Determination of cellular protein expression 
To determine the expression levels of cellular proteins as a result of different 
experimental conditions (see individual results sections), HPC or cells from AML-
derived cell lines (5 million cells for HPC and Mv4;11 and 2 million cells for THP-1 
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and NOMO-1 derived cells) were centrifuged at 270g for 5 min and washed in tris-
buffered saline (TBS) (composed of 1M Tris-HCl, 130mM NaCl (both Sigma)) 
(10mL), followed by centrifugation at 270g for 5 min and the supernatant removed 
and flash frozen in liquid nitrogen. Frozen cells were stored at -80oC or used below. 
2.9.1 Whole cell lysate extraction 
Frozen cell pellets (2.9) were thawed on ice in the presence of DNase (1µg) (Sigma). 
Cells were treated with lysis buffer (composed of 10 mM HEPES-KOH (Invitrogen), 
10 mM 2-mercaptoethanol (Sigma), 1mM magnesium acetate (Fisons Scientific 
Equipment), 0.5 mM EDTA (Sigma), 0.5 mM EGTA (Sigma), 0.25 M sucrose 
(Sigma), 1 mM Na3VO4 (Sigma),1 complete mini EDTA protease inhibitor tablet per 
10 mL (Roche), 1% v/v x100-Triton (Sigma)) (2 x 107 cells/mL), vortexed, incubated 
on ice for 30 min and subjected to occasional vortexing. The cell lysate was 
centrifuged at 12,782g for 5 min at 4oC and the protein concentration of the 
supernatant determined by Bradford assay (2.9.3). 
2.9.2 Nuclear/Cytosol Extraction and Fractionation 
THP-1 cells centrifuged at 270g for 5 min, washed in TBS (10mL) as above and the 
supernatant removed leaving washed cell pellets for nuclear/cytosol fractionation 
using a kit from Biovision (California, USA), according to the manufacturer’s 
instructions. Briefly, cell pellets were resuspended in proprietary cytosol extraction 
buffer A (100µL/million cells) containing protease inhibitor cocktail (2µL) and 
dithiothreitol (1µL). Cells were vortexed (15s), incubated on ice for 10 min, cytosol 
extraction buffer B (5.5µL/million cells) added, vortexed (5 sec) and incubated on 
ice for a further minute. Cells were then vortexed for 5s, centrifuged at 12,782g for 8 
min at 4oC and the supernatant (containing the cytosolic extract) collected and stored 
at -800C. The remaining cell pellet was washed in PBS (Invitrogen) containing 
MgCl2 (0.5mM) (Sigma), centrifuged at 12,782g for 3 min at 4oC, the supernatant 
discarded and the pellet snap frozen in liquid nitrogen. The samples were subjected 
to three rapid freeze/thaw cycles in liquid nitrogen followed by addition of 
Benzonase (25U/µL) (Novagen) at 2µL/million cells. The samples were kept on ice 
for 60 min before TEAB lysis buffer was added at 10µL/million cells.  The samples 
were kept on ice for a further 30 min, subjected to occasional vortexing, before being 
centrifuged at 12,782 x g for 10 min at 4oC and the supernatant stored at -80oC. 
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Protein quantification of the nuclear and cytosol extracts was performed, as 
described below (2.9.3). 
2.9.3 Protein concentration quantification 
Bradford’s reagent (Sigma) was diluted 1:1 with tissue culture grade sterilised water 
(Hameln) and 190μl added to duplicates of the cell lysate sample (10μl), diluted 20-
fold with tissue culture grade sterilised water (Hameln), in a 96-well flat-bottomed 
plate. The plate was equilibrated to RT for 10 min, then absorbance measured 
(590nm) using a spectrophotometer (ASYS Hitech, GmbH, Eugendorf, Austria) and 
compared with BSA protein standards (0-10 μg/mL) assayed in duplicate on the 
same plate. Protein concentration of the cell lysate was determined from the linear 
part of the standard curve as described above (2.7). Variation between duplicates of 
the measured absorbance of the protein standards was limited to a co-efficient of 
variation (CV) of 5% and variation between cell lysates duplicates limited to 10% 
CV.  
2.9.4 Protein electrophoresis and electroblotting 
Proteins were separated by SDS-PAGE using Nu-PAGE 4-12% Bis-Tris Mini Gels 
(Invitrogen) and electroblotted according to the manufacturer’s instructions using 
proprietary Nu-Page reagents purchased from Invitrogen. 
Prior to separation by electrophoresis, denaturation and reduction of disulphide 
bonds was performed. Protein extracts, from the cell lysates, were incubated at 70oC 
for 10 min in the presence of Nu-Page x1 LDS buffer (containing lithium dodecyl 
sulphate) (Invitrogen) and 50mM DTT (Invitrogen). To ensure an equal volume of 
protein across samples in the final denatured protein extracts, the volume of protein 
added was adjusted with tissue culture grade sterilised water (Hameln), according to 
the value determined from the Bradford’s assay (2.9.3), to a final concentration of 
1μg/μL. 
Bis-Tris gels were placed in a X-Cell IITM mini-cell containing x1 running buffer 
(composed of 50mM 3-(N-morpholino)propanesulfonic acid, 50mM tris base, 0.1% 
w/v sodium dodecyl sulphate and 0.25% antioxidant, and proteins loaded (20μg) on 
to the gels alongside x1 LDS buffer, containing 5% v/v MagicMark XPTM, to allow 
visualisation of protein molecular weight. Following 200 volts electrophoresis for 50 
min gels (x1 or x2) were placed in a X-Cell IITM blotting module, next to a 
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nitrocellulose membrane in the presence of x1 transfer buffer containing methanol 
(10% v/v for 1 gel or 20% v/v for 2 gels) and electroblotted at 30 volts for 60 min. 
Electroblotted membranes were washed in dH2O on a plate shaker for 5 min (x2) and 
proteins visualised using Ponceau S solution (1.3mM Ponceau S, 0.83M ethanoic 
acid) (Sigma), in order to facilitate cutting of membrane if required. Membranes 
were subsequently washed as above, incubated on a plate shaker for 60 min in TBS-
T (TBS buffer with 0.1% v/v Tween-20) and 2% w/v milk powder (Marvel), then 
washed for 15 min in TBS-T and then a further three times for 5 min in TBS-T. 
Membranes were subsequently used for immunoblotting. 
2.9.5 Immunoblotting 
Membranes were incubated overnight at 4oC, in 10 mL TBS-T containing 2% w/v 
milk powder, containing antibodies at concentrations described in (Table 2). 
Membranes were washed with 20mL of TBS-T for 15 min on a plate shaker 
followed by three subsequent 20 mL washes for 5 min. Subsequent incubation of the 
membrane occurred at RT on a plate shaker in the presence of TBS-T containing 1% 
w/v milk powder and secondary anti-mouse or anti-rabbit horse radish peroxide 
conjugated antibody (GE Healthcare), diluted 1:5000, for 60 min. Following 
incubation, membranes were washed four times in TBS-T as above and target 
proteins were visualised using the ECL Advance Detection Kit (GE Healthcare), 
according to the manufacturer’s instructions. Chemiluminescence was detected using 
a LAS-3000 image analyser (Fujifilm UK Ltd) and analysed using AIDA Image 
Analyser Version 4.19 (Fujifilm UK Ltd). To confirm equal loading of proteins the 
nitrocellulose membrane was washed and reprobed as above using anti- β-actin or 
anti- α-tubulin for whole cell protein extraction, or anti- β-actin for cytosol protein 
extraction and anti-histone H1 for nuclear protein extraction (Table 2). Relative 
changes in protein expression were measured using AIDA Image Analyser software 
(Raytest, Straubenhardt, Germany). Briefly, the area of a region of interest was 
determined and the pixel density of this region compared with equivalent areas of 
interest. The pixel density of equal sized areas around the comparative areas of 
interest was used to determine the background signal, which was subtracted prior to 
comparison, and the relative pixel density levels normalised to the control sample. 
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2.10 Analysis of microarray data of ROS induced changes in mRNA 
expression in HPC 
Gene expression profiling, using Affymetrix Genechip® whole transcriptome 
microarray, had previously been performed in our laboratory to determine significant 
ROS dependent changes in mRNA expression of human HPC expressing mutant N-
RAS (N-RASG12D) compared with control HPC (Hopkins, 2014). Briefly RNA from 
four transduced cultures (Figure 2-2) was isolated and processed for hybridisation to 
GeneChip® Human Exon 1.0ST array, before being analysed by Central 
Biotechnology Services (University of Cardiff, UK), using the Ambion WT 
Expression Kit, according to the manufacturer’s instructions. 
In this study, identification of ROS mediated changes in mRNA expression of 
glycolytic enzymes was achieved by supervised analysis of the gene expression 
profiling data, using a full extended probe set (probes supported by exon prediction 
algorithms including GeneID, GenScan, Exoniphy, RNAGene, spgGene and 
Twinscan), by Partek Genomics Suite software (ver. 6.6, Partek Inc., USA). Raw 
data files were imported using Affymetrix annotation files and Robust Multi-Array 
analysis algorithm was used for Exon level expression analysis. Adjustments were 
made for guanine-cytosine content and probe sequence on pre-background 
subtracted values, and background correction, quantile normalisation and median 
polishing (to remove chip effect) performed. Log2 data transformation was then 
performed and mRNA expression levels of control HPC were compared with mRNA 
expression levels of control HPC treated with DPI (100nM) and N-RASG12D both 
untreated and treated with DPI. A 2-way ANOVA based on  
Yijk = μ + Ci + Cj + εijk 
where Yijk is the kth observation on the ith condition of the jth cord blood replicate 
(random variability between samples), μ is the common effect for the whole 
experiment, Ci is the ith condition (experimental treatment e.g. DPI), Cj is the jth cord 
blood replicate (random variability between samples) and εijk is the random error of 
the kth observation of the ith condition of the jth replicate, was used to identify 
statistically significant changes in gene expression. Fisher’s Least Significance 
Difference was performed for control vs control + DPI, control vs N-RASG12D and 
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N-RASG12D vs N-RASG12D + DPI (Figure 2-2), and where possible the Benjamini-
Hochberg multiple testing correction was applied or the level of significance was 
reduced to p<0.01. 
2.11 Metabolomic analysis of ROS induced changes in metabolites 
using chromatography-mass-spectroscopy. 
Metabolomics can be used to study relative differences in metabolite levels between 
samples. MetabolonTM (http://www.metabolon.com/) is a company that specialises in 
performing and analysing metabolomic data generated using ultrahigh performance 
liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) and gas-
chromatography mass-spectroscopy (GC-MS). Two studies were designed to 
compare ROS mediated changes in cellular metabolites of both AML-derived cell 
lines and AML patient blasts. 
2.11.1 Strategy for metabolomic study of ROS induced changes in metabolites in 
AML-derived cell lines 
For the cell line study, three cell lines were used: 
- THPSH control cells (2.3.3.1) were compared with THPSH cells treated with 
DPI (100nM) and THP cells in which NOX2 was knocked down using 
shRNA (THP NOX2-KD); 
- NOMOSH control cells (2.3.3.1) were compared with NOMOSH cells 
treated with DPI (100nM) and NOMO cells in which NOX2 was knocked 
down using shRNA (NOMO NOX2-KD); 
- Mv4;11 control cells (treated with 0.0018% v/v DMSO (vehicle control) were 
compared with Mv4;11 cells treated with GOX, either 10mU/mL or 
20mU/mL.  
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Figure 2-2. Strategy for determining ROS mediated changes in mRNA expression in N-
RASG12D. Control HPC and HPC expressing mutant N-RAS were cultured with or without DPI 
(100nM) for 18h and isolated RNA investigated using GeneChipTM Human Exon 1.0ST arrays. 
Significant ROS mediated changes in mRNA expression levels were then determined using Partek 
Genomics Suite software (ver. 6.6, Partek Inc., USA) 
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All cells were seeded at 5 x 105 under the conditions outlined above and incubated 
for a further 24h at 37oC in a humidified incubator with 5% CO2. Following 
incubation cells were counted by flow cytometry (2.3.4), viability determined using 
7-AAD (2.3.5) and glucose uptake measured using the 2-NBDG bioprobe (2.7.2). 
Cell samples (of 30 million cells) were required to show > 90% viability and > 10% 
change in glucose uptake, in order to be processed (see below) and sent for 
metabolomic analysis. Additionally, NOX2 generated superoxide was determined in 
the THP and NOMO cell lines using DiogenesTM (2.6.2), to verify that knock-down 
of NOX2 or DPI treatment decreased superoxide production. Samples fulfilling this 
criteria, were centrifuged at 270g for 10 min at 4oC, in conical propylene centrifuge 
tubes (Scientific Laboratory Supplies, Nottingham, UK), previously treated with 1% 
v/v BSA. Samples meeting the above criteria, were washed in PBS (10mL) (Sigma), 
centrifuged as before, resuspended in PBS (10mL). 30 million cells were pipetted 
into a conical propylene centrifuge tubes pre-treated with 1% v/v BSA, centrifuged 
as previously, flash frozen in liquid nitrogen and stored at -80oC. Quadruplicate 
samples per condition, were shipped on dry ice to MetabolonTM for analysis. 
Additionally, cells from each sample were isolated for future determination of 
relative changes in cellular protein expression and cross reference with other cellular 
protein extractions from other experiments, determined under equivalent 
experimental conditions (2.9). 
2.11.2 Strategy for metabolomic study of ROS induced changes in metabolites in 
AML patient blasts 
Peripheral blood and bone marrow samples collected from a random cohort of AML 
patients who had enrolled in UK MRC/NCRI AML 14-17 clinical trials at point of 
diagnosis, before treatment and following informed consent from patients in 
accordance with the 1964 Declaration of Helsinki, were used in this study. 
Samples (n=36), were selected randomly, thawed (2.3.1), counted and analysed for 
viability using 7-AAD (2.3.5). Only those samples with a cell count greater than 30 
million and a viability greater than 80% were sent for analysis by MetabolonTM 
(n=20). Additionally, mononuclear cells isolated from healthy individuals (n=6) 
were also sent to MetabolonTM as a comparative control. DiogenesTM analysis of 
AML blasts (2.6.2) stratified the patient samples into ROSHi and ROSLo producing 
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AML blasts (Figure 4-14). Samples were not processed to determine glucose uptake, 
but otherwise all steps were performed as above (2.9). 
2.11.3 Metabolomic analysis of studies 
Metabolomic analysis of the samples was carried out by MetabolonTM 
(http://www.metabolon.com/). Briefly, protein removal and metabolite recovery was 
performed by vigorous shaking in methanol, followed by centrifugation. The extract 
was divided into five fractions and organic solvent removed using TurboVapTM. 
Quality control was performed using a pooled matrix sample from all experimental 
samples as a technical replicate, water samples as blanks, solvent samples used in 
extraction and a cocktail of standards (chosen not to interfere with endogenous 
compounds) spiked into each sample to aid chromatographic alignment. Instrument 
variability was determined from the median relative standard deviation of the spiked 
standards (< 2%) and process variability from the median relative standard deviation 
of the endogenous metabolites in the pooled standard (<7%). 
Cell line samples were analysed using UPLC-MS/MS, utilising Waters ACQUITY 
UPLC and Thermoscientific Q-Exactive high resolution mass spectrometer 
interfaced with a heated electrospray ionisation source and Orbitrap mass analyser. 
Four of the sample aliquots were analysed using either a C18 column (Water UPLC 
BEH C18-2.1x100mm, 1.7µM) or a HILIC column (Waters UPLC BEH Amide 
2.1x150mm, 1.7µM), under the following conditions: 
(i) Acidic positive ion conditions, chromatographically optimised for more 
hydrophilic compounds. Extract gradient eluted from a C18 column using 
methanol, acetonitrile, water, 0.05% perfluoropentanoic acid (PFPA) and 
0.1% formic acid. 
(ii) Acidic positive ion conditions, chromatographically optimised for more 
hydrophobic compounds. Extract gradient eluted from a C18 column 
using methanol, acetonitrile, water, 0.05% PFPA and 0.01% formic acid. 
(iii) Basic negative ion conditions. Extract gradient eluted from a C18 column 
using methanol, water, and 6.5mM ammonium bicarbonate (pH 8). 
(iv) Basic negative ion conditions. Extract gradient eluted from a HILIC 
column using water, acetonitrile and 10mM ammonium formate (pH 
10.8). 
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AML patient blast sample extracts were analysed as above except analysis (ii) was 
not performed and analysis of (i) was performed without PFPA. Additionally, GC-
MS was performed on one aliquot. Briefly, samples were dried under vacuum for 
18h, derivatised under dried nitrogen using bistrimethyl-silyltrifluoroacetamide and 
separated on a 5% diphenyl / 95% dimethyl polysiloxane fused silica column (20m x 
0.18mm ID; 0.18µM film thickness) using helium as a carrier gas (temperature range 
60-340oC of 17.5 min). Analysis was performed using a Thermo-Finnigan Trace 
DSQ fast-scanning single quadropole mass spectrometer using electron impact 
ionisation. 
Raw data was extracted, peak identified and quality control processed using 
proprietary MetabolonTM hardware, software and biochemical library database. 
Following normalisation to Bradford protein concentration, log transformation and 
imputation of missing values with the minimum observed value for each compound, 
Welch’s unequal variance two sample t-test was performed to identify significant 
differences between the experimental groups. To account for a potentially high false 
discovery rate (as a consequence of multiple comparisons), a q-value was also 
calculated, where a lower q-value is an indication of higher confidence in the result. 
To better understand variations between samples, principal component analysis 
(PCA) was employed to provide a global analysis of how closely related or 
otherwise any given sample is. Samples that cluster together in PCA show greater 
similarities than those that are more widely distributed (4.3.5.2). Further analysis of 
differences between samples was provided by subjecting the data to a process of 
hierarchical clustering. Hierarchical clustering seeks to determine differences 
between data by grouping together two samples that share the closest values and then 
recomputing the differences between this newly grouped sample and the other 
samples based on the largest difference of the two samples in the paired group 
compared to the other samples. This process is then repeated until all samples are 
paired and the data is often represented by a dendogram (Figure 4-9B). 
2.12 Flow cytometry and data analysis 
Isolation of cells to be analysed by flow cytometry was performed as described in 
individual method sections. A minimum of 10,000 events were collected using an 
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Accuri C6 flow cytometer. Data analysis was performed using FCS express ver.6 
software. 
In general, forward scattered light (FSC) was used to determine size and side 
scattered light (SSC) the granularity. Application of bi-variate gating allowed the 
exclusion of cell debris and other sub-cellular size detected events. Excitation of 
fluorescent molecules was achieved using a diode red laser (λ=640nm) and a solid 
state blue laser (λ=488nm). Emission was detected using 3 standard optical filters, 
filtering light at a λ of 530-535nm, 540-585nm and >670nm. A list of fluorochromes 
with their excitation/emission spectra is given in Table 4. Where multiple 
fluorochromes were employed, ‘spill over’ of fluorescent signal into detectors of 
adjacent wavelengths was compensated for, using compensation settings within the 
FCS express ver. 6 software. Briefly, the median fluorescent intensity of unlabelled 
and fluorochrome labelled cells was adjusted to equivalence in optical detectors with 
wavelengths adjacent to detectors designed to detect any given fluorochromes. 
 
Table 4. List of fluorochromes used in this study. Fluorochromes used to label/identify cells are 
listed in alphabetical order alongside their absorption and emission wavelengths (λ). 
Fluorochrome Absorption λ (nm) Emission λ (nm) 
7-AAD 488 647 
DsRed 558 583 
GFP 489 508 
2-NBDG 465 542 
PE 480 570 
PerCP 490 675 
 
2.13 Statistical analysis 
Significance of difference was determined using one-way ANOVA with Tukey’s 
honestly significance differences test, Student’s paired t-test or one sample t-test 
using Minitab (v17) (Minitab Ltd, Coventry, U.K.). Appropriate statistical tests used 
are labelled in figure legends. 
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 Mutant RAS and NOX2 derived ROS affect glycolysis in 
human haematopoietic progenitor cells and AML 
derived cell lines 
 Introduction 
AML is a heterogeneous haematological malignancy often characterised by a RAS 
mutation (Naoe and Kiyoi, 2013). Using a normal human haematopoietic progenitor 
cell (HPC) model it has previously been shown that constitutively active RAS leads 
to autonomous proliferation of HPC and overproduction of ROS (Hole et al., 2010). 
The authors of this study showed that HPC expressing mutant RAS exhibited 
elevated levels of extracellular superoxide production (as measured by the 
chemiluminescent probe DiogenesTM), no increases in mitochondrial superoxide 
production (as measured by MitoSOX) and increased levels of NOX2 protein 
expression on the plasma membrane when compared to control cells not expressing 
mutant RAS. Treatment with the NOX inhibitor, diphenyleneiodonium (DPI) and the 
antioxidant apocynin resulted in the near ablation of superoxide production with 
concomitant decreases in proliferation, suggesting a NOX dependent mechanism for 
these RAS induced increases in ROS production and proliferation. Overproduction of 
ROS through NOX activation has also been observed in greater than 60% of AML 
patient blasts, where it is associated with increased proliferation (Hole et al., 2013). 
This suggests that these AML blasts are functioning within a highly oxidatively 
stressed extracellular environment, which may, at least in part, be driving these 
proliferative increases. To support this hypothesis, Hole et al (2013), employed the 
enzyme glucose oxidase (GOX) to generate hydrogen peroxide (H2O2), a major 
source of ROS (1.3.1), in culture with two AML cell lines (Mv4;11 and KG-1) and 
observed proliferative increases.  
ROS has been implicated in cellular differentiation, growth and survival via its role 
as a cell signalling molecule. This can occur via inhibition of protein tyrosine 
phosphatases (PTP’s), PTEN and PKC, or through regulation of gene expression via 
transcription factors such as NFκB, TP53 and HIF-1α and/or through epigenetic 
modifications of HDAC’s and DNMT’s (reviewed in Sardina et al., 2012). 
Previously our group have generated preliminary data which have shown significant 
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RAS and ROS attributable gene expression changes, in particular those associated 
with glycolysis and carbohydrate metabolic pathways (Hopkins et al., 2014). RAS 
has been widely reported to upregulate glycolysis in several solid cancers (Mazurek 
et al., 2001, Ying et al., 2012, Gaglio et al., 2011, Zheng et al., 2015), which is a 
hallmark of the Warburg effect (1.4.1). Furthermore, NOX generated ROS has 
previously been reported to modulate cellular glucose uptake in leukaemic cell lines 
(Prata et al., 2008). However, the mechanism by which NOX2 generated ROS 
affects the subsequent metabolism of glucose and how this can affect proliferative 
changes are unknown. Therefore, this chapter specifically addresses the functional 
impact that ROS has on glycolysis in AML cells and examines whether this has a 
correlative effect on proliferation. 
 Aims and objectives 
The main objective of this chapter is to assess the impact that mutant RAS and 
NOX2 derived ROS has on glycolysis. This study therefore aims to:  
• To determine the effect of mutant RAS on glycolysis.  
HPC will be infected with N-RASG12D or H-RASG12V and changes in glycolysis 
will be assayed by glucose uptake and extracellular lactate production and 
compared with HPC not expressing mutant RAS (control). 
• To determine the effect of NOX2 derived ROS on glycolysis and proliferation 
using a HPC model. 
HPC expressing mutant RAS will be treated with NOX inhibitors and their 
effect on glucose uptake, extracellular lactate production and proliferative rate 
will be assessed. 
• To determine the effect of NOX2 derived ROS on glycolysis and proliferation 
using AML cell lines. 
AML cell lines that generate extracellular ROS will be treated with NOX 
inhibitors or have NOX2 knocked-down using shRNA and the effect on 
glucose uptake, extracellular lactate production and proliferative rate will be 
compared with corresponding control cells. Conversely, the AML cell line, 
Mv4;11 (which generates low levels of extracellular ROS) will be treated with 
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H2O2 (GOX) and glucose uptake, extracellular lactate production and 
proliferative rate will be compared with control cells. 
 Results 
3.3.1 Mutant RAS increases glucose uptake and extracellular lactate generation in 
human HPC 
Infection of HPC (CD34+) with mutant RAS has previously been shown to generate 
an increase in NOX derived ROS production and proliferation compared to control 
HPC (Hole et al., 2010). As RAS is commonly mutated in AML (Naoe and Kiyoi, 
2013), HPC infected with mutant RAS were employed to model the effect of this 
mutation on glycolytic function. Human CD34+ cells were isolated from neonatal 
cord blood and retrovirally infected with N-RASG12D or H-RASG12V using the PINCO 
expression vector (gift of Pier Pelicci, European Institute of Oncology, Milan, Italy). 
This vector encodes GFP which acts as a selectable marker. Control cells expressed 
GFP alone. Transduced cells were cultured for six days before being analysed for 
changes in glucose uptake and lactate production as described in the methods (2.7). 
3.3.1.1 Expression of mutant RAS in human HPC 
To confirm successful gene transduction, infected cells were analysed for GFP 
expression by flow cytometry 24h post infection. As shown in Figure 3-1A-C, GFP 
expression levels ranged from 58-76% for control cells, 75-94% for N-RASG12D and 
44-70% for H-RASG12V, demonstrating successful infection was obtained in these 
cells. Figure 3-1D shows that 100% of cells expressed the HPC marker CD34+, 
establishing that nearly all the cultured cells constituted a HPC population. 
To establish that RAS protein was overexpressed in the mutant RAS expressing 
HPC, a western blot was performed. Figure 3-1E shows that in both N-RASG12D and 
H-RASG12V, higher levels of RAS protein can be observed compared to control HPC, 
indicating that RAS is constitutively expressed in these cells. 
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Figure 3-1. Infection of human HPC (CD34+) with mutant RAS. Representative flow cytometric 
histograms showing percentage of HPC cells expressing GFP in (A) Control (green); (B) N-RASG12D 
(blue) and (C) H-RASG12V (red) transduced cells (n=7). Histograms were gated to exclude cell debris 
and dead cells based on FSC/SSC. Background auto fluorescence was established using HPC 
subjected to the equivalent retroviral infection procedure but in the absence of retrovirus (mock HPC) 
(grey) infected cells. Percentage within the black marker line represents proportion of cells showing 
fluorescence greater than background autofluorescence at <0.01%. (D) Representative flow 
cytometric histogram showing expression of the HPC marker CD34. Infected cells were analysed for 
CD34 expression level using anti-CD34 PE. Background non-specific fluorescence (brown) was 
established using isotype matched control antibody, IgG1 PE. (E) Example western blot analysis of 
RAS protein expression comparing control and N-RASG12D and control and H-RASG12V infected 
CD34+ cells. Actin was used as a loading control.  
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3.3.1.2 Mutant RAS promotes increased glucose uptake in human HPC 
Increased aerobic glycolysis is a common feature of cancerous cells with 
concomitant increases in cellular glucose uptake and lactate secretion (reviewed in 
Mikawa et al., 2015). To examine the impact of mutant RAS expression on 
glycolysis, this study initially analysed changes in glucose consumption of mutant 
RAS expressing HPC compared to control HPC. The concentration of glucose 
retained in the culture medium following three days of growth was determined using 
a fluorometric D-glucose assay kit. Figure 3-2A shows that the levels of glucose 
remaining in the culture media were 27% ± 15% less in the media of N-RASG12D and 
a significant 45% ±35% (p=0.023) less in the media of H-RASG12V when compared 
to control. These differences in the concentration of glucose remaining in the culture 
media indicate that mutant RAS expressing HPC consume glucose at a greater rate 
than control cells. 
It is known that culturing cells in high concentrations of growth factors and 
cytokines stimulates proliferation and increases glycolysis in excess of that required 
to support this growth (Bauer et al., 2004). Consequently, it was reasoned that the 
full effect of mutant RAS on glucose uptake may be masked by use of these growth 
factors. Therefore, HPC were cultured in the absence of cytokines over three days 
and the concentration of glucose in the culture media assayed as above. In the 
absence of growth factors N-RASG12D HPC showed a significant 2-fold decrease in 
glucose levels of the culture supernatant compared to control, whilst H-RASG12V 
HPC showed a significant 11-fold decrease (Figure 3-2B). This decrease in 
concentration of glucose in the culture supernatant of both N-RASG12D and H-
RASG12V HPC, suggests that in the absence of cytokines mutant RAS allows growth-
factor independent increases in cellular glucose consumption. 
To confirm that these changes in cellular glucose consumption occurred at the single 
cell level and were not a consequence of increased cellular proliferation, the 
fluorescent glucose bioprobe 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-D-
deoxyglucose (2-NBDG) coupled with flow cytometry was employed. 2-NBDG is a 
fluorescent glucose derivative that is transported into the cell by glucose transporters 
and is phosphorylated to 2-NBDG-6-phosphate before being broken down into non-
fluorescent derivatives (Yoshioka et al., 1996, Yamamoto and Ashida, 2012). 2-
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NBDG emits fluorescence at a wavelength of 542nm which has a spectral overlap 
with GFP emission. Therefore, HPC were alternatively infected with the PINCO 
retroviral expression vector that was modified to co-express DsRed instead of GFP. 
Expression levels of DsRed ranged from 18-88% for control, 41-49% for N-RASG12D 
and 21-22% for H-RASG12V (Figure 3-3A). Glucose uptake of HPC expressing 
mutant RAS were compared with control HPC using the 2-NBDG probe. Figure 
3-3B shows typical flow cytometric histograms demonstrating changes in glucose 
uptake of control, N-RASG12D and H-RASG12V infected HPC (DsRed+) compared to 
uninfected cells (DsRed-). Figure 3-3C shows that H-RASG12V showed a significant 
1.9-fold increase in glucose uptake, whilst a 1.3-fold increase in glucose uptake was 
observed in N-RASG12D, although this did not reach significant. When cells were 
cultured in the absence of cytokines, a significant 2-fold increase in glucose uptake 
was observed for H-RASG12V, whilst a non-significant 1-4-fold increase was 
observed in N-RASG12D (Figure 3-3D). These data demonstrate that expression of 
mutant RAS in normal human HPC increases glucose uptake at the individual cell 
level when compared with control cells and that this increase occurs both in the 
absence and presence of cytokines. 
Taken together, the data above suggests that increased levels of glucose uptake, is 
associated with expression of mutant RAS in normal human haematopoietic 
progenitor cells. 
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Figure 3-2. Depletion of glucose in culture media of human HPC. Depletion of glucose in culture 
media (normalised to control) of transduced HPC supplemented (A) with growth factors (n=5) (B) 
without growth factors (n=4). Following infection, CD34+ cells were cultured for 3 further days (day 
6 of development) at an initial seeding density of 0.5 x 105 cells/ml with growth factors (IL3, SCF, G-
CSF and GM-CSF), and 1.5 x 105 cells/ml without growth factors. Data represents mean ± 1SD. * 
denotes p<0.05 analysed by ANOVA with Tukey’s honestly significance difference. 
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Figure 3-3. Glucose uptake in HPC expressing mutant RAS. (A) Representative flow cytometric 
plots showing percentage of HPC cells expressing DsRed in transduced cells. Data were gated to 
exclude cell debris based on FSC/SSC. (B) Representative flow cytometric histograms showing 
change in glucose uptake in; control (green); N-RASG12D (blue); H-RASG12V (red) DsRed+ cells cf. 
DsRed- cells (grey). (C, D) Glucose uptake (normalised to control (green)) in transduced HPC (C) 
supplemented with growth factors (n=3) and (D) without growth factors (n=3); control (green), N-
RASG12D (blue), H-RASG12V (red). Following infection, CD34+ cells were cultured for 3 further days 
(day 6 of development) at an initial seeding density of 0.5 x 105 cells/ml with growth factors (IL3, 
SCF, G-CSF and GM-CSF), and 1.5 x 105 cells/ml without growth factors. Data represents mean ± 
1SD. * denotes p<0.05 analysed by ANOVA with Tukey’s honestly significance difference.  
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3.3.1.3 Mutant RAS promotes extracellular lactate production in human HPC 
Alongside increases in glucose uptake, the Warburg effect has also been shown to 
result in increases in the generation of extracellular lactate (reviewed in Mikawa et 
al., 2015). To determine whether the observed increases in glucose uptake in mutant 
RAS HPC (3.3.1.2) were also associated with increased extracellular lactate 
secretion, a fluorometric L-lactate assay was used to determine media lactate 
concentration, after three days of growth. 
Figure 3-4A shows no significant increase in extracellular lactate production in HPC 
expressing mutant RAS compared to control was observed when cells were cultured 
in the presence of cytokines. In contrast, in the absence of cytokines, N-RASG12D had 
a 1.3-fold and H-RASG12V a significant 4-fold (p=0.002) increase in extracellular 
lactate secretion compared to control HPC (Figure 3-4B). This suggests that in the 
absence of cytokines mutant RAS results in growth factor independent increases in 
extracellular lactate production. Changes in extracellular lactate production mirror 
the changes observed in glucose uptake (3.3.1.2) and together suggest that mutant 
RAS expressing HPC engender increases in glycolytic function via increased cellular 
glucose uptake and lactate secretion. 
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Figure 3-4. Extracellular concentration of L-lactate per 1000 human HPC. Concentration of 
extracellular L-lactate in culture media of transduced GFP+ HPC, supplemented (A) with growth 
factors (n=5) (B) without growth factors (n=4). Following infection, CD34+ cells were cultured for 3 
further days (day 6 of development) at an initial seeding density of 0.5 x 105 cells/ml with growth 
factors IL3, SCG, G-CSF and GM-CSF, and 1.5 x 105 cells/ml without growth factors. Data 
represents mean ± 1SD. * denotes p<0.05, analysed by ANOVA with Tukey’s honestly significance 
difference.  
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3.3.1.4 Mutant RAS promotes glucose uptake in HPC of transgenic mice 
expressing N-RASD12 
Data above suggests in vitro expression of mutant RAS in HPC leads to increases in 
glycolysis. To support this conclusion, glucose uptake was assayed ex vivo in HPC 
harvested from secondary transplants of transgenic mice expressing N-RASD12 
driven by an MRP8 promoter, as previously described (Omidvar et al., 2007). MRP8 
is primarily expressed by myeloid cells during differentiation and promotes 
expression of genes in myeloid cells (Nacken et al., 1996). Mice expressing N-
RASD12 under control of MRP8 do not develop AML-like disease (Kogan et al., 
1998) but when crossed with mice expressing BCL-2 to generate MRP8[BCL-
2/NRASD12] mice, human AML-like disease occurs (Omidvar et al., 2007). N-
RASD12 mice can therefore be considered a preleukaemic murine model 
approximating to the human HPC RAS model above. To observe the effect of N-
RASD12 on glucose uptake in a pre-leukaemic AML murine model, 2-NBDG was 
employed to investigate glucose uptake in bone marrow cells derived from N-
RASD12 mice. A significant 1.9-fold increase (p<0.05) in glucose uptake was 
observed in N-RASD12 mice compared to wild type control (WT) (Figure 3-5). This 
suggests that both in vitro and in vivo expression of mutant N-RAS results in 
increased cellular glucose uptake when compared to controls cells.  
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Figure 3-5. Glucose uptake in murine bone marrow cells. (A) Representative flow cytometric 
histogram showing change in glucose uptake in; WT control (green) compared with N-RAS12D (blue). 
Histograms were gated to exclude cell debris and dead cells based on FSC/SSC. (B) Cellular glucose 
uptake (normalised to WT control) in N-RASD12 transgenic mice driven by an MRP8 promoter and 
compared to wild type control (n=8). Cells kindly harvested by Dr. Nadar Omidvar as previously 
described (Omidvar et al., 2007) Data represents mean ± 1SD. SD = 48%, 95% CI (150% and 231%) 
calculated by one sample t-test.  
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3.3.2 ROS affects functional changes in glycolysis in human HPC 
The above data suggests expression of mutant RAS, both in human HPC and murine 
HPC, results in increased glycolysis. Given that previous work in our group has 
shown that increases in proliferation, as a consequence of mutant RAS, are at least in 
part attributable to NOX2-derived ROS (Hole et al., 2010), we next determined 
whether these RAS dependent changes in glycolysis were also mediated by ROS. 
Therefore, glucose uptake and lactate production were assayed following NOX 
inhibition in these cultures. 
3.3.2.1 Phosphorylation of p38MAPK in mutant RAS expressing HPC 
ROS normally induces a stress response in cells leading to inhibition of the cell 
cycle, modulated as a result of phosphorylation of the p38 mitogen activated protein 
kinase (p38MAPK) pathway (Kulisz et al., 2002). H-RASG12V HPC have previously 
been shown to have increased levels of p-p38MAPK which is ablated upon addition of 
DPI (Hole et al., 2010). To confirm that this was also true for N-RASG12D and to 
validate that the mutant-RAS expressing HPC were experiencing oxidative stress 
(ROS), western blots were performed to detect the presence of p-p38MAPK. As shown 
in Figure 3-6 HPC expressed equal levels of p38MAPK, however N-RASG12D and H-
RASG12V expressed higher levels of phosphorylated p38MAPK, which was decreased 
upon treatment with DPI. This supports previous data (Hole et al., 2010) that mutant 
RAS expressing HPC experience increased levels of ROS as determined by 
phosphorylation of the p38MAPK pathway and that this ROS induced stress response 
is relieved upon inhibition of NOX2 by addition of DPI. 
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Figure 3-6. Mutant RAS expressing HPC exhibit increased phosphorylation of p38MAPK. Human 
HPC control, N-RASG12D and H-RASG12V were incubated for 24h in the presence and absence of DPI 
(100nM). Expression and phosphorylation state of p38 was determined by western blot using whole 
cell lysates derived from these cells and probed with antibodies recognising p-p38MAPK and p38MAPK. 
Tubulin was used as a loading control. 
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3.3.2.2 ROS promotes increased glucose uptake in human HPC 
HPCs expressing mutant RAS and co-expressing GFP, were treated with 100nM DPI 
(a concentration that has previously been shown not to affect HPC viability (Hopkins 
et al., 2014), but which inhibits 90% of NOX2 activity in the HL60 cell line 
(Hopkins, 2014) for 24h and the concentration of glucose in the cell culture media 
was assayed as above (3.3.1.2). Figure 3-7A shows that both the untreated N-
RASG12D and H-RASG12V HPC had a lower concentration of glucose in the culture 
supernatant after 24h compared to cells not expressing mutant RAS (consistent with 
data reported above (3.3.1.2) and suggesting increased uptake of glucose by these 
cells). However, following NOX inhibition of N-RASG12D and H-RASG12V with DPI, 
a respective 1.4-fold and 1.8-fold increase in the concentration of glucose retained in 
the culture media compared to untreated cells was observed (albeit not statistically 
significant). Treatment of cells not expressing mutant RAS with DPI had minimal 
effect; 1.1-fold increase compared to control. Since DPI is reported as a non-specific 
flavoprotein inhibitor at high concentrations (Aldieri et al., 2008), HPCs were also 
treated with an alternative, more specific NOX inhibitor (reviewed in Altenhofer et 
al., 2012) VAS-2870 (5μM), which has been shown to inhibit NOX2-derived ROS 
in the THP-1 cell line (Dr. Paul Hole, unpublished data). Figure 3-7B shows a 1.4-
fold decrease in media glucose levels for N-RASG12D and a significant 1.9-fold 
decrease for H-RASG12V compared with control HPC after 24h. Treatment with 
VAS-2870 resulted in a 1.2-fold and 1.3-fold increase in the concentration of glucose 
retained in the culture media for N-RASG12D and H-RASG12V respectively, when 
compared to untreated cultures. Commensurate with above, treatment of HPC not 
expressing mutant RAS had minimal changes in glucose consumption when treated 
with VAS-2870; a 1.1-fold increase compared to the untreated cells. These data 
show that glucose concentration of the culture media is reduced in mutant RAS 
expressing HPC after 24h compared to control. Furthermore, treatment of mutant 
RAS expressing HPC with NOX inhibitors partially reverses this effect, suggesting 
that NOX activity may be driving glucose uptake, although further repeats would be 
required to demonstrate statistical significance. 
Glucose uptake at the single cell level using 2-NBDG was also performed in HPC 
expressing mutant RAS (co-expressing DsRed), treated with NOX inhibitors. These 
studies focussed on cells expressing mutant N-RASG12D since in AML, this is the 
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most common RAS mutation (Renneville et al., 2008). Control and N-RASG12D HPC 
were treated with DPI (100nM), VAS-2870 (5μM) or GSK-NOX2 (3μM). GSK-
NOX2 is a specific NOX2 inhibitor a proprietary compound (made available 
courtesy of GlaxoSmithCline) and has been shown to decrease NOX2-derived ROS 
in the NOMO-1 cell line (Professor Richard Darley, unpublished data). Figure 3-8A 
shows typical flow cytometric histograms demonstrating changes in glucose uptake 
of N-RASG12D treated with NOX inhibitors compared with the co-cultured, 
uninfected HPC. When the glucose uptake of untreated N-RASG12D was compared 
with separately cultured, untreated control HPC, N-RASG12D showed a significant 
1.4-fold increase in glucose uptake compared with control HPC. Treatment of N-
RASG12D with VAS-2870 showed a near ablation of this mutant RAS induced 
increase in glucose uptake, whilst GSK-NOX2 reduced increased glucose uptake by 
half, in the N-RASG12D when compared to untreated cells (Figure 3-8B). Treatment 
of control HPC with DPI, VAS-2870 and GSK-NOX2 had little to no effect on 
glucose uptake, whilst surprisingly DPI also had a minimal effect on glucose uptake 
at the single cell level in the N-RASG12D HPC when compared with untreated cells. 
The failure of DPI to reduce glucose uptake in the N-RASG12D HPC may be 
indicative of an off-target effect of this compound (3.4), or may be a statistical 
anomaly requiring further experimental repeats. Overall these data support the 
changes in glucose concentration observed in the culture supernatant of these HPC 
(Figure 3-7). Taken together these data suggests NOX2 derived ROS increases 
glucose uptake in HPC expressing mutant RAS. 
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Figure 3-7. ROS induced changes of glucose concentration in culture media in human HPC. 
Depletion of glucose in culture media (normalised to control) of transduced HPC treated with (A) DPI 
(100nM) and (B) VAS-2870 (5μM) (n=3). Cells were counted (day5) and cultured for a further 24h in 
the presence/absence of inhibitors, without growth factors, at an initial seeding density of 6 x 105 
cells/ml. Data represents mean ± 1SD. * denotes p<0.05, analysed by ANOVA with Tukey’s honestly 
significance difference.  
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Figure 3-8. ROS induced changes in glucose uptake in human HPC. (A)  Representative flow 
cytometric histograms showing change in glucose uptake in N-RASG12D (DsRed+ cells); untreated 
(dark blue); + DPI (100nM) (blue); + VAS-2870 (5μM) (sky blue); + GSK-NOX2 (3μM) (light blue) 
cf. DsRed- cells (grey). Data were gated to exclude cell debris based on FSC/SSC. (B) Cellular 
glucose uptake (normalised to untreated control) in transduced HPC treated with DPI (100nM), VAS-
2870 (5μM) and GSK-NOX2 (3μM); control (green), N-RASG12D (blue). Cells were counted (day5) 
and cultured for a further 24h in the presence/absence of inhibitors, without growth, factors at an 
initial seeding density of 6 x 105 cells/ml (n=3). Data represents mean ± 1SD. * denotes p<0.05 
(compared to untreated control HPC (dark green)), analysed by ANOVA with Tukey’s honestly 
significance difference.  
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3.3.2.3 ROS affects extracellular lactate production in human HPC 
Alongside increased glucose consumption, mutant RAS expressing HPC also 
generate increased extracellular lactate (3.3.1.3). To ascertain whether this increase 
is a function of increased ROS production, lactate was assayed from cultures treated 
with NOX inhibitors as above (3.3.1.3). Surprisingly, treatment of these cells with 
DPI, resulted in 1.5, 2.4 and 1.7-fold increases in extracellular L-lactate production, 
of control, N-RASG12D and H-RASG12V HPC respectively, when compared to 
untreated controls (Figure 3-9A), although these changes did not reach significance. 
Treatment with VAS-2870 resulted in no changes in extracellular lactate production 
(Figure 3-9B). The lack of any significant changes to extracellular lactate production 
in mutant RAS expressing HPC upon treatment with VAS-2870 suggest that NOX2-
derived ROS does not impact on extracellular lactate secretion whilst the increase in 
extracellular lactate secretion of the cells upon treatment with DPI may be the result 
of an off-target effect. Overall these data do not support the idea that NOX2-derived 
ROS is responsible for increases in lactate secretion in mutant RAS expressing HPC. 
3.3.2.4 ROS promotes proliferation in human HPC 
As previously reported by our group, proliferative decreases occur in mutant RAS 
expressing HPC treated with DPI over a 48 h period (Hole et al., 2010). To 
determine whether changes in carbohydrate metabolism observed above, also 
correlated with changes in proliferation, growth rates were assayed using a 
haemocytometer. Both N-RASG12D and H-RASG12V HPC showed decreased 
proliferation when treated with DPI whilst control HPC growth remained unchanged 
(Figure 3-10A). To verify that these proliferative changes were a result of NOX-
derived ROS the above experiment was repeated using VAS-2870. Similar to 
treatment with DPI, no proliferative changes occurred in the control HPC, whilst a 
1.4-fold reduction in proliferation occurred in N-RASG12D and H-RASG12V, which 
reached significance for H-RASG12V (Figure 3-10B). This suggests that the decreases 
in glucose uptake observed above, corresponded with ROS associated proliferative 
changes observed here and previously, and that these proliferative changes in mutant 
RAS expressing HPC were at least in part a function of NOX2-derived ROS.  
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Figure 3-9. ROS induced changes in extracellular L-lactate production in human HPC. 
Concentration of extracellular L-lactate in culture media of transduced CD34+ cells, treated (A) with 
DPI (100nM) (n=3) or (B) with VAS-2870 (5μM) (n=4). Cells were counted (day5) and cultured for a 
further 24h, in the presence/absence of inhibitors, without growth factors at an initial seeding density 
of 6 x 105 cells/ml. Data represents mean ± 1SD. 
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Figure 3-10. ROS induced changes in proliferation of human HPC. Fold change in cell numbers 
of transduced HPC, treated with (A) DPI (100nM) (n=3) or (B) VAS-2870 (10μM) (n=4). Cells were 
counted (day5) and cultured for a further 24h in the presence/absence of inhibitors, without growth 
factors at an initial seeding density of 6 x 105 cells/ml Data represents mean ± 1SD. * denotes p<0.05, 
analysed by ANOVA with Tukey’s honestly significance difference. 
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3.3.3 ROS affects functional changes in glycolysis in AML cell lines 
The data above suggest that NOX-derived ROS affects functional changes in 
glycolysis in human HPC transformed with mutant RAS. To investigate further the 
role of ROS on glycolysis in AML, changes in this pathway were assayed in AML 
derived cell lines with varying ability to produce NOX2 derived extracellular ROS. 
Changes in glucose uptake and extracellular lactate production as a result of 
chemical inhibition or NOX2 knock-down using shRNA were determined.  
Extracellular superoxide generated by NOX2 is rapidly converted to H2O2 in vivo, by 
superoxide dismutase (SOD) (Hole et al., 2011). Glucose oxidase (GOX) an enzyme 
which catalyses the production of H2O2 (Hole et al., 2013) can be used to mimic the 
effect of NOX2-derived ROS in AML cell lines that don’t generate detectable 
extracellular superoxide. These cell lines make good models to study glycolysis, as 
treatment with exogenous ROS, generated through the addition of GOX, allows 
tighter control over levels of cellular exposure to H2O2.  
3.3.3.1 Determination of NOX2 derived ROS in AML cell lines 
An assay to detect extracellular superoxide production using the chemiluminescent 
probe DiogenesTM was used to screen a selection of AML cell lines for their ability 
to produce ROS. Figure 3-11A shows extracellular superoxide levels were detected 
at much higher levels in the NOMO-1 and THP-1 cell lines, compared with the cell 
lines Mv4;11, KG-1 and U937. The specificity of the DiogenesTM probe for 
superoxide has previously been validated (Hole et al., 2010), as the presence of SOD 
in culture quenches DiogenesTM chemiluminescence, whilst treatment with catalase 
(which decomposes H2O2 but not superoxide) does not. This suggests that a major 
source of ROS in NOMO-1 and THP-1 cell lines is superoxide.  
As NOX2 is a major source of extracellular superoxide production, knock-down of 
NOX2 (NOX2-KD) using shRNA provides a good method for examining the effects 
of endogenous NOX2-derived ROS. THP-1 and NOMO-1 cells lentivirally 
transduced with shRNA complementary to NOX2 mRNA and encoding puromycin 
resistance were kindly provided by Professor Richard Darley and were compared 
with control cells (THPSH and NOMOSH) which had been transfected with shRNA 
coding for a non-mammalian target sequence. NOX2 is a transmembrane protein 
(Bedard and Krause, 2007), so to confirm NOX2-KD, NOX2 expression was 
Chapter 3 
130 
determined by flow cytometry using an anti-NOX2 PE-conjugated antibody (Figure 
3-11B). To confirm a functional reduction in superoxide production, NOX2-KD cells 
were assayed using DiogenesTM. Superoxide production in THP cells with NOX2 
knocked-down, was almost completely ablated compared to THPSH, whilst NOMO 
NOX2-KD cells showed a 30% reduction in superoxide production compared with 
NOMOSH (Figure 3-11C). To confirm that treatment of THPSH and NOMOSH 
cells with DPI also resulted in a decrease in NOX2 derived superoxide THPSH and 
NOMOSH cells treated with DPI (100nM) were additionally assayed using 
DiogenesTM. THPSH and NOMOSH cells showed a 90% and 70% reduction in 
superoxide production respectively (Figure 3-11C). 
ROS has previously been shown to result in phosphorylation of p38MAPK pathway as 
part of a stress response in HPC expressing mutant RAS, which is alleviated 
following inhibition of ROS (3.3.2.1). To confirm this mechanism in AML cell lines, 
western blots were performed on NOMO-1 and THP-1 with NOX2 knocked-down 
or treated with DPI (100nM) and compared with control cells. Figure 3-12A shows 
that both the NOMO NOX2-KD and THP NOX2-KD cells showed decreased 
phosphorylation of p38MAPK compared with NOMOSH and THPSH controls, whilst 
treatment with DPI also resulted in decreased phosphorylation of this protein in 
THPSH cells. Expression levels of p38MAPK showed no changes compared to control 
in either NOX2-KD cells or those treated with DPI. This alteration in 
phosphorylation state of p38MAPK indicates that NOMO-1 and THP-1 cells 
experience a stress response arising from NOX2 derived ROS.  
Western blot analysis to determine the phosphorylation state of p38MAPK was also 
undertaken for Mv4;11 cells treated with GOX which constitutively generates H2O2 
in the culture media. Figure 3-12B shows that GOX treated Mv4;11 cells showed 
increased phosphorylation of p38MAPK compared to control and no changes in protein 
expression of p38MAPK upon treatment with GOX. These data show that addition of 
exogenous ROS to Mv4;11 cells results in increased phosphorylation of p38MAPK. 
Overall, these data demonstrate that AML cell lines producing endogenous ROS or 
subjected to exogenous H2O2 induced phosphorylation of p38MAPK and that the levels 
of endogenous ROS can be repressed by chemical inhibition or shRNA knock-down 
targeting the NOX2 oxidase.  
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Figure 3-11. Superoxide production in AML cell lines. (A) Peak superoxide production (relative 
luminescent units/min (RLU/min)) in a panel of AML derived cell lines measured using DiogenesTM. 
(B) Cell surface NOX2 expression in (i) THPSH (control) (dark blue), THP NOX2-KD (light blue) 
and (ii) NOMOSH (control) (dark green) NOMO NOX2-KD (light green) determined using an anti-
NOX2-PE conjugated antibody and compared to IgG1 isotype control (grey). (C) Superoxide 
production (normalised to control) in (i) THPSH (control) (dark blue), THP NOX2-KD (blue) 
THPSH treated with DPI (100nM) (mid blue) and (ii) NOMOSH (control) (dark green), NOMO 
NOX2-KD (green), NOMOSH treated with DPI (100nM) (mid green).  
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Figure 3-12. AML cell lines exhibit ROS induced stress response of p38MAPK pathway. AML cell 
lines were incubated for 24h under the conditions described. Expression and phosphorylation state of 
p38MAPK was determined by western blot using whole cell lysates derived from these cells and probed 
with antibodies recognising p-p38MAPK and p38MAPK in (A) NOMOSH and THPSH control cells, 
compared with NOMO NOX2 KD and THP NOX2 KD cells and NOMOSH and THPSH incubated in 
the presence and absence of DPI (100nM) and (B) Mv4;11 cells treated with GOX. Tubulin was used 
as a loading control. 
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3.3.3.2 ROS promotes glucose uptake in AML cell lines 
To investigate further the impact that ROS has on glycolysis in AML, cellular 
glucose uptake in the THP and NOMO cell lines, was measured using 2-NBDG. 
Glucose uptake levels in these cells were then compared with the glucose uptake of 
cells in which NOX2 had been knocked-down using shRNA, or chemically 
inhibited. To ensure that knock-down of NOX2 or treatment with chemical inhibitors 
did not affect cell viability, cells were stained with 7-aminoactinomycin D (7-AAD) 
and analysed by flow cytometry. Figure 3-13 shows that knock-down of NOX2 with 
shRNA or chemical inhibition did not impact on the viability of THP or NOMO 
cells. This suggests that any changes in glucose uptake in the cells were a result of 
experimentally controlled variables and not the viability of the cells. 
Knock-down of NOX2 in THP cells showed a significant 1.5-fold decrease in 
cellular glucose uptake compared to control. Pharmacological inhibition with DPI, 
VAS-2870 and GSK-NOX2 also resulted in significant 4-fold, 1.2-fold and 1.2-fold 
respective decreases, in glucose uptake compared to control (Figure 3-14A). In 
NOMO cells, NOX2 knock-down generated a significant 1.3-fold decrease in 
glucose uptake, whilst treatment with DPI resulted in a significant 1.6-fold decrease 
in glucose uptake (Figure 3-14B). These results show that decreases in the levels of 
extracellular ROS experienced by these cell lines results in decreases in cellular 
glucose uptake and that NOX2 generated ROS is, in part, responsible for changes in 
these levels of glucose consumption. 
Given that cellular glucose uptake can be decreased by inhibition of extracellular 
ROS, it was reasoned that increasing levels of exogenous ROS would result in an 
increase in glucose uptake. To test this, Mv4;11 cells were treated with different 
concentrations of GOX (hence H2O2) and the amount of cellular glucose uptake 
measured, as above, using 2-NBDG. To test whether GOX did not affect the viability 
of the cells, treated cells were incubated with 7-AAD, analysed by flow cytometry 
and compared with control. No changes in cell viability was observed in the cells 
treated with GOX compared for control (Figure 3-15A). Treatment of the Mv4;11 
cells with 10mU/ml and 20mU/ml of GOX resulted in a significant 1.2-fold and 1.3-
fold increase in glucose uptake respectively (Figure 3-15B). These data show that 
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increased extracellular H2O2 levels result in an increase in glucose uptake in the 
Mv4;11 cell line. 
Together, these data demonstrate that ROS is an important mediator of glucose 
uptake in these AML cell lines and that NOX2 generated ROS is an important 
contributor to these changes. 
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Figure 3-13. Viability of THP-1 and NOMO-1 cells. Representative flow cytometric density plots 
showing percentage of viable THP and NOMO cells infected with (A) shRNA control, (B) NOX2KD 
shRNA; or control cells treated with (C) DPI (100nM) (D) VAS-2870 (5μM) (E) GSK-NOX2 (3μM) 
(THP only) and cultured for 24h, in the presence/absence of inhibitors, (initial seeding 5 x 105 
cells/ml). Data were gated to exclude cell debris based on FSC/SSC. Cells were incubated with 7-
AAD, gated areas show proportion of viable cells.  
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Figure 3-14. NOX derived ROS induced changes in glucose uptake in ROS generating AML cell 
lines. Cellular glucose uptake (normalised to control). (A) THP; control (non-mammalian encoding 
shRNA) (dark blue), NOX2-KD (blue), treated with DPI (100nM) (mid blue), VAS-2870 (5μM) 
(light blue) GSK-NOX2 (3μM) (pale blue) (n≥3).  (B) NOMO; control (non-mammalian encoding 
shRNA) (dark green), NOX2-KD (green), treated with DPI (100nM) (mid green) (n≥3). Cells were 
seeded at 5 x 105 cells/ml and cultured for 24h, in the presence/absence of inhibitors. Data represents 
mean ± 1SD. * denotes p<0.05 analysed by ANOVA with Tukey’s honestly significance difference.  
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Figure 3-15. Exogenous ROS induced changes in glucose uptake in the AML derived cell line 
Mv4;11. (A). Representative flow cytometric density plots showing percentage of viable GOX treated 
(10mU/ml and 20mU/ml) Mv4;11 cells compared for untreated control. Data were gated to exclude 
cell debris based on FSC/SSC. Cells were incubated with 7-AAD, gated area shows proportion of 
viable cells. (B) Cellular glucose uptake (normalised to control) of Mv4;11 cells treated with GOX. 
Cells were seeded at 5 x 105 cells/ml and cultured for 24h in the presence/absence of GOX (n≥17). 
Data represents mean ± 1SD. * denotes p<0.05 analysed by ANOVA with Tukey’s honestly 
significance difference.  
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3.3.3.3 ROS affects extracellular lactate production in AML cell lines 
To examine whether these ROS induced changes in glucose uptake in AML cell 
lines occurred contiguously with changes in extracellular lactate production, cells 
were cultured as in 3.3.3.2, and the levels of lactate in the culture media assayed as 
above (3.3.1.3). 
Figure 3-16A shows that THP cells with NOX2 knocked-down showed a 2.4-fold 
increase in extracellular lactate production compared with control. Knock-down of 
NOX2 in NOMO cells resulted in 1.3-fold increase in extracellular lactate compared 
to control, whilst treatment with the NOX inhibitor VAS-2870 generated a 1.7-fold 
increase (Figure 3-16B). These results suggest that inhibition of NOX2 generated 
ROS, result in an increase in the production of extracellular lactate. This ROS 
dependent increase in extracellular lactate, alongside decreases in glucose uptake, 
whilst unexpected, agree with the ROS induced changes observed in extracellular 
lactate production in HPC (3.3.2.3). 
In THP and NOMO cells decreases in ROS lead to decreases in cellular glucose 
uptake, whilst simultaneously increasing extracellular lactate production. To test the 
effect of increases in levels of exogenous ROS on AML cell lines Mv4;11 cells were 
cultured and treated with GOX, as in 3.3.3.2, and the concentration of lactate in the 
culture supernatant assayed as above. Surprisingly, treatment with 10mU/ml of GOX 
resulted in a 1.3-fold increase in extracellular lactate production, whilst treatment 
with 20mU/ml of GOX caused a 1.6-fold increase (Figure 3-16C). In the context of 
Mv4;11 cells, increases in ROS lead to increases in both cellular glucose uptake 
(Figure 3-15B) and extracellular lactate levels (Figure 3-16C) which emulate the 
mutant RAS induced changes observed in HPC (Figure 3-4). 
Paradoxically, these data, together with the data generated from the HPC model, 
suggests that whilst ROS alters extracellular lactate secretion, in an AML context it 
may not do so in a manner consistent with the Warburg effect. Instead, from a ROS 
perspective, it appears that changes in extracellular lactate production are likely both 
cell and context dependent (3.4). 
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Figure 3-16. ROS induced changes in extracellular lactate production in AML derived cell lines. 
Concentration of extracellular L-lactate in the culture media of AML cell lines (A) THP; control (non-
mammalian encoding shRNA) (dark blue), NOX2-KD (blue) (n=3) (B) NOMO; control (non-
mammalian encoding shRNA) (dark green), NOX2-KD (green), treated with VAS (5μM) (light 
green) (n=6). (C) Mv4;11 cells treated with GOX (n=3). Cells were seeded at 5 x 105 cells/ml and 
cultured for 24h, in the presence/absence of inhibitors/GOX. Data represents mean ± 1SD. 
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3.3.3.4 ROS promotes proliferation in AML cell lines 
It has previously been reported that elevated ROS levels, lead to proliferative 
increases in both AML blasts and the AML cell lines Mv4;11 and KG-1 (Hole et al., 
2013). To examine whether these ROS dependent changes were also observed in the 
THP-1 and NOMO-1 cell lines, cells cultured as in 3.3.3.2 were counted by both 
haemocytometer and flow cytometry. 
Knock-down of NOX2 in THP cells resulted in a significant 1.3-fold decrease in 
proliferation compared to control. Pharmacological inhibition with DPI or VAS-
2870, resulted in a 1.2-fold and 1.1-fold decrease respectively. Interestingly 
treatment with GSK-NOX2 had no effect on proliferation (Figure 3-17A), although it 
is worth noting that whilst, at these concentrations, this compound works well in in 
vitro assays of superoxide production, its longer-term stability under culture 
conditions has not been demonstrated. Knock-down of NOX2 in NOMO cells 
resulted in a significant 1.2-fold decrease in proliferation compared to control. 
Treatment with DPI resulted in a significant 1.3-fold decrease, whilst treatment with 
VAS-2870 yielded a 1.2-fold decrease in proliferation compared to control, although 
this did not reach significance (Figure 3-17B). These data show that in these AML 
cell lines, NOX2 derived ROS can promote the proliferative rate of these cells. 
To examine whether the addition of exogenous ROS would lead to an increase in 
proliferation, Mv4;11 cells were treated with GOX. Figure 3-17C shows that Mv4;11 
cells experienced a significant 1.5-fold and 1.4-fold increase in proliferation, when 
treated with 10mU/ml and 20mU/ml of GOX respectively. This shows that increases 
in exogenous ROS in the Mv4;11 cell line result in increases in proliferation of these 
cells. 
Taken together these data shows that, in AML cell lines, levels of extracellular ROS 
influence the proliferative rate of these cells. 
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Figure 3-17. ROS promotes proliferation in AML-derived cell lines. Percentage proliferative 
change (normalised to control) in the AML cell lines (A) THP; control (non-mammalian encoding 
shRNA) (dark blue), NOX2-KD (blue), treated with DPI (100nM) (mid blue), VAS-2870 (5μM) 
(light blue) GSK-NOX2 (3μM) (pale blue) (n≥3).  (B) NOMO; control (non-mammalian encoding 
shRNA) (dark green), NOX2-KD (green), treated with DPI (100nM) (mid green); VAS-2870 (5μM) 
(light green) (n≥3). (C) Mv4;11 cells treated with GOX (n≥6). Cells were seeded at 5 x 105 cells/ml 
and cultured for 24h, in the presence/absence of inhibitors/GOX. Data represents mean ± 1SD. * 
denotes p<0.05, analysed by ANOVA with Tukey’s honestly significance difference.  
C 
A 
B 
0
20
40
60
80
100
120
Control NOX2-KD DPI VAS GSK
Pr
ol
ife
ra
tio
n 
(%
 o
f c
on
tro
l)
*
0
20
40
60
80
100
120
Control NOX2-KD DPI VAS
Pr
ol
ife
ra
tio
n 
(%
 o
f c
on
tro
l)
* *
0
50
100
150
200
0 10 20
Pr
ol
ife
ra
tio
n 
(%
 o
f c
on
tro
l)
*
*
p = 0.004 by ANOVA 
p < 0.001 by ANOVA 
p = 0.002 by ANOVA 
Chapter 3 
142 
 Discussion 
The data presented in this chapter indicates that both mutant RAS and NOX2 derived 
ROS impact on glycolysis. Specifically, mutant RAS expressing HPC showed 
increases in both glucose uptake and lactate secretion compared to normal HPC and 
murine N-RAS12D HPC also showed elevated levels of glucose uptake compared to 
control. Inhibition of NOX2 in these cells with DPI or VAS-2870, resulted in a 
decrease in both glucose uptake and proliferation. Surprisingly, increased lactate 
secretion was observed in mutant RAS expressing HPC treated with DPI, whilst no 
changes were observed in HPC treated with VAS-2870. Additionally, two AML 
derived cell lines generating NOX2 derived ROS showed decreased glucose uptake 
and proliferation upon knock-down or chemical inhibition of NOX2, although lactate 
secretion was increased. Finally, the addition of exogenous ROS to the AML derived 
cell line Mv4;11, resulted in increased glucose uptake, lactate secretion and 
proliferation. The data presented is summarised in Table 5. 
Mutational RAS activation accounts for approximately 15-30% of AML cases 
(reviewed in Naoe and Kiyoi, 2013) and oncogenic RAS is widely reported to be 
linked to increases in glycolysis, though little is known in the context of AML. 
Specifically, Racker et al., 1985 were the first to show, that rat cells transfected with 
oncogenic RAS showed a 6-fold increase in lactate production compared to control. 
More recently Zheng et al., 2015 reported a 2.4-fold increase in intracellular lactate 
levels in human breast epithelial cells transformed with the H-RAS oncogene. 
Mechanistically, RAS is known to stabilise c-MYC and HIF-1α and activate the 
PI3K/AKT pathway, all of which have been associated with increased expression of 
glycolytic enzymes and increased glycolytic flux (reviewed in Chesney and Telang, 
2013). Studies examining glycolytic rate in AML are relatively scarce. A very small 
study involving 23 patient samples suggested high glycolytic metabolism correlated 
with an increased overall survival rate, all be it with increased drug resistance (Herst 
et al., 2011). However, a recent, larger, metabolomic study of 400 AML patients 
compared with 446 healthy controls, identified elevated levels of the glycolytic 
intermediates 3-phosphoglycerate, pyruvate and lactate as conferring a poor 
prognosis for survival (Chen et al., 2014). 
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Table 5. Summary of data presented in chapter 3. Table shows a summary of the changes in 
glucose uptake, lactate secretion and proliferation of human haematopoietic progenitor cells (HPC) 
infected with mutant RAS, murine bone marrow (BM) cells and AML cell lines compared with 
appropriate control cells, as presented in chapter 3. * represents data that showed significant changes 
compared to controls. n/a indicates that this data was not measured. Details of individual test 
conditions and the statistical analysis can be found in the appropriate results section of the chapter. 
Mutational status of RAS in NOMO-1, THP-1 and Mv4;11 was obtained from the Catalogue of 
Somatic Mutations in Cancer http://cancer.sanger.ac.uk/cell_lines/gene/analysis?  
 
  
Cell RAS 
mutation 
Treatment Glucose 
Uptake 
Lactate 
Secretion 
Proliferation 
Human 
HPC 
N-RASG12D None Increased Increased n/a 
 H-RASG12V None  Increased*  Increased* n/a 
Murine BM 
cell 
N-RAS12D None Increased n/a n/a 
Human 
HPC 
None DPI Unchanged Increased Unchanged 
  VAS-2870 Unchanged Unchanged Unchanged 
  GSK-NOX2 Unchanged n/a n/a 
 N-RASG12D DPI Unchanged Increased Decreased 
  VAS-2870 Decreased* Unchanged Decreased 
  GSK-NOX2 Decreased* n/a n/a 
NOMO-1 K-RASG13D NOX2-KD Decreased* Increased  Decreased* 
  DPI Decreased* n/a  Decreased* 
  VAS n/a n/a Decreased 
THP-1 N-RASG12D NOX2-KD Decreased* Increased  Decreased* 
  DPI Decreased* n/a Decreased 
  VAS Decreased* Increased Decreased 
  GSK-NOX2 Decreased* n/a Unchanged 
Mv4;11 None GOX 
(10mU/ml) 
Increased* Increased Increased* 
  GOX 
(20mU/ml) 
Increased* Increased Increased* 
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Previous work in our group suggests that mutant RAS expressing HPC’s are 
decoupled from normal proliferative regulatory mechanisms, exhibiting elevated 
growth factor independent survival and proliferation compared with normal human 
HPC (Hole et al., 2010). Data presented here shows that overexpression of mutant 
RAS in HPC also leads to changes in the glycolytic function of these cells, with both 
cellular glucose uptake (3.3.1.2) and lactate secretion (3.3.1.3) significantly 
increased, consistent with the Warburg effect. This suggests a correlation between 
increased aerobic glycolysis in mutant RAS expressing HPC and an increased 
proliferative rate in these cells. 
In support of this, the increase in the proliferative rate of mutant RAS expressing 
HPC described above (Hole et al., 2010) was found to be linked to increases in 
NOX2-derived ROS and data presented here show that increased levels of ROS 
result in increased proliferation and glucose uptake in HPC expressing mutant RAS. 
Specifically, treatment of both N-RASG12D and H-RASG12V with a panel of NOX 
inhibitors resulted in decreased proliferation (3.3.2.4) and decreased glucose uptake 
in all cases (3.3.2.2). Additionally, in the ROS generating AML cell lines 
investigated, chemical inhibition or NOX2 knock-down with shRNA also resulted in 
significant decreases in proliferation (3.3.3.4)  and cellular glucose uptake (3.3.3.2), 
whilst treatment of Mv4;11 cells (which do not generate significant levels of NOX2 
derived ROS) with exogenous ROS instigated significant increases in proliferation 
(3.3.3.4) and cellular glucose uptake (3.3.3.2). In support of this role for NOX 
derived ROS as a modulator of glycolytic activity NOX activated ROS production 
has been reported to increase glucose transporter-1 activity in leukaemic cell lines 
(Prata et al., 2008). Further, a recent study (Zeng et al., 2016) reported that NOX4 
generated ROS promoted glycolysis, glutaminolysis and increased pentose 
phosphate pathway (PPP) activity in non-small cell lung cancer cell lines. 
Additionally, Hole et al., 2013 reported that over 60% of AML patient blasts showed 
increased levels of ROS, which correlated with increased proliferation in these cells. 
Overall, data presented here and elsewhere, is congruent with the hypothesis that 
elevated ROS increases glucose uptake which generates an increased proliferative 
rate.  
Interestingly however, whilst elevated ROS led to increases in cellular glucose 
uptake corresponding increases in extracellular lactate were only observed in the 
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GOX treated Mv4;11 cells (3.3.3.3). Chemical inhibition of NOX2 in mutant RAS 
expressing HPC showed elevated levels of lactate secretion upon treatment with DPI, 
whilst treatment with VAS-2870 showed no significant effect (3.3.2.3). It is 
recognised that at micro-molar concentrations, DPI inhibits not only NOX but also 
mitochondrial respiration through the inhibition of NAPDH cytochrome P450 
oxidoreductase, as well as, nitric oxide synthase, and xanthine oxidase (reviewed in 
Aldieri et al., 2008). Additionally, it has been reported (Riganti et al., 2004), that 
DPI inhibits not only the citric acid cycle but also the PPP, the first step of which 
regenerates NADPH, an important reducing agent for ROS. Inhibition of the citric 
acid cycle could potentially explain increases in extracellular lactate as an 
accumulation of pyruvate (the final product of glycolysis) would also generate 
proportional increases in the concentration of intracellular lactate. Similarly, the PPP 
offers an alternative pathway by which glucose may be metabolised and its inhibition 
would potentially also lead to an accumulation of pyruvate and de facto, lactate. 
However, this DPI inhibition of the PPP and of mitochondrial respiration was 
instigated at micro-molar concentrations of DPI and a recent study (Bulua et al., 
2011) suggests that at nano-molar concentrations (comparable with those used in this 
study), inhibition of NOX but not mitochondrial respiration is observed. 
Nonetheless, whilst off-target effects of DPI (4.4.1.1) offer one plausible explanation 
for increased lactate secretion, apparent ROS dependent increases in extracellular 
lactate secretion observed in AML cell lines treated with VAS-2870 or with NOX2 
genetically knocked-down (3.3.3.3), suggest other potential rationale for these 
results. 
One hypothesis for the observed changes in lactate secretion involve the enzyme 
pyruvate kinase. Lactate is generated because of enzymatic conversion of 
phosphoenolpyruvate to pyruvate by pyruvate kinase followed by its subsequent 
conversion to lactate by lactate dehydrogenase A (1.4.3); and both its production and 
transport are subject to several regulatory mechanisms. Whilst lactate production is 
increased in many cancers as a result of the upregulation of the M2 isoform of 
pyruvate kinase (PKM2) (Tamada et al., 2012) and activation of HIF-1 α (Luo et al., 
2011), ROS promotes dissociation of PKM2 from its active tetrameric form to an 
inactive dimeric form (Anastasiou et al., 2011). This results in the accumulation of 
phosphoenolpyruvate and other glycolytic intermediates and a reduction in lactate 
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production.  Increased tetrameric PKM2 as result of decreased ROS via chemical 
inhibition or NOX2 knock-down, could then potentially explain the lactate increases 
observed above.  
An alternative hypothesis that explains the decoupling of ROS induced increases in 
glucose uptake from lactate secretion, involves the recycling of lactate to generate 
increased NADPH. The anti-oxidant capacity of cells is partly dependent on the 
glutathione and thioredoxin systems (1.3.2.4) which requires the donation of 
electrons from nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine 
dinucleotide phosphate (NADPH) for its antioxidant effect (reviewed in Hole et al., 
2011). An important mechanism for re-generating NADPH is via the conversion of 
glucose-6-phosphate to 6-phosphogluconolactone, the first step of the PPP (1.4.4). 
Additionally the PPP is an important metabolic pathway for generating nucleotides 
for biosynthesis and is known to be dysregulated in a number of cancers (reviewed in 
(Patra and Hay, 2014). Given the correlation between ROS and proliferation 
observed above (3.3.2.4 and 3.3.3.4) it is conceivable that lactate rather than being 
transported out of the cell could instead be diverted into the PPP, resulting in a 
negative correlation between ROS and lactate secretion. 
Regardless of the mechanism by which these ROS induced changes in lactate 
secretion occur, taken together with the observed changes in glucose uptake and 
proliferation, it appears that changes in cellular ROS levels are an important feature 
in modulating glycolytic function in both mutant RAS expressing HPC and in AML 
cell lines. Given that changes in glycolytic metabolism have been reported in AML 
patients (Herst et al., 2011, Chen et al., 2014), the next chapter examines changes in 
the expression of glycolytic genes and the levels of glycolytic metabolites because of 
ROS modulation in order to determine the mechanisms by which these changes 
occur. 
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 Determination of the effect of ROS on glycolytic gene 
expression and glycolytic metabolites 
4.1 Introduction 
Having observed functional changes in glycolysis as a result of the expression of 
mutant RAS and/or exposure to increased levels of exogenous ROS, it was postulated 
that modulation of expression or activity of a number of enzymatic proteins involved 
in carbohydrate metabolism may explain this phenomenon. In support of this, 
previous transcriptome analysis Hopkins et al., 2014 showed significant ROS 
induced changes in global messenger RNA (mRNA) levels using the HPC model. 
More specifically, MetacoreTM pathway analysis of these data identified glycolysis 
as the most dysregulated pathway (Hopkins, 2014). It is well established that 
glycolysis is dysregulated in many solid cancers and nearly all the enzymes in the 
glycolytic pathway have been implicated in this dysregulation (reviewed in Hu et al., 
2014). Haematological malignancies by contrast are less well studied. A study by 
Ryland et al., 2013 showed increased expression of glyceraldehyde phosphate 
dehydrogenase (GAPDH) in chronic lymphocytic leukaemia patients compared to 
healthy controls; increased glycogen synthase has been reported in AML patients 
(Bhanot et al., 2015); and most recently increased mRNA levels of glucose 
transporter 1 (GLUT1), hexokinase II (HK2) and HIF1-α were reported in AML 
patients who did not enter remission following treatment compared to both healthy 
controls and those showing complete remission (Song et al., 2016). However, within 
an AML context, no studies on the effect of ROS on glycolytic gene expression have 
been reported. Therefore, this chapter examines changes in glycolytic enzyme 
expression in mutant RAS expressing HPC, with specific focus on ROS induced 
changes and using whole cell metabolomics to explore ROS modulated changes in 
metabolite concentration. 
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4.2 Aims and objectives 
The main objective of this chapter is to determine the effect of NOX2-derived ROS 
on mRNA and protein expression levels of glycolytic enzymes and resultant changes 
in the relative abundancies of key carbohydrate metabolites. To achieve this, this 
chapter has the following aims:- 
• To determine the effect of ROS on mRNA levels of glycolytic enzymes. A 
supervised analysis, specifically focussing on glycolytic enzymes, of the 
previously generated microarray data (Hopkins et al., 2014) will be 
performed to identify any significant changes in mRNA expression. 
• To determine the effect of ROS on protein expression levels of glycolytic 
enzymes in human HPC expressing mutant RAS. Western blots will be 
performed on cell lysates of mutant RAS expressing HPC, both untreated and 
treated with DPI and compared to control HPC. 
• To determine the effect of ROS on protein expression levels of glycolytic 
enzymes in AML cell lines. Western blots will be performed on cell lysates 
of ROS generating cell lines in which NOX2 has been inhibited or knocked- 
down, and compared with control. Additionally, western blots will be 
performed on cell lysates of Mv4;11 cells subjected to increased exogenous 
ROS levels, to determine any changes in protein expression of glycolytic 
enzymes. 
• To determine ROS-induced changes in key carbohydrate metabolite levels. 
ROS generating AML cell lines with NOX2 inhibited or knocked-down and 
Mv4;11 cells subjected to increased exogenous ROS (and controls) will be 
sent to MetabolonTM for ultra-performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS) analysis for global metabolite 
quantitation. Additionally, MS will be employed to identify significant ROS 
induced changes in metabolite concentrations of AML patient blasts 
characterised as low/high ROS producers. 
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4.3 Results 
4.3.1 Mutant RAS and ROS induce changes in mRNA expression of genes 
involved in carbohydrate metabolism in human HPC 
Previous work in our laboratory, employing Affymetrix Genechip® whole 
transcriptome microarray coupled with an unsupervised analytical approach on the 
Core Probe set list1 has shown significant ROS dependent changes in mRNA 
expression of human HPC expressing mutant N-RAS (N-RASG12D) compared with 
control HPC (Hopkins et al., 2014). Further, MetacoreTM pathway analysis of these 
changes identified glycolysis as the most dysregulated pathway. To refine the 
analysis and identify which glycolytic enzymes showed significant changes in 
mRNA expression, a supervised approach (focussing on enzymes involved in 
carbohydrate metabolism), using the full extended probe set2 of the above 
microarray data was performed. To achieve this, gene expression profiling data was 
analysed using Partek Genomics Suite software (ver. 6.6, Partek Inc., USA). Raw 
data files were imported using Affymetrix annotation files and Robust Multi-Array 
analysis algorithm was used for background correction, normalisation and median 
polishing (to remove chip effect); log2 data transformation was then performed (see 
methods for full details, 2.10). Figure 4-1 shows the glycolytic enzymes whose 
mRNA expression significantly changed in N-RASG12D compared to control and N-
RASG12D treated with DPI compared with the untreated N-RASG12D cells; but which 
were not significant for control HPC treated with DPI compared with untreated 
control. As shown in Figure 4-2 the relative mRNA expression levels of these 
enzymes for each condition, is represented in box plots. These data show that several 
glycolytic genes have a ROS-dependent change in their mRNA expression.  
                                               
1 Core probe set list refers to probes validated from RefSeq database containing complete coding 
sequence information. 
2 Full probe set list refers to probes supported by exon prediction algorithms including GeneID, 
GenScan, Exoniphy, RNAGene, spgGene and Twinscan. 
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Figure 4-1. ROS dependent fold changes in mRNA expression of glycolytic enzymes in human 
HPC. Fold changes in mRNA expression for N-RASG12D transduced HPC compared to control HPC 
(blue), N-RASG12D HPC treated with DPI (100nM) compared to untreated N-RASG12D (blue gradient) 
and control HPC treated with DPI (100nM) compared for untreated control HPC (green gradient). 
DPI treatment occurred for 24 h at 37oC, 5% CO2. GLUT3 (glucose transporter 3), GLUT5 (glucose 
transporter 5), GLUT14 (glucose transporter 14), HK1 (hexokinase 1), PFKFB3 (6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3), PFK(P) (phosphofructokinase platelet), FBP1 (fructose-1,6-
bisphosphatase 1), ENO (enolase), PK(M) (pyruvate kinase muscle), LDH(A) (lactate dehydrogenase 
A), MCT4 (monocarboxylate transporter 4).  Data represents mean fold change of n=4; p-value 
calculated by 2-way ANOVA with Benjamini-Hochberg multiple testing correction (see methods).  
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Figure 4-2. mRNA expression levels of glycolytic enzymes significantly altered by ROS. 
Normalised log2 expression of mRNA in control HPC (green), control HPC treated with 100nM DPI 
(green gradient), N-RASG12D HPC (blue) and N-RASG12D HPC treated with DPI (blue gradient). DPI 
treatment occurred for 24 h at 37oC, 5% CO2. GLUT3 (glucose transporter 3), GLUT5 (glucose 
transporter 5), GLUT14 (glucose transporter 14), HK1 (hexokinase 1), PFKFB3 (6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3), PFK(P) (phosphofructokinase platelet), FBP1 (fructose-1,6-
bisphosphatase 1), ENO (enolase), PK(M) (pyruvate kinase muscle), LDH(A) (lactate dehydrogenase 
A), MCT4 (monocarboxylate transporter 4). Box plots represent median quartile ranges, x represents 
mean value (n=4).  
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4.3.2 Mutant-RAS and ROS induce changes in protein expression of glycolytic 
enzymes in HPC 
The data above show changes in mRNA expression of glycolytic enzymes as a result 
of mutant N-RAS expression and that these changes are in part ROS mediated. 
However it is well established that mRNA levels do not necessarily correspond with 
protein expression levels (reviewed in Vogel and Marcotte, 2012). Therefore, to 
determine if changes in expression of mRNA translated into changes in the 
biologically functional proteins, western blot analysis was performed in human HPC 
and AML cell lines. 
4.3.2.1 Mutant RAS and ROS modifies protein expression of key glycolytic 
enzymes in human HPC 
Changes in mRNA expression of glycolytic enzymes, were observed in response to 
modulating exposure of mutant RAS expressing cells to various levels of ROS 
(4.3.1). To determine whether these responses translated to changes on protein 
expression of glycolytic enzymes in human HPC, western blots were performed. 
Figure 4-3A shows that increases in levels of protein expression were seen in H-
RASG12V compared with control for glucose transporter 3 (GLUT3), glucose 
transporter 5 (GLUT5), hexokinase 1 (HK1), phosphoglucose isomerase (PGI), 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), 
phosphofructokinase platelet (PFK(P)), aldolase C (ALDO(C)), phosphoglycerate 
kinase (PGK), pyruvate kinase muscle 1 (PK(M)1) and lactate dehydrogenase A 
(LDH(A)) and were most marked with GLUT3, PFKFB3, PFK(P) and PGK. In N-
RASG12D increased protein expression was observed in GLUT3, GLUT5, PGI, 
PFKFB3, PFK(P), ALDO(C) and PK(M)1 compared to control HPC (Figure 4-3A). 
These data indicate that numerous changes occur in expression of enzymatic 
glycolytic proteins as a result of expression of mutant RAS in HPC. Interestingly the 
most marked changes in expression occur predominantly with enzymes involved in 
catalysing the initial stages of glycolysis or in transporting glucose into the cell (4.4).  
Having confirmed that mutant RAS expressing HPC elicit a ROS induced response 
in p38MAPK (Figure 3-12), the effect of ROS inhibition on expression of glycolytic 
enzymes was also determined. Figure 4-3 shows that the only observable ROS 
dependent change occurred upon treatment of N-RASG12D HPC with DPI (100nM) 
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for 24h, which resulted in a 3-fold decrease in expression of PFKFB3 compared with 
untreated cells. No other ROS associated changes were observed in the panel of 
glycolytic enzymes tested, either in N-RASG12D or H-RASG12V. No changes in 
PFKFB3 expression or any glycolytic enzyme tested, were seen in the DPI treated 
control HPC compared with untreated cells. Overall, this suggests that the increase in 
PFKFB3 expression observed in N-RASG12D compared with control HPC is 
operating as a result of a ROS dependent mechanism. Interestingly this decrease in 
PFKFB3 expression was not observable in H-RASG12V upon treatment with DPI 
compared to untreated H-RASG12V (Figure 4-3). This suggests that either increased 
PFKFB3 expression functions independently of ROS in these cells, or that the 
concentration of DPI was not sufficient to quash the effect of ROS on this enzyme, 
in these cells.  
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Figure 4-3. Mutant RAS and ROS dependent changes in protein expression of glycolytic 
enzymes. Human HPC control, N-RASG12D and H-RASG12V were incubated for 24h in the presence or 
absence of DPI (100nM) followed by whole cell protein extraction. (A) Example western blots 
showing expression of GLUT3, GLUT5, HK1, PGI (phosphoglucose isomerase), PFKFB3, PFK(P), 
FBP1, ALDO(A) (aldolase A), ALDO(C) (aldolase C), TPI (triphosphate isomerase), GAPDH 
(glyceraldehyde phosphate dehydrogenase), PGK (phosphoglycerate kinase), PGAM1 
(phosphoglycerate mutase 1), ENO, PK(M)1 (pyruvate kinase muscle 1), PK(M)2 (pyruvate kinase 
muscle 2), LDH(A) and MCT4. Actin was used as a loading control. (B) Relative protein expression 
(as measured by pixel density of equivalent regions of interest (ROI) between different samples on the 
same blot then normalised to control) of PFKFB3 in control HPC c.f. (i) N-RASG12D and (ii) H-
RASG12V HPC (n=2) determined by western blot using whole cell lysates from these cells and 
densitometry analysed using AIDA software. Data represents mean ± 1SD.  
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4.3.3 ROS affects PFKFB protein expression in AML cell lines 
The data above suggests that increased ROS levels leads to increased expression of 
PFKFB3 in N-RASG12D expressing cells. In order to observe the effect of ROS on 
glycolytic enzymes in other AML contexts, western blots were performed on THP-1 
and NOMO-1 (AML cells which generate extracellular ROS (Figure 3-11)) and the 
AML cell line Mv4;11 treated with GOX. 
4.3.3.1 Inhibition of ROS leads to a decrease in expression of PFKFB3 in the 
AML cell line THP-1 
Previously it was shown that chemical inhibition of ROS production and knock-
down of NOX2 in the AML cell lines NOMO-1 and THP-1, resulted in a decrease in 
glucose uptake (Figure 3-14). To determine whether this change was accompanied 
by changes in protein expression of glycolytic enzymes, western blots were 
performed in these cell lines. Western blot analysis in THP-1 cells, on a panel of 
glycolytic enzymes, show the only significant change occurred in PFKFB3 
expression, which was reduced by 60% in THP NOX2-KD cells compared to 
THPSH control and 40% in THPSH control treated with DPI (100nM) for 24h 
compared to untreated control (Figure 4-4A and B(i)). Interestingly in NOMO-1 
cells, which also generate extracellular ROS no changes in PFKFB3 expression were 
observed (see 4.4.1) (Figure 4-4A and B(ii)), although a decrease in expression of 
FBP1 was seen when compared with control (Figure 4-4A). Together these data 
suggest that ROS can elicit changes in expression of glycolytic enzymes in these 
AML cell lines, and together with the data from 4.3.2.1, suggest that PFKFB3 
expression may be a function of ROS regulation. 
4.3.3.2 Treatment of Mv;411 with exogenous ROS leads to an increase in 
expression of glycolytic enzymes. 
Treatment of Mv4;11 cells with GOX was previously shown to increase the glucose 
uptake of these cells (Figure 3-15). To determine whether the addition of exogenous 
ROS led to changes in protein expression of glycolytic enzymes in MV4:11 cells, 
western blots were performed on cells treated with GOX for 24h and compared with 
untreated control. Figure 4-5A demonstrates that Mv4;11 cells treated with 
increasing levels of GOX had increased protein expression of HK1, PFKFB3 and 
PFK(P) compared with untreated controls. PFKFB3 expression was increased 3.5-
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fold in Mv4;11 cells treated with 10mU/ml GOX and a significant 10-fold increase 
(p<0.05) when treated with 20mU/ml GOX compared to untreated cells (Figure 
4-5B(i)). Additionally, PFK(P) was increased 1.6-fold and 8.4-fold (Figure 4-5B(ii)) 
and HK1 increased 1.2-fold and 1.6-fold (Figure 4-5C(iii)) in Mv4;11 cells treated 
with 10mU/ml and 20mU/ml GOX respectively, compared with the untreated cells. 
To confirm that this increase in expression of HK1, PFKFB3 and PFK(P) was 
directly related to increases in H2O2 levels incurred through the addition of GOX, 
Mv4;11 cells were additionally treated with GOX in the presence of catalase which 
decomposes H2O2 (Hole et al., 2010). Western blot analysis showed that treatment 
with GOX led to an increase in protein expression of these enzymes, which was 
suppressed upon addition of catalase (Figure 4-6). This indicates that increased 
levels of exogenous H2O2 in Mv4;11 cells lead to increases in expression of 
glycolytic enzymes. 
Taken together with 4.3.3.1 these data show that modulation of ROS levels in AML 
cell lines modifies the expression of several glycolytic enzymes and commensurate 
with data for N-RASG12D HPC (4.3.2.1) suggests modulation of ROS frequently 
alters levels of PFKFB3 expression. 
  
Chapter 4 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. ROS dependent changes in protein expression of glycolytic enzymes in the AML 
derived cell lines NOMO-1 and THP-1. NOMO-1; control (non-mammalian encoding shRNA), 
NOX2-KD, NOMO-1 control treated with DPI (100nM) and THP-1; control (non-mammalian 
encoding shRNA), NOX2-KD, THP-1 control treated with DPI were incubated for a further 24h 
followed by whole cell protein extraction. (A) Example western blots showing expression of GLUT3, 
GLUT5, HK1, PGI, PFKFB3, PFK(P), FBP1, ALDO(A), ALDO(C), TPI, GAPDH, PGK, PGAM1, 
ENO, PK(M)1, PK(M)2, LDH(A) and MCT4. Actin was used as a loading control. (B) Relative 
protein expression (as measured by pixel density of equivalent ROI between different samples on the 
same blot then normalised to control) of PFKFB3 in (i) NOMO and (ii) THP cells (n=3) determined 
by western blot using whole cell lysates from these cells and densitometry analysed using AIDA 
software. Data represents mean ± 1SD.  
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Figure 4-5. ROS dependent changes in protein expression of glycolytic enzymes in the AML 
derived cell line Mv4;11. Mv4;11 cells treated with GOX (10mU/ml or 20mU/ml) were incubated 
for a further 24h followed by whole cell protein extraction. (A) Example western blots showing 
expression of GLUT3, GLUT5, HK1, PGI, PFKFB3, PFK(P), FBP1, ALDO(A), ALDO(C), TPI, 
GAPDH, PGK, PGAM1, ENO, PK(M)1, PK(M)2, LDH(A), MCT4. Actin was used as a loading 
control. (B) Relative protein expression (as measured by pixel density of equivalent ROI between 
different samples on the same blot then normalised to control) of (i) PFKFB3 (n=5), (ii) PFK(P) 
(n=3), (iii) HK1 (n=3) determined by western blot using whole cell lysates from these cells and 
analysed by AIDA image analyser. Data represents mean ± 1SD. * denotes p<0.05 analysed by 
ANOVA with Tukey’s honestly significance difference.  
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Figure 4-6. Exposure of MV4;11 cells to exogenous ROS increases protein expression of HK1, 
PFKFB3 and PFK(P). Mv4;11 cells were treated with GOX (10mU/ml or 20mU/ml) or GOX 
(20mU/ml) and catalase (100µg/ml) and incubated for a further 24h prior to whole cell lysis. Western 
blots show expression of HK, PFKFB3 and PFK(P). Actin was used as a loading control. 
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4.3.4 Post translational modifications and translocation of PFKFB3 in mutant RAS 
expressing HPC and AML cell lines. 
The data above suggests that changes in ROS levels result in changes in protein 
expression of PFKFB3 (a key regulatory enzyme in glycolysis (1.5)), in N-RASG12D 
HPC and in some AML cell lines. Since phosphorylation (Novellasdemunt et al., 
2013) and nuclear translocation of PFKFB3 (Yalcin et al., 2009a) has been shown to 
play a role in glycolytic flux and cell cycle progression, western blots were analysed 
to determine ROS induced changes in these key regulatory functions. 
4.3.4.1 ROS does not induce phosphorylation of PFKFB3 
It has previously been reported that in COS-7 cells (a cell line derived from colon 
cancer), increased phosphorylation of PFKFB3 at Ser461 results in increased lactate 
production and increased proliferation (Bando et al., 2005) and increases in F-2,6-BP 
in the breast cancer cell line T47D (Novellasdemunt et al., 2012). Phosphorylation of 
PFKFB3 has also been shown to increase its kinase activity (Marsin et al., 2002). To 
determine whether ROS induced phosphorylation of PFKFB3 occurred in mutant 
RAS expressing HPC, whole cell lysates of untreated and DPI treated cells were 
analysed by western blot using an antibody recognising phosphorylated PFKFB3 (p-
PFKFB3). As shown in Figure 4-7A, N-RASG12D HPC, but not H-RASG12V HPC 
treated with DPI have reduced expression of p-PFKFB3 compared to untreated cells, 
with a relative change similar to that observed for PFKFB3. No changes in p-
PFKFB3 expression of control HPC treated with DPI were observed. These data 
indicate that in N-RASG12D HPC, ROS had no effect on phosphorylation of PFKFB3 
as the relative ROS induced changes in p-PFKFB3 and PFKFB3 are broadly 
equivalent.  
To determine whether ROS affected phosphorylation of PFKFB3 in AML cell lines, 
western blot analysis on whole cell lysates of THP NOX2-KD cells, THPSH cells 
treated with DPI and Mv4;11 cells treated with GOX compared with control cells 
was performed. Figure 4-7B and C show that in all cases no changes in 
phosphorylation of PFKFB3 occurred when compared to control cells. However, 
ROS inhibition and knockdown in THP-1 cells decreased expression of total 
PFKFB3 protein and Mv4;11 cells treated with GOX showed increased levels of 
total PFKFB3 protein compared to untreated control. Given the ROS dependent 
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changes in total PFKFB3 protein levels, it might be expected that if ROS was 
exhibiting no effect on PFKFB3 phosphorylation, pPFKFB3 protein levels would 
exhibit an equivalent pattern. The failure of pPFKFB3 protein levels to mirror the 
changes observed in total PFKFB3 protein levels indicates that ROS may prevent 
phosphorylation of this enzyme in AML cell lines (see 4.4). 
Overall, whilst N-RASG12D HPC did show a decrease in p-PFKFB3 expression upon 
treatment with DPI in agreement with decreases in total PFKFB3 protein expression, 
data from the AML cell lines indicate that ROS may prevent phosphorylation of this 
enzyme, suggesting a role for ROS in the phosphorylation of PFKFB3 that is context 
dependent (see 4.4). 
4.3.4.2 ROS does not cause translocation of PFKFB3 to the nucleus in THP-1 
It has been shown previously in a number of cell lines, that PFKFB3 translocates to 
the nucleus (Yalcin et al., 2006). Ectopic expression of PFKFB3 in the nucleus of 
cervical, colon and breast cancer cell lines led to increased cell proliferation without 
impacting on the overall glycolytic rate (Yalcin et al., 2009a). This led the authors to 
speculate that in this context PFKFB3 may, in addition to its role in regulating 
glycolytic rate, also have a regulatory role in cell cycle progression. In order to 
examine whether ROS played a role in nuclear translocation of PFKFB3 in the AML 
cell line THP, cytosol/nuclear fractionated lysates of THP NOX2-KD, THPSH cells 
treated with DPI and untreated THPSH control cells were isolated. Western blot 
analysis shows that no PFKFB3 protein expression was observed in the nuclear 
fractions of either the ROS inhibited cells or control cells (Figure 4-8). This suggests 
that ROS does not play a role in translocation of PFKFB3 to the nucleus. 
Furthermore, the failure to detect expression of PFKFB3 in the nucleus of control 
cells suggests that in THP-1 cells, nuclear translocation of PFKFB3 is not a factor in 
cell cycle progression. 
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Figure 4-7. ROS induced phosphorylation of PFKFB3. Example western blot showing expression 
of p-PFKFB3 using whole cell lysates derived from (A) control, N-RASG12D and H-RASG12V HPC 
treated and untreated with DPI (100nM) and incubated for a further 24h; (B) THPSH, THP NOX2-
KD and THPSH cells treated with DPI (100nM) and incubated for a further 24h; (C) Mv4;11 
untreated and treated with 10mU/ml and 20mU/ml GOX and incubated for a further 24h. Actin (A) 
and histone (B) and (C) were used as loading controls (n=2). 
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Figure 4-8. PFKFB3 is not observed in the nucleus of THP-1 cells. Cytosol/nuclear fractionated 
lysates of THPSH control, THP NOX2-KD and THPSH cells treated with 100nM DPI and incubated 
for a further 24h were analysed by western blot using an antibody recognising PFKFB3. Histone and 
Actin were used as loading controls. N.B. bands observed slightly below the molecular weight of 
actin in the nuclear fraction are likely the result of non-specific binding of the histone antibody, the 
failure to detect PFKFB3 in the nuclear fraction indicates a lack of cytosolic contamination. 
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4.3.5 Biochemical metabolite concentrations are changed in models of AML 
Using mass spectrometry as an analytical tool, the relatively new field of 
metabolomics is providing insights, both in establishing biomarkers of disease in 
patients (Wang et al., 2013) and as a research tool in determining relative changes in 
metabolite concentrations in disease models (Bhanot et al., 2015). Through 
manipulation of ROS in AML cell lines, changes in glucose uptake (3.3.3.2), lactate 
output (3.3.3.3), proliferation (3.3.3.4) and protein expression of glycolytic enzymes 
(4.3.3.1 and 4.3.3.2), have been observed in these cells. To understand dynamically 
the impact these ROS induced changes had on metabolite concentrations in 
metabolic pathways related to glycolysis, cell line samples in which ROS had been 
chemically manipulated or NOX2 genetically knocked-down, were prepared as 
previously described (2.11.1) and analysed by MetabolonTM 
(http://www.metabolon.com/) a company specialising in the analysis of the 
metabolome (2.11). 
4.3.5.1 Sample preparation and quality control for GCMS 
Mass spectrometry (using a variety of platforms, see 2.11.3) was performed on 
quadruplicate samples of NOMO and THP cells untreated, treated with DPI (100nM) 
for 24h and with NOX2 knocked-down. Further, Mv4;11 cells untreated or treated 
with GOX for 24h were also included in the study. Prior to mass spectrometry 
analysis, DiogenesTM assay was performed to confirm superoxide production and 
inhibition in the THP and NOMO samples as previously demonstrated (data not 
shown: 3.3.3.1). Additionally, the cells were analysed to confirm that the changes in 
glucose uptake and proliferation observed in (3.3.3.2,3.3.3.4) were also replicated in 
these samples. Samples needed to show a minimum 10% change in both 
proliferation and glucose uptake (data not shown). Additionally, samples were 
stained with 7AAD to determine viability of the cells (2.3.5), with a minimum of 
90% viability being set as a prerequisite for further analysis. 
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4.3.5.2 Principal component analysis indicates differences between AML cell 
lines and cell line treatments.  
To better understand the overall biochemical variations between each sample, 
principal component analysis (PCA) can be employed to provide a global analysis of 
how closely related or otherwise any given sample is. As shown in Figure 4-9A, 
PCA performed by MetabolonTM, show that sample type (e.g. cell line) was one of 
the largest determining factor in differences of biochemical metabolite composition 
between samples. However, the PCA clearly shows that treatment of both NOMO 
and THP cell lines with DPI changed the global metabolite composition of these 
cells as evidenced by separation of the treated replicated samples from the control, 
an effect also observed between NOX2-KD cells and the SH control. In contrast, the 
smallest variation observed was in the Mv4;11 cells treated with GOX. Taken 
together, these data indicate that whilst cell line origin was the largest determining 
factor in changes in global biochemical metabolite variation, exposure to ROS 
affects the metabolome or global biochemical metabolite composition. 
To support these data, hierarchical clustering (performed by MetabolonTM) as shown 
in Figure 4-9B, also demonstrates that the largest variation between samples 
occurred between different cell lines, with treatment providing the next largest 
variation and differences between replicates showing the least variation.  
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Figure 4-9. Variation in biochemical metabolites between samples analysed by MetabolonTM. 
(A) PCA analysis representing variation between samples, where circles represent control, squares 
represent DPI treated cells (100nM) NOMO (red), THP (blue) and GOX treated cells (10mU/ml) 
Mv4;11 (green) and triangles represent NOX2-KD cells NOMO(red), THP (blue) and GOX treated 
cells (20mU/ml) Mv4;11 (green). All cells chemically treated were incubated for 24h following 
treatment. (B) Dendrogram representing variation between samples subjected to hierarchical 
clustering analysis, NOMO (red), THP (blue), Mv4;11 (green). All calculations were performed by 
MetabolonTM, samples were loaded equally across the platform, normalised to Bradford protein 
concentration, each biochemical is then rescaled to set the median equal to l, imputation of missing 
values (if any) with minimum value for each compound is performed and data log transformed. Green 
represents lower and red higher concentration of biochemical relative to median value. Graphs 
constructed by MetabolonTM (n=4).  
A 
B 
Mv4;11 THP-1 NOMO-1 
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4.3.5.3 ROS affects change in relative concentrations of biochemical metabolites 
of the glycolytic pathway 
The data above (4.3.5.2) suggests ROS induced changes in global biochemical 
metabolite levels in AML cell lines. To determine whether ROS induced changes in 
glycolytic metabolites, the above dataset was analysed specifically for metabolites 
within this pathway. 
Knock-down of NOX2 results in changed glycolytic metabolite profile. 
The data above (4.3.3.1) have demonstrated that knock-down of NOX2 in the THP 
cell line decreases PFKFB3 expression, a key regulatory enzyme in glycolysis 
(1.5.1). To ascertain whether NOX2KD additionally changed glycolytic metabolite 
levels, mass spectrometry was performed on THP and NOMO cells with NOX2 
knocked-down and the data analysed by MetabolonTM. In THP cells, knock-down of 
NOX2 using shRNA resulted in a reduction of the glycolytic metabolites, F-1,6-BP 
(1.4-fold), dihydroxyacetone phosphate (DHAP) (2-fold), and a significant reduction 
of pyruvate (1.3-fold, p=0.016) and lactate (1.9-fold, p=0.003) compared to control 
cells. Interestingly a non-significant increase was observed in F-6-P (5.2-fold) and in 
3-PG (1.2-fold) (Figure 4-10). In NOMO NOX2-KD cells, a reduction in the 
metabolites F-6-P (2.5-fold), F-1,6-BP (2.3-fold) and DHAP (1.3-fold) was observed 
compared to control, which reached significance for F-1,6-BP (p=0.005), whilst 3-
PG showed a non-significant increase (1.2-fold) (Figure 4-10). Taken together these 
data are supportive of the idea that lower levels of ROS, result in decreased glucose 
uptake in these cell lines, in agreement with the observations in (3.3.3.2).  
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Figure 4-10. Changes in glycolytic intermediates in AML derived cell lines with NOX2 knocked-
down. Schematic diagram of glycolysis, showing variation in glycolytic metabolite levels, as detected 
by mass spectrometry, in THPSH (dark blue), THP NOX2-KD (blue), NOMOSH (dark green), 
NOMO NOX2-KD (green) cells. Data shows relative values following normalisation to Bradford 
protein concentration, log transformation and imputation of missing values with the minimum 
observed value for each compound (n=4). Box plots represent median quartile ranges, x represents 
mean value. * denotes p<0.05 and Ϯ denotes p<0.005 for NOX2-KD cells compared with SH control 
as analysed by Welch’s two sample t-test.  
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Chemical inhibition of NOX2 results in changed glycolytic metabolite profile. 
Decreased protein expression of the glycolytic enzyme PFKFB3 was found to be 
reduced in THP cells treated with DPI, whilst a decrease in expression of FBP1 was 
observed in NOMO cells treated with DPI, when compared with control cells 
(4.3.3.1). To examine whether DPI altered glycolytic metabolite levels, mass 
spectrometry was performed by MetabolonTM on both THP and NOMO samples 
treated with DPI (as previously described, 3.3.3.2) and compared with the levels in 
untreated cells. Treatment of THP cells with DPI (100nM) for 24h resulted in a 
significant decrease in lactate (2.2-fold, p=0.001), whilst decreases were also 
observed in F-6-P (1.5-fold) and F-1,6-BP (1.2-fold), compared with untreated cells. 
Interestingly significant increases in both pyruvate (4.4-fold, p<0.0001) and 3-PG 
(8.1-fold, p=0.002) were also observed (Figure 4-11), which may be the result of off 
target effects of the DPI (4.4). NOMO cells showed significant decreases in the 
glycolytic metabolites F-6-P (3.8-fold, p=0.004), F-1,6-BP (4-fold, p=0.0001), 
DHAP (2-fold, p=0.0005) and lactate (2.9-fold, p<0.0001), upon treatment with DPI. 
No change in the relative amounts of pyruvate was observed, whilst analogous to the 
results observed in THP a significant increase in 3-PG (3.6-fold, p=.002) was also 
seen (Figure 4-11). The significant decrease in glycolytic metabolites in NOMO cells 
treated with DPI alongside the significant decrease in lactate and decreases in F-6-P 
and F-1,6-BP in the THP cells are supportive of an overall decrease in glucose 
uptake as seen in (3.3.3.2).  
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Figure 4-11. Changes in glycolytic intermediates in AML derived cell lines with NOX2 
chemically inhibited. Schematic diagram of glycolysis, showing variation in glycolytic metabolite 
levels, as detected by mass spectrometry, in THPSH (dark blue), THPSH + DPI (100nM) (light blue), 
NOMOSH (dark green), NOMOSH + DPI (100nM) (light green) cells. All cells incubated for 24h 
following DPI treatment. Data shows relative values following normalisation to Bradford protein 
concentration, log transformation and imputation of missing values with the minimum observed value 
for each compound (n=4). Box plots represent median quartile ranges, x represents mean value. * 
denotes p<0.05, Ϯ denotes p<0.005 and ϮϮ denotes p<0.001 for DPI treated cells compared with 
untreated control as analysed by Welch’s two sample t-test.  
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Increased exogenous ROS in Mv4;11 cells results in changed glycolytic 
metabolite profile. 
When Mv4;11 cells were treated with exogenous ROS increases in protein 
expression levels of the glycolytic enzymes HK1, PFK(P) and PFFKFB3 were all 
observed (4.3.3.2). To further detail how ROS impacted on metabolism in these 
cells, mass spectrometry was performed (as previously described, 2.11.3) on Mv4;11 
cells treated with 10mU/ml and 20mU/ml of GOX, incubated for a further 24h and 
compared with untreated cells. The addition of GOX 10mU/ml to the cell line 
Mv4;11 resulted in a significant increase in the glycolytic metabolite pyruvate (1.3-
fold, p=0.001), although interestingly this increase is not observed at the higher dose 
(GOX 20mU/ml). Additionally, decreases in F-6-P (1.4-fold), DHAP (1.2-fold) and 
3-PG (1.8-fold) were also observed, although none of these changes reached 
significance. Treatment with the higher dose (GOX 20mU/ml) resulted in a 
significant (1.5-fold, p=0.02) decrease in intracellular lactate levels, whilst a non-
significant decrease in 3-PG (2.4-fold) was additionally observed. Conversely a non-
significant increase in F-1,6-BP (1.2-fold) was also detected (Figure 4-12). Whilst 
significant increases in pyruvate are observed in Mv4;11 cells treated with GOX 
10mU/ml, the absence of any change in pyruvate levels, alongside the significant 
decrease in intracellular lactate levels in Mv4;11 cells treated with higher dose of 
GOX, does not offer support to the idea of an increase in glycolytic flux in these 
cells. It is worth noting however, that increases in extracellular lactate levels were 
observed in Mv4;11 cells treated with both the lower and higher levels of GOX, and 
therefore the failure to detect increases in glycolytic metabolite intermediaries maybe 
a function of enhanced lactate export (4.4). 
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Figure 4-12. Changes in glycolytic intermediates in Mv4;11 cells experiencing increased 
exogenous ROS. Schematic diagram of glycolysis, showing variation in glycolytic metabolite levels, 
as detected by mass spectrometry, in Mv4;11 cells; untreated (dark red), treated with GOX 
(10mU/ml) (red) and GOX (20mU/ml) (light red). Cells incubated for 24h following treatment. Data 
shows relative values following normalisation to Bradford protein concentration, log transformation 
and imputation of missing values with the minimum observed value for each compound (n=4). Box 
plots represent median quartile ranges, x represents mean value. * denotes p<0.05 for GOX treated 
cells compared with untreated control as analysed by Welch’s two sample t-test.  
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4.3.5.4 ROS induces changes in metabolite levels of other metabolic pathways 
The mass spectrometry data above shows changes in concentrations of glycolytic 
metabolites as a result of changes in ROS levels, which are broadly supportive of the 
ROS induced changes in glucose uptake observed in 3.3.3.2. Glycolysis is only one 
component of cellular metabolism, with many other metabolic pathways feeding into 
and branching off from glycolytic intermediates (1.4.4). Whilst a detailed analysis of 
ROS induced changes in these pathways is beyond the scope of this study, some 
significant changes are worthy of note. 
DPI treatment results in decreases in fumarate, a key intermediate in the citric 
acid cycle 
Otto Warburg initially ascribed his observation that cancer cells exhibited increased 
aerobic glycolysis to defective mitochondrial function in these cells (Warburg, 
1956), although a number of subsequent studies have shown functional mitochondria 
is important in cancer cell metabolism (reviewed in Wallace, 2012). The citric acid 
cycle commences from the reaction of acetyl CoA with oxaloacetate to form citrate. 
Acetyl CoA is generated following the decarboxylation of pyruvate catalysed by the 
enzyme pyruvate dehydrogenase, whilst oxaloacetate is regenerated from the citric 
acid cycle. Importantly the metabolic step which converts succinate to fumarate 
involves the reduction of flavin adenine dinucleotide which generates the proton 
gradient necessary for oxidative phosphorylation. Furthermore, it has been shown 
that whilst HSC require fumarate hydratase (the enzyme that catalyses this step) for 
self-renewal and maintenance, LSC do not (Guitart et al., 2017). Therefore, ROS 
induced changes in fumarate levels may be indicative of changes in the cellular rates 
of oxidative phosphorylation. Analysis of the mass spectrometry data by 
MetabolonTM showed no significant changes in fumarate levels were observed in 
either THP or NOMO cells with NOX2 knocked-down, however treatment of both 
cell lines with DPI resulted in a significant 4.2-fold (p<0.0001) and 2.4-fold 
(p=0.009) decrease in fumarate respectively. Treatment of Mv4;11 cells with GOX 
10mU/ml showed no change in fumarate levels, although a treatment dose of 
20mU/ml resulted in a significant 1.5-fold reduction (p=0.024) (Figure 4-13A). 
These data suggest that genetic silencing of NOX2 in THP and NOMO cells does 
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not affect the rate of oxidative phosphorylation, whilst the changes observed through 
chemical inhibition of NOX2 with DPI may be the result of an off-target effect.  
ROS induces changes in 6-phosphogluconolactone, a key intermediate in the 
PPP. 
One potential explanation for increased aerobic glycolysis in cancer cells is a 
facilitation of increased flux through the PPP, which generates nucleotides for 
biosynthesis and a recent paper (Chen et al., 2016c) reported that PPP enzymes were 
upregulated in 61% of AML patients. The rate limiting step in the PPP is the 
conversion of glucose-6-phosphate to 6-phosphogluconolactone (6-PG) and this is 
also the step that generates NADPH, which combats oxidative stress (reviewed in 
Patra and Hay, 2014). Therefore, the mass spectrometry data from the samples, was 
analysed by MetabolonTM for changes in 6-PG levels, in order to assess the impact of 
ROS on this pathway. Knock-down of NOX2 in NOMO and THP cells resulted in a 
non-significant decrease (1.2-fold) and a non-significant increase (3.3-fold) in 6-PG, 
respectively. Inhibition of these cell lines with DPI both generated decreases in 6-PG 
levels, 1.3-fold in the THP cells and 2.2-fold in NOMO and this was significant in 
the NOMO cells (p=0.004). Treatment of Mv4;11 cells with GOX (10mU/ml) 
resulted in a significant (p=0.033) 1.8-fold increase in 6-PG, whilst treatment with 
20mU/ml of GOX showed a non-significant 1.3-fold increase (Figure 4-13B). Whilst 
the observed increase in 6-PG in THP NOX2-KD cells is inconsistent with the idea 
of ROS induced increases in the PPP, overall these data are supportive of the idea 
that increased ROS levels result in increased PPP metabolism. 
ROS induces changes in other significant metabolites. 
In addition to the changes in metabolic pathways identified above, mass 
spectrometry analysis of the samples revealed significant ROS dependent changes in 
amino acid levels and metabolites involved in sphingolipid metabolism, which are 
important in biosynthesis.  
Knock-down of NOX2 in THP cells decreased levels of nineteen of the twenty 
amino acids, and this was significant for eleven of them. NOMO NOX2-KD cells 
showed significant decreases in proline and aspartate, although significant increases 
in serine, asparagine and isoleucine were also observed. Treatment of THP cells with 
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DPI, resulted in a decrease in sixteen of the twenty amino acids, of which eleven 
were significant, whilst treatment of NOMO cells with DPI showed a decrease in all 
twenty amino acids, which were significant for sixteen. Additionally, treatment of 
Mv4;11 cells with GOX (10mU/ml) led to increase in eighteen of the twenty amino 
acids, six of which were significant, although treatment at the higher dose (GOX 20 
mU/ml) led to a depletion of amino acids, five of which were significant (Table 6). 
These data suggest that increased levels of ROS lead to increases in cellular levels of 
amino acids. 
Significant reductions in a number of metabolites involved in sphingolipid 
metabolism were observed in both THP and NOMO cells which had NOX2 
knocked-down, although this was not observed in cells treated with DPI, whilst 
conversely addition of exogenous ROS to Mv4;11 cells resulted in significant 
increases of metabolites involved in sphingolipid metabolism (data not shown). 
Overall these data suggest that ROS has significant impacts not only on the 
glycolytic function of cells but also on a number of other metabolic pathways.  
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Figure 4-13. ROS induced changes in fumarate and 6-phosphogluconolactone. Box plots showing 
relative changes in metabolite levels, as detected by mass spectrometry of (A) fumarate and (B) 6-
phosophogluconolactone in THPSH (dark blue), THP NOX2-KD (blue), THPSH treated with DPI 
(100nM) (light blue), NOMOSH (dark green), NOMO NOX2-KD (green), NOMOSH treated with 
DPI (100nM) (light green), Mv4;11 untreated (dark red), Mv4;11 treated with GOX (10mU/ml) (red) 
and GOX (20mU/ml) (light red) cells. All cells incubated for further 24h following chemical 
treatment. Data shows relative values following normalisation to Bradford protein concentration, log 
transformation and imputation of missing values with the minimum observed value for each 
compound (n=4). * denotes p<0.05, Ϯ denotes p<0.005 and ϮϮ denotes p<0.001 for DPI or GOX 
treated cells compared with untreated control as analysed by Welch’s two sample t-test.  
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Table 6. ROS induced variation in amino acid metabolite levels in AML-derived cell lines Table 
shows mean fold changes in amino acids, as detected by mass spectrometry, in THPSH and 
NOMOSH cells, THP and NOMO cells with NOX2 genetically silenced, THPSH and NOMOSH 
cells treated with DPI (100nM) and Mv4;11 cells untreated and treated with GOX. All cells incubated 
for further 24h following treatment. Data shows relative values following normalisation to Bradford 
protein concentration, log transformation and imputation of missing values with the minimum 
observed value for each compound (n=4). Boxes shaded green indicate significant decreases and 
boxes shaded red indicate significant increases (p<0.05) performed using Welch’s two sample t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 NOX2 KD vs 
Control  DPI vs Control 
 NOX2 KD vs 
Control  DPI vs Control 
GOX 10mU/ml vs 
Control
 GOX 20mU/ml vs 
Control
Glycine 0.75 1.31 1.02 0.84 1.11 0.85
Serine 0.78 0.37 1.19 0.63 1.09 0.72
Threonine 0.77 0.83 1.1 0.51 1.28 1
Alanine 0.75 0.57 1.19 0.43 0.98 0.73
Asparagine 0.67 0.64 1.25 0.48 1.13 0.86
Glutamate 0.75 0.95 0.95 0.9 1.06 0.82
Glutamine 0.16 1.64 1.27 0.42 1.14 0.73
Histidine 0.81 0.74 1.16 0.72 1.28 0.97
Phenylalanine 0.79 0.51 1.06 0.65 1.18 0.91
Tryptophan 0.8 0.63 1.12 0.7 1.23 1.03
Leucine 0.77 0.64 1.07 0.71 1.16 0.86
Methionine 0.83 0.63 1.14 0.86 1.2 0.82
Cysteine 0.52 1.08 0.83 0.79 1.19 0.97
Proline 0.74 0.89 0.88 0.71 1.23 1.03
Aspartate 1.38 0.54 0.77 0.41 0.84 0.64
Arginine 0.93 1.32 1.06 0.86 1.09 0.78
Isoleucine 0.82 0.89 1.13 0.84 1.28 1.03
Valine 0.85 0.73 1.06 0.73 1.28 0.95
Lysine 0.86 0.84 0.91 0.63 1.15 0.89
Tyrosine 0.74 0.47 1.11 0.68 1.18 0.92
THP-1 NOMO Cell Lines MV411 Cells
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4.3.6 AML patient samples show ROS induced changes in biochemical metabolite 
concentrations 
The metabolomic data above suggests that changes in cellular metabolite levels can 
occur as a consequence of ROS modulation in AML. To determine whether changes 
in biochemical metabolite levels vary between AML patients stratified according to 
production of ROS and compared to normal human mononuclear cells, AML blasts 
from 20 AML patients were sent to MetabolonTM for metabolomic analysis. As 
shown in Figure 4-14, DiogenesTM analysis of AML blasts stratified the patient 
samples into ROSHi and ROSLo producing AML blasts.  
PCA on patient samples and controls as shown in Figure 4-15 demonstrate that the 
global biochemical metabolite composition of control samples differentiated from 
patient samples. Further, patient samples deemed high ROSHi producers 
predominantly clustered separately from those deemed ROSLo. These data indicate 
that variations in global biochemical metabolite composition are a consequence of 
both AML and the ROS produced by AML blasts. 
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Figure 4-14. Superoxide production in AML patient blasts. Peak superoxide production (relative 
luminescent units/min (RLU/min)) in a panel of AML patient blasts measured using DiogenesTM. 
Blasts were stratified by median into ROSHi (red triangle, n=10) and ROSLo (yellow circle, n=10) 
blasts.  
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Figure 4-15. PCA showing variation between samples in biochemical metabolites analysed by 
MS. White circles represent healthy human mononuclear control cells (Ctrl_MN), yellow cones 
represent AML blasts with low ROS (AML_Low) and red pyramids represent AML blasts with high 
ROS (AML_High). All calculations were performed by MetabolonTM, samples were loaded equally 
across the platform, normalised to Bradford protein concentration, log transformed and imputation of 
missing values (if any) with minimum value for each compound (n=4). Graph constructed by 
MetabolonTM. 
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4.3.6.1 AML patient samples show changes in glycolytic metabolite levels and 
this is modulated by ROS 
Having determined variation in global metabolite levels between AML patient blasts 
and healthy controls, the mass spectrometry data was analysed further to determine 
variations in glycolytic metabolites. AML blasts show increased levels of glucose 
uptake (2.6-fold) and significantly increased levels (2.4-fold) of intracellular lactate 
(p=0.004) compared to mononuclear controls. Significantly decreased levels of the 
glycolytic intermediates, F-1,6-BP (1.3-fold, p=0.006), 3-PG (1.6-fold, p=0.045), 2-
PG (1.5-fold, p=0.007) and pyruvate (1.4-fold, p=0.003) were also observed 
alongside a non-significant decrease in G-6-P (1.3-fold). Additionally, a non-
significant increase in F-6-P (1.2-fold) and a significant (2-fold) increase in DHAP 
(p=0.012), was also seen (Figure 4-16). Overall, the increase in glucose uptake and 
significant increase in lactate output in AML blasts are supportive of the idea of 
increased glycolysis in AML patients. 
To determine ROS induced changes in glycolytic metabolites in AML patients, the 
data was analysed between ROSHi and ROSLo AML blasts. Significant increases 
were observed in glucose (2.4-fold, p=0.008), G-6-P (2-fold, p=0.01) and F-6-P (1.9-
fold, p=0.018) metabolite levels in the ROS high blasts. Increases were also 
observed in the metabolite levels of F-1,6-BP (1.6-fold), DHAP (1.5-fold), 2-PG 
(1.3-fold) of ROS high blasts when compared with ROS low blasts, although these 
were not significant. Conversely, there were non-significant decreases in the 
metabolite levels of 3-PG (1.5-fold), PEP (1.5-fold) and pyruvate (1.4-fold) in the 
ROS high blasts compared to the ROS low blasts (Figure 4-17). Interestingly, 
intracellular lactate levels showed only a 1.1-fold increase in the ROS high blasts 
compared to the ROS low blasts, which may be a function of increased lactate 
excretion or alternative ROS induced mechanism (4.4). Overall, the significant 
increase in intracellular glucose levels, alongside the increase in a number of 
glycolytic intermediates in ROS high blasts are supportive of a ROS induced 
increase in glycolysis in AML patients.  
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Figure 4-16. Changes in glycolytic intermediates in AML patient samples compared with 
healthy controls. Schematic diagram of glycolysis, showing variation in glycolytic metabolite levels, 
as detected by mass spectrometry, in healthy human mononuclear cells (grey) and AML patient blasts 
(purple). Data shows relative values following normalisation to Bradford protein concentration, log 
transformation and imputation of missing values with the minimum observed value for each 
compound (n=6 control, n=20 AML blasts). Box plots represent median quartile ranges, x represents 
mean value, • or ◦ represent individual data points. * denotes p<0.05, ** denotes p<0.01 and Ϯ denotes 
p<0.005 as analysed by Welch’s two sample t-test.  
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Figure 4-17. Changes in glycolytic intermediates in ROS high AML blast compared with ROS 
low AML blasts. Schematic diagram of glycolysis, showing variation in glycolytic metabolite levels, 
as detected by mass spectrometry, in ROS low AML blasts (orange) and ROS high AML blasts 
(yellow); Data shows relative values following normalisation to Bradford protein concentration, log 
transformation and imputation of missing values with the minimum observed value for each 
compound (n=10). Box plots represent median quartile ranges, x represents mean value, • or ◦ 
represent individual data points. * denotes p<0.05 and ** denotes p<0.01 as analysed by Welch’s two 
sample t-test.  
** 
** 
Glucose 
Glucose-6-phosphate 
Fructose-6-phosphate 
Fructose-1,6-biphosphate 
Dihydroxyacetone Phosphate Glyceraldehyde-3-phosphate 
1,3-Biphosphoglycerate 
3-Phosphoglycerate 
2-Phosphoglycerate 
Phosphoenolpyruvate 
Pyruvate 
Lactate 
* 
** 
** 
 
 
 
 
 
 
  
 
 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
G
en
e 
ex
pr
es
sio
n 
(lo
g 2
) 
Chapter 4 
184 
4.3.6.2 AML patient samples show changes in pentose phosphate pathway 
metabolite profile 
As described earlier (4.3.5.4), the PPP generates nucleotides for biosynthesis and 
NADPH an important antioxidant. AML cell lines showed ROS dependent changes 
in 6-PG the first intermediate of the PPP pathway. Further metabolism along this 
pathway generates ribose-5-phosphate (R-5-P), a key metabolite in the synthesis of 
nucleotides and xylulose-5-phosphate (X-5-P) (reviewed in Samland and Sprenger, 
2009). Therefore, to examine whether AML blasts show changes in PPP metabolites 
and to determine if ROS is a factor in these changes, the mass spectrometry data was 
analysed by MetabolonTM, for changes in these metabolites. AML blasts showed 
non-significant increases in 6-PG (1.2-fold) and X-5-P (2.2-fold), whilst a significant 
increase in R-5-P (3.7-fold, p=0.004) was observed when compared to mononuclear 
controls (Table 7). Interestingly when the ROS high blasts were compared with the 
ROS low blasts a non-significant decrease in both 6-PG (2.5-fold) and R-5-P (1.3-
fold) was observed, however a significant 2-fold (p=0.002) increase in X-5-P was 
also seen (Table 8). These data suggest that AML patient blasts show increased 
utilisation of PPP compared to healthy controls, although the data on the impact of 
ROS on this pathway is more equivocal.  
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Table 7. Variation in PPP metabolite levels in AML patient samples compared with healthy 
controls. Table shows median and mean fold changes in detectable PPP metabolites in AML patient 
blasts compared with healthy human mononuclear cells , as detected using gas chromatography mass 
spectrometery. Boxes shaded dark purple indicate significant differences performed on the mean 
(p<0.05) using Welch’s two sample t-test, q-values represent the false discovery rate. 
 
 
 
 
 
 
 
Table 8. Variation in PPP metabolite levels in ROS high AML blasts compared with ROS low 
AML blasts. Table shows median and mean fold changes in detectable PPP metabolites in ROS high 
AML blasts compared with ROS low AML blasts, as detected using gas chromatography mass 
spectrometery. Boxes shaded dark yellow indicate significant differences performed on the mean 
(p<0.05) using Welch’s two sample t-test, q-values represent the false discovery rate. 
 
 
 
 
 
 
 
  
Metabolite
Median Fold Change Mean Fold Change p-value q-value
6-Phosphogluconolactone 0.62 1.17 0.2238 0.0618
Ribose-5-phosphate 3.91 3.73 0.0042 0.0021
Xyulose-5-phosphate 2.11 2.20 0.0532 0.0184
AML blasts vs human mononuclear control cells
Metabolite
Median Fold Change Mean Fold Change p-value q-value
6-Phosphogluconolactone 1.01 0.40 0.6552 0.479
Ribose-5-phosphate 1.10 0.77 0.3167 0.3269
Xyulose-5-phosphate 2.82 2.03 0.0022 0.0288
ROS high vs ROS low AML blasts
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4.4 Discussion 
This chapter presented data which supports the hypothesis that changes in aerobic 
glycolysis are mediated by increased levels of ROS in both mutant-RAS expressing 
HPC and in AML derived cell lines. Further, it was also demonstrated that these 
effects are potentially mediated by changes in several proteins involved in 
carbohydrate metabolism with strongest changes observed in PFKFB3. Finally, 
metabolomic analysis of levels of glycolytic metabolites in cell line models and 
AML patient samples offer further evidence to support ROS modulating glycolytic 
activity in AML. 
4.4.1 The effect of RAS and ROS on glycolysis and PFKFB3 expression 
Oncogenic RAS has been widely reported to show increased glycolytic activity and is 
linked with increased activity of GLUT1, PFK1, GAPDH and PKM2 (reviewed in 
Chesney and Telang, 2013). Recent work by Song et al., 2016 and Chen et al., 
2016b have also shown increased expression of GLUT1 and GLUT5 mRNA 
respectively, within an AML context. A new analysis of previously generated 
microarray data by our group, specifically focussing on glycolytic enzymes, showed 
increased mRNA transcription of several glycolytic enzymes in N-RASG12D HPC 
compared to control HPC (4.3.1). Furthermore, this increased mRNA expression of 
glycolytic enzymes is decreased in N-RASG12D HPC when ROS is inhibited by 
treatment of the cells with DPI. However, as noted previously, changes in mRNA 
expression do not necessarily correlate with increased protein expression. Analysis 
of mutant-RAS expressing HPC showed increased protein expression of several 
glycolytic enzymes (most markedly GLUT3, PFK(P) and PFKFB3), but only 
PFKFB3 showed a ROS dependent change in protein expression and then only in N-
RASG12D HPC (Figure 4-3). The discrepancy between N-RASG12D and H-RASG12V 
HPC may reflect an alternate mechanism for PFKFB3 overexpression in H-RASG12V 
compared with N-RASG12D or may be a result of a sub-optimal DPI dose in these 
cells, which generate significantly more ROS than their N-RASG12D counterparts 
(Hole et al., 2010). 
PFKFB3 catalyses the reaction of F-6-P to F-2,6-BP (1.5.1). F-2,6-BP is a powerful 
allosteric activator of PFK which catalyses F-6-P to F-1,6-BP (reviewed in Ros and 
Schulze, 2013) a rate limiting step in glycolysis (Xie et al., 2016) and increased 
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PFKFB3 expression has been shown to increase glucose uptake and cellular lactate 
generation in a number of solid tumour cell lines. Heterozygotic genomic deletion of 
PFKFB3 in mouse lung fibroblasts resulted in decreased F-2,6-BP production and 
decreased lactate secretion (Telang et al., 2006); chemical inhibition of PFKFB3 in 
Jurkat T cell leukaemia cells results in decreased proliferation, glucose uptake and 
lactate secretion (Clem et al., 2008) and a recent study showed glucose uptake and 
lactate secretion was decreased upon chemical inhibition of PFKFB3 in HNSCC cell 
lines (Li et al., 2017a). PFKFB3 mRNA expression has been shown to be 
upregulated in a number of solid tumours including colon, breast, prostrate, ovary 
and thyroid (Atsumi et al., 2002) and a recent study showed increased 
immunohistochemical staining of PFKFB3 in 111 head and neck squamous cell 
carcinoma patient samples when compared with normal surrounding tissue (Li et al., 
2017a). 
Here, inhibition of NOX2-derived ROS in the THP-1 cell line resulted in decreased 
expression of PFKFB3, whilst analysis of other glycolytic enzymes showed no ROS 
associated changes in protein expression levels. This suggests that ROS modulates 
PFKFB3 expression in these cells and is a key player in ROS induced changes in 
glycolysis. Additionally, increased exogenous ROS levels, in the Mv4;11 cell line, 
resulted in increased protein expression of PFKFB3, as well as increased HK1 and 
PFK(P) expression (Figure 4-5). Furthermore, treatment of this cell line with both 
GOX and catalase (which decomposes H2O2, but not superoxide) did not increase 
protein expression of these enzymes, providing further evidence that it is NOX-
derived ROS that modulates expression levels of this protein (4.3.3.2). Curiously, 
knock-down of NOX2 in the NOMO-1 cell line did not result in changes in 
expression levels of any of the glycolytic enzymes tested whilst chemical inhibition 
with DPI resulted in decreased expression but only of FBP1 (Figure 4-4). NOMO-1 
cells generate much higher levels of superoxide than THP-1; furthermore, whilst 
knock-down of NOX2 in these cells decreased superoxide production by 30%, THP 
NOX2-KD cells showed a 90% decrease in superoxide production (3.3.3.1). Whilst 
chemical inhibition of NOMO-1 cells with DPI decreased superoxide production by 
65%, it is worth noting that this reduction would still mean these cells were 
generating superoxide levels similar to those generated in untreated THP-1 cells. 
These much higher levels of superoxide production in NOMO-1 cells, coupled with 
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a less efficient knock-down of NOX2, may offer one possible explanation for the 
absence of decreased PFKFB3 expression. Alternatively, FBP1 (an enzyme involved 
in gluconeogenesis, which catalyses the reaction F-1,6-BP to F-6-P, the reverse step 
of the glycolytic reaction catalysed by PFK), showed decreased expression levels in 
DPI treated NOMO-1 cells, which could suggest that the mechanism by which ROS 
modulates glycolytic change may vary between cell lines. 
In N-RASG12D HPC and the THP-1 and Mv4;11 cell lines, changes in protein 
expression of PFKFB3 were observed in conjunction with changes in NOX2 derived 
ROS levels. PFKFB3 has additionally been shown to translocate to the nucleus of 
cell lines (Yalcin et al., 2006), leading to increased cellular proliferation (Yalcin et 
al., 2009a). Given that ROS modulation resulted in proliferative changes in mutant 
RAS expressing HPC (3.3.2.4) and AML derived cell lines (3.3.3.4), nuclear 
expression of PFKFB3 was examined in THP-1 cells. No expression of PFKFB3 was 
found in either the nucleus of the ROS inhibited THP-1 cells or the THP control 
cells, demonstrating that PFKFB3 does not translocate to the nucleus and that this 
mechanism is not involved in proliferative changes in these cells. It has also been 
reported that phosphorylation of PFKFB3 at Ser-461 increases glycolytic flux 
(Novellasdemunt et al., 2013). Here, analysis of p-PFKFB3 expression in N-
RASG12D HPC demonstrated that ROS did not lead to changes in phosphorylation of 
this protein, as chemical inhibition of ROS in these cells resulted in similar relative 
changes in expression of both p-PFKFB3 and total PFKFB3. Conversely in AML 
cell lines, whilst ROS leads to changes in PFKFB3 expression in both THP-1 and 
Mv4;11 cells, no changes were observed in the relative expression levels of p-
PFKFB3, which may suggest a ROS induced inhibition of phosphorylation in these 
cells. The discrepancy between these results and those observed in N-RASG12D HPC 
may well reflect a lack of specificity with this antibody and there are issues with 
detecting phosphorylated proteins by western blot (Campa and Kypta, 2011). 
However, given the variety of ROS related post-translational modifications to 
PFKFB3 reported in the literature (1.5.1.2) and the potential impact on metabolic 
regulation (4.4.2), further examination of the data described above may be 
warranted. 
Further evidence that NOX2-derived ROS affects glycolysis was provided through 
metabolomic analysis. Metabolomic data from patient samples showed significant 
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increases in cellular glucose, G-6-P and F-6-P levels in ROSHi compared with ROSLo 
AML blasts (Figure 4-17), supportive of ROS induced increases in glucose uptake in 
these cells.  
4.4.1.1 The effect of ROS and PFKFB3 expression on cellular lactate levels 
Whilst data presented above and in chapter 3 demonstrates a clear association 
between increased ROS levels and increased glucose uptake, the link between 
increased ROS and increased lactate is less clear. Metabolomic analysis of THP-1 
cells, in which NOX2 was knocked-down or chemically inhibited with DPI, showed 
that intracellular lactate levels are significantly decreased compared to control 
(4.3.5.3), supportive of the idea that ROS associated increases in PFKFB3 
expression are synonymous with increased glycolysis. Supportive of this, in NOMO 
NOX2-KD cells, which showed no observable changes in PFKB3 expression 
compared to control, no changes in intracellular lactate levels were seen. However, 
treatment of NOMO-1 cells with DPI (which also show no changes in PFKFB3 
expression) did lead to a significant decrease in intracellular lactate levels. This 
decrease may be a function of the decreased FBP1 expression (which could result in 
decreased lactate recycling (4.4.2)), or may be an off-target effect. 
Contrary to the hypothesis that decreased ROS results in decreased intracellular 
lactate levels is that, in Mv4;11 cells, exposure to increased exogenous ROS, 
resulted in either, no change in intracellular lactate levels (GOX 10mU/ml) or a 
significant decrease in intracellular lactate levels (GOX 20mU/ml). One possible 
explanation for this discrepancy is that ROS may affect the rate at which these cells 
transport lactate across the cellular membrane. Supportive of this, is the observation 
that Mv4;11 cells subjected to increased exogenous ROS show increased levels of 
lactate secretion (3.3.3.3). Monocarboxylic transporters (MCT) are responsible for 
the transfer of lactate across the plasma membrane and the isoform MCT4 has been 
shown to be overexpressed in highly glycolytic tissues, induced by hypoxia and 
overexpressed in a number of tumour types (reviewed in Baltazar et al., 2014). 
Interestingly, the microarray data in N-RASG12D HPC (4.3.1) show ROS dependent 
increases in MCT4 expression in mutant RAS expressing HPC. However, no ROS 
associated changes in MCT4 protein expression were observed either in mutant RAS 
expressing HPC or cell lines. Overexpression of other MCT isoforms have been 
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reported in a several cancers however, therefore it remains possible that the ROS 
induced increases in lactate secretion observed in the Mv4;11 cell line, are a result of 
upregulation of one of these alternate isoforms. 
4.4.2 The effect of ROS and PFKFB3 expression on the Pentose Phosphate 
Pathway 
Further complexity in determining the effect of ROS on lactate generation, is the 
observation that ROS inhibition, in both the THP-1 and NOMO-1 cell lines and 
mutant RAS expressing HPC, leads to an increase in extracellular lactate (3.3.2.3, 
3.3.3.3). One frequently cited hypothesis for increased aerobic glycolysis in cancer 
cells is the accumulation of glycolytic intermediates important in biosynthesis 
(reviewed in Mayers and Vander Heiden, 2015). One important metabolic pathway 
for nucleotide biosynthesis is the PPP (1.4.4) and as noted previously (3.4), one 
potential explanation for the increase in extracellular lactate in ROS inhibited THP-1 
and NOMO-1 cells may involve increased recycling of lactate into the PPP, which is 
known to be dysregulated in a number of cancers (reviewed in Patra and Hay, 2014). 
Additionally, the first step of the PPP (G-6-P to 6-PG) generates NADPH an 
important molecule in relieving the cellular oxidative stress generated by excess 
ROS. Data discussed above (4.4.1) demonstrated that AML ROSHi blasts had 
significantly higher levels of G-6-P and F-6-P than ROSLo blasts, whilst both THP-1 
cells and Mv4;11 cells showed no equivalent changes in pPFKFB3 expression 
because of ROS modulation, such as those observed in PFKFB3 expression. Given 
that it has been reported (Novellasdemunt et al., 2013), that phosphorylation of 
PFKFB3 at Ser-461 generates an increase in glycolytic flux, these data suggest that 
increased ROS may lead to both an increase in glucose uptake (as a result of 
increased PFKFB3 expression) whilst simultaneously modulating glycolytic flux via 
phosphorylation of PFKFB3 and diverting intermediates into the PPP. Interestingly, 
metabolomic data from THP-1 and NOMO-1 cells treated with DPI and in NOMO 
NOX2-KD cells, shows decreased levels of 6-PG, whilst Mv4;11 cells treated with 
GOX show increased levels of 6-PG (4.3.5.4), data supportive of this idea. Whilst 
AML blasts showed higher levels of PPP intermediates than human mononuclear 
cells (Table 7), the data for ROSHi compared with ROSLo blasts was more equivocal. 
X-5-P (xyulose-5-phosphate) levels showed a significant 2-fold increase in ROSHi 
blasts compared to ROSLo blasts supportive of the idea that increased ROS results in 
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increased flux through the PPP. However, both 6-PG and R-5-P levels were reduced 
in ROSHi compared with ROSLo blasts, although this did not reach significance 
(Table 8). Taken together these data indicate that increased levels of ROS may result 
in a metabolic shift into the PPP to relieve cellular oxidative stress, which is at least 
partially enabled by lactate recycling, an idea further supported by the decreased 
expression of FBP1 in NOMO-1 cells treated with DPI (4.3.3.1). Futhermore, lactate 
is a known inhibitor of PFK (Leite et al., 2007), this suggests that in cells with lower 
ROS levels, cellular NADPH requirements will be reduced and in order to maintain 
energy production via glycolysis, the need for cells to excrete lactate will be 
increased. These data then suggest another potential ROS related glycolytic 
regulatory mechanism, that balances the energy requirements of cells with the need 
to provide molecules for biosynthesis and manage oxidative stress. 
In contrast, the argument that increased ROS leads to an increase in PPP flux is not 
supported by the observation that THP NOX2-KD cells show a 3.3-fold increase in 
6-PG levels compared to control cells (4.3.5.4). However, given that these cells show 
a larger decrease in PFKFB3 protein expression when NOX2 is knocked-down 
compared with chemical inhibition with DPI (Figure 4-4A), this anomaly could be 
the result of a larger decrease in the conversion of F-6-P to F-1,6-BP in the NOX2-
KD cells compared to the DPI treated cells, resulting in an accumulation of 
glycolytic intermediates above this step. This idea is supported by the 5.2-fold 
increase in F-6-P observed in THP NOX2-KD cells, which contrasts with a reduction 
in this metabolite in THP-1 and NOMO-1 cells treated with DPI and in NOMO 
NOX2-KD cells (4.3.5.3). This suggests that the impact of ROS on glycolysis and 
the PPP may vary between cell lines and variations in glycolytic and PPP 
metabolites may be dynamically affected by cellular ROS levels. 
4.4.3 The effect of ROS on 3-phosphoglycerate levels and serine synthesis 
Whilst the metabolomic data presented above broadly supports the hypothesis that 
inhibition of ROS in THP and NOMO cell lines results in decreases in glycolytic 
intermediates (4.3.5.3), one anomaly is that levels of 3-PG are increased in both cell 
lines when NOX2 is knocked-down and significantly increased upon treatment with 
DPI. 3-PG has previously been shown to inhibit the enzyme 6-phosphogluconate 
dehydrogenase which catalyses the third step of the PPP (Hitosugi et al., 2013) and 
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is also the first step in the serine synthesis pathway (SSP) which also generates 
NADPH (see below). Consequently, when cellular ROS levels are increased, 
decreases in this glycolytic intermediate (as observed above) would enable, via the 
SSP and relieved inhibition of the PPP, increased generation of NADPH to relieve 
oxidative stress. PGAM, which catalyses the conversion of 3-PG to 2-PG is 
negatively regulated by TP53 (1.4.3), which is in turn regulated by ROS (1.3.3.4). It 
may then be, that the increase in 3-PG observed in NOMO and THP cells when ROS 
is reduced (compared with a reduction in other glycolytic metabolites) is reflective of 
a positive feedback loop which maintains intracellular ROS levels. 
3PG is the first step in the synthesis of the amino acid, serine as well as in the 
synthesis of sphingolipids. Sphingolipid metabolites are reduced in THP and NOMO 
cells with NOX2 knocked-down and increased in Mv4;11 cells treated with GOX, 
suggesting that ROS may be associated with increased flux through this pathway, 
which in turn would generate metabolites for biosynthesis. Interestingly, a recent 
study reported that the HeLa cell line and the large cell lung cancer cell line H460, 
both utilised exogenous lactate to synthesise a large percentage of their lipids 
offering another potential explanation for anomalous ROS related changes in 
extracellular lactate levels (Chen et al., 2016d). The first step of the SSP involves the 
conversion of 3-PG to 3-phosphohydroxypyruvate, catalysed by phosphoglycerate 
dehydrogenase, which has been shown to be upregulated in a variety of cancer cell 
lines (Possemato et al., 2011, Locasale et al., 2011). Analysis of metabolomic data 
above shows that serine levels are significantly reduced in THP NOX2-KD cells 
(though not NOMO NOX2-KD cells) and THP and NOMO cells treated with DPI 
(Table 6), again suggesting that increased levels of ROS may be associated with 
increased serine production, thus generating nucleotides for biosynthesis and 
NADPH (Ye et al., 2014). Additionally, it is noteworthy that ROS inhibition 
decreased nearly all amino acid metabolite levels in THP cells whilst addition of the 
lower dose of GOX in Mv4;11 cells resulted in increased amino acid production 
(Table 6).  
One potential implication of an interplay between ROS levels and serine synthesis is 
that serine activates the tetramer form of PKM2, promoting the PEP to pyruvate 
reaction and increasing glycolytic flux (reviewed in Mazurek, 2011). However it has 
also been reported by Anastasiou et al., 2011 that ROS promotes dissociation of the 
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tetramer PKM2 form to its inactive dimer form, leading to a decrease in PEP to 
pyruvate reaction and a decrease in glycolytic flux. Given that PEP is also known to 
inhibit PFK (Blangy et al., 1968), these counteracting mechanisms involving ROS 
suggest a carefully balanced feedback loop that dynamically alters the metabolic flux 
of the glycolytic, pentose phosphate and serine synthesis pathways in accordance 
with cellular ROS levels. These mechanisms may help explain the apparent 
antithetical ROS induced changes in lactate generation observed between different 
cell lines (see chapter 6).  
4.4.4 Concluding remarks 
Data presented in this chapter suggests that not only does mutant RAS and ROS 
affect glucose uptake and lactate secretion, but it does this by changing the protein 
expression levels of several key glycolytic enzymes. Further, analysis of 
metabolomic data in conjunction with western blot analysis suggests that ROS may 
be involved in a complex network of glycolytic regulation, where increases in ROS, 
lead to increases in expression of glycolytic enzymes, predominantly in the early part 
of the glycolytic pathway, which drives this increase in glucose uptake and 
glycolytic rate. Alongside this, increased ROS levels increase oxidative stress within 
the cell which are managed via ROS mediated control of glycolytic metabolites in 
the later part of the glycolytic pathway, controlling flux through the PPP and 
generating NADPH, an important component in relieving oxidative stress (1.3.2.4). 
This would suggest that whilst glucose uptake is a useful measure of ROS induced 
changes in glycolysis, lactate production as a measure of glycolytic changes, maybe 
confounded by the antioxidant and biosynthetic requirements of the cell. 
The predominance of ROS associated changes in PFKFB3 expression in the data 
presented above strongly suggest a role for ROS in modulating this enzymes 
expression. The data from chapter 3 suggests that increases in ROS lead to increases 
in glucose uptake and cellular proliferation. As ROS appears to have additional 
regulatory functions in controlling glycolytic flux, lactate may not be a good marker 
as a measure for increased glycolysis. Therefore, the next chapter will focus on 
examining the implications for cellular glucose uptake and proliferation when 
PFKFB3 activity is inhibited or knocked-down or overexpressed.
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 Modulation of PFKFB3 activity correlates with glucose 
uptake and proliferation in AML derived cell lines and 
this is function of ROS 
5.1 Introduction 
Chapter 3 demonstrated ROS modulated changes in glucose uptake and proliferation 
in mutant RAS expressing HPC and AML cell lines. Further, protein expression and 
metabolomic analysis of these models provided additional evidence that ROS affects 
cellular glycolytic activity (chapter 4) possibly mediated via changes in PFKFB3 
protein expression. PFKFB3 is a key regulator of glycolysis (1.5.1) and has been 
shown to be overexpressed in numerous solid cancers (Atsumi et al., 2002). 
Computational modelling has previously led to the identification of a molecular 
inhibitor of PFKFB3, 3PO, which was shown to decrease glycolytic flux in the 
Jurkat T-cell leukaemia cell line and result in decreased proliferation in several 
human cancer cell lines. Furthermore, in vivo experiments employing 3PO on three 
established xenograft models of, Lewis lung carcinomas, MDA-MB231 breast 
adenocarcinoma cells and HL-60 promyelocytic leukaemia cells in mice, reduced 
glucose uptake and suppressed tumour growth (Clem et al., 2008). Therefore, this 
study next sought to examine the role of PFKFB3 in mediating the effects of ROS on 
glycolysis by chemical inhibition, knock-down or overexpression of this enzyme. 
Furthermore, HIF-1α, a master regulator of cellular oxygen homeostasis (1.4.2.1), 
has been shown to upregulate many glycolytic enzymes, including PFKFB3 
(reviewed in Yalcin et al., 2009b). HIF-1α is upregulated as a physiological response 
to low oxygen levels with concomitant upregulation of a number of glycolytic genes 
(Greijer et al., 2005). It is also known to be upregulated in a number of solid tumours 
(reviewed in Lu and Kang, 2010, Semenza, 2010b). Mutant RAS is known to 
upregulate HIF-1α (Chen et al., 2001, Lim et al., 2004); further, Obach et al., 2004 
identified HIF-1α binding sites in the gene promoter region of the PFKFB3 gene and 
it has been demonstrated that PFKFB3 mRNA is induced, both in vitro and in vivo 
as part of this hypoxic response (Minchenko et al., 2002). Additionally, ROS is also 
known to be implicated in HIF-1α upregulation (Niecknig et al., 2012). In the 
osteosarcoma cell line U2OS, treatment with exogenous H2O2 resulted in increased 
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HIF-1α protein expression after 1 hr, which was reversed after 6 hr. This was linked 
to direct ROS inhibition of PHD2, which was alleviated by upregulation of PHD2 
after 2-4 hrs (1.4.2.1). However, its exact role is still to be established; though a 
recent study provided evidence of a ROS driven HIF-1α response to hypoxia in 
endothelial cells (Paik et al., 2017). Together these reports suggest that a potential 
mechanism exists, whereby increased ROS, results in increased expression and 
stabilisation of HIF-1α, which could, in turn leads to increased expression of 
PFKFB3 and increased glucose uptake. Coupled with the fact that HIF-1α is also 
upregulated in many cancers (Semenza, 2010b) this chapter additionally examines 
the potential interplay of ROS, HIF-1α and PFKFB3 to determine a potential 
mechanism for the ROS modulated changes in cellular glucose uptake, observed in 
chapter 3. 
5.2 Aims and objectives 
The main objective of this chapter is to determine the effect of modulating PFKFB3 
expression on cellular glucose uptake and proliferation in AML cell lines and in 
HPC infected with mutant RAS. To achieve this, this chapter has the following 
aims:- 
- To determine the effect of inhibiting PFKFB3 activity in AML cell lines and 
N-RASG12D HPC. To achieve this, cells will be treated with either chemical 
inhibitors of PFKFB3 or PFKFB3 expression will be knocked-down using 
shRNA and glucose uptake determined; 
- To determine the effect of PFKFB3 overexpression on glucose uptake and 
proliferation in Mv4;11 cells and normal human HPC; 
- To determine the effect on proliferation of PFKFB3 inhibition using PFK158 
in combination with cytarabine (Ara-C), in AML cell lines; 
- To determine the role of HIF-1α in mediating ROS induced changes in 
PFKFB3 expression. Inhibition of NOX2-derived ROS on protein expression 
levels of HIF-1α will be determined in THP-1 cells. The impact of HIF-1α 
knock-down on glucose uptake in this cell line will also be investigated. 
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5.3 Results 
5.3.1 Pharmacological inhibition of PFKFB3 decreases glucose uptake and 
proliferation in AML cell lines and decreases glucose uptake in HPC 
Previously it was shown that addition of exogenous ROS to the AML cell line 
Mv4;11 generated increased cellular glucose uptake and proliferation (3.3.3) which 
correlated with increased protein expression of the key glycolytic enzyme PFKFB3 
(4.3.3.2). Furthermore, in the ROS producing AML cell line, THP-1, 
pharmacological inhibition or knock-down of NOX2 using shRNA, decreased 
protein expression of PFKFB3 (4.3.3.1), which was observed alongside decreased 
cellular glucose uptake and proliferation (3.3.3). Consequently, it was reasoned that 
these changes in glucose uptake and proliferation, may be a function of cellular 
changes in PFKFB3 expression and activity.  
5.3.1.1 Pharmacological inhibition of PFKFB3 with 3-PO and PFK158 
decreases glucose uptake in the Mv4;11 cell line 
Two chemical inhibitors of PFKFB3 (3PO and PFK158) were employed to examine 
the hypothesis that this protein mediates changes in ROS induced glucose uptake and 
proliferation. To determine an effective inhibitory dose for 3PO and PFK158, 
Mv4;11 cells were treated with serial dilutions of the inhibitors over 24h. Using 
CellTiter-GloTM, which measures metabolic activity based on ATP generation, (2.8) 
Figure 5-1A(i) established an EC50 for 3PO (6.25μM) and Figure 5-1A(ii) 625nM 
for PFK158 in this cell line. To assess the impact of PFKFB3 inhibition on glucose 
uptake, Mv4;11 cells were treated with either 3PO (5μM), PFK158 (200nM or 
625nM) and/or GOX (10mU/mL) (which generates H2O2 in the cell culture media) 
and incubated at 37oC, 5% CO2 for 24 h followed by glucose uptake analysis using 
2-NBDG. To ensure these chemicals did not affect cell viability, cell death was 
analysed using flow cytometry (Figure 5-1B). No change in viability in Mv4;11 cells 
treated with 3PO, GOX or 3PO and GOX combined when compared to vehicle 
control, was observed. Figure 5-1C shows that these cells tolerated 100nM PFK158 
both in the absence and presence of exogenous ROS. Interestingly higher 
concentrations of PFK158 (625nM) were tolerated by the Mv4;11 cells in the 
absence of exogenous ROS, but cell death increased when they were treated with 
GOX (10mU/mL) (see 5.4).  
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Figure 5-1. Determination of EC50 of 3PO and PFK158 and effect on cell viability on the 
Mv4;11 cell line. (A) Mv4;11 cells were seeded at 1 x 105 and cultured for 24h in the presence of (i) 
3PO and (ii) PFK158 and subsequently assayed using CellTiter-GloTM. Red line represents cells 
treated with inhibitor, grey line represents cells treated with vehicle control (DMSO (i) 0.002-1% (ii) 
8 x 10-5-0.04%) (n=1). Representative flow cytometric density plots showing percentage of viable 
Mv4;11 cells, seeded at 2 x 105 cells/mL, treated with (B) GOX (10mU/mL) and/or 3PO (5μM) (C) 
GOX (10mU/mL) and/or PFK158 (100nM or 625nM) for 72h and compared for vehicle control ((B) 
DMSO 0.025%), (C) DMSO 0.0013%)). Data were gated to exclude cell debris based on FSC/SSC. 
Cells were incubated with 7-AAD, gated area shows proportion of viable cells (n=3). 
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Treatment of Mv4;11 cells with GOX (10mU/mL) resulted in a 1.2-fold increase in 
glucose uptake compared with control (as expected), whilst combined treatment with 
GOX (10mU/mL) and 3PO (5μM) ablated the response to GOX (Figure 5-2A). 
Treatment with 3PO alone did not alter glucose uptake when compared to control 
cells. These data indicate that chemical inhibition of PFKFB3 with 3PO counteracts 
the effect of increased exogenous ROS on glucose uptake in the Mv4;11 cell line. 
Figure 5-2B shows treatment of Mv4;11 cells with GOX (10mU/mL) resulted in 
increased cellular glucose uptake (15% ±5%), however when these cells were 
additionally treated with either 200nM or 625nM PFK158, this increase in glucose 
uptake was not observed. No changes were observed in glucose uptake as a 
consequence of treatment with this compound alone. This suggests that treatment of 
Mv4;11 cells with the alternative PFKFB3 inhibitor PFK158, also negates ROS 
induced increases in cellular glucose uptake. 
5.3.1.2 Pharmacological inhibition of PFKFB3 with 3-PO and PFK158 
decreases glucose uptake and proliferation in the THP-1 cell line 
To verify the data above, the ROS generating THP-1 cell line, was also treated with 
3-PO and PFK158. To determine an effective inhibitory dose for PFK158 in this cell 
line, THP-1 cells were treated with serial dilutions of the inhibitor, cultured for a 
further 24h and assayed using CellTiter-GloTM. Figure 5-3A established an EC50 for 
this compound of 5µM in this cell line. Figure 5-3B shows that no significant 
changes in cell viability were observed in THP-1 cells treated with 3PO at a range of 
concentrations up to 10μM, but at 20µM, a loss in cell viability was observed. 
Treatment of this cell line with PFK158 was tolerated at 500nM and 1µM doses, 
whilst treatment with 5µM reduced cell viability (Figure 5-3C). To assess the impact 
of these compounds on glucose uptake, THP-1 cells were treated with 3PO or 
PFK158 and incubated for a further 24h prior to analysis with 2-NBDG.  
Figure 5-4A shows that treatment with 5µM or 10µM 3PO resulted in a 17% ±13% 
and significant 19% ± 8% respective reduction in glucose uptake. Treatment with 
1μM and 5μM PFK158, resulted in a respective 8% ±14% and 20% ±8% reduction 
in glucose uptake in these cells compared to control, whilst no change was observed 
upon treatment with 500nM PFK158 (Figure 5-4B).  
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To determine whether these changes in glucose uptake were reflected in 
proliferation, THP-1 cells were treated with 3PO and PFK158 for 72h. Treatment 
with 3PO resulted in a significant dose dependent decrease in proliferation of THP-1 
cells (Figure 5-5A), whilst treatment with PFK158 significantly reduced 
proliferation by 35% (±5%) and 81% (±13%) at 1µM and 5µM respectively, whilst 
no change was observed at 500nM (Figure 5-5B). These data show that chemical 
inhibition of PFKFB3, results in decreased cellular glucose uptake and proliferation 
and taken together with the ROS dependent changes in PFKFB3 expression observed 
in chapter 4, suggests a potential ROS dependent mechanism for these changes. 
5.3.1.3 Pharmacological inhibition of PFKFB3 with 3PO decreases glucose 
uptake in HPC expressing mutant RAS 
It was previously shown that N-RASG12D HPC show increased levels of PFKFB3 
expression compared to control which is decreased upon treatment with DPI, 
implicating ROS in mediating this effect (4.3.2.1). Glucose uptake was also 
increased in N-RASG12D compared with normal HPC and inhibition of ROS 
ameliorated this effect (3.3.1.2). To determine whether PFKFB3 inhibition also 
affected glucose uptake in HPC, N-RASG12D HPC (co-expressing DsRed) were 
treated with 3PO (5μM) and incubated for 24h, before glucose uptake was measured 
using 2-NBDG. As previously (3.3.1.2), N-RASG12D HPC showed a significant 1.4-
fold increase in glucose uptake compared to control, however N-RASG12D HPC 
treated with 3PO (5μM) showed only a 1.1-fold increase compared to control, whilst 
treatment of control HPC with 3PO resulted in a 17% ±3% decrease in glucose 
uptake (Figure 5-6). These data show that PFKFB3 is important in regulating cellular 
glucose uptake in N-RASG12D HPC and that inhibition of this enzyme with 3-PO, 
results in decreased glucose uptake.  
In summary, these data suggest that ROS associated increases in glucose uptake are 
ameliorated upon PFKFB3 inhibition with 3PO. 
  
Chapter 5 
200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2. Chemical inhibition of PFKFB3 decreases cellular glucose uptake in the Mv4;11 cell 
line. Glucose uptake (normalised to control) in Mv4;11 cells seeded at 5 x 105 and incubated for 24h 
in the presence/absence of (A) 3PO (5µM) and/or GOX (10mU/mL) (B) PFK158 (200nM or 625nM) 
and/or GOX (10mU/mL) (n=3). Vehicle control ((A) DMSO 0.025%, (B) DMSO 0.0013%)) (dark 
red), GOX (10mU/mL) treated (deep red), PFK158 (200nM) treated (mid-red), GOX (10mU/mL) and 
3PFK158 (200nM) treated (light-red), PFK158 (625nM) treated (dark pink), GOX (10mU/mL) and 
3PFK158 (625nM) treated (light pink). Data represents mean ± 1SD. 
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Figure 5-3. Determination of EC50 of PFKFB3 inhibitors and effect on cell viability on the 
THP-1 cell line. (A) THP-1 cells were seeded at 1 x 105 and cultured for 24h in the presence of 
PFK158. Cells were subsequently assayed using CellTiter-GloTM. Blue line represents cells treated 
with 3PO, grey line represents cells treated with vehicle control (DMSO 8 x 10-5-0.04%) (n=1). 
Representative flow cytometric density plots showing percentage of viable THP-1 cells, seeded at 4 x 
105 cells/mL, treated with (B) 3PO or (C) PFK158 for 72h and compared for vehicle control ((B) 
DMSO 0.1%, (C) DMSO 0.01%)). Data were gated to exclude cell debris based on FSC/SSC. Cells 
were incubated with 7-AAD, gated area shows proportion of viable cells (n=3).  
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Figure 5-4. Chemical inhibition of PFKFB3 decreases cellular glucose uptake in the THP-1 cell 
line. Glucose uptake (normalised to control) in THP-1 cells, seeded at 5 x 105, treated with (A) 3PO, 
vehicle control (DMSO 0.05%) (dark blue), 3PO (5μM) (light blue), 3PO (10μM) (pale blue); or (B) 
PFK158, vehicle control (DMSO 0.01%) (dark blue), PFK158 (500nM) (blue), PFK158 (1μM) (light 
blue), PFK158 (5μM) (pale blue); and incubated for a further 24h (n=4). Data represents mean ± 1SD. 
* denotes p<0.05, analysed by ANOVA with Tukey’s honestly significance difference.  
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Figure 5-5. Chemical inhibition of PFKFB3 decreases cellular proliferation in the THP-1 cell 
line. Proliferation (normalised to control) in THP-1 cells, seeded at 4 x 105, treated with (A) 3PO, 
vehicle control (DMSO 0.05%) (dark blue), 3PO (5μM) (light blue), 3PO (10μM) (pale blue) (n=6); 
or (B) PFK158, vehicle control (DMSO 0.01%) (dark blue), PFK158 (500nM) (blue), PFK158 (1μM) 
(light blue), PFK158 (5μM) (pale blue) (n=3); and incubated for a further 72h (n=4). Data represents 
mean ± 1SD. * and ** denotes p<0.05 and represent significantly different groups from control, 
analysed by ANOVA with Tukey’s honestly significance difference. 
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Figure 5-6. Inhibition of PFKFB3 with 3PO decreases cellular glucose uptake in N-RASG12D 
expressing HPC. Cellular glucose uptake (normalised to untreated control) in transduced HPC 
treated with 3PO (5μM). Cells were counted (day5) and cultured for a further 24h in the 
presence/absence of 3PO, without growth factors at an initial seeding of 6 x 105 cells/mL (n=3). 
Untreated control (solid green), N-RASG12D HPC (solid blue), control treated with 3PO (gradient 
green) and N-RASG12D HPC treated with 3PO (gradient blue). Data represents mean ± 1SD. * denotes 
p<0.05, analysed by ANOVA with Tukey’s honestly significance difference. 
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 Knock-down of PFKFB3 expression with shRNA results in decreased 
proliferation but not glucose uptake in the THP-1 cell line 
The data above suggests that inhibition of PFKFB3 results in decreased glucose 
uptake in AML cell lines and N-RASG12D. In order to support these data using a 
more specific targeted approach, five shRNA sequences complementary to PFKFB3 
and encoding puromycin resistance were lentivirally infected into Mv4;11 and 
THP-1 cells. To confirm successful knock-down of PFKFB3, western blots were 
performed on whole cell lysates. Figure 5-7A shows that knock-down of PFKFB3 in 
Mv4;11 cells was not successful, as treatment with GOX (20mU/mL maintained an 
increase in expression of PFKFB3, similar to the observed increase in control cells. 
However, Figure 5-7B shows that infection of THP-1 cells generated a decrease in 
PFKFB3 expression in two of the five shRNA clones. Three of the five shRNA 
clones, failed to proliferate, despite initially surviving puromycin selection (5.4). Of 
the two surviving clones, Clone 1 showing the largest decrease in PFKFB3 
expression was used to analyse glucose uptake and proliferation. Figure 5-8A shows 
that knock-down of PFKFB3 had no effect on the viability of these cells when 
compared with control cells lentivirally infected with shRNA coding for a non-
mammalian target sequence. Surprisingly, whilst knock-down of PFKFB3 in THP-1 
cells resulted in a 1.8-fold reduction in proliferation compared to control (Figure 
5-8B), no change in glucose uptake was observed (Figure 5-8C). This suggests that 
while PFKFB3 expression is important in maintaining the proliferative rate of these 
cells, it does not do so by modulating glucose uptake (5.4). 
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Figure 5-7. Knock-down of PFKFB3 in AML cell lines assayed by western blot. (A) Expression 
of PFKB3 in Mv4;11 cells with PFKFB3 knocked-down and treated with GOX (20mU/mL) cf. 
control (3 clones representative of 5). (B) Expression of PFKFB3 in THP-1 cells with PFKFB3 
knocked-down cf. control. Actin was used as a loading control. 
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Figure 5-8. Effect of PFKFB3 knock-down on proliferation and glucose uptake in THP-1 cells. 
(A) Representative flow cytometric density plots showing percentage of viable THP PFKFB3-KD 
cells compared for control. Plots were gated to exclude cell debris based on FSC/SSC. Cells were 
incubated with 7-AAD, gated area shows proportion of viable cells (n=3). (B) Percentage 
proliferation (normalised to control) of THP PFKFB3-KD cells (bright blue) cf. control (dark blue); 
cells were seeded at 4 x 105 cells/mL and incubated for 72h (n=9). (C) Cellular glucose uptake 
(normalised to control) of THP PFKFB3-KD cells (bright blue) cf. control (dark blue); cells were 
seeded at 5 x 105 and incubated for 24h (n=5). Data represents mean ±1SD. ϮϮ denotes p<0.001 
statistical significance calculated by Student’s paired t-test.  
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 Overexpression of PFKFB3 increases glucose uptake and proliferation in an 
AML cell line but not HPC 
The above data demonstrates that pharmacological inhibition of PFKFB3 decreases 
cellular glucose uptake and proliferation (5.3.1). Furthermore, knock-down of 
PFKFB3 in THP-1 cells resulted in decreased levels of proliferation, though not 
glucose uptake. Therefore, it was reasoned that overexpression of this protein may 
lead to increases in glucose uptake and cellular proliferation. To study this, the DNA 
sequence of PFKFB3 was directionally subcloned into two different retro/lentiviral 
vectors (i) PINCO co-expressing DsRed and (ii) pHIV co-expressing GFP (2.2). 
Mv4;11 cells were infected with the pHIV vector (as these cells resist infection with 
retrovirus), HPC were infected with the PINCO vector co-expressing DsRed (to 
allow analysis using the 2-NBDG probe) and changes in proliferation and glucose 
consumption/uptake compared with controls. 
5.3.3.1 Generation of PFKFB3 overexpressing retro- and lenti-viral vectors 
The DNA sequence for PFKFB3 was directionally subcloned into the PINCO vector 
expressing DsRed and the pHIV vector expressing GFP. PFKFB3 cDNA was 
excised from the expression plasmid, pEX-K4, using BamHI and EcoRI, or XbaI HF 
and HpaI HF restriction enzymes. As shown in Figure 5-9A, restriction digest results 
in expected DNA fragments observed around 1.5kb and 2.5kb. As a control, 
undigested DNA showed a DNA fragment migrating at around 4kb. PFKFB3 DNA 
was subsequently ligated into the PINCO and pHIV vectors, transformed into 
competent cells and plasmid DNA extracted using a Qiagen Maxi/Miniprep kit 
(2.2.2). To verify successful ligation and orientation of the PFKFB3 DNA, a ‘test 
digest’ was performed using the restriction enzymes SmaI for the pHIV and ScaI for 
PINCO vector (2.2.3.3). Predicted DNA migrating patterns for the digested PINCO 
vector were 10.7kb and 3.6kb, whilst for the pHIV vector predicted DNA fragment 
sizes were 7.8kb and 1.5kb. Figure 5-9B shows that ligations into both the PINCO 
and pHIV vector contained the PFKFB3 DNA sequence in the correct orientation. 
Integrity of the inserted PFKFB3 DNA was confirmed by Sanger sequencing 
(courtesy of Eurofins MWG, Ebersberg, Germany).   
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Figure 5-9. PFKFB3 DNA sequence “dropped” from pEX-K4 vector and ligated into PINCO 
and pHIV retro and lentiviral vectors. (A) Agarose gel demonstrating (i) excision of PFKFB3 from 
pEX-K4 vector using HpaI and XbaI restriction enzymes, PFKFB3 fragment 1.57kb; (ii) test digests 
of PINCO and pHIV vectors containing PFKFB3 DNA (PINCO vector digested using ScaI restriction 
enzyme and pHIV vector digested using SmaI restriction enzyme, fragments conform to predicted 
band sizes (2.2.3.3)). Example partial sequence of reverse 5’ to 3’ DNA sequence provided by 
Eurofins MWG (Cytosine (C), Adenine (A), Thymine (T), Guanine (G)), and alignment of forward 
primer (P1, P3, P4) sequences across subcloning sites compared with published PFKFB3 sequence in 
(B) pHIV and (C) PINCO vectors (Figure 2-1). Full sequences are shown in appendices 3 and 4.  
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PFKFB3(var.2)      tgcccttcaggaaagcctgtgggccaaagctgaccaactcccccaccgtcatcgtcatgg 
P1                 TGCCCTTCAGGAAAGCCTGTGGGCCAAAGCTGACCAACTCCCCCACCGTCATCGTCATGG 
                   ************************************************************ 
 
PFKFB3(var.2)      tgggcctccccgcccggggcaagacctacatctccaagaagctgactcgctacctcaact 
P1                 TGGGCCTCCCCGCCCGGGGCAAGACCTACATCTCCAAGAAGCTGACTCGCTACCTCAACT 
                   ************************************************************ 
P4                 TGTCGCTGATCAAGGTGATTGACGTGGGCCGGAGGTTCCTGGTGAACCGGGTGCAGGACC 
PFKFB3(var.2)      tgtcgctgatcaaggtgattgacgtgggccggaggttcctggtgaaccgggtgcaggacc 
P3                 TGTCGCTGATCAAGGTGATTGACGTGGGCCGGAGGTTCCTGGTGAACCGGGTGCAGGACC 
                   ************************************************************ 
 
P4                 ACATCCAGAGCCGCATCGTGTACTACCTGATGAACATCCACGTGCAGCCGCGTACCATCT 
PFKFB3(var.2)      acatccagagccgcatcgtgtactacctgatgaacatccacgtgcagccgcgtaccatct 
P3                 ACATCCAGAGCCGCATCGTGTACTACCTGATGAACATCCACGTGCAGCCGCGTACCATCT 
                   ************************************************************ 
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5.3.3.2 Overexpression of PFKFB3 results in increased proliferation and 
increased glucose uptake in Mv4;11 cells  
To investigate the effect of PFKFB3 overexpression on glucose uptake and 
proliferation, Mv4;11 cells were lentivirally infected with PFKFB3, (using pHIV) 
and compared with control cells lentivirally transduced with shRNA coding for a 
non-mammalian target sequence. To confirm successful infection and expression of 
PKFFB3, Mv4;11 cells were analysed by flow cytometry for GFP expression and 
western blots for PFKFB3 protein expression. Flow cytometric analysis shows that 
91% of control cells (Figure 5-10A) and 60% of PFKFB3 overexpression cells 
(PFKFB3-OE) (Figure 5-10B) expressed GFP, whilst Figure 5-10C demonstrates 
that PFKFB3-OE cells overexpress PFKFB3 protein compared to control. To assess 
the impact of PFKFB3 overexpression on cell viability, cells were analysed for 7-
AAD fluorescence by flow cytometry. Figure 5-10D shows that overexpression of 
PFKFB3 did not affect cell viability.  
Cells overexpressing PFKFB3 showed a 1.7-fold increase in proliferation over 72h 
compared to control cells (Figure 5-11A). As the PFKFB3-OE cells co-express GFP, 
glucose levels in the culture media were assayed, as previously (2.7.1), to determine 
changes in cellular glucose consumption. Figure 5-11B shows that the concentration 
of glucose in the culture media of PFKFB3-OE cells after 24h was 15nmol/µL 
compared with 23nmol/µL in control cells. The initial concentration of glucose in 
IMDM media is 25nmol/µL. These data suggest that, Mv4;11 cells in which 
PFKFB3 is overexpressed, show increased levels of proliferation (1.7-fold), 
alongside increased levels of glucose consumption which are 5-fold higher than that 
for control cells, and are therefore above that required as a consequence of the 
increased proliferation. 
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Figure 5-10. Generation of Mv4;11 cells overexpressing PFKFB3. Representative flow cytometric 
histograms showing percentage of Mv4;11 cells expressing GFP in (A) Control (green); (B) PFKFB3-
OE (red). Histograms were gated to exclude cell debris based on FSC/SSC. Background auto 
fluorescence was established using Mv4;11 subjected to the equivalent lentiviral infection procedure 
but in the absence of lentivirus (mock Mv4;11) (grey) infected cells. Percentage within the black 
marker line represents proportion of cells showing fluorescence greater than background 
autofluorescence at <0.01%. (C) Western blot analysis of PFKFB3 protein comparing control and 
PFKFB3-overexpression (OE) Mv4;11 cells. Actin was used as a loading control. (D) Representative 
flow cytometric density plots showing percentage of viable Mv4;11 PFKFB3-OE cells compared for 
control. Plots were gated to exclude cell debris based on FSC/SSC. Cells were incubated with 7-
AAD, gated area shows proportion of viable cells (n=3).  
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Figure 5-11. Effect of PFKFB3 overexpression on proliferation and glucose uptake in Mv4;11 
cells. (A) Percentage proliferation (normalised to control) of Mv4;11 PFKFB3 over-expressed (OE) 
cells (bright red) cf. control (dark red); cells were seeded at 2 x 105 cells/mL and incubated for 72h 
(n=6). (C) Concentration of glucose in the culture media of Mv4;11 PFKFB3-OE cells (bright red) cf. 
control (dark red) after 24h incubation (n=5). Data represents mean ±1SD. Ϯ denotes p<0.005 and ϮϮ 
denotes p<0.001 statistical significance calculated by Student’s paired t-test. 
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5.3.3.3 Overexpression of PFKFB3 in normal HPC does not affect proliferation 
or glucose uptake 
The data above demonstrates that overexpression of PFKFB3 in Mv4;11 results in 
increased proliferation and glucose uptake. To examine the effect of PFKFB3 
overexpression on normal HPC, CD34+ cells were isolated from neo-natal cord 
blood and retrovirally infected with PFKFB3 using the PINCO expression vector co-
expressing DsRed. To confirm successful gene transduction, HPC were analysed by 
flow cytometric analysis and western blot. Flow cytometric analysis shows that 25-
40% of control cells (Figure 5-12A) and 64-73% of PFKFB3-OE cells (Figure 
5-12B) expressed DsRed, whilst Figure 5-12C demonstrates that PFKFB3 
overexpressing cells have elevated PFKFB3 protein expression compared to control. 
The effects of PFKFB3 overexpression on HPC growth was examined using a 
haemocytometer. As shown in Figure 5-13A no changes in growth or proliferation 
were observed because of PFKFB3 overexpression in HPC. Further, using 2-NBDG, 
no changes in glucose uptake was observed between control HPC and HPC in which 
PFKFB3 was overexpressed (Figure 5-13B). These data suggest that overexpression 
of PFKFB3 does not increase glucose uptake or proliferation in normal human HPC 
(5.4). 
 Treatment of AML derived cell lines with Ara-C and PFK158 does not 
augment decreased proliferation compared to Ara-C alone. 
The data above demonstrates that chemical inhibition of PFKFB3 with 3PO and 
PFK158 results in decreased glucose uptake and proliferation in THP-1 cells (5.3.1). 
Specifically, THP-1 cells showed reduced glucose uptake and proliferation when 
treated with 1µM PFK158, whilst no changes in glucose uptake or proliferation were 
observed in cells treated with 500nM PFK158. Conventional chemotherapy which 
uses Ara-C and daunorubicin to treat AML has reached its therapeutic limit, so the 
need for adjuncts or alternative treatments targeting specific pathways is clear 
(Lowenberg et al., 2011). Therefore, to determine whether pharmacological 
inhibition of PFKFB3 would augment Ara-C treatment, THP-1 cells were treated 
with a combination of Ara-C and PFK158.  
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Figure 5-12. Generation of CD34+ HPC overexpressing PFKFB3. Representative flow cytometric 
histograms showing percentage of HPC expressing DsRed in (A) Control (green); (B) PFKFB3-OE 
(lime). Histograms were gated to exclude cell debris based on FSC/SSC. Background auto 
fluorescence was established using HPC subjected to the equivalent retroviral infection procedure but 
in the absence of retrovirus (mock HPC) (grey) infected cells. Percentage within the black marker line 
represents proportion of cells showing fluorescence greater than background autofluorescence at 
<0.01% (n=3). (C) Western blot analysis of PFKFB3 protein comparing control and PFKFB3-OE 
HPC. Actin was used as a loading control.  
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Figure 5-13. Effect of PFKFB3 overexpression on proliferation and glucose uptake in HPC. 
Cells were counted (day5), and cultured for a further 24h without growth factors at an initial seeding 
of 6 x 105 cells/mL. (A) Percentage proliferation and (B) Glucose uptake, of transduced HPC 
(normalised to control); PFKFB3-OE (bright green) control (green) (n=3). Data represents mean 
±1SD.  
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To determine an effective dose for Ara-C in this cell line, cells were assayed as 
described previously, using CellTiter-GloTM (2.8). Figure 5-14A shows an EC50 of 
660nM for THP-1 cells treated with Ara-C. To determine if additional treatment with 
PFK158 lowered the EC50 of Ara-C, THP-1 cells were treated with 300nM and 
1µM doses of PFK158 and serial dilutions of Ara-C. No changes in the EC50 for 
Ara-C were observed in cells additionally treated with 300nM PFK158. Treatment of 
THP-1 cells with 1µM PFK158 however did reduce the EC50 for Ara-C most 
markedly at a concentration of 330nM (Figure 5-14A).  
To determine whether the combined treatment of Ara-C and PFK158 would decrease 
proliferation in THP cells, THP cells were treated with a combination of the drugs at 
different doses. Figure 5-14B shows that as expected, treatment with 100nM and 
330nM Ara-C resulted in decreased proliferation. Treatment of THP-1 cells with 
100nM or 300nM PFK158 did not affect proliferation at either Ara-C dose, whilst 
treatment of THP-1 cells with 1μM PFK158 and 100nM Ara-C resulted in an 
additional 7% ± 2% decrease in proliferation compared to Ara-C treatment alone. 
These data suggest that these compounds demonstrate no apparent synergistic 
beneficial effect, compared to treatment with each compound alone.  
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Figure 5-14. Determination of EC50 for Ara-C and Ara-C & PFK158 combined and effect on 
proliferation. (A) THP-1 cells were seeded at 1 x 105 and cultured for 24h in the presence of Ara-C 
alone or Ara-C and PFK158. Cells were subsequently assayed using CellTiter-GloTM and 
luminescence measured using a Chameleon Hidex luminescent plate reader. Blue line represents cells 
treated with Ara-C alone, orange line represents cells treated with Ara-C and PFK158 (300nM), 
yellow line represents cells treated with Ara-C and PFK158 (1μM) (n=1). (B) Proliferation 
(normalised to control) in THP-1 cells, seeded at 4 x 105, treated with Ara-C alone or Ara-C and 
PFK158 and incubated for a further 72h (n=4). Data represents mean ±1SD.  
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 ROS does not induce HIF-1α overexpression in the THP-1 cell line 
Mutant RAS expressing HPC have been shown to exhibit increased glucose uptake 
and proliferation, which is mediated by ROS (3.3.2). Modulation of ROS in AML 
cell lines has additionally been shown to alter cellular glucose uptake and 
proliferation (3.3.3). Further, both modulation of ROS in N-RASG12D HPC and in 
THP-1 and Mv4;11 cell lines has been shown to alter protein expression levels of 
PFKFB3 (4.3.2.1,4.3.3). In this chapter, chemical inhibition of PFKFB3, knock-
down and overexpression of this protein, have all been shown to affect cellular 
glucose uptake and proliferation in AML cell lines. However, the mechanism 
governing this effect is not known. 
HIF-1α is known to be upregulated in several solid tumours and has been shown to 
induce increased PFKFB3 mRNA expression under conditions of hypoxia and ROS 
is implicated in its regulation (5.1). Therefore, to assess whether ROS may be 
implicated in the upregulation of HIF-1α in AML, our transcriptome microarray data 
was analysed (2.10) to identify whether ROS induced changes in mRNA expression 
of this gene. Figure 5-15A shows that N-RASG12D HPC show a significant 4.7-fold 
increase in expression of HIF-1α mRNA compared to controls, whilst treatment of 
these cells with DPI resulted in a 7.8-fold decrease compared with untreated N-
RASG12D HPC. Figure 5-15B shows the relative mRNA expression of HIF-1α for 
each condition. These data suggest that increased mRNA expression of HIF-1α in 
mutant RAS expressing HPC is at least partly dependent on cellular ROS. 
As observed previously (Hopkins et al., 2014) mRNA expression levels do not 
necessarily correlate with changes in protein expression levels. This is potentially 
pertinent in the case of HIF-1α as under conditions of normoxia, HIF-1α is rapidly 
degraded by the proteasome within 5 min (D'Angelo et al., 2003). To determine if 
increased ROS, generated increased HIF-1α protein expression, western blots were 
performed on THP-1 cells with NOX2 knocked-down or inhibited using DPI. 
Interestingly, Figure 5-15C demonstrates that under conditions of normoxia, HIF-1α 
was not expressed at detectable levels in THP cells, regardless of NOX2 status. 
Treatment of THP-1 cells with cobalt chloride (CoCl2) (which inhibits HIF-1α 
degradation (Yuan et al., 2003)), acted as positive control and confirmed antibody 
specificity. These data suggest that ROS does not impact of HIF-1α protein 
expression in these cells.  
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Although HIF-1α protein was not detectable in THP-1 cells by western blot, given its 
rapid degradation in normoxic conditions and its elevated mRNA expression levels 
in N-RASG12D HPC, it was reasoned that low levels of this protein may still be 
affecting glucose uptake and PFKFB3 expression in these cells. Therefore, three 
shRNA sequences complementary to HIF-1α and encoding puromycin resistance 
were lentivirally transduced into THP-1 cells. One clone did not survive the 
puromycin selection process, suggesting that these cells had not been successfully 
transfected. To confirm knock-down of HIF-1α in the other two shRNA clones, 
western blots were performed on whole cell lysates treated with CoCl2. Of the two 
surviving clones, Clone 1 failed to upregulate HIF-1α when treated with CoCl2, 
suggesting that HIF-1α was successfully knocked down in this clone (Figure 5-16A) 
(western blot provided courtesy of Dr. Namrata Rastogi). Western blot was 
performed on the whole cell lysate of Clone 1 to determine PFKFB3 expression. 
Figure 5-16B shows that knock-down of HIF-1α did not result in any changes in 
PFKFB3 expression, whilst additionally, no changes in the cellular glucose uptake of 
these cells were observed (Figure 5-16C). Overall these data are consistent with the 
idea HIF-1α protein expression does not impact on PFKFB3 expression or cellular 
glucose uptake in THP-1 cells. 
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Figure 5-15. ROS dependent changes in mRNA expression of HIF-1α in human HPC. (A) Fold 
changes in mRNA expression for N-RASG12D transduced HPC compared to control HPC (blue), N-
RASG12D HPC treated with DPI (100nM) compared to untreated N-RASG12D (blue gradient) and 
control HPC treated with DPI (100nM) compared for untreated control HPC (green gradient).  DPI 
treatment occurred for 24 h at 37oC, 5% CO2. Data represents mean fold change of n=4; p-value 
calculated by 2-way ANOVA with Bonferroni multiple testing correction (see methods). (B) 
Normalised log2 expression of mRNA in control HPC (green), control HPC treated with 100nM DPI 
(green gradient), N-RASG12D HPC (blue) and N-RASG12D HPC treated with DPI (blue gradient). Box 
plots represent median quartile ranges, x represents mean value (n=4). (C) Western blots showing 
expression of HIF-1α comparing control THP-1, THP NOX2-KD, THP-1 cells treated with DPI 
(100nM), THP-1 cells treated with CoCl2 (100µM) and HIF-1α recombinant protein (positive 
control). Cells were seeded at 5 x 105 and incubated for a further 24h following treatment. Actin was 
used as loading control.  
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Figure 5-16. HIF-1α dependent changes on PFKFB3 expression and glucose uptake in THP-1 
cells. Western blots showing expression of (A) HIF-1α, comparing control THP-1 and two THP-1 
clones with HIF-1α knocked down untreated and treated with CoCl2 100µM, for 24h, and (B) 
PFKFB3, comparing control THP-1 and THP-1 with HIF-1α knocked-down. Actin was used as 
loading control. (C) Cellular glucose uptake (normalised to control) of THP HIF-1α KD cells (blue) 
cf. control (dark blue); cells were seeded at 5 x 105 and incubated for 24h (n=3). Data represents mean 
±1SD. 
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5.4 Discussion 
The data above shows the effect of loss of PFKFB3 expression or inhibition in AML 
cell lines and N-RASG12D HPC on glucose uptake and cellular proliferation. 
Additionally, the effect of PFKFB3 overexpression on these functions was also 
determined, both in AML cell lines and normal HPC. Finally, a potential mechanism 
of ROS induced PFKFB3 expression was investigated. The main findings presented 
in this chapter are summarised in Table 9 
The PFKFB3 inhibitor 3PO has been shown to reduce glucose uptake and tumour 
burden in xenograft models of several solid tumours (Clem et al., 2008). Alongside 
its more potent analogues PFK-15 and PFK158 (Clem et al., 2013) its therapeutic 
potential in cancer as an inhibitor of glycolysis has been investigated and PFK158 is 
currently undergoing phase I clinical trials (1.5.1.3). In line with studies in solid 
tumours (O'Neal et al., 2016, Zhu et al., 2016, Imbert-Fernandez et al., 2014), data 
presented here shows that in the AML cell line THP-1, treatment with either 3PO or 
PFK158 reduced glucose uptake in a dose dependent manner, whilst proliferation 
was significantly reduced with the use of either inhibitor (5.3.1.2). The efficacy of 
3PO in reducing glucose uptake was also shown in N-RASG12D expressing HPC, 
where a significant decrease in glucose uptake was observed in cells treated with the 
inhibitor (5.3.1.3). Previously in this study it has been established that the addition of 
exogenous ROS to the AML cell line Mv4;11 results in increased glucose uptake by 
these cells (3.3.3.2) as well as increased PFKFB3 protein expression (4.3.3.2). To 
establish whether there is a link between the ROS induced increases in PFKFB3 
expression and ROS induced increases in glucose uptake, Mv4;11 cells were treated 
with exogenous ROS in the presence of 3PO and PFK158. Whilst Mv4;11 cells 
treated with exogenous ROS showed increases in glucose uptake compared to 
control, cells treated with exogenous ROS in the presence of either inhibitor showed 
no equivalent increase (5.3.1.1). Together this data suggests that both 3PO and 
PFK158 inhibition of PFKFB3 is effective in reducing cellular glucose uptake. 
Furthermore, the data presented in the Mv4;11 cell line is suggestive of a 
mechanistic link between increased levels of cellular ROS, increased PFKFB3 
expression and increased cellular glucose uptake. 
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Table 9. Summary of data presented in chapter 5. Table shows a summary of the changes in 
glucose uptake and proliferation of human haematopoietic progenitor cells (HPC) infected with 
mutant RAS, human HPC and AML cell lines compared with appropriate control cells, as presented 
in chapter 5. ↑ indicates an increase compared to control, ↓ represents a decrease compared to control, 
- represents no observed changes compared to control. * represents data that showed significant 
changes compared to controls. n/a indicates that this data was not measured. Details of individual test 
conditions and the statistical analysis can be found in the appropriate results section of the chapter. 
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The role of PFKFB3 was explored further in the THP-1 cell line, via the use of 
shRNA to knock-down expression of this protein in this cell line. Whilst, knock-
down of PFKFB3 significantly reduced proliferation (1.8-fold), no changes in 
glucose uptake were observed (4). Given the link established above between 
PFKFB3 inhibition and glucose uptake this result was surprising. One potential 
reason for the discrepancy between these results could arise due to differences in the 
relative degrees of suppression of PFKFB3. For instance, partial inhibition of 
PFKFB3 may result in decreased proliferation as cells try to restore energy 
homeostasis by diverting metabolites away from metabolic pathways important in 
generating molecules for biosynthesis. A more complete inhibition of PFKFB3 
however, may not only compromise a cells ability to proliferate, but additionally to 
generate energy via glycolysis at all. Alternatively, discrepancies between these 
results may be the function of the mode of inhibition. The kinase activity of 
PFKFB3, which generates F-2,6-BP and activates PFK thus increasing glycolytic 
flux, and its inhibition is a well-known regulatory mechanism in glycolysis (1.5.1). 
The inhibitory effect of 3PO is a consequence of competitive inhibition of the F-6-P 
binding site responsible for the kinase activity of this enzyme (Clem et al., 2008), 
with the phosphatase site remaining active, whilst shRNA knock-down results in a 
decrease in PFKFB3 protein levels and thus total enzyme activity. However, how 
this difference would mechanistically explain this anomalous data is not clear, but it 
may be that in the absence of PFKFB3 protein some regulatory mechanism is 
instigated, leading to the upregulation of compensatory metabolic pathways that 
preserve glucose uptake. Finally although no specific off-target effects of 3PO or 
PFK-158 have been reported in the literature, larger than predicted apoptopic effects 
compared with metabolic reduction in Jurkat T-cell leukaemia cells treated with 
PFK15 mean that an impact on mitochondrial mechanism, by this class of inhibitors, 
cannot be ruled out (Clem et al., 2013). 
In order to investigate the link between PFKFB3 expression, glucose uptake and 
proliferation further, the PFKFB3 gene was overexpressed in Mv4;11 cells and in 
normal HPC. Significant increases in glucose consumption and proliferation was 
observed in the cell cultures of Mv4;11 cells overexpressing this gene (5.3.3.2). 
These results add further weight to the idea that PFKFB3 is a key enzyme in 
modulating cellular glucose uptake and proliferation. Interestingly however, 
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overexpression of PFKFB3 in normal HPC did not result in increased glucose uptake 
or proliferation (5.3.3.3), suggesting, perhaps, that in the context of non-transformed 
haematopoietic cells, regulatory mechanisms exist to prevent excessive glycolysis 
due to increased PFKFB3 expression. For instance, whilst not investigated in this 
study, PTEN is known to inhibit PFKFB3 activity (1.5.1.1) and is frequently mutated 
in cancer. It may be that in non-transformed cells, PTEN activity is increased in 
response to increased glycolysis, whereas in transformed cells this response has 
become decoupled. 
Whilst survival rates of patients with AML has improved greatly over the last thirty 
years (under 60’s  20-75%), in patients over 60, 3-5 year survival rate is still around 
10% (Gutierrez and Romero-Oliva, 2013). Consequently, the need for alternative 
treatments or adjuncts to current treatment programmes is exigent. One effect of 
chemotherapy is to increase intracellular ROS levels, which can be ameliorated by 
an increase in cellular antioxidant capacity, of which NADPH production is a crucial 
component (1.3.2.4). Given that the use of PFKFB3 inhibitors above (5.3.1.1 and 
5.3.1.2) and elsewhere (1.5.1.3) results in decreased glucose uptake (which is 
required for NADPH production via the PPP or SSP (1.4.4)), it was reasoned that use 
of these inhibitors alongside Ara-C may increase cellular oxidative stress and be of 
benefit in treating AML. Whilst in THP-1 cells most combined doses showed little 
improvement on Ara-C treatment alone, a combination dose of 100nM Ara-C and 
1μM PFK158 decreased cellular proliferation by a further 7% compared to Ara-C 
monotherapy. Whilst this suggests that further optimisation of doses and proper drug 
combination studies may further impact on proliferation of these cells, overall these 
data do not indicate beneficial synergistic effect. Interestingly, a recent study 
reported increased PFKFB3 expression in AML cell lines following knock-down of 
the tumour suppressor protein, tuberous sclerosis 2 (Feng and Wu, 2017). Treatment 
of these cells with the mTOR inhibitor rapamycin and the PFKFB3 inhibitor PFK-15 
resulted in synergistic decreases in cellular proliferation. Given that inhibition of 
mTOR by rapamycin in ROS high HSC is known to restore quiescence (1.3.3.3) and 
that mTOR upregulates glycolytic enzymes (1.4.3.1), increases nucleotide and lipid 
biosynthesis (1.4.2) and is known to upregulate G-6-PD (1.4.4), use of rapamycin 
alongside the PFKFB3 inhibitors used above, suggests another alternative 
mechanism that may be explored in future experiments. 
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The data presented in chapter 3 shows a ROS dependent increase in glucose uptake 
and proliferation, whilst in chapter 4 a ROS dependent increase in protein expression 
of PFKFB3 was observed. The data, presented in this chapter suggests that changes 
in glucose uptake and proliferation are directly linked to these changes in PFKFB3 
expression. Therefore, potential mediators of this role were investigated. Analysis of 
microarray data revealed ROS dependent changes of the master regulator of hypoxia 
HIF-1α in N-RASG12D expressing HPC (5.3.5). HIF-1α is stabilised under conditions 
of hypoxia but degraded under conditions of normoxia. However it has been shown 
that HIF-1α is also stabilised in many cancers even in the presence of normal oxygen 
levels (reviewed in Semenza, 2010b) and is responsible for the upregulation of 
numerous glycolytic genes, including PFKFB3 (Yalcin et al., 2009b). One possible 
mechanism proposed for the normoxic stabilisation of HIF-1α is ROS induced 
inhibition of PHD, which in the presence of O2, normally targets HIF-1α for 
degradation (Niecknig et al., 2012). Whilst the role of ROS in stabilising HIF-1α 
remains controversial (reviewed in Hagen, 2012), arguments against its participation 
in normal cells may not apply in transformed cells (1.4.2.1). Cancer cells generate 
and tolerate much higher levels of ROS than normal cells (1.3.3.4) suggesting PHD 
inhibition may still be a factor in these cells. Increased NOX activity in cancer cells 
(1.3.3.4) provides an alternative source of ROS to the mitochondrial ROS source 
proposed as a requirement in normal cells. Finally, the proper regulation of HIF-1α 
in transformed cells may not occur, therefore relief of FIH inhibition from ROS and 
hence inactivation of HIF-1α may not be a requirement in these cells. Therefore, 
given the ROS dependent changes observed in HIF-1α mRNA levels in the N-
RASG12D HPC, it was investigated whether ROS dependent changes in HIF-1α 
protein might also be observed. However, immunoblotting of whole cell lysates of 
the ROS generating AML cell line THP (3.3.3.1), showed no detectable HIF-1α 
expression. Furthermore, knock-down of HIF-1α in this cell line revealed no changes 
in PFKFB3 expression, glucose uptake or proliferation (5.3.5). This suggests that 
ROS modulation of PFKFB3 expression is not mediated by HIF-1α. 
Overall the data presented in this chapter shows that inhibition of PFKFB3 decreases 
cellular proliferation and inhibits glucose uptake, whilst overexpression in 
transformed cells increases glucose uptake and proliferation. Furthermore, this 
mechanism appeared to be a function of ROS. Whilst not analysed rigorously, a 
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superficial examination of the potential benefits of Ara-C treatment augmented with 
PFK158 proved disappointing. This may reflect a need for improved dosage 
optimisation or may reflect regulatory mechanisms of PFKFB3 that protect against 
increased ROS levels (6). Finally, HIF-1α was identified as a potential mechanistic 
candidate for the regulation of ROS induced PFKFB3 expression. However, whilst 
elevated at a transcriptional level by ROS, this elevation was not observed at the 
translational level. 
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 General Discussion 
 Summary 
AML is a heterogeneous disease, which typically affects older people. Currently, the 
median age at diagnosis in the U.S.A is 68, with a 1 in 200 chance of being 
diagnosed with this disease during a person’s lifetime. The standard treatment of one 
or two courses of 3 days of daunorubicin combined with 7 days Ara-C (Burnett, 
2012) bring about remission rates in the under 60’s and over 60’s of 80% and 65% 
respectively (Newland, 2002); however relapse rates are 50% and 85% in these 
respective age groups (Burnett et al., 2011). Furthermore, whilst 5-year relative 
survival rates in the U.S.A have improved from 11.4% in 1980 to 28.1% in 2009 
(Estey and Gale, 2017) with a similar picture observed in the UK (1.2.1), this figure 
falls to <10% in patients over the age of 60. Further, the discovery of revolutionary 
drugs such as ATRA in the treatment of APL (reviewed in McCulloch et al., 2017) 
and the development of Imatinib as targeted therapy in CML (reviewed in Deininger 
et al., 2005), combined with the fact that current treatments appear to have reached 
their therapeutic limit, mean the need for a similar paradigm shift in the treatment of 
AML is clear. 
Mutations of RAS are common in AML (Table 1) leading to its constitutive 
activation, hyperactivation of signalling pathways such as RAF/MEK/ERK and 
PI3K/AKT/mTOR, resulting in consequences for cellular proliferation, growth and 
differentiation which were discussed earlier (1.2.2.3). Previous work in our group 
linking mutational RAS activation with increased NOX2 derived ROS production 
and cellular proliferation in HPC (Hole et al., 2010), was supported by studies on 
AML patient blasts and AML cell lines (Hole et al., 2013). Additionally, FLT3-ITD, 
another common mutation in AML (Table 1), has been shown to increase levels of 
ROS. This is associated with increased DNA DSB (Sallmyr et al., 2008) which was 
subsequently shown to be attributable to NOX4 (Stanicka et al., 2015). The 
consequence was development of leukaemia-like disease and proliferation in murine 
models, via inactivation of DEP-1/PTPRTJ, a PTP which regulates FLT3 (Jayavelu 
et al., 2016b). Clinically, elevated ROS levels have also been observed in ALL and 
CML patient samples (Devi et al., 2000), whilst a Chinese study of AML patients 
indicates a causal link between ROS and relapse (Zhou et al., 2010). 
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ROS also has implications for metabolism, having previously been shown in 
endothelial cells to increase HIF-1α expression which in turn upregulates numerous 
glycolytic enzymes (Paik et al., 2017). ROS can also affect other transcription 
factors involved in metabolic regulation, such as STAT3 and Nf-κB (1.4.2) linked to 
the promotion of lung cancer metastasis in murine models (Zhao et al., 2014). 
Building on the work by Hole et al, 2010, it was found by our group, that HPC 
expressing constitutively active RAS not only generated increased levels of NOX2 
derived ROS, but that this ROS specifically led to changes in mRNA expression 
levels of glycolytic enzymes (Hopkins et al., 2014).  
This study has shown for the first time that in HPC infected with mutant RAS, both 
glucose uptake and lactate secretion are increased (3.3.1). Furthermore, inhibition of 
ROS in this model, results in both a decrease in glucose uptake and proliferation, 
accompanied, interestingly by an increase in lactate secretion (3.3.2). Support for 
these findings was provided using AML cell lines, where ROS levels were depleted 
through chemical inhibition or knock-down of NOX2, or increased (using lines that 
generate little NOX2 derived ROS) through the addition of exogenous ROS. 
Inhibition of ROS led to decreased glucose uptake and proliferation, whereas 
increased glucose uptake and proliferation was associated with exposure to increased 
ROS levels (3.3.3.2, 3.3.3.4). These data are supportive of an earlier study in the 
megakaryoblastic cell line M-O7e, which showed decreased ROS, glucose uptake 
and cell survival in these cells after treatment with DPI or with NOX2 knocked-
down. Curiously, whilst depletion of ROS in two AML cell lines led to an increase 
in lactate secretion, mirroring the results found in mutant RAS expressing HPC 
treated with DPI, increasing ROS in the Mv4;11 cell line also led to increased lactate 
secretion (3.3.3.3). Although the reasons for this discrepancy are not clear, they may 
be context specific or related to relative ROS levels mediating a balance between 
cellular energy requirements and managing oxidative stress (4.4). 
To obtain better insight into the mechanisms of how ROS can lead to changes in 
carbohydrate metabolism, previously generated microarray data (Hopkins, 2014) was 
re-evaluated using a supervised approach focussing on glycolytic enzymes. This 
approach offered a more restrictive analysis by focussing on over 100 genes related 
to glycolysis and associated genes involved in carbohydrate metabolism; as opposed 
to analysing the whole genome consisting of over 28,900 genes. Analysis, revealed 
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several ROS dependent changes in mRNA expression (Figure 4-1), however, at the 
protein level only the enzyme PFKFB3 showed ROS dependent changes especially 
in N-RASG12D expressing HPC (the more clinically relevant mutation in AML) 
(Figure 4-3). These ROS dependent changes in PFKFB3 were confirmed in the AML 
cell line THP-1 through the inhibition of ROS using DPI and NOX2 knock-down 
which led to decreased PFKFB3 protein expression (Figure 4-4), and in the Mv4;11 
cell line, through the addition of exogenous ROS, which resulted in increased 
PFKFB3 protein expression (Figure 4-5). 
Subsequently, mass spectrometry was employed to determine ROS modulated 
changes in metabolites in AML cell lines with a focus on carbohydrate metabolism. 
Importantly, hierarchical clustering demonstrated that whilst different cell lines 
provided the largest variation between samples (as expected), ROS modulation 
within cell lines clearly separated populations. Pleasingly variation in the replicates 
was minimal (Figure 4-9). Whilst analysis of this data revealed different patterns of 
metabolite variation dependent on cell line and the nature of ROS modulation, in 
general, observations were broadly supportive of the functional changes in glycolysis 
previously observed (4.3.5.3), that decreased ROS levels correlate with decreased 
levels of glycolytic metabolites and thus decreased glycolysis. Further support for 
this data was provided by an equivalent experiment using AML patient blast 
samples, which had been categorised into ROSHi and ROSLo producing blasts. 
Analysis of this data showed ROSHi blasts had higher intracellular glucose levels 
than ROSLo blasts and additionally AML blasts had higher levels of intracellular 
glucose and lactate than normal haematopoietic (control) cells (4.3.6.1). 
Interestingly, ROS modulation in cell lines resulted in changes in intracellular lactate 
levels that were antithetical to those obtained for extracellular lactate levels. Both 
NOX2 knock-down, chemical inhibition of ROS and addition of ROS resulted in 
decreased intracellular lactate levels. Furthermore, in response to ROS modulation, 
changes in metabolites associated with both the PPP, the SSP and sphingolipid 
metabolism were observed. These data are suggestive of a reprogramming of 
metabolic pathways to allow potential recycling of lactate (6.2) the generation of 
NADPH as a mechanism for managing increased oxidative stress and increases in 
biosynthetic precursors such as nucleotides for DNA repair and cell growth. In 
support of this, upregulation of the transcription factor Nrf2, which regulates gene 
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expression of the peroxiredoxin and glutathione systems, as well as PPP enzymes 
such as G-6-PD (reviewed in Taguchi and Yamamoto, 2017), has been reported in 
primary cells collected from AML patients (Rushworth et al., 2012). 
Increased PFKFB3 expression has been reported in a variety of solid tumours and is 
associated with increased glycolysis (1.5.1.3). Here, overexpression of the PFKFB3 
gene in the AML cell line Mv4;11 was also shown to lead to increases in glucose 
uptake, accompanied by increased proliferation (5.3.3.2), though this effect was not 
observed in HPC (5.3.3.3). Conversely, chemical inhibition of PFKFB3 led to 
decreased glucose uptake in AML cell lines and importantly this was shown to be an 
effect of changes in ROS levels (5.3.1). Several post-translational modifications of 
PFKFB3 have been reported in the literature as a result of changes in ROS levels 
(1.5.1.2). Therefore, ROS induced phosphorylation of PFKFB3 at Ser-461 was 
investigated as part of this study, however results were equivocal and may represent 
non-specific binding of the antibody, rather than any actual ROS effect (4.3.4.1). To 
try to mechanistically understand how exposure to ROS leads to changes in PFKFB3 
expression, this study analysed our microarray data for HIF-1α expression. The data 
showed increased expression of HIF-1α mRNA correlated with increased ROS levels 
and given that PFKFB3 is known to be a target of HIF-1α (1.5.1) it was reasoned 
that changes in HIF-1α expression may be driving PFKFB3 expression. However, 
immunoblotting showed that HIF-1α was not expressed at detectable levels in the 
AML cell line THP-1 and furthermore knock-down of the mRNA for this protein did 
not result in any changes in glucose uptake (5.3.5). 
The role of ROS as a signalling molecule is now well documented (1.3.3.2). The 
antioxidant enzyme Prx1 has been shown to transduce a H2O2 signal through 
oxidation of the apoptosis signal-regulating kinase 1 protein, resulting in activation 
of the p38MAPK pathway, in the AML cell line U937 (Jarvis et al., 2012). Activation 
of p38MAPK by ROS was shown to occur in this study in both AML cell lines (Figure 
3-12) and HPC expressing mutant RAS (Figure 3-6), whilst the promoter region of 
the PFKFB3 gene contains a serum response element which has been shown to be 
activated by the p38MAPK pathway (Novellasdemunt et al., 2013). This then 
represents an alternative mechanism by which ROS may modulate PFKFB3 
expression. 
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ROS is also known to activate both AKT and AMPK which upregulates catabolic 
metabolic processes, increases glycolytic flux and mediates against ROS 
accumulation (reviewed in Zhao et al., 2017). Whilst outside the scope of this study, 
metabolomic data generated as part of this study indicated increased levels of ROS 
correlated with an increase in fatty acid metabolites and sphingomyelins (data not 
shown). Fatty acid metabolism generates NADPH and is activated by AMPK 
(reviewed in Carracedo et al., 2013), whilst sphingomyelinase activity has been 
shown to increase NOX2 derived ROS (Loehr et al., 2015), suggesting that ROS 
maybe important in these pathways. This activation of fatty acid metabolism by 
AMPK is interesting given that ROS activation of AMPK has also been shown to 
potentially mediate HSC differentiation (Liu et al., 2015), whilst increased PFKFB3 
expression and increased glycolysis via phosphorylation of PFKFB3 at Ser-461 have 
also been shown to be a consequence of AMPK activation (Mendoza et al., 2012). 
AMPK therefore represents another potential candidate by which ROS modulation of 
PFKFB3 could be enacted. 
GAPDH has also been shown to operate as a ROS sensor through oxidation of cys-
152 and renders GAPDH inactive until NADPH levels are restored and this offers a 
further mechanism by which ROS may modulate glycolytic flux (Peralta et al., 
2015). 
 Comparisons to current knowledge and future directions 
Whilst this study clearly establishes a link between ROS, PFKFB3 expression 
cellular glucose uptake and proliferation, several areas warrant further investigation. 
Firstly, it is often stated as a key tenet of the Warburg effect, that transformed cells 
show an increase in aerobic glycolysis, accompanied by increased cellular glucose 
uptake and lactate secretion. In this study, whilst increases in ROS were shown to 
increase cellular glucose uptake, corresponding changes in lactate secretion were not 
observed and the reasons for this have not been delineated. Indeed, data presented 
here suggests that typically, increased ROS led to decreased lactate secretion, 
although curiously intracellular lactate levels were increased. One plausible 
explanation is that ROS effects changes in MCT or LDH expression, resulting in 
decreased lactate excretion, or increased lactate uptake and increased conversion of 
lactate into pyruvate. The conversion of pyruvate to lactate is catalysed by LDHA 
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and whilst in this study no changes in expression of LDHA were observed, 
expression of LDHB was not investigated. Alternatively, the main transporter of 
lactate out of the cell is the monocarboxylic transporter, MCT4. However, there are 
fourteen isoforms of MCT and again while MCT4 showed no ROS dependent 
changes in expression, expression of MCT1 the main transporter of lactate into the 
cell was not examined. Overexpression of MCT1 has been observed in several 
cancers and imported lactate can be used for both energy production and 
biosynthesis (reviewed in San-Millan and Brooks, 2017). In support of this, a recent 
study showed that both HeLa cells and the lung cancer cell line H460 use lactate to 
synthesise lipids during proliferation and as an alternative to pyruvate as a point of 
entry into the mitochondria and the generation of energy through the citric acid cycle 
(Chen et al., 2016d). Furthermore, the process of converting pyruvate into lactate 
additionally generates NAD+, which can then be used to support an increased 
glycolytic rate. This then suggests a model whereby lactate, rather than being 
secreted by the cell is instead retained for internal energy production and lipid 
synthesis. 
The increased excretion of lactate in many cancers means inhibition of the isoform 
LDH5 (comprising of four LDHA subunits (1.4.3)), represents an attractive target for 
inhibition in the treatment of cancer. Whilst numerous inhibitors have been 
identified, problems with selectivity, pharmokinetic properties or cellular entry mean 
that none, as of yet, have entered clinical trials (reviewed in Rani and Kumar, 2016). 
The lactate transporters MCT also represent an attractive target. Recently, a MCT1 
inhibitor based on the alpha-cyano-4-hydoxycinnamic acid has been shown to inhibit 
tumour growth in colorectal adenocarcinoma xenograft models (Gurrapu et al., 
2015), whilst another compound, AZD3965 was shown to be effective in tissue 
samples of small cell lung cancer patients expressing high levels of MCT1 (Polanski 
et al., 2014). The application of these inhibitors within the models used in this study, 
may then provide useful insights into discerning better the effect of ROS on 
metabolic mechanisms and their potential for therapeutic benefit in these cells. 
Alternatively, lactate is known to inhibit PFK activity (Leite et al., 2007) and thus 
glycolytic flux. Increased cellular ROS generates oxidative stress, and the removal of 
this ROS is facilitated by the generation of NADPH. Inhibition of glycolytic flux, 
may result in the diversion of glycolytic metabolites into the PPP, which is a major 
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metabolic pathway in the production of NADPH. Recently it was reported that PPP 
genes were upregulated in >60% of AML patients, whilst inhibition of G-6-PD using 
the inhibitor 6-aminonictoinamide inhibited growth and migration of AML in vitro 
(Chen et al., 2016c). More recently, inhibition of 6-PGD with Physicon in 
combination with dihydroartemisinin (an antimalarial drug) decreased tumour 
growth of the K562 cell line in xenograft models (Elf et al., 2017). Further support 
for the idea that ROS may decrease glycolytic flux can be found from the 
observations that ROS can potentially decrease PFKFB3 kinase activity by S-
glutathionylation of Cys-206 (Seo and Lee, 2014) or by mediating phosphorylation 
of the enzyme at Ser-269 (Reid et al., 2016). Analysis of metabolomic data presented 
in this study is consistent with the idea that increased ROS results in increased flux 
through the PPP (4.4.2) and further examination of both changes in expression of 
PPP enzymes and post-translational modifications of PFKFB3, alongside the use of 
PPP inhibitors, may lend further support to this hypothesis. 
It is perhaps worth reiterating that data in this study clearly show a link between 
increased ROS levels and increased PFKFB3 expression, which is known to increase 
glycolytic flux. What is proposed above is that these increased levels of total 
PFKFB3 protein, are subject to further regulation by ROS in order to manage 
oxidative stress and cellular energy requirements (Figure 6-1). 
Linked to this potential regulatory mechanism is another glycolytic enzyme that in 
this context is worthy of further study, PKM2. PKM2 is upregulated in many cancers 
and exists both as an active tetramer and inactive dimer (1.4.3). Whilst in this study 
ROS was not shown to modulate total PKM2 expression, the effect of ROS on the 
PKM2 tetramer/dimer ratio was not investigated.  
 235 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1. Regulation of glycolysis by reactive oxygen species (ROS) based on published 
literature and observations of this study. Schematic illustration of the regulation of 6-
phosphofructo-2-kinase/fructoste-2,6-bisphosphatase (PFKFB3) and other key glycolytic enzymes. 
ROS upregulates the bifunctional enzyme PFKFB3, which promotes glycolysis. The kinase activity 
(KA) of PFKFB3 generates fructose-2,6-bisphosphate (F-2,6-BP) which activates 
phosphofructokinase (PFK) and is inhibited by ROS and by phosphoenolpyruvate (PEP). Inhibition of 
PFKFB3 KA results in increased fructose-6-phosphate (F-6-P) an accumulation of glycolytic 
intermediates and potential diversion (orange arrows) of glucose-6-phosphate (G-6-P) into the pentose 
phosphate pathway (PPP). ROS is also known to inhibit glyceraldehyde phosphate dehydrogenase 
(GAPDH) and also promote the dimerisation (and hence inhibition) of pyruvate kinase muscle 2 
(PKM2), with a corresponding accumulation of glycolytic intermediates. The production of 
nicotinamide adenine dinucleotide phosphate (NADPH) either via the PPP or serine synthesis helps 
maintain redox homeostasis. Serine promotes PKM2 tetramer formation and the production of 
pyruvate.  
Key: 
Blue arrows represent transport across the cell membrane (CM), green arrows represent activation, 
red ‘T’ represent inhibition. Ribulose-5-phosphate (R-5-P), 6-phosphogluconate dehydrogenase (6-
PGD), 6-phosphogluconate (6-PG), gluconolactonase (G-6-PGL), 6-phosphogluconolactone (6-PGL), 
glucose-6-phosphate dehydrogenase (G-6-PD), hexokinase (HK), phosphoglucose isomerase (PGI), 
fructose-1,6-bisphosphate (F-1,6-BP), glyceraldehyde-3-phosphate (G-3-P), dihydroxyacetone 
phosphate (DHAP), aldolase (ALDO), triosephosphate isomerase (TPI), 1,3-bisphosphoglycerate 
(1,3-BPG), phosphoglycerate kinase (PGK), 3-phosphoglycerate (3-PG), 2-phosphoglycerate (2-PG), 
phosphoglycerate mutase (PGM), enolase (ENO), phosphoglycerate dehydrogenase (PHGDH), 3-
phosphohydroxypyruvate (3-PHP), lactate dehydrogenase (LDH), glucose transporter (GLUT), 
monocarboxylic transporter (MCT), phosphatase activity (PA).  
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However high levels of ROS have been shown to induce PKM2 dimerisation, which 
correlates with decreased lactate production and increased PEP levels (Anastasiou et 
al., 2011) and furthermore PEP is an inhibitor of PFKFB3 kinase activity (Manes 
and El-Maghrabi, 2005, Kim et al., 2007). Increased PKM2 dimer formation would 
then inhibit glycolytic flux and potentially divert intermediates into the PPP, and 
whilst this would not explain the ROS related changes in lactate secretion observed 
in this study, it would correlate with the observed increases in intracellular lactate 
levels. 
Serine synthesis through the SSP is another avenue worthy of exploration. The SSP 
and folate cycle are another source of NADPH generation, and the metabolomic data 
here showed reduced ROS levels correlated with decreased serine levels. 
Interestingly, serine promotes PKM2 tetramer formation (Chaneton et al., 2012) and 
increased utilisation of this pathway would both increase glycolysis and help manage 
cellular ROS levels. Analogues of the compound piperazine-1-carbothioamide have 
been shown to inhibit the SSP enzyme PHGDH and to inhibit growth of breast 
cancer cells in vivo and in vitro (Pacold et al., 2016). 
Finally, the mechanistic pathways for ROS modulation of PFKFB3 outlined above 
(4), whilst yet to be investigated, all represent potential targets in the treatment of 
AML, should a link be established. 5-aminoimidazole-4-carboxamide is an inhibitor 
of AMPK and was recently shown to have efficacy in combination with the anti-
obesity drug, Orlistat, in prostate cancer cell lines (Wright et al., 2017), whilst the 
activity of GAPDH was shown to be inhibited in hepatoma cell lines (Ganapathy-
Kanniappan et al., 2009). Numerous inhibitors of the p38MAPK pathway have been 
developed and whilst this pathway has been shown to be important in tumour 
suppression, its role in metastasis and chemotherapy resistance make it a potential 
target in cancer treatment (Igea and Nebreda, 2015). 
 Concluding remarks 
Data presented in this study establishes for the first time a link between increased 
ROS production, glycolysis and increased expression of the key glycolytic 
regulatory enzyme PFKFB3 in AML. Increased ROS in human HPC expressing 
mutant RAS (a common mutation in AML) resulted in increased cellular glucose 
uptake, as measured by the glucose bioprobe 2-NBDG, and increased proliferation. 
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Modulation of ROS in AML cell lines was supportive of these findings. Gene 
expression profiling of HPC expressing mutant RAS showed ROS related changes in 
several glycolytic enzymes, whilst immunoblotting revealed translational changes in 
the regulatory glycolytic enzyme PFKFB3. As before, these ROS dependent changes 
in PFKFB3 expression were verified in AML cell lines. Metabolomic analysis of the 
AML cell lines in which ROS was modulated compared to controls, revealed 
significant changes in key glycolytic metabolites and further, suggested metabolic 
changes consistent with increased PPP and SSP flux, which generate the key 
antioxidant NADPH. Overexpression of PFKFB3 in Mv4;11 cells resulted in 
increased glucose uptake and cellular proliferation, whilst chemical inhibition of 
PFKFB3 decreased glucose uptake and cellular proliferation in THP-1 cells and HPC 
expressing mutant RAS. Furthermore, treatment of the Mv4;11 cell line with 
exogenous ROS increased glucose uptake in these cells, which was ablated upon 
treatment with PFKFB3 inhibitors, establishing a causal link between ROS levels, 
cellular glucose uptake and PFKFB3 activity. Upregulation of HIF-1α was 
investigated as a potential mechanism, but no ROS induced changes in protein 
expression were observed. Further studies will aim to elucidate this mechanism, 
which may, in combination with PFKFB3 inhibitors, offer new therapeutic windows 
for treatment of AML.  
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Appendices 
 
Appendix 1. shRNA sequences complementary to PFKFB3. (i) TRC2 N0000314690, (ii) TRC2 
N0000314746, (iii) N0000314747, (iv) N0000314748, (v) TRC2 N0000381874. 
(i) Sequence: 
CCGGACCCGCTCATGAGACGCAATACTCGAGTATTGCGTCTCATGAGCGGGTTTTTTG  
(ii) Sequence: 
CCGGCGTGTCGGTTCCATTCCATTTCTCGAGAAATGGAATGGAACCGACACGTTTTTG  
(iii) Sequence: 
CCGGCGTGACTGTTTGGTGCATCTTCTCGAGAAGATGCACCAAACAGTCACGTTTTTG  
(iv) Sequence: 
CCGGTGTCGCTGATCAAGGTGATTGCTCGAGCAATCACCTTGATCAGCGACATTTTTG 
(v) Sequence: 
GTACCGGTCTCCAGCCCGGATTACAAAGCTCGAGCTTTGTAATCCGGGCTGGAGATTTTT
TG 
 
Appendix 2. shRNA sequences complementary to HIF-1α. (i) TRC N0000003808, (ii) 
N0000003809, (iii) N0000003810, (iv) N0000003811, (v) TRC N0000010819 
(i) Sequence: 
CCGGCCGCTGGAGACACAATCATATCTCGAGATATGATTGTGTCTCCAGCGGTTTTT 
(ii) Sequence:  
CCGGCCAGTTATGATTGTGAAGTTACTCGAGTAACTTCACAATCATAACTGGTTTTT  
(iii) Sequence: 
CCGGGTGATGAAAGAATTACCGAATCTCGAGATTCGGTAATTCTTTCATCACTTTTT 
(iv) Sequence: 
CCGGCGGCGAAGTAAAGAATCTGAACTCGAGTTCAGATTCTTTACTTCGCCGTTTTT 
(v) Sequence: 
CCGGTGCTCTTTGTGGTTGGATCTACTCGAGTAGATCCAACCACAAAGAGCATTTTT 
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Appendix 3. PFKFB3 DNA sequence “dropped” from pEX-K4 vector and ligated into PINCO 
retroviral vector. Sequence of reverse 5’ to 3’ DNA sequence provided by Eurofins MWG (Cytosine 
(C), Adenine (A), Thymine (T), Guanine (G)), and alignment of forward primer (P1) and reverse 
primer (P2) sequences across subcloning sites compared with published PFKFB3 sequence. 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  -----------------------------------------------------------a 
P1             CGGGGGTGGACCATCCTCTAGACTGCCGGATCCTAGATAACTGATCAAGATCTGCCACCA 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  tgcccttcaggaaagcctgtgggccaaagctgaccaactcccccaccgtcatcgtcatgg 
P1             TGCCCTTCAGGAAAGCCTGTGGGCCAAAGCTGACCAACTCCCCCACCGTCATCGTCATGG 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  tgggcctccccgcccggggcaagacctacatctccaagaagctgactcgctacctcaact 
P1             TGGGCCTCCCCGCCCGGGGCAAGACCTACATCTCCAAGAAGCTGACTCGCTACCTCAACT 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  ggattggcgtccccacaaaagtgttcaacgtcggggagtatcgccgggaggctgtgaagc 
P1             GGATTGGCGTCCCCACAAAAGTGTTCAACGTCGGGGAGTATCGCCGGGAGGCTGTGAAGC 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  agtacagctcctacaacttcttccgccccgacaatgaggaagccatgaaagtccggaagc 
P1             AGTACAGCTCCTACAACTTCTTCCGCCCCGACAATGAGGAAGCCATGAAAGTCCGGAAGC 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  aatgtgccttagctgccttgagagatgtcaaaagctacctggcgaaagaagggggacaaa 
P1             AATGTGCCTTAGCTGCCTTGAGAGATGTCAAAAGCTACCTGGCGAAAGAAGGGGGACAAA 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  ttgcggttttcgatgccaccaatactactagagagaggagacacatgatccttcattttg 
P1             TTGCGGTTTTCGATGCCACCAATACTACTAGAGAGAGGAGACACATGATCCTTCATTTTG 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  ccaaagaaaatgactttaaggcgtttttcatcgagtcggtgtgcgacgaccctacagttg 
P1             CCAAAGAAAATGACTTTAAGGCGTTTTTCATCGAGTCGGTGTGCGACGACCCTACAGTTG 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  tggcctccaatatcatggaagttaaaatctccagcccggattacaaagactgcaactcgg 
P1             TGGCCTCCAATATCATGGAAGTTAAAATCTCCAGCCCGGATTACAAAGACTGCAACTCGG 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  cagaagccatggacgacttcatgaagaggatcagttgctatgaagccagctaccagcccc 
P1             CAGAAGCCATGGACGACTTCATGAAGAGGATCAGTTGCTATGAAGCCAGCTACCAGCCCC 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  tcgaccccgacaaatgcgacagggacttgtcgctgatcaaggtgattgacgtgggccgga 
P1             TCGACCCCGACAAATGCGACAGGGACTTGTCGCTGATCAAGGTGATTGACGTGGGCCGGA 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  ggttcctggtgaaccgggtgcaggaccacatccagagccgcatcgtgtactacctgatga 
P1             GGTTCCTGGTGAACCGGGTGCAGGACCACATCCAGAGCCGCATCGTGTACTACCTGATGA 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  acatccacgtgcagccgcgtaccatctacctgtgccggcacggcgagaacgagcacaacc 
P1             ACATCCACGTGCAGCCGCGTACCATCTACCTGTGCCGGCACGGC---------------- 
 
P2             ------------------------------------------------------------ 
PFKFB3(var.2)  tccagggccgcatcgggggcgactcaggcctgtccagccggggcaagaagtttgccagtg 
P1             ------------------------------------------------------------ 
 
 
P2             CTCTGAGCAAGTTCGTGGAGGAGCAGAACCTGAAGGACCTGCGCGTGTGGACCAGCCAGC 
PFKFB3(var.2)  ctctgagcaagttcgtggaggagcagaacctgaaggacctgcgcgtgtggaccagccagc 
P1             ------------------------------------------------------------ 
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P2             TGAAGAGCACCATCCAGACGGCCGAGGCGCTGCGGCTGCCCTACGAGCAGTGGAAGGCGC 
PFKFB3(var.2)  tgaagagcaccatccagacggccgaggcgctgcggctgccctacgagcagtggaaggcgc 
P1             ------------------------------------------------------------ 
 
P2             TCAATGAGATCGACGCGGGCGTCTGTGAGGAGCTGACCTACGAGGAGATCAGGGACACCT 
PFKFB3(var.2)  tcaatgagatcgacgcgggcgtctgtgaggagctgacctacgaggagatcagggacacct 
P1             ------------------------------------------------------------ 
 
P2             ACCCTGAGGAGTATGCGCTGCGGGAGCAGGACAAGTACTATTACCGCTACCCCACCGGGG 
PFKFB3(var.2)  accctgaggagtatgcgctgcgggagcaggacaagtactattaccgctaccccaccgggg 
P1             ------------------------------------------------------------ 
 
P2             AGTCCTACCAGGACCTGGTCCAGCGCTTGGAGCCAGTGATCATGGAGCTGGAGCGGCAGG 
PFKFB3(var.2)  agtcctaccaggacctggtccagcgcttggagccagtgatcatggagctggagcggcagg 
P1             ------------------------------------------------------------ 
 
P2             AGAATGTGCTGGTCATCTGCCACCAGGCCGTCCTGCGCTGCCTGCTTGCCTACTTCCTGG 
PFKFB3(var.2)  agaatgtgctggtcatctgccaccaggccgtcctgcgctgcctgcttgcctacttcctgg 
P1             ------------------------------------------------------------ 
 
P2             ATAAGAGTGCAGAGGAGATGCCCTACCTGAAATGCCCTCTTCACACCGTCCTGAAACTGA 
PFKFB3(var.2)  ataagagtgcagaggagatgccctacctgaaatgccctcttcacaccgtcctgaaactga 
P1             ------------------------------------------------------------ 
 
P2             CGCCTGTCGCTTATGGCTGCCGTGTGGAATCCATCTACCTGAACGTGGAGTCCGTCTGCA 
PFKFB3(var.2)  cgcctgtcgcttatggctgccgtgtggaatccatctacctgaacgtggagtccgtctgca 
P1             ------------------------------------------------------------ 
 
P2             CACACCGGGAGAGGTCAGAGGATGCAAAGAAGGGACCTAACCCGCTCATGAGACGCAATA 
PFKFB3(var.2)  cacaccgggagaggtcagaggatgcaaagaagggacctaacccgctcatgagacgcaata 
P1             ------------------------------------------------------------ 
 
P2             GTGTCACCCCGCTAGCCAGCCCCGAACCCACCAAAAAGCCTCGCATCAACAGCTTTGAGG 
PFKFB3(var.2)  gtgtcaccccgctagccagccccgaacccaccaaaaagcctcgcatcaacagctttgagg 
P1             ------------------------------------------------------------ 
 
P2             AGCATGTGGCCTCCACCTCGGCCGCCCTGCCCAGCTGCCTGCCCCCGGAGGTGCCCACGC 
PFKFB3(var.2)  agcatgtggcctccacctcggccgccctgcccagctgcctgcccccggaggtgcccacgc 
P1             ------------------------------------------------------------ 
 
P2             AGCTGCCTGGACAAAACATGAAAGGCTCCCGGAGCAGCGCTGACTCCTCCAGGAAACACT 
PFKFB3(var.2)  agctgcctggacaaaacatgaaaggctcccggagcagcgctgactcctccaggaaacact 
P1             ------------------------------------------------------------ 
 
P2             GAGAATTCGATCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTAT 
PFKFB3(var.2)  ga---------------------------------------------------------- 
P1             ------------------------------------------------------------ 
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Appendix 4. PFKFB3 DNA sequence “dropped” from pEX-K4 vector and ligated into pHIV 
lentiviral vector. Sequence of reverse 5’ to 3’ DNA sequence provided by Eurofins MWG (Cytosine 
(C), Adenine (A), Thymine (T), Guanine (G)), and alignment of forward primer (P3 and P4) and 
reverse primer (P5) sequences across subcloning sites compared with published PFKFB3 sequence. 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  --------------------------------atgcccttcaggaaagcctgtgggccaa 
P3             GGATCCTAGATAACTGATCAAGATCTGCCACCATGCCCTTCAGGAAAGCCTGTGGGCCAA 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  agctgaccaactcccccaccgtcatcgtcatggtgggcctccccgcccggggcaagacct 
P3             AGCTGACCAACTCCCCCACCGTCATCGTCATGGTGGGCCTCCCCGCCCGGGGCAAGACCT 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  acatctccaagaagctgactcgctacctcaactggattggcgtccccacaaaagtgttca 
P3             ACATCTCCAAGAAGCTGACTCGCTACCTCAACTGGATTGGCGTCCCCACAAAAGTGTTCA 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  acgtcggggagtatcgccgggaggctgtgaagcagtacagctcctacaacttcttccgcc 
P3             ACGTCGGGGAGTATCGCCGGGAGGCTGTGAAGCAGTACAGCTCCTACAACTTCTTCCGCC 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  ccgacaatgaggaagccatgaaagtccggaagcaatgtgccttagctgccttgagagatg 
P3             CCGACAATGAGGAAGCCATGAAAGTCCGGAAGCAATGTGCCTTAGCTGCCTTGAGAGATG 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  tcaaaagctacctggcgaaagaagggggacaaattgcggttttcgatgccaccaatacta 
P3             TCAAAAGCTACCTGGCGAAAGAAGGGGGACAAATTGCGGTTTTCGATGCCACCAATACTA 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  ctagagagaggagacacatgatccttcattttgccaaagaaaatgactttaaggcgtttt 
P3             CTAGAGAGAGGAGACACATGATCCTTCATTTTGCCAAAGAAAATGACTTTAAGGCGTTTT 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  tcatcgagtcggtgtgcgacgaccctacagttgtggcctccaatatcatggaagttaaaa 
P3             TCATCGAGTCGGTGTGCGACGACCCTACAGTTGTGGCCTCCAATATCATGGAAGTTAAAA 
 
P5             ------------------------------------------------------------ 
P4             ------------------------------------------------------------ 
PFKFB3(var.2)  tctccagcccggattacaaagactgcaactcggcagaagccatggacgacttcatgaaga 
P3             TCTCCAGCCCGGATTACAAAGACTGCAACTCGGCAGAAGCCATGGACGACTTCATGAAGA 
 
P5             ------------------------------------------------------------ 
P4             ------------------AGCGCTACCAGCCCCTCGACCCCGACAAATGCGACAGGGACT 
PFKFB3(var.2)  ggatcagttgctatgaagccagctaccagcccctcgaccccgacaaatgcgacagggact 
P3             GGATCAGTTGCTATGAAGCCAGCTACCAGCCCCTCGACCCCGACAAATGCGACAGGGACT 
 
P5             ------------------------------------------------------------ 
P4             TGTCGCTGATCAAGGTGATTGACGTGGGCCGGAGGTTCCTGGTGAACCGGGTGCAGGACC 
PFKFB3(var.2)  tgtcgctgatcaaggtgattgacgtgggccggaggttcctggtgaaccgggtgcaggacc 
P3             TGTCGCTGATCAAGGTGATTGACGTGGGCCGGAGGTTCCTGGTGAACCGGGTGCAGGACC 
 
P5             ------------------------------------------------------------ 
P4             ACATCCAGAGCCGCATCGTGTACTACCTGATGAACATCCACGTGCAGCCGCGTACCATCT 
PFKFB3(var.2)  acatccagagccgcatcgtgtactacctgatgaacatccacgtgcagccgcgtaccatct 
P3             ACATCCAGAGCCGCATCGTGTACTACCTGATGAACATCCACGTGCAGCCGCGTACCATCT 
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P5             ------------------------------------------------------------ 
P4             ACCTGTGCCGGCACGGCGAGAACGAGCACAACCTCCAGGGCCGCATCGGGGGCGACTCAG 
PFKFB3(var.2)  acctgtgccggcacggcgagaacgagcacaacctccagggccgcatcgggggcgactcag 
P3             ACCTGTGCCGGCACGGCGAGAACGAGCACAACCTCCAGGGCCGCATCGGGGGCGACTCAG 
 
P5             ------------------------------------------------------------ 
P4             GCCTGTCCAGCCGGGGCAAGAAGTTTGCCAGTGCTCTGAGCAAGTTCGTGGAGGAGCAGA 
PFKFB3(var.2)  gcctgtccagccggggcaagaagtttgccagtgctctgagcaagttcgtggaggagcaga 
P3             GCCTGTCCAGCCGGGGCAAGAAGTTTGCCAGTGCTCTGAGCAAGTTCGTGG--------- 
 
P5             ------------------------------------------------------------ 
P4             ACCTGAAGGACCTGCGCGTGTGGACCAGCCAGCTGAAGAGCACCATCCAGACGGCCGAGG 
PFKFB3(var.2)  acctgaaggacctgcgcgtgtggaccagccagctgaagagcaccatccagacggccgagg 
P3             ------------------------------------------------------------ 
 
P5             ------------------------------------------------------------ 
P4             CGCTGCGGCTGCCCTACGAGCAGTGGAAGGCGCTCAATGAGATCGACGCGGGCGTCTGTG 
PFKFB3(var.2)  cgctgcggctgccctacgagcagtggaaggcgctcaatgagatcgacgcgggcgtctgtg 
P3             ------------------------------------------------------------ 
 
P5             ----GGTGACCTACGAGGAGATCAGGGACACCTACCCTGAGGAGTATGCGCTGCGGGAGC 
P4             AGGAGCTGACCTACGAGGAGATCAGGGACACCTACCCTGAGGAGTATGCGCTGCGGGAGC 
PFKFB3(var.2)  aggagctgacctacgaggagatcagggacacctaccctgaggagtatgcgctgcgggagc 
P3             ------------------------------------------------------------ 
 
P5             AGGACAAGTACTATTACCGCTACCCCACCGGGGAGTCCTACCAGGACCTGGTCCAGCGCT 
P4             AGGACAAGTACTATTACCGCTACCCCACCGGGGAGTCCTACCAGGACCTGGTCCAGCGCT 
PFKFB3(var.2)  aggacaagtactattaccgctaccccaccggggagtcctaccaggacctggtccagcgct 
P3             ------------------------------------------------------------ 
 
P5             TGGAGCCAGTGATCATGGAGCTGGAGCGGCAGGAGAATGTGCTGGTCATCTGCCACCAGG 
P4             TGGAGCCAGTGATCATGGAGCTGGAGCGGCAGGAGAATGTGCTGGTCATCTGCCACCAGG 
PFKFB3(var.2)  tggagccagtgatcatggagctggagcggcaggagaatgtgctggtcatctgccaccagg 
P3             ------------------------------------------------------------ 
 
P5             CCGTCCTGCGCTGCCTGCTTGCCTACTTCCTGGATAAGAGTGCAGAGGAGATGCCCTACC 
P4             CCGTCCTGCGCTGCCTGCTTGCCTACTTCCTGGATAAGAGTGCAGAGGAGATGCCCTACC 
PFKFB3(var.2)  ccgtcctgcgctgcctgcttgcctacttcctggataagagtgcagaggagatgccctacc 
P3             ------------------------------------------------------------ 
 
P5             TGAAATGCCCTCTTCACACCGTCCTGAAACTGACGCCTGTCGCTTATGGCTGCCGTGTGG 
P4             TGAAATGCCCTCTTCACACCGTCCTGAAACTGACGCCTGTCGCTTATGGCTGCCGTGTGG 
PFKFB3(var.2)  tgaaatgccctcttcacaccgtcctgaaactgacgcctgtcgcttatggctgccgtgtgg 
P3             ------------------------------------------------------------ 
 
P5             AATCCATCTACCTGAACGTGGAGTCCGTCTGCACACACCGGGAGAGGTCAGAGGATGCAA 
P4             AATCCATCTACCTGAACGTGGAGTCCGTCTGCACACACCGGGAGAGGTCAGAGGATGCAA 
PFKFB3(var.2)  aatccatctacctgaacgtggagtccgtctgcacacaccgggagaggtcagaggatgcaa 
P3             ------------------------------------------------------------ 
 
P5             AGAAGGGACCTAACCCGCTCATGAGACGCAATAGTGTCACCCCGCTAGCCAGCCCCGAAC 
P4             AGAAGGGACCTAACCCGCTCATGAGACGCAATAGTGTCACCCCGCTAGCCAGCCCCGAAC 
PFKFB3(var.2)  agaagggacctaacccgctcatgagacgcaatagtgtcaccccgctagccagccccgaac 
P3             ------------------------------------------------------------ 
 
P5             CCACCAAAAAGCCTCGCATCAACAGCTTTGAGGAGCATGTGGCCTCCACCTCGGCCGCCC 
P4             CCACCAAAAAGCCTCGCATCAACAGCTTTGAGGAGCATGTGGCCTCCACCTCGGCCGCCC 
PFKFB3(var.2)  ccaccaaaaagcctcgcatcaacagctttgaggagcatgtggcctccacctcggccgccc 
P3             ------------------------------------------------------------ 
 
P5             TGCCCAGCTGCCTGCCCCCGGAGGTGCCCACGCAGCTGCCTGGACAAAACATGAAAGGCT 
P4             TGCCCAGCTGCCTGCCCCCGGAGGTGCCCACGCAGCTGCCTGGACAAAACATGAAAGGCT 
PFKFB3(var.2)  tgcccagctgcctgcccccggaggtgcccacgcagctgcctggacaaaacatgaaaggct 
P3             ------------------------------------------------------------ 
 
P5             CCCGGAGCAGCGCTGACTCCTCCAGGAAACACTGAGAATTCCCCGGGAGATCCTCTAGAG 
P4             CCCGGAGCAGCGCTGACTCCTC-------------------------------------- 
PFKFB3(var.2)  cccggagcagcgctgactcctccaggaaacactga------------------------- 
